data_2cud_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2cud _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.498 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 12.9 m-20 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.839 0.352 . . . . 0.0 110.89 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -105.06 148.25 26.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.444 HD12 ' CE2' ' A' ' 52' ' ' TRP . 4.8 mt -129.93 114.2 15.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -83.11 126.26 32.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.118 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 93.1 t -62.33 104.3 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.095 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.429 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 10.8 mt -66.44 -33.48 75.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.889 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.426 ' O ' ' C ' ' A' ' 25' ' ' ASP . 28.8 t -156.17 120.43 4.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 24' ' ' SER . 4.3 p-10 -35.97 140.07 0.13 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.572 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.1 OUTLIER -156.75 147.65 16.45 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 0.0 110.899 -179.866 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.565 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -173.57 8.6 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.351 -0.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 m -75.8 156.21 84.69 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.727 0.775 . . . . 0.0 110.841 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 3.33 2.82 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.691 2.261 . . . . 0.0 112.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -106.92 -16.55 14.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -112.2 -46.53 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.164 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -165.75 163.0 12.87 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.685 0.755 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 133.33 25.23 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.365 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 120.37 7.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 0.0 112.333 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.3 mp -79.15 -25.87 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.11 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.485 ' CG ' HD23 ' A' ' 42' ' ' LEU . 12.5 m-85 -131.22 93.83 3.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.95 155.27 8.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 55.7 ttp85 -54.82 148.11 13.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -16.28 11.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.483 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -68.98 138.35 54.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.918 0.39 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -92.74 137.65 32.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.485 HD23 ' CG ' ' A' ' 36' ' ' PHE . 6.0 mt -131.16 147.6 52.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.921 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.2 ttt180 -99.41 132.11 44.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 90.9 t -68.04 110.28 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.149 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.434 ' CG2' ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -87.47 -52.38 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.117 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 m -143.59 146.91 33.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -111.27 116.7 31.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.852 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 6.6 mm-40 -125.66 85.94 2.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.76 -122.52 30.29 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 -22.52 63.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.519 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.575 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 26.3 m95 -110.84 137.33 48.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.305 . . . . 0.0 110.899 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.444 ' CE2' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.27 164.37 27.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.875 -179.994 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.536 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 38.5 tttt -100.09 140.9 33.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.82 160.01 43.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.427 HG13 ' C ' ' A' ' 61' ' ' ARG . 18.5 tt -131.45 141.54 45.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.4 t -76.48 130.45 37.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.85 6.58 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.2 t -109.7 -44.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 53.2 p -103.53 -34.68 8.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.156 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.95 32.46 23.66 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.519 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.427 ' C ' HG13 ' A' ' 55' ' ' ILE . 28.1 mtt180 -95.83 125.26 40.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.777 0.322 . . . . 0.0 110.88 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -91.51 118.13 30.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 36' ' ' PHE . 4.2 m -147.01 168.81 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.824 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.536 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 31.6 m-85 -113.28 120.33 40.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.963 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -130.43 151.27 78.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.632 0.73 . . . . 0.0 111.124 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.575 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.77 132.23 22.87 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.699 2.266 . . . . 0.0 112.306 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -45.17 -33.97 4.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.494 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.7 tp -61.37 -34.75 62.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.351 . . . . 0.0 111.111 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.15 -13.86 61.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.9 m -124.93 171.78 13.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.161 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.429 ' HB1' ' CD2' ' A' ' 23' ' ' LEU . . . -131.73 132.5 43.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.093 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 3.2 tpp85 -65.87 102.82 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.937 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -106.32 146.82 29.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.882 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.415 HD21 ' CH2' ' A' ' 52' ' ' TRP . 7.4 mt -131.91 108.96 9.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.01 128.64 33.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 74.1 t -65.25 100.05 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.465 ' CD1' ' O ' ' A' ' 70' ' ' VAL . 7.6 mt -61.48 -26.69 68.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -166.64 132.47 2.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.93 142.43 0.91 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.657 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 150.46 12.93 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.643 0.735 . . . . 0.0 110.911 -179.807 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.55 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.8 175.08 38.12 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.652 -1.812 . . . . 0.0 112.342 -0.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.4 p -68.5 156.31 90.85 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.679 0.752 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 5.24 1.75 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.88 -6.42 18.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.896 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.56 -53.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.03 163.93 23.4 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.683 0.754 . . . . 0.0 110.849 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 134.53 28.19 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.692 2.262 . . . . 0.0 112.354 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.14 11.81 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.72 2.28 . . . . 0.0 112.368 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -87.66 -23.66 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.467 ' CG ' HD22 ' A' ' 42' ' ' LEU . 15.7 m-85 -134.74 101.37 4.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.8 mmt85 -60.95 158.98 12.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.445 ' HD2' ' N ' ' A' ' 39' ' ' GLY . 6.6 tmm_? -56.87 144.34 33.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.858 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.445 ' N ' ' HD2' ' A' ' 38' ' ' ARG . . . 83.69 -16.07 33.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -68.78 138.68 55.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.936 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.62 142.05 27.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.467 HD22 ' CG ' ' A' ' 36' ' ' PHE . 3.0 mt -138.71 135.16 34.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.934 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -87.3 133.54 33.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.866 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.6 t -68.39 113.58 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.125 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -91.28 -50.41 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.155 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.1 p -143.8 150.36 38.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.9 p-10 -114.3 115.66 27.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.92 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.0 mt-10 -122.17 85.84 2.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.935 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.45 -119.62 18.23 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.506 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.48 -24.12 61.42 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.51 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.57 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 18.3 m95 -110.81 140.31 45.36 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.781 0.325 . . . . 0.0 110.945 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.415 ' CH2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.18 164.32 27.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.911 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.54 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 33.4 tttt -98.26 145.62 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 tt -127.68 144.95 35.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.9 t -78.13 129.16 34.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.844 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.28 8.95 6.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.8 m -114.75 -44.22 3.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.9 p -101.26 -41.82 6.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.114 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.32 25.87 17.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.483 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 40.1 mtt180 -92.27 125.93 37.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -93.75 117.92 30.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 17.7 m -146.87 169.35 19.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.54 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 19.8 m-85 -112.06 118.83 36.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.401 ' CD1' ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.43 151.25 69.78 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.148 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.57 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.6 Cg_endo -69.74 133.11 24.81 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.697 2.265 . . . . 0.0 112.331 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.9 -31.26 5.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.466 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 9.1 tt -64.27 -32.59 58.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.776 0.322 . . . . 0.0 111.097 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.3 m -75.58 -13.05 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.465 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 35.6 m -126.97 175.23 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.46 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -141.84 139.83 32.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.119 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -67.9 110.45 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.129 179.934 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.845 0.355 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -105.11 149.88 25.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.839 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 14.5 mt -132.71 115.13 14.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.48 120.47 26.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.7 t -55.68 106.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.46 ' CD2' ' HB2' ' A' ' 71' ' ' ALA . 10.1 mt -66.79 -34.01 76.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.917 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.9 t -157.2 128.13 6.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.852 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.97 134.05 2.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.643 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.87 149.74 22.76 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 110.942 -179.811 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.557 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.48 11.0 Favored 'Cis proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.304 -0.045 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.1 m -73.61 155.65 89.11 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.671 0.748 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 2.92 3.09 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.699 2.266 . . . . 0.0 112.359 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -106.82 -16.61 14.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -111.81 -46.94 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.172 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.11 162.01 14.34 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.622 0.725 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 135.94 31.59 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.637 2.224 . . . . 0.0 112.348 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 124.87 11.48 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.684 2.256 . . . . 0.0 112.338 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -87.52 -25.08 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.504 ' CG ' HD21 ' A' ' 42' ' ' LEU . 15.1 m-85 -131.65 89.77 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -50.49 156.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.872 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -58.43 150.97 21.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.62 -6.4 17.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.455 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -76.09 135.41 39.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 35.0 tttt -86.12 137.78 32.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.504 HD21 ' CG ' ' A' ' 36' ' ' PHE . 9.7 mt -132.98 154.51 50.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.9 ttp180 -105.06 131.42 52.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.9 t -70.88 112.73 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -87.88 -51.66 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.8 t -151.83 159.36 43.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.828 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -116.33 111.71 20.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.3 mt-10 -110.53 86.41 2.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.98 -122.68 31.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.23 -21.62 78.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.496 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.8 m95 -114.97 151.87 33.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.09 164.52 27.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.941 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.46 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 25.8 tttt -100.85 143.88 30.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.81 160.95 42.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.461 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -129.88 146.76 33.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.5 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 87.6 p -81.37 128.52 33.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.871 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.4 mt -77.49 8.66 4.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.5 m -99.9 -52.69 3.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.816 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.4 p -107.37 -45.4 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.193 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.92 29.43 4.35 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.9 mtt180 -86.95 123.99 32.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.746 0.308 . . . . 0.0 110.864 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.461 ' HG3' ' CD1' ' A' ' 55' ' ' ILE . 6.2 mt-10 -93.97 117.86 30.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -147.19 165.63 29.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.873 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.46 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 17.0 m-85 -107.27 123.93 49.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.935 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.451 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.36 151.25 77.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.671 0.748 . . . . 0.0 111.144 179.905 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.574 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.75 132.56 23.61 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.646 2.231 . . . . 0.0 112.382 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.66 -31.33 7.22 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.462 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.0 tt -63.92 -31.91 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 111.108 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.2 m -76.6 -11.12 59.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.455 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 31.0 m -127.84 169.72 18.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.46 ' HB2' ' CD2' ' A' ' 23' ' ' LEU . . . -127.85 129.08 46.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -64.8 108.8 1.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.9 t . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.181 179.942 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.45 ' OD2' ' NH2' ' A' ' 72' ' ' ARG . 1.2 m-20 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.865 0.364 . . . . 0.0 110.861 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -108.46 153.7 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.851 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.6 mt -140.03 114.55 9.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.9 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.65 128.93 34.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 109.44 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.072 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.449 HD23 ' CB ' ' A' ' 71' ' ' ALA . 6.5 mt -68.8 -31.93 71.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.932 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.436 ' O ' ' C ' ' A' ' 25' ' ' ASP . 24.6 t -160.76 125.98 3.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.7 OUTLIER -35.37 148.34 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.846 179.953 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.59 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -166.04 148.89 6.49 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.64 0.733 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.574 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.8 -174.27 9.41 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.347 0.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -71.17 153.63 94.27 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 0.0 110.876 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 3.04 3.02 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.678 2.252 . . . . 0.0 112.338 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -106.0 -23.13 12.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.5 -57.15 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.128 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 m -150.8 162.93 25.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.679 0.752 . . . . 0.0 110.851 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 132.89 24.17 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.339 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 122.59 9.26 Favored 'Trans proline' 0 N--CA 1.465 -0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.347 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mp -87.17 -26.11 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.407 ' CD1' ' OG ' ' A' ' 56' ' ' SER . 6.0 m-85 -128.87 99.22 5.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 28.6 mmm-85 -63.44 157.75 22.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 ttm180 -56.81 143.82 35.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.03 9.42 86.96 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -93.15 136.0 33.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 22.1 ttmt -87.99 139.6 30.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.94 146.86 45.93 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.1 ttm180 -100.5 125.34 46.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.927 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 43.6 t -63.44 111.03 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.12 -47.74 16.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -149.09 157.89 43.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -117.21 113.15 21.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.2 mt-10 -115.22 86.25 2.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 57.68 -118.4 12.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.43 -23.0 61.41 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.508 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.577 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.9 m95 -112.28 135.72 52.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.76 0.314 . . . . 0.0 110.896 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -124.75 164.76 19.26 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.932 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.562 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 14.5 tttp -102.61 147.77 26.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.74 163.81 39.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.104 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 19.5 tt -131.47 151.33 35.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.156 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.407 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 49.1 m -83.18 127.77 33.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.3 mt -78.43 9.38 3.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 m -116.8 -43.88 2.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 68.6 p -101.4 -42.74 6.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.02 25.79 16.19 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 50.8 mtt-85 -89.86 124.49 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.779 0.323 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.92 117.38 30.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.867 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.1 t -147.76 166.28 27.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.832 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.562 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 12.9 m-85 -108.79 122.74 47.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -129.8 151.12 77.62 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.65 0.738 . . . . 0.0 111.157 179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.577 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.79 134.8 28.78 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.325 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.75 -30.58 9.03 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.469 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.42 HG22 ' N ' ' A' ' 69' ' ' CYS . 6.2 tp -65.39 -30.46 50.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . 0.42 ' N ' HG22 ' A' ' 68' ' ' ILE . 2.7 m -78.6 -6.87 56.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.838 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.424 ' N ' HD13 ' A' ' 23' ' ' LEU . 27.5 m -133.02 167.57 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.449 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -128.94 134.67 48.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.6 tpt85 -64.98 112.36 3.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 -179.986 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.486 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 13.2 m-20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.89 0.376 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -103.14 152.66 21.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -137.51 112.89 9.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.923 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 125.52 30.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.075 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.63 99.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.143 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.462 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 7.9 mt -57.33 -33.69 67.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.894 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.2 t -157.95 133.17 8.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.36 135.29 3.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.65 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -153.39 150.18 23.01 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.665 0.745 . . . . 0.0 110.929 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.561 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.76 -175.09 10.34 Favored 'Cis proline' 0 C--O 1.231 0.156 0 C-N-CA 122.723 -1.782 . . . . 0.0 112.33 -0.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 31.2 m -75.24 155.64 86.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.729 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 1.14 4.69 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.682 2.255 . . . . 0.0 112.394 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.16 -5.38 18.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.863 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.72 -47.03 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.1 161.63 14.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.638 0.732 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 134.28 27.62 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.367 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 125.29 12.01 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.67 2.247 . . . . 0.0 112.357 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -87.19 -25.22 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.114 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.509 ' CG ' HD22 ' A' ' 42' ' ' LEU . 13.6 m-85 -134.89 96.94 3.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.81 162.95 1.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.868 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -59.88 149.66 30.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.08 -9.76 17.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.99 137.09 48.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.878 0.371 . . . . 0.0 110.891 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -90.89 138.94 31.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.509 HD22 ' CG ' ' A' ' 36' ' ' PHE . 2.7 mt -137.99 142.63 40.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.941 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.6 ttt-85 -94.97 131.66 40.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 69.0 t -68.01 109.84 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.149 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.42 ' CG2' ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -83.65 -46.26 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.94 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 68.8 m -156.27 152.75 28.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -110.91 117.09 32.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.885 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -120.43 86.09 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.7 -122.99 30.63 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.01 -23.37 66.53 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.511 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.561 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.6 m95 -112.42 146.72 37.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.747 0.308 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -135.55 164.45 27.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.921 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.471 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 34.7 tttt -100.37 143.39 30.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.27 163.26 39.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.078 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 12.0 tt -133.9 136.89 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.116 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.6 t -70.87 129.09 38.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.69 8.64 5.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.946 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.7 m -112.6 -44.91 3.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.811 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 70.6 p -103.24 -33.65 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.79 29.44 32.04 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.48 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -92.24 123.94 35.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.793 0.33 . . . . 0.0 110.903 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -90.88 117.63 29.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.6 m -147.26 167.41 24.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.832 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.471 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.6 m-85 -110.5 115.72 30.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -123.49 151.4 63.15 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.641 0.734 . . . . 0.0 111.173 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.561 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.4 Cg_endo -69.77 134.41 27.9 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.686 2.257 . . . . 0.0 112.351 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -50.36 -28.85 15.27 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.513 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 18.2 tt -66.0 -28.0 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.8 0.334 . . . . 0.0 111.107 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 6.4 m -85.1 1.13 49.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.37 157.99 37.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.462 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -120.45 130.83 54.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.053 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -64.89 107.63 1.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.958 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.434 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 5.8 m-20 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.858 0.361 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -104.72 152.73 22.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.843 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mt -134.62 108.71 8.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.5 125.47 29.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.6 t -63.9 103.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.453 HD22 ' CB ' ' A' ' 71' ' ' ALA . 11.8 mt -62.54 -33.28 74.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.421 ' O ' ' C ' ' A' ' 25' ' ' ASP . 35.3 t -158.34 123.24 4.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.873 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.3 OUTLIER -36.36 144.55 0.05 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.841 179.993 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.601 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 148.9 11.6 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.743 . . . . 0.0 110.939 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.566 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.75 178.69 24.56 Favored 'Cis proline' 0 N--CA 1.465 -0.147 0 C-N-CA 122.713 -1.786 . . . . 0.0 112.358 -0.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -66.36 153.33 92.93 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.724 0.773 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.86 3.16 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.663 2.242 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -104.48 -23.99 13.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.847 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.23 -54.51 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.167 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.53 164.18 21.76 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.684 0.754 . . . . 0.0 110.888 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 131.54 21.48 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.72 3.79 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.664 2.242 . . . . 0.0 112.324 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -75.65 -27.56 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.527 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 8.2 m-85 -129.5 102.3 6.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -62.65 162.77 10.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.926 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.5 ttt180 -62.15 146.95 49.12 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.5 -9.75 26.81 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.498 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -73.06 131.62 42.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.916 0.389 . . . . 0.0 110.854 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 25.3 ttmt -81.52 136.48 35.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.892 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.449 HD22 ' CG ' ' A' ' 36' ' ' PHE . 13.7 mt -129.36 139.67 51.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.9 ttp-105 -90.38 129.8 36.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.434 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 99.3 t -69.46 111.77 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.153 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -87.6 -52.89 10.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 t -152.88 159.82 43.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -115.96 112.27 21.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -110.61 85.9 2.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.33 -122.16 29.17 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.14 -23.62 75.55 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.575 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -113.67 152.66 30.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.763 0.315 . . . . 0.0 110.978 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.11 164.29 28.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.92 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -101.28 139.55 36.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.88 168.7 20.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.8 tt -135.75 140.35 44.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.527 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 96.3 p -79.42 128.27 33.14 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.9 mt -78.7 9.49 4.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.888 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.0 t -104.15 -45.34 4.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.918 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.7 p -110.69 -34.83 6.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.95 24.11 25.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -87.94 128.25 35.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.799 0.333 . . . . 0.0 110.866 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -95.55 117.79 31.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 44.7 t -147.11 159.48 43.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.882 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -98.2 129.9 44.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.504 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -138.16 151.45 69.78 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.552 0.691 . . . . 0.0 111.182 179.884 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.575 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.71 132.02 22.54 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.703 2.269 . . . . 0.0 112.329 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.45 -29.77 7.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.505 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.433 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 12.3 tt -64.94 -30.87 51.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 111.118 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.4 m -77.68 -11.52 59.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 67' ' ' GLY . 19.2 m -126.71 165.58 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.089 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.453 ' CB ' HD22 ' A' ' 23' ' ' LEU . . . -124.21 130.22 52.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 tpt180 -67.12 99.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 179.945 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.502 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 41.5 m-20 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.794 0.33 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -102.97 151.2 22.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.534 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 4.7 mt -135.54 109.18 7.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.69 131.32 35.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.056 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 63.7 t -65.81 109.11 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.159 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.465 ' CD2' ' HB2' ' A' ' 71' ' ' ALA . 5.0 mt -74.52 -29.63 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 25' ' ' ASP . 29.2 t -157.02 115.52 3.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -34.99 139.96 0.08 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.588 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -156.65 148.59 17.38 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.687 0.756 . . . . 0.0 110.924 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.568 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.74 -174.67 9.79 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 -1.801 . . . . 0.0 112.358 -0.074 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.477 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 4.0 m -77.0 158.8 79.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.696 0.76 . . . . 0.0 110.857 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 5.15 1.79 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 29.4 p-10 -104.26 -27.93 11.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 7.3 mt -101.95 -53.45 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -159.47 163.82 22.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 137.71 35.97 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 124.82 11.48 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.713 2.276 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -86.89 -20.85 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.505 ' CG ' HD22 ' A' ' 42' ' ' LEU . 19.5 m-85 -134.47 87.17 2.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.887 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.402 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.2 OUTLIER -49.77 156.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.926 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.417 ' HG3' ' C ' ' A' ' 23' ' ' LEU . 2.6 ttm105 -60.68 144.03 52.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.65 -9.41 62.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.471 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -76.95 136.15 38.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 110.911 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.408 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 49.8 tttt -84.26 137.55 33.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.505 HD22 ' CG ' ' A' ' 36' ' ' PHE . 9.9 mt -131.64 150.0 52.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -105.09 128.85 53.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 91.5 t -64.35 110.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -87.79 -51.73 12.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.4 p -146.9 135.51 22.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -100.06 115.82 30.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.0 mm-40 -127.3 86.89 2.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.95 -123.41 32.6 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.49 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.39 63.06 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.593 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 32.1 m95 -113.98 123.26 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.735 0.302 . . . . 0.0 110.88 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.534 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -123.2 164.29 18.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.924 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.571 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.9 tttp -98.5 144.7 27.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.884 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.95 152.66 31.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.107 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.418 HG13 ' C ' ' A' ' 61' ' ' ARG . 12.6 tt -126.23 131.84 71.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -68.77 128.82 38.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 4.5 mt -79.22 9.37 4.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.0 t -109.26 -45.53 3.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.841 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.5 p -102.02 -39.73 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.14 32.15 9.16 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.418 ' C ' HG13 ' A' ' 55' ' ' ILE . 36.7 mtt180 -98.19 127.0 43.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.826 0.346 . . . . 0.0 110.867 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.468 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 8.4 mt-10 -93.19 117.24 29.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.861 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.2 m -147.89 168.31 22.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.571 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 30.0 m-85 -109.66 135.64 50.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.464 ' N ' HD13 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -144.36 151.37 50.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.59 0.71 . . . . 0.0 111.165 179.86 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.593 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.2 Cg_endo -69.72 133.81 26.55 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.56 -30.21 8.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.411 HG22 ' N ' ' A' ' 69' ' ' CYS . 4.6 tp -65.54 -30.45 50.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.816 0.341 . . . . 0.0 111.164 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . 0.411 ' N ' HG22 ' A' ' 68' ' ' ILE . 2.9 m -78.5 -3.84 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.463 ' N ' HD13 ' A' ' 23' ' ' LEU . 27.2 m -136.59 169.8 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.465 ' HB2' ' CD2' ' A' ' 23' ' ' LEU . . . -133.98 139.25 45.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.2 tpp85 -68.62 112.03 5.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.876 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.8 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.105 -179.994 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.499 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 10.9 m-20 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.867 0.365 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.44 152.13 21.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.522 HD23 ' CZ2' ' A' ' 52' ' ' TRP . 3.7 mt -134.78 112.3 10.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.913 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.24 119.96 24.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.055 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' A' ' 36' ' ' PHE . 98.4 t -57.27 99.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.423 HD12 ' N ' ' A' ' 70' ' ' VAL . 7.4 mt -59.34 -23.44 62.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 47.2 t -169.76 133.67 1.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.835 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.28 146.54 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.868 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.651 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -164.75 149.95 8.5 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.702 0.763 . . . . 0.0 110.913 -179.826 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.558 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.75 -174.69 9.83 Favored 'Cis proline' 0 C--N 1.342 0.201 0 C-N-CA 122.711 -1.787 . . . . 0.0 112.377 -0.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.463 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 44.2 m -72.29 154.58 91.99 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.641 0.734 . . . . 0.0 110.878 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 3.52 2.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.679 2.253 . . . . 0.0 112.357 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.463 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 23.6 p-10 -109.39 -17.03 13.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -109.44 -46.43 6.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -164.77 163.17 14.44 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.672 0.749 . . . . 0.0 110.821 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 131.67 21.66 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 124.74 11.37 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.377 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.422 HG23 ' CD ' ' A' ' 61' ' ' ARG . 1.6 mp -89.22 -24.38 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.155 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.511 ' CG ' HD22 ' A' ' 42' ' ' LEU . 14.4 m-85 -130.98 103.02 6.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -64.22 160.34 18.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.6 ttp85 -58.37 149.4 24.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.928 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.75 -9.71 22.04 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -71.13 154.12 41.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.902 0.382 . . . . 0.0 110.904 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 7.9 tttp -107.16 140.24 40.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.914 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.511 HD22 ' CG ' ' A' ' 36' ' ' PHE . 2.3 mt -136.85 135.26 37.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -86.48 131.02 34.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 60.5 t -66.99 108.8 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.459 HD11 ' CG2' ' A' ' 55' ' ' ILE . 1.0 OUTLIER -87.74 -52.36 11.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -143.82 155.03 43.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -119.49 113.05 20.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -117.31 86.39 2.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.4 -123.6 33.87 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.39 -21.07 78.22 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.486 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -113.26 144.74 42.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.724 0.297 . . . . 0.0 110.941 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.522 ' CZ2' HD23 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.83 164.46 27.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.92 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.532 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 28.9 tttt -101.04 141.04 34.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.906 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.17 162.57 39.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CG2' HD11 ' A' ' 45' ' ' ILE . 16.4 tt -134.67 134.55 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -69.8 128.28 35.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.843 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 2.0 mt -78.78 2.68 19.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.89 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.3 m -99.41 -47.81 5.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.3 p -105.33 -37.35 6.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.142 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.85 29.34 9.94 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.422 ' CD ' HG23 ' A' ' 35' ' ' ILE . 33.7 mtt180 -90.04 127.8 36.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.873 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -97.86 118.0 33.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.1 t -147.02 167.38 24.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.532 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 14.8 m-85 -110.07 114.33 27.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.404 ' H ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.91 151.18 60.64 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.63 0.729 . . . . 0.0 111.164 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.568 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 54.2 Cg_endo -69.78 133.88 26.59 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.673 2.249 . . . . 0.0 112.341 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.44 -30.26 5.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 tp -65.09 -32.47 58.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.801 0.334 . . . . 0.0 111.116 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 8.0 m -78.91 -4.82 51.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.423 ' N ' HD12 ' A' ' 23' ' ' LEU . 32.4 m -132.56 166.08 30.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.407 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -130.53 129.45 42.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.069 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.95 107.6 1.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.859 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.099 179.987 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.468 ' CB ' HG22 ' A' ' 44' ' ' VAL . 85.7 m-20 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.827 0.346 . . . . 0.0 110.883 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -111.17 150.15 29.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.562 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 9.3 mt -133.38 114.08 13.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.42 127.12 32.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.08 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 95.8 t -65.04 98.6 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.149 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.452 HD22 ' CB ' ' A' ' 71' ' ' ALA . 8.6 mt -59.71 -31.49 69.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.931 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.7 t -161.3 127.95 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.77 138.98 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.647 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.72 150.12 17.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.695 0.76 . . . . 0.0 110.936 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.557 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -175.28 10.64 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.695 -1.794 . . . . 0.0 112.337 -0.048 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 3.1 m -76.28 158.29 81.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -102.07 -22.39 14.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 mt -109.25 -54.99 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -155.3 163.44 24.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.615 0.721 . . . . 0.0 110.888 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 137.81 36.43 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 119.04 6.05 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.679 2.252 . . . . 0.0 112.371 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -83.06 -25.71 8.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.128 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.516 ' CG ' HD23 ' A' ' 42' ' ' LEU . 13.3 m-85 -131.4 96.24 3.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.0 mmm-85 -56.41 158.38 4.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 52.1 ttt-85 -61.08 144.5 53.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.62 -14.46 35.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -72.75 136.54 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.5 ttmt -87.02 137.84 32.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.516 HD23 ' CG ' ' A' ' 36' ' ' PHE . 10.4 mt -132.17 140.6 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.919 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -91.12 134.49 34.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.468 HG22 ' CB ' ' A' ' 18' ' ' ASP . 97.6 t -71.43 112.11 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -86.05 -46.32 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -155.56 147.75 23.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.46 116.07 31.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.902 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -122.35 85.91 2.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.12 -120.7 23.89 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.33 -23.08 59.4 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.438 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.562 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 21.9 m95 -111.68 137.9 48.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.79 0.329 . . . . 0.0 110.88 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.562 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.3 164.83 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.578 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.4 tttp -101.49 141.95 33.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.911 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.13 168.34 22.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 21.3 tt -138.39 142.45 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.113 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.5 p -76.82 133.49 39.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.6 mt -82.96 8.86 11.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.2 t -104.78 -42.77 5.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -113.56 -44.57 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.103 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 103.35 27.88 6.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -84.19 122.04 28.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 110.853 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.47 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 5.6 mt-10 -92.09 117.48 29.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.0 t -147.44 169.61 19.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.905 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.578 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 7.1 m-85 -112.1 118.09 34.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -125.5 151.26 69.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.656 0.741 . . . . 0.0 111.153 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.562 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.0 Cg_endo -69.79 132.67 23.75 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.704 2.27 . . . . 0.0 112.312 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.45 -33.5 5.99 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 12.8 tt -61.81 -33.39 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.359 . . . . 0.0 111.177 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.1 -15.92 61.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.406 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 35.7 m -125.47 175.86 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.452 ' CB ' HD22 ' A' ' 23' ' ' LEU . . . -136.72 134.5 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -66.32 102.44 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 179.964 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.413 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 14.1 m-20 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.799 0.333 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -108.79 154.42 22.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.98 111.68 7.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.881 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.12 122.81 28.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.092 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 92.2 t -55.33 104.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.428 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 8.6 mt -65.74 -33.81 76.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.7 t -155.35 128.95 8.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -39.43 146.55 0.09 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.605 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.77 148.82 6.73 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.659 0.742 . . . . 0.0 110.944 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.568 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.83 -174.27 9.44 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 -1.796 . . . . 0.0 112.295 0.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.9 m -70.57 153.77 94.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.656 0.741 . . . . 0.0 110.873 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 1.21 4.59 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.676 2.251 . . . . 0.0 112.37 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -106.26 -18.37 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -107.29 -54.03 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.16 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.4 m -155.71 162.63 26.97 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 134.37 27.82 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.327 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 120.87 7.59 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.724 2.282 . . . . 0.0 112.314 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mp -85.6 -30.45 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.51 ' CG ' HD23 ' A' ' 42' ' ' LEU . 11.8 m-85 -124.0 90.82 3.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -51.07 161.16 0.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.896 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 16.2 ttt-85 -66.17 144.15 56.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.35 -9.89 65.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.403 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -83.09 132.64 35.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 110.906 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.446 ' CD ' HG21 ' A' ' 73' ' ' VAL . 19.5 ttpt -88.99 143.74 26.65 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 36' ' ' PHE . 0.4 OUTLIER -135.0 141.25 46.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.89 179.94 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 35.8 ttt180 -85.64 127.57 34.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.413 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 84.5 t -64.46 111.37 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.48 ' CG2' ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -78.62 -54.7 11.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.094 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.1 t -155.58 150.85 26.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.846 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -102.26 121.99 43.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.923 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 44.5 mm-40 -126.5 86.15 2.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.907 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.44 -121.5 24.24 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -85.08 -18.57 60.75 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.529 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.579 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.5 m95 -115.71 140.09 49.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.71 0.291 . . . . 0.0 110.937 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -132.79 164.44 26.82 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.878 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.542 ' HE3' ' CE2' ' A' ' 64' ' ' TYR . 3.7 ttmt -101.58 151.56 21.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -159.11 150.1 19.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 18.4 tt -116.34 144.34 24.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.13 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.408 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 6.7 m -73.59 130.6 40.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.5 mt -78.21 9.71 3.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 t -116.92 -52.79 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.828 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.411 ' HG1' ' N ' ' A' ' 60' ' ' GLY . 48.2 p -95.9 -34.56 11.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.411 ' N ' ' HG1' ' A' ' 59' ' ' THR . . . 86.85 31.57 17.55 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.496 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.0 mtt180 -91.37 122.1 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -91.9 117.76 30.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.418 ' HB3' ' CE2' ' A' ' 36' ' ' PHE . 18.4 t -147.32 169.51 19.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.542 ' CE2' ' HE3' ' A' ' 53' ' ' LYS . 4.2 m-85 -110.26 122.34 47.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.468 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.21 151.47 78.42 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.597 0.713 . . . . 0.0 111.113 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.579 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.3 Cg_endo -69.8 131.87 22.08 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.7 2.267 . . . . 0.0 112.279 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.408 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.78 -30.57 4.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.476 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.3 tt -64.72 -33.33 62.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 0.0 111.11 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 7.4 m -78.05 -7.58 57.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 67' ' ' GLY . 33.8 m -128.69 164.98 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.428 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -131.44 134.88 46.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.7 tpp180 -61.41 110.14 1.36 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.831 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.446 HG21 ' CD ' ' A' ' 41' ' ' LYS . 2.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.174 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.466 ' CB ' HG22 ' A' ' 44' ' ' VAL . 1.5 m-20 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.811 0.338 . . . . 0.0 110.866 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -112.14 150.68 30.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.48 HD21 ' CZ2' ' A' ' 52' ' ' TRP . 7.2 mt -134.83 110.66 9.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.912 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.39 122.06 27.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -58.53 100.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.457 ' CD1' ' O ' ' A' ' 70' ' ' VAL . 7.8 mt -59.94 -36.14 76.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.936 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.6 t -155.97 127.08 7.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.874 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.21 135.09 1.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.645 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.08 149.6 23.73 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.716 0.77 . . . . 0.0 110.887 -179.807 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.546 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.82 -178.67 17.33 Favored 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.371 -0.023 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 59.6 m -68.36 153.44 95.6 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.652 0.739 . . . . 0.0 110.861 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 2.46 3.52 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.344 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.61 -10.09 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -118.44 -52.14 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -156.45 162.15 28.09 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 0.0 110.805 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 134.2 27.35 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . 0.46 ' HG2' ' CZ ' ' A' ' 37' ' ' ARG . 53.9 Cg_endo -69.71 114.09 3.58 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -74.57 -30.46 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.136 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.443 ' CE2' ' OG ' ' A' ' 63' ' ' SER . 14.8 m-85 -130.99 94.95 3.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.46 ' CZ ' ' HG2' ' A' ' 34' ' ' PRO . 20.4 mmt180 -53.89 160.24 1.49 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -62.73 151.99 36.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.58 -18.02 7.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.405 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -71.43 132.37 44.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.871 0.367 . . . . 0.0 110.903 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 25.6 ttmt -85.41 135.73 33.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.3 mt -128.14 148.41 50.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.873 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -98.62 130.51 45.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.878 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 18' ' ' ASP . 57.6 t -68.58 114.17 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.125 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -90.4 -53.46 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.147 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 t -146.45 154.15 41.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.847 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -120.04 119.07 32.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -127.62 98.9 5.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.15 -130.43 50.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.65 9.0 63.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.531 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -137.07 140.39 41.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 110.926 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.48 ' CZ2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.77 164.64 26.78 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.918 179.995 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.562 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 16.1 tttp -104.09 147.03 27.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.904 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.6 159.77 42.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.131 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.3 tt -126.39 141.71 45.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 20.1 p -78.25 129.87 35.58 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.7 mt -80.51 9.26 6.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.966 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -99.24 -49.4 4.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.812 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.2 p -112.77 -39.69 4.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.097 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.74 27.52 5.7 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.437 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -83.08 128.07 34.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.761 0.315 . . . . 0.0 110.862 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.478 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 8.1 mt-10 -102.02 117.27 34.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.443 ' OG ' ' CE2' ' A' ' 36' ' ' PHE . 1.8 p -147.58 169.27 19.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.562 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 24.8 m-85 -110.08 118.98 37.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -125.69 150.01 67.07 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.654 0.74 . . . . 0.0 111.081 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.565 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.77 134.03 26.97 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.308 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.99 -31.13 5.51 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.482 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.7 tp -64.84 -32.74 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.806 0.336 . . . . 0.0 111.113 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 11.6 m -80.35 2.85 23.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.457 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 33.4 m -140.52 170.63 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.35 125.99 32.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.075 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 -65.74 108.19 2.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.119 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.438 ' OD2' ' NH2' ' A' ' 72' ' ' ARG . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.825 0.345 . . . . 0.0 110.887 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -108.63 145.02 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.56 HD21 ' CH2' ' A' ' 52' ' ' TRP . 1.7 mt -134.49 110.56 9.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.63 127.09 31.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.103 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.7 t -61.75 101.36 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.1 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.464 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 8.6 mt -61.92 -31.01 71.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -160.21 128.17 4.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -40.12 140.82 0.54 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.844 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.615 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -158.94 149.18 15.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.687 0.756 . . . . 0.0 110.914 -179.848 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.569 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.3 Cg_endo -69.8 -174.52 9.7 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.34 -0.064 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -73.22 154.09 90.37 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 1.63 4.29 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.655 2.236 . . . . 0.0 112.369 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -105.86 -14.69 15.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.81 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -113.05 -51.96 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 m -158.34 162.26 27.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 133.99 26.88 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.699 2.266 . . . . 0.0 112.339 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 124.08 10.72 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.75 2.3 . . . . 0.0 112.307 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -86.84 -25.28 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.146 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.529 ' CG ' HD21 ' A' ' 42' ' ' LEU . 10.3 m-85 -130.97 93.92 3.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -56.29 150.16 15.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 39.9 ttp85 -50.76 147.56 4.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.05 -17.84 8.87 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -68.04 138.37 55.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.926 0.394 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.5 ttmp? -89.94 143.12 27.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.529 HD21 ' CG ' ' A' ' 36' ' ' PHE . 1.7 mt -139.41 142.4 37.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.951 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.3 ttt180 -95.45 132.03 40.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.864 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.47 HG21 ' CD1' ' A' ' 20' ' ' LEU . 95.8 t -68.0 112.63 3.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.096 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.459 HD13 ' CG2' ' A' ' 55' ' ' ILE . 1.1 mp -91.39 -53.28 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 m -137.66 143.07 41.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.09 115.01 28.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.865 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -126.68 85.97 2.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.893 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.1 -125.36 38.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.81 -19.07 73.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.49 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.579 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 24.3 m95 -113.39 131.87 55.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.56 ' CH2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -131.94 164.35 26.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.918 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.558 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.0 tttp -99.95 144.16 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.894 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.0 160.33 44.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.07 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CG2' HD13 ' A' ' 45' ' ' ILE . 20.4 tt -130.55 139.66 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.078 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.1 m -72.37 129.41 38.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.857 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.0 mt -79.15 5.66 11.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.1 t -106.03 -51.08 3.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.7 p -99.31 -44.24 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.185 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 100.95 26.76 7.75 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.518 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 64.5 mtt180 -86.19 128.19 34.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.448 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 12.9 mt-10 -98.21 117.45 32.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.1 t -147.34 169.38 19.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 9.2 m-85 -112.63 114.79 27.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.405 ' CD1' ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.53 150.76 58.6 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 111.138 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.579 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.81 135.99 31.75 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.637 2.225 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.9 -36.86 20.9 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.539 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.464 HG22 ' N ' ' A' ' 69' ' ' CYS . 8.3 tt -59.96 -26.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.808 0.337 . . . . 0.0 111.071 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . 0.464 ' N ' HG22 ' A' ' 68' ' ' ILE . 1.7 m -82.56 -7.6 59.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.8 m -131.22 164.45 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.149 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.464 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -125.93 133.31 51.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.092 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.438 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.2 tpt180 -61.0 97.72 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 3.8 t . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.144 179.944 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.432 ' CB ' HG22 ' A' ' 44' ' ' VAL . 28.1 m-20 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.839 0.352 . . . . 0.0 110.86 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -107.24 150.04 27.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 7.3 mt -132.56 121.31 23.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -92.09 119.54 31.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.063 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.462 ' CG2' HD13 ' A' ' 42' ' ' LEU . 96.2 t -59.11 96.67 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.16 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.493 ' CD1' ' O ' ' A' ' 68' ' ' ILE . 7.7 mt -54.95 -35.32 64.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.929 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 t -157.46 128.65 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.841 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.69 137.98 1.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.881 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.609 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -155.18 148.55 18.48 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.685 0.755 . . . . 0.0 110.918 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.548 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.4 Cg_endo -69.71 -173.98 9.0 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.379 -0.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 6.1 m -74.67 155.51 87.15 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.689 0.757 . . . . 0.0 110.843 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 3.44 2.79 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.658 2.238 . . . . 0.0 112.379 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -107.77 -18.22 13.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -109.18 -47.92 7.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.0 OUTLIER -164.1 163.58 15.25 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.644 0.735 . . . . 0.0 110.864 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 132.24 22.87 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.675 2.25 . . . . 0.0 112.309 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 118.24 5.57 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.649 2.233 . . . . 0.0 112.306 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.31 -28.42 13.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.091 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.507 ' CG ' HD23 ' A' ' 42' ' ' LEU . 16.8 m-85 -127.3 98.42 5.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.65 160.38 4.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.854 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -62.22 144.61 55.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.23 -11.43 23.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.461 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -71.25 130.56 41.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.869 0.366 . . . . 0.0 110.896 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -81.46 137.02 35.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.507 HD23 ' CG ' ' A' ' 36' ' ' PHE . 4.4 mt -133.16 139.78 47.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttt180 -90.19 130.66 36.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.831 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.432 HG22 ' CB ' ' A' ' 18' ' ' ASP . 57.3 t -66.89 110.66 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.481 ' CG2' ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -80.19 -54.97 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.124 179.896 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 70.9 m -157.32 147.46 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -98.58 115.47 28.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 35.5 mt-10 -113.99 85.78 2.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.72 -122.99 30.58 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -77.77 -22.58 69.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.473 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 10.1 m95 -113.92 150.51 33.62 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.754 0.312 . . . . 0.0 110.915 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.428 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -136.08 164.2 28.57 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.949 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.53 ' HE2' ' CE2' ' A' ' 64' ' ' TYR . 4.7 ttmm -103.22 150.83 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.937 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -158.91 143.77 15.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.072 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.2 tt -108.1 144.62 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.1 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 p -83.68 130.27 34.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.0 mt -77.21 7.94 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.3 t -95.18 -51.96 4.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.843 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.8 p -111.29 -43.16 3.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.144 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.69 26.45 5.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -86.27 127.72 34.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.763 0.316 . . . . 0.0 110.857 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -99.15 118.11 35.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 9.0 t -147.11 167.75 23.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.53 ' CE2' ' HE2' ' A' ' 53' ' ' LYS . 4.3 m-85 -105.96 129.42 54.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.942 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.478 HD11 ' N ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -135.16 150.97 74.3 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.594 0.711 . . . . 0.0 111.125 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.563 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.9 Cg_endo -69.74 133.21 25.06 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.732 2.288 . . . . 0.0 112.332 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.59 -30.02 8.17 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.465 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.493 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 13.5 tt -65.5 -30.12 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.834 0.349 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . 0.433 ' N ' HG21 ' A' ' 68' ' ' ILE . 4.8 m -80.36 -5.72 56.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.461 ' N ' HD12 ' A' ' 23' ' ' LEU . 34.9 m -135.03 171.35 17.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.465 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -134.64 132.43 38.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.076 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -69.3 106.79 3.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.857 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.6 t . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.432 ' CB ' HG22 ' A' ' 44' ' ' VAL . 60.7 m-20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.823 0.344 . . . . 0.0 110.858 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -101.62 143.68 31.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.921 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.558 HD22 ' CH2' ' A' ' 52' ' ' TRP . 11.0 mt -130.45 108.76 10.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.06 122.92 28.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.063 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 57.3 t -58.86 103.62 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.12 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.47 HD21 ' CB ' ' A' ' 71' ' ' ALA . 11.5 mt -67.17 -33.42 75.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 25' ' ' ASP . 27.6 t -153.64 121.85 6.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.834 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -37.03 149.38 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.875 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.646 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -169.82 150.52 3.85 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.685 0.755 . . . . 0.0 110.922 -179.85 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.576 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.3 10.69 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.304 -0.059 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 48.0 m -74.74 155.06 87.22 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.662 0.744 . . . . 0.0 110.855 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 3.42 2.76 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.716 2.277 . . . . 0.0 112.359 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -105.27 -22.33 13.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.843 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.7 mt -105.77 -48.59 8.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.7 OUTLIER -164.11 164.67 14.14 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.682 0.753 . . . . 0.0 110.836 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 135.62 30.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.642 2.228 . . . . 0.0 112.35 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 125.24 11.88 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.298 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -86.6 -26.4 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.524 ' CG ' HD23 ' A' ' 42' ' ' LEU . 10.5 m-85 -131.9 100.58 5.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -63.28 155.25 29.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.814 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -55.21 150.35 11.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.807 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.3 -10.36 16.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -72.4 151.52 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.868 0.366 . . . . 0.0 110.906 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.2 tttt -102.26 138.76 38.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.928 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.524 HD23 ' CG ' ' A' ' 36' ' ' PHE . 5.6 mt -135.12 152.52 51.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.927 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.4 ttt180 -105.1 129.65 53.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.87 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.432 HG22 ' CB ' ' A' ' 18' ' ' ASP . 99.1 t -65.19 111.82 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.406 HD11 ' CG2' ' A' ' 55' ' ' ILE . 1.0 OUTLIER -93.19 -52.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.161 179.882 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.8 m -141.15 150.96 43.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -118.43 109.82 16.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.875 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -116.31 86.0 2.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.75 -123.27 32.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.64 -23.51 69.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.48 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.572 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.3 m95 -109.91 141.93 41.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.558 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.15 164.27 28.05 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.563 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.2 tttp -100.75 141.51 33.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.905 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.46 159.75 44.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.455 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -131.81 130.82 61.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 t -67.82 130.88 44.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.69 9.4 5.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.946 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 15.1 t -105.55 -48.01 3.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.2 p -104.41 -35.79 7.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.45 27.84 18.87 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.496 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.418 ' C ' HG13 ' A' ' 55' ' ' ILE . 44.0 mtt85 -89.25 124.98 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.797 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.475 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 5.0 mt-10 -94.31 117.33 29.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.943 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.2 t -147.6 169.63 19.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.824 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 28.3 m-85 -110.96 118.13 35.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.55 HG22 ' CD1' ' A' ' 26' ' ' TYR . 0.2 OUTLIER -126.19 152.54 73.66 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.593 0.711 . . . . 0.0 111.146 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.572 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.77 137.66 35.97 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.679 2.252 . . . . 0.0 112.351 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.81 -33.23 6.39 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.5 tp -64.88 -31.11 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 111.162 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.1 t -72.87 -12.77 61.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 20' ' ' LEU . 18.4 m -131.04 170.21 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.47 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -133.48 136.45 45.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -67.94 108.37 3.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.141 179.961 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.46 ' CB ' HG22 ' A' ' 44' ' ' VAL . 73.3 m-20 . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.829 0.347 . . . . 0.0 110.883 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -111.77 152.63 27.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.506 HD12 ' CE2' ' A' ' 52' ' ' TRP . 7.7 mt -137.43 116.03 12.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.57 127.52 33.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.469 ' CG2' HD13 ' A' ' 42' ' ' LEU . 84.4 t -66.85 97.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.454 HD21 ' CB ' ' A' ' 71' ' ' ALA . 9.4 mt -57.19 -35.93 70.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.5 t -156.38 128.2 7.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.898 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -39.1 149.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.639 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -170.61 150.05 3.14 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.729 0.776 . . . . 0.0 110.911 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.553 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.7 -174.7 9.79 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.717 -1.785 . . . . 0.0 112.355 -0.098 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.6 m -80.35 158.46 71.65 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.874 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 3.52 2.75 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.649 2.232 . . . . 0.0 112.321 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -103.89 -13.22 16.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.3 mt -119.95 -49.34 3.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.101 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -162.83 163.46 17.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.717 0.77 . . . . 0.0 110.843 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 133.56 25.8 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.676 2.251 . . . . 0.0 112.353 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 114.74 3.81 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.313 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 mp -73.45 -30.52 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.57 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.3 m-85 -130.66 110.83 11.67 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.92 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -69.56 165.79 20.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.443 ' CG ' ' O ' ' A' ' 23' ' ' LEU . 2.4 tmt_? -67.22 141.14 57.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.46 11.52 81.85 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.486 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.4 ' OE1' ' O ' ' A' ' 41' ' ' LYS . 0.4 OUTLIER -100.35 138.22 37.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.976 0.417 . . . . 0.0 110.843 -179.857 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.4 ' O ' ' OE1' ' A' ' 40' ' ' GLU . 30.2 ttmt -85.54 140.63 30.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.469 HD13 ' CG2' ' A' ' 22' ' ' VAL . 10.1 mt -134.2 149.69 51.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 29.7 ttt180 -103.89 129.15 51.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.46 HG22 ' CB ' ' A' ' 18' ' ' ASP . 45.8 t -67.97 114.82 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.095 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -88.8 -52.58 10.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.9 t -157.53 128.32 6.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -89.15 125.95 35.26 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -125.06 85.96 2.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.898 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.68 -128.08 37.49 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.8 -24.99 75.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 13.2 m95 -112.69 146.55 38.51 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.786 0.327 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.506 ' CE2' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.98 164.84 26.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.992 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.575 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.0 tttp -103.37 145.15 30.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.45 163.72 38.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.458 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 21.0 tt -131.19 135.21 60.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.57 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 37.4 p -76.23 129.09 36.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.8 mt -77.59 9.28 3.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.1 m -95.92 -49.74 5.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 12.2 p -114.75 -28.92 6.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.143 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.11 26.48 18.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.508 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 23.7 mtt85 -83.12 128.08 34.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.756 0.312 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.458 ' HG3' ' CD1' ' A' ' 55' ' ' ILE . 10.1 mt-10 -97.66 117.26 31.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.4 t -147.55 170.11 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.575 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 10.6 m-85 -110.78 123.62 50.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.467 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -130.2 150.64 76.66 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.669 0.747 . . . . 0.0 111.134 179.909 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.574 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.9 Cg_endo -69.73 130.67 19.78 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.675 2.25 . . . . 0.0 112.374 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.13 -36.21 7.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 6.3 tt -58.9 -33.55 50.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 111.111 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' GLY . 25.5 m -125.13 174.04 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.454 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -134.21 132.15 39.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.115 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.452 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.1 tpp85 -62.77 105.66 0.69 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.83 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.0 t . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.138 179.96 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.499 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.873 0.368 . . . . 0.0 110.829 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.78 150.68 22.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.525 HD21 ' CZ2' ' A' ' 52' ' ' TRP . 10.0 mt -132.91 111.03 10.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.926 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.46 126.33 31.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.2 96.25 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.165 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 7.9 mt -59.13 -28.84 66.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.916 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.7 t -161.27 125.67 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.838 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -38.79 143.48 0.15 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.859 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -160.28 150.32 14.81 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.67 0.747 . . . . 0.0 110.917 -179.811 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.566 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.77 171.49 53.48 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.684 -1.798 . . . . 0.0 112.381 -0.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.17 148.38 11.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.634 0.731 . . . . 0.0 110.852 -179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 5.28 1.76 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.7 2.267 . . . . 0.0 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -109.01 -21.75 12.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -101.65 -53.43 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.097 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.51 164.28 21.03 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.669 0.747 . . . . 0.0 110.832 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 132.16 22.84 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.27 . . . . 0.0 112.364 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 124.42 11.06 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.666 2.244 . . . . 0.0 112.366 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mp -89.25 -25.31 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.165 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.565 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.6 m-85 -127.47 89.65 2.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.885 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 20.3 mmm-85 -51.01 160.11 0.52 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.449 ' CZ ' ' O ' ' A' ' 23' ' ' LEU . 11.1 ttt85 -61.58 147.22 46.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.97 -13.3 14.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -69.7 136.5 51.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.895 0.379 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -86.63 139.06 31.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.869 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.505 HD23 ' CG ' ' A' ' 36' ' ' PHE . 8.1 mt -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.7 ttt-85 -87.53 132.94 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 58.2 t -71.22 108.2 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -78.56 -50.15 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.177 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -158.71 157.43 31.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -109.1 118.85 37.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.877 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.8 mm-40 -120.44 85.92 2.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.47 -126.02 38.71 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.1 -25.0 74.63 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.554 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.4 m0 -111.69 153.53 26.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.765 0.317 . . . . 0.0 110.923 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.525 ' CZ2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.04 164.13 28.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.561 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.8 tttm -98.94 143.07 29.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.895 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.94 164.08 39.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.416 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 19.3 tt -132.02 146.15 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.115 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.565 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 82.0 p -86.21 126.44 34.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.6 mt -76.09 5.92 6.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.6 t -90.6 -49.84 6.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.6 p -116.28 -34.7 4.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.14 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.46 23.89 8.65 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.457 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.9 mtt180 -82.08 124.51 29.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.846 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.418 ' HB3' ' NZ ' ' A' ' 53' ' ' LYS . 8.1 mt-10 -98.87 118.55 35.88 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.5 t -147.23 169.97 18.25 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.1 m-85 -105.05 119.79 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.437 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.42 147.52 60.51 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.663 0.744 . . . . 0.0 111.09 179.904 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.554 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.78 133.77 26.34 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.694 2.262 . . . . 0.0 112.345 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.33 -30.88 6.13 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.503 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.8 tp -64.68 -32.69 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 9.4 m -80.01 6.94 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.416 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 36.0 m -147.56 169.81 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.459 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -134.2 136.08 43.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.136 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.437 ' NH1' ' OD2' ' A' ' 18' ' ' ASP . 2.9 tpp85 -68.13 112.44 5.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.951 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.434 ' CB ' HG22 ' A' ' 44' ' ' VAL . 2.6 m-20 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.861 0.363 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -105.29 148.95 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.4 mt -135.87 109.53 8.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.08 126.15 30.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.466 HG23 ' CD1' ' A' ' 42' ' ' LEU . 84.0 t -60.8 101.6 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.432 HD23 ' CB ' ' A' ' 71' ' ' ALA . 16.2 mt -62.13 -30.84 71.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.3 t -158.4 127.54 5.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -40.72 145.52 0.19 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.837 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.581 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.9 148.43 6.43 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.636 0.732 . . . . 0.0 110.959 -179.849 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.558 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.81 -174.12 9.26 Favored 'Cis proline' 0 C--O 1.231 0.154 0 C-N-CA 122.708 -1.788 . . . . 0.0 112.331 -0.036 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.5 m -77.06 155.83 82.38 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.651 0.739 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 2.78 3.23 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.676 2.251 . . . . 0.0 112.346 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -106.71 -14.04 15.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.02 -48.66 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -163.58 163.04 16.74 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.675 0.75 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 133.03 24.56 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.719 2.28 . . . . 0.0 112.316 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 119.7 6.6 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -81.02 -22.81 10.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.51 ' CG ' HD23 ' A' ' 42' ' ' LEU . 13.6 m-85 -134.66 99.77 4.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.881 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -58.65 163.9 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.442 ' HD3' ' N ' ' A' ' 39' ' ' GLY . 3.8 tmt_? -65.69 142.44 58.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.826 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.442 ' N ' ' HD3' ' A' ' 38' ' ' ARG . . . 77.96 6.81 87.5 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -86.36 144.0 27.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.464 ' CG ' HD13 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -87.29 141.1 28.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 36' ' ' PHE . 4.8 mt -140.0 145.1 37.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -103.78 128.48 51.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.434 HG22 ' CB ' ' A' ' 18' ' ' ASP . 59.5 t -65.87 108.53 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.147 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.422 ' CG2' ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -79.87 -50.51 17.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.125 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.4 t -163.14 135.83 5.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -89.45 129.3 35.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -130.05 86.2 2.38 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 65.29 -131.46 35.58 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.509 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.42 -20.36 78.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.467 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.57 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -116.89 152.12 35.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.741 0.305 . . . . 0.0 110.923 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.18 164.23 28.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.56 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 19.3 tttp -102.17 142.53 33.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.953 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.54 156.14 36.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.135 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.404 HG13 ' C ' ' A' ' 61' ' ' ARG . 19.6 tt -124.08 137.17 57.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.1 t -68.04 128.16 35.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.865 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.464 HD13 ' CG ' ' A' ' 41' ' ' LYS . 6.4 mt -78.32 8.39 5.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.6 t -111.65 -45.98 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.862 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.416 ' HG1' ' N ' ' A' ' 60' ' ' GLY . 51.4 p -102.14 -36.14 8.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.135 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.416 ' N ' ' HG1' ' A' ' 59' ' ' THR . . . 86.58 33.13 13.93 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.469 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.404 ' C ' HG13 ' A' ' 55' ' ' ILE . 42.7 mtt180 -96.8 125.96 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.761 0.315 . . . . 0.0 110.89 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -90.66 117.43 29.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.6 t -147.66 169.99 18.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.812 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.56 ' CE1' ' HG3' ' A' ' 53' ' ' LYS . 18.9 m-85 -112.75 117.37 32.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.889 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -126.78 151.12 73.1 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.629 0.728 . . . . 0.0 111.123 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.57 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.83 135.76 31.09 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.661 2.241 . . . . 0.0 112.331 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.17 -30.95 8.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 69' ' ' CYS . 6.7 tp -65.55 -30.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.831 0.348 . . . . 0.0 111.162 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . 0.463 ' N ' HG22 ' A' ' 68' ' ' ILE . 4.4 m -79.78 -0.19 33.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.99 163.11 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.432 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -128.2 137.48 52.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.063 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.33 112.19 2.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.851 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.139 179.972 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.437 ' CB ' HG22 ' A' ' 44' ' ' VAL . 3.9 m-20 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.805 0.336 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -109.89 150.8 27.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.556 HD23 ' CZ2' ' A' ' 52' ' ' TRP . 5.3 mt -129.64 114.47 16.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.22 116.73 23.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 95.2 t -54.92 103.65 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.114 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.467 HD13 ' N ' ' A' ' 70' ' ' VAL . 8.6 mt -66.53 -31.0 71.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 25' ' ' ASP . 30.6 t -160.33 118.79 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.859 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 24' ' ' SER . 10.4 p-10 -34.28 140.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.644 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.14 149.81 18.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.69 0.757 . . . . 0.0 110.923 -179.801 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.56 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.85 179.54 22.2 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.319 -0.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 p -72.46 157.2 89.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.05 2.41 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.677 2.252 . . . . 0.0 112.316 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -101.28 -13.18 18.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.839 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 4.8 mt -120.53 -60.6 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -147.96 163.07 28.82 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.651 0.738 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 137.36 35.06 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.681 2.254 . . . . 0.0 112.323 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 118.96 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.424 HG22 ' CD ' ' A' ' 61' ' ' ARG . 2.4 mp -80.86 -26.19 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.525 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 13.6 m-85 -131.32 93.55 3.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -54.8 161.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.8 ttm180 -62.06 147.79 46.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.96 -5.85 57.45 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -79.85 134.42 36.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.924 0.392 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -84.33 138.06 33.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.522 HD21 ' CG ' ' A' ' 36' ' ' PHE . 9.0 mt -130.56 141.32 50.46 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.3 ttp180 -93.18 126.73 38.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.437 HG22 ' CB ' ' A' ' 18' ' ' ASP . 96.1 t -66.05 112.16 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -88.27 -53.3 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.15 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -144.45 145.31 31.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.838 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -108.68 118.41 36.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -129.4 86.44 2.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.881 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.26 -123.78 33.99 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.05 -19.03 65.93 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 25.3 m95 -113.42 131.56 55.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.752 0.311 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.556 ' CZ2' HD23 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.44 164.36 26.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.956 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.572 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 8.3 tttp -100.2 142.27 31.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -150.78 157.83 43.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.112 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 19.0 tt -121.78 145.26 28.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.525 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 6.1 p -86.75 126.0 34.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 8.0 mt -75.14 5.75 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 t -92.01 -48.83 6.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.9 p -118.11 -28.69 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.85 25.92 13.94 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.48 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.424 ' CD ' HG22 ' A' ' 35' ' ' ILE . 76.6 mtt180 -80.86 132.29 35.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.306 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.439 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 4.9 mt-10 -103.29 117.38 34.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.866 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.0 t -147.67 170.18 18.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.572 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 38.5 m-85 -110.55 120.8 43.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.909 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.405 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.13 149.69 70.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.56 0.695 . . . . 0.0 111.174 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.574 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.72 134.58 28.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.67 2.247 . . . . 0.0 112.382 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.81 -30.33 8.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 69' ' ' CYS . 6.5 tp -65.36 -30.1 49.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.802 0.334 . . . . 0.0 111.152 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . 0.444 ' N ' HG22 ' A' ' 68' ' ' ILE . 16.6 m -84.19 8.23 16.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.467 ' N ' HD13 ' A' ' 23' ' ' LEU . 22.9 m -148.95 168.9 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.461 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -131.62 131.98 43.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -68.92 112.18 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.885 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.164 179.956 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.7 t0 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.896 0.379 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -109.11 144.87 36.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.493 HD22 ' CH2' ' A' ' 52' ' ' TRP . 4.2 mt -131.05 112.07 12.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.61 126.38 30.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.144 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.424 ' CG2' HD13 ' A' ' 42' ' ' LEU . 95.4 t -66.52 102.44 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.461 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 4.7 mt -61.84 -32.16 72.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.906 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.3 t -156.23 125.24 6.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.846 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -41.47 148.09 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.57 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -167.37 148.42 5.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.778 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.563 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.76 -174.36 9.47 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.323 -0.081 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.9 m -81.59 158.57 68.34 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.69 0.757 . . . . 0.0 110.85 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 3.17 2.95 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.668 2.245 . . . . 0.0 112.324 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -107.16 -6.15 17.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.39 -43.17 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.151 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.2 m -170.92 163.32 5.43 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.653 0.74 . . . . 0.0 110.842 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 131.62 21.66 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.387 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.18 3.61 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.378 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.7 mp -72.56 -29.21 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.489 ' CD1' ' OG ' ' A' ' 56' ' ' SER . 10.1 m-85 -127.75 104.64 7.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.88 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.451 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.9 OUTLIER -65.59 159.65 24.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.859 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 25.6 ttp180 -62.49 141.39 58.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.25 7.69 88.3 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -91.92 139.75 30.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -88.54 137.2 32.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.933 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.424 HD13 ' CG2' ' A' ' 22' ' ' VAL . 4.9 mt -134.65 149.71 50.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.7 ttp180 -100.62 131.66 46.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.479 HG22 ' CD1' ' A' ' 20' ' ' LEU . 45.7 t -71.41 116.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -89.58 -49.41 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -152.3 149.36 28.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -108.52 119.27 39.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.842 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -122.93 85.84 2.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.67 -122.14 28.08 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.509 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.76 -24.99 61.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.0 m95 -111.6 141.67 44.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.79 0.329 . . . . 0.0 110.942 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.493 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.35 164.71 25.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.893 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.56 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 19.0 tttt -99.73 146.61 26.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.56 167.07 31.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 18.7 tt -138.49 146.8 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.155 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.489 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 5.7 m -81.18 132.66 35.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.3 mt -80.08 9.43 5.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.939 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 m -113.17 -51.12 2.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 77.8 p -97.49 -33.95 11.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.31 27.79 35.38 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 54.2 mtt-85 -90.05 122.87 33.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.804 0.335 . . . . 0.0 110.882 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -92.54 118.53 31.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.3 m -147.11 165.78 28.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.56 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 27.9 m-85 -108.73 120.2 41.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.914 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.467 ' N ' HD12 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.36 151.81 75.34 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.636 0.731 . . . . 0.0 111.149 179.909 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.563 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.69 130.14 18.91 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.37 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.45 -31.69 6.96 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.503 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 11.7 tt -63.0 -31.92 54.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.838 0.352 . . . . 0.0 111.125 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.7 m -77.08 -15.51 59.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 25.2 m -121.3 167.77 14.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.108 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.461 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -131.15 131.64 44.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.448 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 7.1 tpp85 -63.14 106.14 0.81 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.155 179.99 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.461 ' CB ' HG21 ' A' ' 44' ' ' VAL . 70.4 m-20 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.807 0.337 . . . . 0.0 110.898 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 m-85 -105.21 148.11 27.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.416 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . 6.7 mt -130.21 107.89 9.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.37 123.42 26.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 58.5 t -60.09 97.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.13 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.471 ' CD1' ' O ' ' A' ' 70' ' ' VAL . 11.2 mt -61.02 -33.9 73.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -162.25 130.1 3.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.913 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 p30 -41.15 146.73 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.634 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.85 149.67 7.1 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.633 0.73 . . . . 0.0 110.929 -179.841 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.553 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.8 Cg_endo -69.76 -177.42 14.5 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.314 -0.031 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 1.2 t -69.55 153.92 95.29 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.722 0.773 . . . . 0.0 110.86 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 4.0 2.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.685 2.256 . . . . 0.0 112.325 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -107.87 -24.34 11.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.869 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.2 mt -101.59 -54.78 6.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.129 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -153.95 164.34 20.99 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.91 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 128.28 15.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 121.0 7.71 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.727 2.285 . . . . 0.0 112.355 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -80.24 -28.08 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.521 ' CG ' HD22 ' A' ' 42' ' ' LEU . 12.6 m-85 -131.14 110.51 11.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.4 ' O ' ' C ' ' A' ' 38' ' ' ARG . 10.0 mmm180 -78.11 138.11 38.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.414 ' NH1' ' HB3' ' A' ' 38' ' ' ARG . 15.3 ttp-105 -37.51 144.99 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.21 -8.66 79.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.498 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -88.14 146.4 25.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.885 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.6 ttmp? -99.33 147.7 24.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.869 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.521 HD22 ' CG ' ' A' ' 36' ' ' PHE . 5.6 mt -137.2 153.92 50.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -108.38 127.92 54.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.461 HG21 ' CB ' ' A' ' 18' ' ' ASP . 61.6 t -61.99 109.61 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -86.1 -55.05 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.5 t -152.07 125.65 8.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -88.05 126.17 34.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -129.97 85.86 2.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.72 -127.48 36.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.513 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.53 -22.69 74.9 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' TRP . . . . . 0.582 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 19.6 m95 -113.76 137.1 52.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.789 0.328 . . . . 0.0 110.923 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.401 ' CZ2' ' HA2' ' A' ' 67' ' ' GLY . 0.1 OUTLIER -129.05 164.64 22.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.566 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 11.5 tttp -100.9 142.94 31.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.68 159.67 43.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.117 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.41 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 18.6 tt -131.83 138.84 51.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.138 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.1 t -74.39 126.52 30.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.1 mt -77.28 8.57 3.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.7 t -107.34 -44.8 4.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.4 p -104.7 -41.22 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.188 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.9 32.68 7.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.41 ' C ' HG13 ' A' ' 55' ' ' ILE . 45.8 mtt180 -97.6 122.71 41.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.811 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.41 ' HG3' ' CD1' ' A' ' 55' ' ' ILE . 8.5 mt-10 -91.15 116.99 29.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.6 t -147.96 165.99 29.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 15.0 m-85 -105.6 128.99 53.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.479 HD11 ' N ' ' A' ' 65' ' ' ILE . 0.3 OUTLIER -138.57 151.13 68.32 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.656 0.741 . . . . 0.0 111.12 179.9 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.582 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.7 133.7 26.31 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.65 2.233 . . . . 0.0 112.35 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.401 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -31.57 6.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.459 HG23 ' N ' ' A' ' 69' ' ' CYS . 6.1 tp -64.63 -32.03 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.821 0.343 . . . . 0.0 111.142 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' CYS . . . . . 0.459 ' N ' HG23 ' A' ' 68' ' ' ILE . 1.8 m -75.28 -12.68 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.888 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.471 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 13.3 m -127.29 169.86 18.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.467 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -129.96 132.54 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.115 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -69.53 105.13 2.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.0 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.151 179.972 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 59.0 p -45.33 129.4 8.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.864 0.364 . . . . 0.0 110.85 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.9 t -85.28 -60.34 2.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.869 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.48 -167.94 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.6 t -148.47 152.64 37.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.906 0.384 . . . . 0.0 110.829 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 52.2 p -90.54 117.04 28.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.868 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.37 -157.52 13.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 157.63 59.85 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.688 2.259 . . . . 0.0 112.393 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 mt -74.27 148.39 86.17 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -42.16 3.63 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.661 2.241 . . . . 0.0 112.351 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -38.31 144.84 0.36 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.665 0.745 . . . . 0.0 110.904 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.43 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.7 Cg_endo -69.78 -7.63 21.56 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.674 2.249 . . . . 0.0 112.315 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 12' ' ' PRO . 0.5 OUTLIER 35.48 41.28 0.09 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.874 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.94 -49.31 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.481 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.2 mp -105.95 116.53 32.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.826 0.346 . . . . 0.0 110.899 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.07 143.97 47.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.4 t -94.68 161.35 14.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.84 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.498 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 12.9 m-20 -77.99 126.9 31.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.89 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -105.06 148.25 26.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.444 HD12 ' CE2' ' A' ' 52' ' ' TRP . 4.8 mt -129.93 114.2 15.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -83.11 126.26 32.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.118 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 93.1 t -62.33 104.3 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.095 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.429 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 10.8 mt -66.44 -33.48 75.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.889 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.426 ' O ' ' C ' ' A' ' 25' ' ' ASP . 28.8 t -156.17 120.43 4.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 24' ' ' SER . 4.3 p-10 -35.97 140.07 0.13 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.572 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.1 OUTLIER -156.75 147.65 16.45 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 0.0 110.899 -179.866 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.565 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -173.57 8.6 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.351 -0.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 m -75.8 156.21 84.69 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.727 0.775 . . . . 0.0 110.841 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 3.33 2.82 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.691 2.261 . . . . 0.0 112.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -106.92 -16.55 14.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -112.2 -46.53 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.164 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -165.75 163.0 12.87 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.685 0.755 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 133.33 25.23 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.365 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 120.37 7.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 0.0 112.333 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.3 mp -79.15 -25.87 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.11 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.485 ' CG ' HD23 ' A' ' 42' ' ' LEU . 12.5 m-85 -131.22 93.83 3.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.95 155.27 8.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 55.7 ttp85 -54.82 148.11 13.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -16.28 11.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.483 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -68.98 138.35 54.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.918 0.39 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -92.74 137.65 32.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.485 HD23 ' CG ' ' A' ' 36' ' ' PHE . 6.0 mt -131.16 147.6 52.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.921 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.2 ttt180 -99.41 132.11 44.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 90.9 t -68.04 110.28 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.149 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.434 ' CG2' ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -87.47 -52.38 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.117 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 m -143.59 146.91 33.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -111.27 116.7 31.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.852 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 6.6 mm-40 -125.66 85.94 2.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.76 -122.52 30.29 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 -22.52 63.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.519 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.575 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 26.3 m95 -110.84 137.33 48.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.305 . . . . 0.0 110.899 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.444 ' CE2' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.27 164.37 27.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.875 -179.994 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.536 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 38.5 tttt -100.09 140.9 33.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.82 160.01 43.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.427 HG13 ' C ' ' A' ' 61' ' ' ARG . 18.5 tt -131.45 141.54 45.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.4 t -76.48 130.45 37.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.85 6.58 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.2 t -109.7 -44.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 53.2 p -103.53 -34.68 8.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.156 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.95 32.46 23.66 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.519 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.427 ' C ' HG13 ' A' ' 55' ' ' ILE . 28.1 mtt180 -95.83 125.26 40.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.777 0.322 . . . . 0.0 110.88 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -91.51 118.13 30.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 36' ' ' PHE . 4.2 m -147.01 168.81 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.824 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.536 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 31.6 m-85 -113.28 120.33 40.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.963 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -130.43 151.27 78.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.632 0.73 . . . . 0.0 111.124 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.575 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.77 132.23 22.87 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.699 2.266 . . . . 0.0 112.306 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -45.17 -33.97 4.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.494 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.7 tp -61.37 -34.75 62.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.351 . . . . 0.0 111.111 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.15 -13.86 61.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.9 m -124.93 171.78 13.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.161 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.429 ' HB1' ' CD2' ' A' ' 23' ' ' LEU . . . -131.73 132.5 43.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.093 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 3.2 tpp85 -65.87 102.82 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.6 t -73.19 145.27 11.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.7 m -105.44 -49.99 3.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.871 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 176.14 168.93 37.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.498 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 -175.66 1.21 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.713 2.275 . . . . 0.0 112.382 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 79.9 p -129.09 -46.7 1.23 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.7 t -95.13 114.05 25.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.92 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.4 p -108.14 134.95 50.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.887 0.375 . . . . 0.0 110.84 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.5 t -123.06 83.75 2.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.79 97.34 0.31 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.487 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 34.4 t -125.52 155.66 40.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.837 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.9 m -77.19 -51.72 10.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.94 143.54 3.73 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -176.65 1.54 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.235 . . . . 0.0 112.385 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.0 mt -67.41 154.08 93.66 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.941 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -35.43 12.54 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 p-10 -175.02 148.42 1.11 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.617 0.722 . . . . 0.0 110.864 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -2.94 11.04 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.318 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.43 38.57 22.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.43 -40.44 6.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.5 mp -118.41 151.34 37.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -87.56 171.0 10.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.533 ' HG ' ' NE ' ' A' ' 43' ' ' ARG . 38.7 t -108.24 155.4 20.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -100.95 127.51 47.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.865 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -106.32 146.82 29.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.882 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.415 HD21 ' CH2' ' A' ' 52' ' ' TRP . 7.4 mt -131.91 108.96 9.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.01 128.64 33.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 74.1 t -65.25 100.05 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.465 ' CD1' ' O ' ' A' ' 70' ' ' VAL . 7.6 mt -61.48 -26.69 68.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -166.64 132.47 2.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.93 142.43 0.91 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.657 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 150.46 12.93 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.643 0.735 . . . . 0.0 110.911 -179.807 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.55 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.8 175.08 38.12 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.652 -1.812 . . . . 0.0 112.342 -0.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.4 p -68.5 156.31 90.85 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.679 0.752 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 5.24 1.75 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.88 -6.42 18.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.896 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.56 -53.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.03 163.93 23.4 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.683 0.754 . . . . 0.0 110.849 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 134.53 28.19 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.692 2.262 . . . . 0.0 112.354 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.14 11.81 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.72 2.28 . . . . 0.0 112.368 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -87.66 -23.66 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.467 ' CG ' HD22 ' A' ' 42' ' ' LEU . 15.7 m-85 -134.74 101.37 4.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.8 mmt85 -60.95 158.98 12.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.445 ' HD2' ' N ' ' A' ' 39' ' ' GLY . 6.6 tmm_? -56.87 144.34 33.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.858 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.445 ' N ' ' HD2' ' A' ' 38' ' ' ARG . . . 83.69 -16.07 33.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -68.78 138.68 55.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.936 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.62 142.05 27.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.467 HD22 ' CG ' ' A' ' 36' ' ' PHE . 3.0 mt -138.71 135.16 34.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.934 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.533 ' NE ' ' HG ' ' A' ' 17' ' ' SER . 50.4 ttt180 -87.3 133.54 33.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.6 t -68.39 113.58 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.125 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -91.28 -50.41 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.155 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.1 p -143.8 150.36 38.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.9 p-10 -114.3 115.66 27.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.92 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.0 mt-10 -122.17 85.84 2.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.935 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.45 -119.62 18.23 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.506 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.48 -24.12 61.42 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.51 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.57 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 18.3 m95 -110.81 140.31 45.36 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.781 0.325 . . . . 0.0 110.945 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.415 ' CH2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.18 164.32 27.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.911 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.54 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 33.4 tttt -98.26 145.62 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 tt -127.68 144.95 35.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.9 t -78.13 129.16 34.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.844 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.28 8.95 6.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.8 m -114.75 -44.22 3.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.9 p -101.26 -41.82 6.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.114 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.32 25.87 17.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.483 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 40.1 mtt180 -92.27 125.93 37.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -93.75 117.92 30.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 17.7 m -146.87 169.35 19.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.54 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 19.8 m-85 -112.06 118.83 36.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.401 ' CD1' ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.43 151.25 69.78 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.148 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.57 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.6 Cg_endo -69.74 133.11 24.81 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.697 2.265 . . . . 0.0 112.331 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.9 -31.26 5.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.466 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 9.1 tt -64.27 -32.59 58.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.776 0.322 . . . . 0.0 111.097 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.3 m -75.58 -13.05 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.465 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 35.6 m -126.97 175.23 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.46 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -141.84 139.83 32.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.119 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -67.9 110.45 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 23.7 t -81.88 144.37 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.129 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.4 t -166.32 142.91 4.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.87 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 149.04 -158.74 27.77 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 77' ' ' SER . 53.8 Cg_endo -69.76 2.78 3.22 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 76' ' ' PRO . 10.2 p -34.9 134.88 0.21 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 54.8 m -92.74 171.12 9.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.832 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.475 179.996 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 m -117.25 128.87 55.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.858 0.361 . . . . 0.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.1 p -153.68 147.01 24.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.813 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 61.78 152.72 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.0 t -83.58 157.94 22.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.832 0.349 . . . . 0.0 110.891 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.7 p -152.64 122.29 6.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.816 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.46 137.18 3.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.523 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -174.51 0.92 Allowed 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.687 2.258 . . . . 0.0 112.366 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.467 ' CD2' ' HD2' ' A' ' 10' ' ' PRO . 13.5 mt -90.64 157.67 43.76 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.617 0.722 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.467 ' HD2' ' CD2' ' A' ' 9' ' ' LEU . 53.4 Cg_endo -69.77 1.95 3.98 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.672 2.248 . . . . 0.0 112.316 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.447 ' C ' ' O ' ' A' ' 10' ' ' PRO . 7.5 t-20 -34.64 135.56 0.39 Allowed Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.695 0.76 . . . . 0.0 110.84 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 1.67 4.28 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.662 2.242 . . . . 0.0 112.313 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -47.14 101.63 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.14 -47.77 0.58 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.532 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.1 mt -87.16 113.83 23.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 110.934 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -87.06 157.12 19.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.4 t -117.85 152.8 34.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -66.65 135.32 53.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -105.11 149.88 25.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.839 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 14.5 mt -132.71 115.13 14.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.48 120.47 26.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.7 t -55.68 106.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.46 ' CD2' ' HB2' ' A' ' 71' ' ' ALA . 10.1 mt -66.79 -34.01 76.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.917 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.9 t -157.2 128.13 6.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.852 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.97 134.05 2.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.643 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.87 149.74 22.76 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 110.942 -179.811 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.557 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.48 11.0 Favored 'Cis proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.304 -0.045 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.1 m -73.61 155.65 89.11 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.671 0.748 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 2.92 3.09 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.699 2.266 . . . . 0.0 112.359 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -106.82 -16.61 14.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -111.81 -46.94 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.172 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.11 162.01 14.34 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.622 0.725 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 135.94 31.59 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.637 2.224 . . . . 0.0 112.348 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 124.87 11.48 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.684 2.256 . . . . 0.0 112.338 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -87.52 -25.08 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.504 ' CG ' HD21 ' A' ' 42' ' ' LEU . 15.1 m-85 -131.65 89.77 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -50.49 156.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.872 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -58.43 150.97 21.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.62 -6.4 17.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.455 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -76.09 135.41 39.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 35.0 tttt -86.12 137.78 32.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.504 HD21 ' CG ' ' A' ' 36' ' ' PHE . 9.7 mt -132.98 154.51 50.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.9 ttp180 -105.06 131.42 52.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.9 t -70.88 112.73 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -87.88 -51.66 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.8 t -151.83 159.36 43.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.828 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -116.33 111.71 20.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.3 mt-10 -110.53 86.41 2.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.98 -122.68 31.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.23 -21.62 78.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.496 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.8 m95 -114.97 151.87 33.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.09 164.52 27.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.941 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.46 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 25.8 tttt -100.85 143.88 30.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.81 160.95 42.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.461 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -129.88 146.76 33.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.5 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 87.6 p -81.37 128.52 33.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.871 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.4 mt -77.49 8.66 4.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.5 m -99.9 -52.69 3.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.816 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.4 p -107.37 -45.4 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.193 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 107.92 29.43 4.35 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.9 mtt180 -86.95 123.99 32.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.746 0.308 . . . . 0.0 110.864 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.461 ' HG3' ' CD1' ' A' ' 55' ' ' ILE . 6.2 mt-10 -93.97 117.86 30.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -147.19 165.63 29.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.873 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.46 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 17.0 m-85 -107.27 123.93 49.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.935 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.451 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.36 151.25 77.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.671 0.748 . . . . 0.0 111.144 179.905 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.574 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.75 132.56 23.61 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.646 2.231 . . . . 0.0 112.382 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.66 -31.33 7.22 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.462 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.0 tt -63.92 -31.91 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 111.108 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.2 m -76.6 -11.12 59.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.455 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 31.0 m -127.84 169.72 18.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.46 ' HB2' ' CD2' ' A' ' 23' ' ' LEU . . . -127.85 129.08 46.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -64.8 108.8 1.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.9 t -91.23 160.27 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.181 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 50.7 m -140.55 154.65 46.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.86 162.73 45.11 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.513 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 1.27 4.6 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.697 2.265 . . . . 0.0 112.315 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 78' ' ' SER . 86.1 p -49.31 -50.87 37.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.882 -179.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.41 ' C ' ' O ' ' A' ' 77' ' ' SER . 27.8 p -37.06 124.91 0.93 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.871 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.962 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.489 -0.245 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 97.2 p 38.36 41.86 0.47 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.947 0.403 . . . . 0.0 110.897 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 t -98.27 154.95 17.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.869 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -98.87 -93.38 2.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.3 p 40.56 44.72 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.361 . . . . 0.0 110.81 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.3 p -37.79 -38.91 0.32 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.836 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 149.02 179.28 24.78 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.493 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 163.24 38.97 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.701 2.267 . . . . 0.0 112.351 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 68.5 mt -129.75 150.73 76.63 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.55 0.691 . . . . 0.0 110.926 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.29 23.23 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -118.53 134.74 23.46 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.615 0.722 . . . . 0.0 110.893 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -4.77 14.72 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.729 2.286 . . . . 0.0 112.31 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -87.96 49.35 1.79 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -85.51 -80.09 1.14 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.497 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.1 mp -79.78 102.96 9.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.793 0.33 . . . . 0.0 110.931 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -90.58 -179.22 5.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.7 t -129.23 151.97 49.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.45 ' OD2' ' NH2' ' A' ' 72' ' ' ARG . 1.2 m-20 -87.39 115.36 24.75 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.861 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -108.46 153.7 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.851 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.6 mt -140.03 114.55 9.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.9 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.65 128.93 34.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 109.44 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.072 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.449 HD23 ' CB ' ' A' ' 71' ' ' ALA . 6.5 mt -68.8 -31.93 71.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.932 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.436 ' O ' ' C ' ' A' ' 25' ' ' ASP . 24.6 t -160.76 125.98 3.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.7 OUTLIER -35.37 148.34 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.846 179.953 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.59 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -166.04 148.89 6.49 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.64 0.733 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.574 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.8 -174.27 9.41 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.347 0.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -71.17 153.63 94.27 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 0.0 110.876 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 3.04 3.02 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.678 2.252 . . . . 0.0 112.338 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -106.0 -23.13 12.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.5 -57.15 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.128 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 m -150.8 162.93 25.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.679 0.752 . . . . 0.0 110.851 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 132.89 24.17 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.339 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 122.59 9.26 Favored 'Trans proline' 0 N--CA 1.465 -0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.347 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mp -87.17 -26.11 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.407 ' CD1' ' OG ' ' A' ' 56' ' ' SER . 6.0 m-85 -128.87 99.22 5.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 28.6 mmm-85 -63.44 157.75 22.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 ttm180 -56.81 143.82 35.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.03 9.42 86.96 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -93.15 136.0 33.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 22.1 ttmt -87.99 139.6 30.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.94 146.86 45.93 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.1 ttm180 -100.5 125.34 46.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.927 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 43.6 t -63.44 111.03 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -85.12 -47.74 16.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -149.09 157.89 43.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -117.21 113.15 21.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.2 mt-10 -115.22 86.25 2.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 57.68 -118.4 12.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.43 -23.0 61.41 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.508 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.577 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.9 m95 -112.28 135.72 52.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.76 0.314 . . . . 0.0 110.896 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -124.75 164.76 19.26 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.932 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.562 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 14.5 tttp -102.61 147.77 26.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.74 163.81 39.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.104 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 19.5 tt -131.47 151.33 35.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.156 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.407 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 49.1 m -83.18 127.77 33.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.3 mt -78.43 9.38 3.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 m -116.8 -43.88 2.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 68.6 p -101.4 -42.74 6.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.02 25.79 16.19 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 50.8 mtt-85 -89.86 124.49 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.779 0.323 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.92 117.38 30.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.867 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.1 t -147.76 166.28 27.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.832 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.562 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 12.9 m-85 -108.79 122.74 47.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -129.8 151.12 77.62 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.65 0.738 . . . . 0.0 111.157 179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.577 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.79 134.8 28.78 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.325 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.75 -30.58 9.03 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.469 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.42 HG22 ' N ' ' A' ' 69' ' ' CYS . 6.2 tp -65.39 -30.46 50.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . 0.42 ' N ' HG22 ' A' ' 68' ' ' ILE . 2.7 m -78.6 -6.87 56.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.838 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.424 ' N ' HD13 ' A' ' 23' ' ' LEU . 27.5 m -133.02 167.57 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.449 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -128.94 134.67 48.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.6 tpt85 -64.98 112.36 3.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 19.1 t -87.2 144.49 9.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.0 t -143.62 118.58 10.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.18 160.73 32.28 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -40.87 4.82 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.658 2.239 . . . . 0.0 112.316 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 80.8 p -57.76 -45.19 86.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 67.0 m -120.55 120.22 35.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.853 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.451 179.981 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 t 67.29 42.09 2.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.934 0.397 . . . . 0.0 110.916 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 t -64.02 100.34 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.855 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -43.81 125.72 5.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.7 m -79.1 91.21 4.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.824 0.345 . . . . 0.0 110.864 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 71.0 m -132.49 127.82 36.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.842 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.82 173.37 14.06 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.522 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 140.78 43.66 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.715 2.276 . . . . 0.0 112.314 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.0 mt -62.78 144.33 96.56 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 80.02 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.672 2.248 . . . . 0.0 112.33 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -49.07 109.99 1.38 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.634 0.73 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -5.38 16.08 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.36 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -85.25 33.84 0.56 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.63 -82.92 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.455 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 44.0 mt -101.2 121.96 42.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.767 0.317 . . . . 0.0 110.945 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.47 175.76 5.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 t -118.04 149.72 40.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.486 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 13.2 m-20 -93.23 117.02 29.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -103.14 152.66 21.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -137.51 112.89 9.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.923 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 125.52 30.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.075 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.63 99.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.143 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.462 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 7.9 mt -57.33 -33.69 67.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.894 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.2 t -157.95 133.17 8.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.36 135.29 3.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.65 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -153.39 150.18 23.01 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.665 0.745 . . . . 0.0 110.929 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.561 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.76 -175.09 10.34 Favored 'Cis proline' 0 C--O 1.231 0.156 0 C-N-CA 122.723 -1.782 . . . . 0.0 112.33 -0.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 31.2 m -75.24 155.64 86.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.729 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 1.14 4.69 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.682 2.255 . . . . 0.0 112.394 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.16 -5.38 18.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.863 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.72 -47.03 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.1 161.63 14.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.638 0.732 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 134.28 27.62 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.367 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 125.29 12.01 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.67 2.247 . . . . 0.0 112.357 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 mp -87.19 -25.22 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.114 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.509 ' CG ' HD22 ' A' ' 42' ' ' LEU . 13.6 m-85 -134.89 96.94 3.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.81 162.95 1.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.868 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -59.88 149.66 30.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.08 -9.76 17.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.99 137.09 48.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.878 0.371 . . . . 0.0 110.891 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -90.89 138.94 31.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.509 HD22 ' CG ' ' A' ' 36' ' ' PHE . 2.7 mt -137.99 142.63 40.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.941 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.6 ttt-85 -94.97 131.66 40.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 69.0 t -68.01 109.84 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.149 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.42 ' CG2' ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -83.65 -46.26 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.94 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 68.8 m -156.27 152.75 28.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -110.91 117.09 32.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.885 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -120.43 86.09 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.7 -122.99 30.63 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.01 -23.37 66.53 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.511 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.561 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.6 m95 -112.42 146.72 37.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.747 0.308 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -135.55 164.45 27.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.921 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.471 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 34.7 tttt -100.37 143.39 30.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.27 163.26 39.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.078 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 12.0 tt -133.9 136.89 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.116 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.6 t -70.87 129.09 38.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.69 8.64 5.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.946 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.7 m -112.6 -44.91 3.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.811 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 70.6 p -103.24 -33.65 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.79 29.44 32.04 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.48 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -92.24 123.94 35.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.793 0.33 . . . . 0.0 110.903 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -90.88 117.63 29.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.6 m -147.26 167.41 24.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.832 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.471 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.6 m-85 -110.5 115.72 30.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -123.49 151.4 63.15 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.641 0.734 . . . . 0.0 111.173 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.561 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.4 Cg_endo -69.77 134.41 27.9 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.686 2.257 . . . . 0.0 112.351 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -50.36 -28.85 15.27 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.513 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 18.2 tt -66.0 -28.0 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.8 0.334 . . . . 0.0 111.107 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 6.4 m -85.1 1.13 49.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.9 m -136.37 157.99 37.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.462 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -120.45 130.83 54.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.053 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -64.89 107.63 1.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.08 144.09 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 44.1 t -114.96 107.19 15.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.21 179.09 41.4 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -40.11 5.67 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.708 2.272 . . . . 0.0 112.304 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 73.8 m 42.51 43.04 3.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.6 p -115.24 130.33 56.88 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.838 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.0 t -98.56 140.0 33.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.887 0.375 . . . . 0.0 110.848 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.2 p -126.89 151.29 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.7 168.57 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.529 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.1 p -163.41 124.67 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.352 . . . . 0.0 110.883 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.7 t 68.3 49.15 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.847 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.72 143.12 15.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 155.16 66.78 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.65 2.233 . . . . 0.0 112.356 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.7 mt -132.07 153.93 81.51 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 110.872 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.453 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.8 Cg_endo -69.8 3.0 3.05 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.66 2.24 . . . . 0.0 112.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 10' ' ' PRO . 8.5 m-20 -33.32 143.21 0.18 Allowed Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.601 0.715 . . . . 0.0 110.938 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.497 ' O ' ' N ' ' A' ' 14' ' ' GLY . 54.0 Cg_endo -69.67 2.5 3.42 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.704 2.269 . . . . 0.0 112.337 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 -50.65 87.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 123.29 -49.9 0.87 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.524 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 68.1 mt -114.27 130.52 56.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.864 0.364 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.02 136.8 33.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.869 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.3 t -96.58 155.06 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.434 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 5.8 m-20 -69.17 132.68 46.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -104.72 152.73 22.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.843 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 3.8 mt -134.62 108.71 8.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.5 125.47 29.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.6 t -63.9 103.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.453 HD22 ' CB ' ' A' ' 71' ' ' ALA . 11.8 mt -62.54 -33.28 74.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.421 ' O ' ' C ' ' A' ' 25' ' ' ASP . 35.3 t -158.34 123.24 4.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.873 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.3 OUTLIER -36.36 144.55 0.05 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.841 179.993 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.601 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 148.9 11.6 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.743 . . . . 0.0 110.939 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.566 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.75 178.69 24.56 Favored 'Cis proline' 0 N--CA 1.465 -0.147 0 C-N-CA 122.713 -1.786 . . . . 0.0 112.358 -0.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -66.36 153.33 92.93 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.724 0.773 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.86 3.16 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.663 2.242 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -104.48 -23.99 13.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.847 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.23 -54.51 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.167 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.53 164.18 21.76 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.684 0.754 . . . . 0.0 110.888 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 131.54 21.48 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.72 3.79 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.664 2.242 . . . . 0.0 112.324 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -75.65 -27.56 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.527 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 8.2 m-85 -129.5 102.3 6.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -62.65 162.77 10.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.926 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.5 ttt180 -62.15 146.95 49.12 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.5 -9.75 26.81 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.498 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -73.06 131.62 42.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.916 0.389 . . . . 0.0 110.854 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 25.3 ttmt -81.52 136.48 35.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.892 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.449 HD22 ' CG ' ' A' ' 36' ' ' PHE . 13.7 mt -129.36 139.67 51.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.9 ttp-105 -90.38 129.8 36.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.434 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 99.3 t -69.46 111.77 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.153 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -87.6 -52.89 10.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 t -152.88 159.82 43.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -115.96 112.27 21.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -110.61 85.9 2.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.33 -122.16 29.17 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.14 -23.62 75.55 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.575 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -113.67 152.66 30.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.763 0.315 . . . . 0.0 110.978 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.11 164.29 28.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.92 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -101.28 139.55 36.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.88 168.7 20.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.8 tt -135.75 140.35 44.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.527 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 96.3 p -79.42 128.27 33.14 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.9 mt -78.7 9.49 4.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.888 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.0 t -104.15 -45.34 4.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.918 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.7 p -110.69 -34.83 6.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.95 24.11 25.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -87.94 128.25 35.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.799 0.333 . . . . 0.0 110.866 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -95.55 117.79 31.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 44.7 t -147.11 159.48 43.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.882 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -98.2 129.9 44.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.504 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -138.16 151.45 69.78 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.552 0.691 . . . . 0.0 111.182 179.884 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.575 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.71 132.02 22.54 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.703 2.269 . . . . 0.0 112.329 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.45 -29.77 7.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.505 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.433 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 12.3 tt -64.94 -30.87 51.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 111.118 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.4 m -77.68 -11.52 59.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 67' ' ' GLY . 19.2 m -126.71 165.58 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.089 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.453 ' CB ' HD22 ' A' ' 23' ' ' LEU . . . -124.21 130.22 52.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 tpt180 -67.12 99.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.4 t -75.51 154.12 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -118.37 49.94 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 42.74 -156.47 0.11 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.16 2.22 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.665 2.244 . . . . 0.0 112.326 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 50.7 m -55.25 -56.61 17.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 3.3 t -133.56 162.52 31.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.831 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.8 m -88.36 -47.46 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.864 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -64.35 -47.38 79.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.881 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.98 -133.79 11.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.2 m -101.65 102.86 13.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.912 0.387 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -169.39 167.41 10.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.896 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.49 159.87 17.55 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.496 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 179.08 3.98 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.701 2.267 . . . . 0.0 112.339 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 11.0 mt -127.41 144.01 49.33 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.535 0.684 . . . . 0.0 110.958 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 80.1 0.88 Allowed 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.74 2.293 . . . . 0.0 112.356 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -74.65 143.99 79.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.653 0.74 . . . . 0.0 110.86 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 0.24 5.97 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.672 2.248 . . . . 0.0 112.34 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -61.94 108.75 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -101.13 -50.44 1.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.482 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 12.9 mt -120.41 155.67 32.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.779 0.324 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -53.48 157.27 2.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.892 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.7 t -83.03 158.62 22.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.502 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 41.5 m-20 -60.7 130.54 47.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -102.97 151.2 22.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.534 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 4.7 mt -135.54 109.18 7.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.69 131.32 35.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.056 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 63.7 t -65.81 109.11 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.159 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.465 ' CD2' ' HB2' ' A' ' 71' ' ' ALA . 5.0 mt -74.52 -29.63 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 25' ' ' ASP . 29.2 t -157.02 115.52 3.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -34.99 139.96 0.08 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.588 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -156.65 148.59 17.38 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.687 0.756 . . . . 0.0 110.924 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.568 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.74 -174.67 9.79 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 -1.801 . . . . 0.0 112.358 -0.074 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.477 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 4.0 m -77.0 158.8 79.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.696 0.76 . . . . 0.0 110.857 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 5.15 1.79 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 29.4 p-10 -104.26 -27.93 11.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 7.3 mt -101.95 -53.45 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -159.47 163.82 22.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 137.71 35.97 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 124.82 11.48 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.713 2.276 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -86.89 -20.85 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.505 ' CG ' HD22 ' A' ' 42' ' ' LEU . 19.5 m-85 -134.47 87.17 2.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.887 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.402 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.2 OUTLIER -49.77 156.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.926 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.417 ' HG3' ' C ' ' A' ' 23' ' ' LEU . 2.6 ttm105 -60.68 144.03 52.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.65 -9.41 62.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.471 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -76.95 136.15 38.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 110.911 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 49.8 tttt -84.26 137.55 33.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.505 HD22 ' CG ' ' A' ' 36' ' ' PHE . 9.9 mt -131.64 150.0 52.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -105.09 128.85 53.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 91.5 t -64.35 110.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -87.79 -51.73 12.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.4 p -146.9 135.51 22.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -100.06 115.82 30.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.0 mm-40 -127.3 86.89 2.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.95 -123.41 32.6 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.49 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.39 63.06 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.593 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 32.1 m95 -113.98 123.26 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.735 0.302 . . . . 0.0 110.88 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.534 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -123.2 164.29 18.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.924 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.571 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.9 tttp -98.5 144.7 27.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.884 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.95 152.66 31.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.107 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.418 HG13 ' C ' ' A' ' 61' ' ' ARG . 12.6 tt -126.23 131.84 71.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -68.77 128.82 38.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 4.5 mt -79.22 9.37 4.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.0 t -109.26 -45.53 3.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.841 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.5 p -102.02 -39.73 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.14 32.15 9.16 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.418 ' C ' HG13 ' A' ' 55' ' ' ILE . 36.7 mtt180 -98.19 127.0 43.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.826 0.346 . . . . 0.0 110.867 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.468 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 8.4 mt-10 -93.19 117.24 29.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.861 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.2 m -147.89 168.31 22.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.571 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 30.0 m-85 -109.66 135.64 50.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.464 ' N ' HD13 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -144.36 151.37 50.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.59 0.71 . . . . 0.0 111.165 179.86 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.593 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.2 Cg_endo -69.72 133.81 26.55 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.56 -30.21 8.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.411 HG22 ' N ' ' A' ' 69' ' ' CYS . 4.6 tp -65.54 -30.45 50.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.816 0.341 . . . . 0.0 111.164 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . 0.411 ' N ' HG22 ' A' ' 68' ' ' ILE . 2.9 m -78.5 -3.84 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.463 ' N ' HD13 ' A' ' 23' ' ' LEU . 27.2 m -136.59 169.8 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.465 ' HB2' ' CD2' ' A' ' 23' ' ' LEU . . . -133.98 139.25 45.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.2 tpp85 -68.62 112.03 5.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.876 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.8 t -83.18 143.92 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.105 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 15.1 t -69.8 -44.85 69.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.854 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.54 -158.11 22.64 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.527 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 154.15 68.06 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.718 2.279 . . . . 0.0 112.375 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 11.0 t -125.94 -55.66 1.48 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.893 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 16.1 t -91.96 86.75 5.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.81 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.461 -179.999 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.2 t -133.26 116.83 16.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 t -155.09 150.99 27.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.859 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.55 164.69 11.62 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m -66.97 114.16 5.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.858 0.361 . . . . 0.0 110.848 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.1 p -91.11 172.63 8.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.74 144.88 1.38 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.448 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 143.84 51.87 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.662 2.241 . . . . 0.0 112.315 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.9 mt -48.73 143.04 8.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.593 0.711 . . . . 0.0 110.94 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -10.9 29.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.656 2.238 . . . . 0.0 112.359 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -97.64 114.61 65.17 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -8.91 24.8 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.262 . . . . 0.0 112.323 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.0 mm-40 -79.24 87.6 4.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.867 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.48 -91.84 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.451 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 20.1 mt -79.47 113.18 17.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.87 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -64.35 -179.47 0.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.881 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 43.1 t -122.0 163.28 19.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.85 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.499 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 10.9 m-20 -57.03 130.6 46.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.44 152.13 21.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.522 HD23 ' CZ2' ' A' ' 52' ' ' TRP . 3.7 mt -134.78 112.3 10.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.913 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.24 119.96 24.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.055 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.405 HG21 ' CB ' ' A' ' 36' ' ' PHE . 98.4 t -57.27 99.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.423 HD12 ' N ' ' A' ' 70' ' ' VAL . 7.4 mt -59.34 -23.44 62.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 47.2 t -169.76 133.67 1.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.835 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.28 146.54 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.868 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.651 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -164.75 149.95 8.5 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.702 0.763 . . . . 0.0 110.913 -179.826 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.558 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.75 -174.69 9.83 Favored 'Cis proline' 0 C--N 1.342 0.201 0 C-N-CA 122.711 -1.787 . . . . 0.0 112.377 -0.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.463 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 44.2 m -72.29 154.58 91.99 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.641 0.734 . . . . 0.0 110.878 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 3.52 2.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.679 2.253 . . . . 0.0 112.357 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.463 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 23.6 p-10 -109.39 -17.03 13.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -109.44 -46.43 6.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -164.77 163.17 14.44 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.672 0.749 . . . . 0.0 110.821 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 131.67 21.66 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 124.74 11.37 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.377 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.422 HG23 ' CD ' ' A' ' 61' ' ' ARG . 1.6 mp -89.22 -24.38 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.155 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.511 ' CG ' HD22 ' A' ' 42' ' ' LEU . 14.4 m-85 -130.98 103.02 6.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -64.22 160.34 18.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.6 ttp85 -58.37 149.4 24.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.928 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.75 -9.71 22.04 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -71.13 154.12 41.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.902 0.382 . . . . 0.0 110.904 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 7.9 tttp -107.16 140.24 40.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.914 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.511 HD22 ' CG ' ' A' ' 36' ' ' PHE . 2.3 mt -136.85 135.26 37.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -86.48 131.02 34.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 60.5 t -66.99 108.8 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.459 HD11 ' CG2' ' A' ' 55' ' ' ILE . 1.0 OUTLIER -87.74 -52.36 11.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -143.82 155.03 43.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -119.49 113.05 20.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -117.31 86.39 2.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.4 -123.6 33.87 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.39 -21.07 78.22 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.486 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -113.26 144.74 42.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.724 0.297 . . . . 0.0 110.941 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.522 ' CZ2' HD23 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.83 164.46 27.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.92 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.532 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 28.9 tttt -101.04 141.04 34.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.906 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.17 162.57 39.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CG2' HD11 ' A' ' 45' ' ' ILE . 16.4 tt -134.67 134.55 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -69.8 128.28 35.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.843 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 2.0 mt -78.78 2.68 19.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.89 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.3 m -99.41 -47.81 5.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.3 p -105.33 -37.35 6.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.142 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.85 29.34 9.94 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.422 ' CD ' HG23 ' A' ' 35' ' ' ILE . 33.7 mtt180 -90.04 127.8 36.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.873 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -97.86 118.0 33.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.1 t -147.02 167.38 24.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.532 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 14.8 m-85 -110.07 114.33 27.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.404 ' H ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.91 151.18 60.64 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.63 0.729 . . . . 0.0 111.164 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.568 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 54.2 Cg_endo -69.78 133.88 26.59 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.673 2.249 . . . . 0.0 112.341 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.44 -30.26 5.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 tp -65.09 -32.47 58.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.801 0.334 . . . . 0.0 111.116 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 8.0 m -78.91 -4.82 51.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.423 ' N ' HD12 ' A' ' 23' ' ' LEU . 32.4 m -132.56 166.08 30.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.407 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -130.53 129.45 42.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.069 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.95 107.6 1.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.859 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.435 ' O ' ' C ' ' A' ' 74' ' ' SER . 4.0 t -72.38 142.21 15.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.099 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 73' ' ' VAL . 48.4 p -35.06 137.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.87 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -179.66 -177.95 48.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.428 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 124.58 11.26 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.368 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 17.7 t -72.0 -45.24 61.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.864 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 47.1 t -56.61 136.9 54.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 -179.99 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.504 -0.239 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.1 t -124.05 -45.31 2.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.7 p -52.58 135.5 34.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.859 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -168.08 -46.4 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.481 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.6 t -73.86 126.26 30.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.941 0.4 . . . . 0.0 110.839 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 m -107.23 105.87 16.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.862 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 138.5 -120.26 1.93 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.495 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 -174.93 1.01 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.714 2.276 . . . . 0.0 112.304 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 63.7 mt -86.44 155.6 56.83 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.64 0.733 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 2.39 3.62 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.659 2.239 . . . . 0.0 112.343 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -85.8 136.98 36.07 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.663 0.744 . . . . 0.0 110.868 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.8 Cg_endo -69.8 2.88 3.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.643 2.229 . . . . 0.0 112.361 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.436 ' C ' ' O ' ' A' ' 12' ' ' PRO . 8.0 tt0 -34.57 116.45 0.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.869 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -144.28 69.1 0.41 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 22.7 mt -107.17 130.92 54.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.783 0.325 . . . . 0.0 110.927 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.9 147.81 25.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -107.2 167.5 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.833 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.468 ' CB ' HG22 ' A' ' 44' ' ' VAL . 85.7 m-20 -84.54 130.84 34.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.883 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -111.17 150.15 29.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.562 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 9.3 mt -133.38 114.08 13.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.42 127.12 32.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.08 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 95.8 t -65.04 98.6 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.149 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.452 HD22 ' CB ' ' A' ' 71' ' ' ALA . 8.6 mt -59.71 -31.49 69.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.931 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.7 t -161.3 127.95 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.77 138.98 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.647 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.72 150.12 17.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.695 0.76 . . . . 0.0 110.936 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.557 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -175.28 10.64 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.695 -1.794 . . . . 0.0 112.337 -0.048 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 3.1 m -76.28 158.29 81.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -102.07 -22.39 14.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 mt -109.25 -54.99 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -155.3 163.44 24.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.615 0.721 . . . . 0.0 110.888 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 137.81 36.43 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 119.04 6.05 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.679 2.252 . . . . 0.0 112.371 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -83.06 -25.71 8.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.128 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.516 ' CG ' HD23 ' A' ' 42' ' ' LEU . 13.3 m-85 -131.4 96.24 3.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.0 mmm-85 -56.41 158.38 4.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 52.1 ttt-85 -61.08 144.5 53.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.62 -14.46 35.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -72.75 136.54 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.5 ttmt -87.02 137.84 32.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.516 HD23 ' CG ' ' A' ' 36' ' ' PHE . 10.4 mt -132.17 140.6 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.919 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -91.12 134.49 34.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.468 HG22 ' CB ' ' A' ' 18' ' ' ASP . 97.6 t -71.43 112.11 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -86.05 -46.32 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -155.56 147.75 23.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.46 116.07 31.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.902 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -122.35 85.91 2.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.12 -120.7 23.89 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.33 -23.08 59.4 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.438 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.562 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 21.9 m95 -111.68 137.9 48.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.79 0.329 . . . . 0.0 110.88 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.562 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.3 164.83 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.578 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.4 tttp -101.49 141.95 33.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.911 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.13 168.34 22.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 21.3 tt -138.39 142.45 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.113 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.5 p -76.82 133.49 39.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.6 mt -82.96 8.86 11.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.2 t -104.78 -42.77 5.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -113.56 -44.57 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.103 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 103.35 27.88 6.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.473 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -84.19 122.04 28.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 110.853 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.47 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 5.6 mt-10 -92.09 117.48 29.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.0 t -147.44 169.61 19.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.905 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.578 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 7.1 m-85 -112.1 118.09 34.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -125.5 151.26 69.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.656 0.741 . . . . 0.0 111.153 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.562 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.0 Cg_endo -69.79 132.67 23.75 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.704 2.27 . . . . 0.0 112.312 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.45 -33.5 5.99 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 12.8 tt -61.81 -33.39 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.359 . . . . 0.0 111.177 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.1 -15.92 61.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.406 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 35.7 m -125.47 175.86 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.452 ' CB ' HD22 ' A' ' 23' ' ' LEU . . . -136.72 134.5 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -66.32 102.44 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 74' ' ' SER . 20.4 t -73.94 144.45 12.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.437 ' N ' HG12 ' A' ' 73' ' ' VAL . 3.6 t 62.38 49.15 4.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.847 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.37 175.33 25.72 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 77' ' ' SER . 53.9 Cg_endo -69.77 0.91 4.96 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.654 2.236 . . . . 0.0 112.331 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 76' ' ' PRO . 38.0 m -35.04 132.71 0.34 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.853 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.1 t -75.45 162.32 28.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.859 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.5 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -82.99 156.56 23.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.909 0.385 . . . . 0.0 110.867 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 t -171.79 112.89 0.33 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.1 147.39 0.15 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.467 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.1 m -93.76 93.94 8.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.878 0.371 . . . . 0.0 110.845 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 t -113.05 33.59 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.904 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -56.65 -158.2 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.489 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -168.23 0.26 Allowed 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.711 2.274 . . . . 0.0 112.324 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.466 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 2.6 pp -111.82 152.21 44.02 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.623 0.725 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.444 ' O ' ' C ' ' A' ' 11' ' ' ASN . 54.0 Cg_endo -69.8 -45.77 1.45 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 2.258 . . . . 0.0 112.317 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.444 ' C ' ' O ' ' A' ' 10' ' ' PRO . 1.7 m-80 -34.61 150.19 0.08 OUTLIER Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.573 0.701 . . . . 0.0 110.929 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 1.63 4.24 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -100.23 73.69 1.71 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.893 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.27 99.52 0.18 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.435 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.1 mp -104.6 147.88 27.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.866 0.365 . . . . 0.0 110.884 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -68.14 168.09 12.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.908 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.4 t -129.86 153.06 48.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.836 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.413 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 14.1 m-20 -72.44 127.98 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.881 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -108.79 154.42 22.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.98 111.68 7.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.881 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.12 122.81 28.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.092 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 92.2 t -55.33 104.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.428 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 8.6 mt -65.74 -33.81 76.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.7 t -155.35 128.95 8.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -39.43 146.55 0.09 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.605 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.77 148.82 6.73 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.659 0.742 . . . . 0.0 110.944 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.568 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.83 -174.27 9.44 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 -1.796 . . . . 0.0 112.295 0.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.9 m -70.57 153.77 94.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.656 0.741 . . . . 0.0 110.873 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 1.21 4.59 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.676 2.251 . . . . 0.0 112.37 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -106.26 -18.37 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -107.29 -54.03 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.16 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.4 m -155.71 162.63 26.97 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 134.37 27.82 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.327 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 120.87 7.59 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.724 2.282 . . . . 0.0 112.314 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mp -85.6 -30.45 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.51 ' CG ' HD23 ' A' ' 42' ' ' LEU . 11.8 m-85 -124.0 90.82 3.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -51.07 161.16 0.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.896 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 16.2 ttt-85 -66.17 144.15 56.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.35 -9.89 65.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.403 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -83.09 132.64 35.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 110.906 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.446 ' CD ' HG21 ' A' ' 73' ' ' VAL . 19.5 ttpt -88.99 143.74 26.65 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 36' ' ' PHE . 0.4 OUTLIER -135.0 141.25 46.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.89 179.94 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 35.8 ttt180 -85.64 127.57 34.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.413 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 84.5 t -64.46 111.37 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.48 ' CG2' ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -78.62 -54.7 11.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.094 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.1 t -155.58 150.85 26.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.846 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -102.26 121.99 43.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.923 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 44.5 mm-40 -126.5 86.15 2.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.907 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.44 -121.5 24.24 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -85.08 -18.57 60.75 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.529 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.579 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.5 m95 -115.71 140.09 49.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.71 0.291 . . . . 0.0 110.937 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -132.79 164.44 26.82 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.878 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.542 ' HE3' ' CE2' ' A' ' 64' ' ' TYR . 3.7 ttmt -101.58 151.56 21.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -159.11 150.1 19.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 18.4 tt -116.34 144.34 24.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.13 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.408 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 6.7 m -73.59 130.6 40.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.5 mt -78.21 9.71 3.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 t -116.92 -52.79 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.828 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.411 ' HG1' ' N ' ' A' ' 60' ' ' GLY . 48.2 p -95.9 -34.56 11.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.411 ' N ' ' HG1' ' A' ' 59' ' ' THR . . . 86.85 31.57 17.55 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.496 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.0 mtt180 -91.37 122.1 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -91.9 117.76 30.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.418 ' HB3' ' CE2' ' A' ' 36' ' ' PHE . 18.4 t -147.32 169.51 19.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.542 ' CE2' ' HE3' ' A' ' 53' ' ' LYS . 4.2 m-85 -110.26 122.34 47.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.468 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.21 151.47 78.42 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.597 0.713 . . . . 0.0 111.113 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.579 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.3 Cg_endo -69.8 131.87 22.08 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.7 2.267 . . . . 0.0 112.279 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.408 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.78 -30.57 4.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.476 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.3 tt -64.72 -33.33 62.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 0.0 111.11 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 7.4 m -78.05 -7.58 57.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 67' ' ' GLY . 33.8 m -128.69 164.98 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.428 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -131.44 134.88 46.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.7 tpp180 -61.41 110.14 1.36 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.831 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.446 HG21 ' CD ' ' A' ' 41' ' ' LYS . 2.9 t -70.94 139.6 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.174 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 m -107.77 79.4 1.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 55.71 161.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.496 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 168.23 22.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.698 2.266 . . . . 0.0 112.324 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.4 t -78.68 136.05 37.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.847 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 34.3 t -51.11 106.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.814 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.252 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.441 -179.987 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.0 m -99.1 149.42 23.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.881 0.372 . . . . 0.0 110.859 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.6 t -123.93 -53.47 1.75 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.843 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.39 -42.65 14.22 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 48.8 m -57.71 152.88 14.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.917 0.389 . . . . 0.0 110.853 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.3 t -166.82 154.32 9.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 -179.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.05 -75.49 0.19 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 143.17 49.64 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.658 2.239 . . . . 0.0 112.325 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.401 ' HB2' ' ND2' ' A' ' 11' ' ' ASN . 30.8 mt -85.78 156.12 58.5 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.628 0.728 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 11' ' ' ASN . 54.1 Cg_endo -69.79 2.98 3.06 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.277 . . . . 0.0 112.322 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PRO . 65.4 m-20 -34.61 144.02 0.2 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.4 Cg_endo -69.82 1.72 4.22 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.677 2.252 . . . . 0.0 112.332 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.449 ' C ' ' O ' ' A' ' 12' ' ' PRO . 17.7 mm-40 32.62 48.69 0.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -101.37 -38.64 3.22 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.499 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 mp -71.88 101.5 2.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -63.17 138.0 58.41 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.827 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.4 t -87.41 161.6 17.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.466 ' CB ' HG22 ' A' ' 44' ' ' VAL . 1.5 m-20 -94.01 136.46 34.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -112.14 150.68 30.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.48 HD21 ' CZ2' ' A' ' 52' ' ' TRP . 7.2 mt -134.83 110.66 9.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.912 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.39 122.06 27.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -58.53 100.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.141 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.457 ' CD1' ' O ' ' A' ' 70' ' ' VAL . 7.8 mt -59.94 -36.14 76.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.936 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.6 t -155.97 127.08 7.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.874 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.21 135.09 1.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.645 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.08 149.6 23.73 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.716 0.77 . . . . 0.0 110.887 -179.807 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.546 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.82 -178.67 17.33 Favored 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.371 -0.023 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 59.6 m -68.36 153.44 95.6 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.652 0.739 . . . . 0.0 110.861 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 2.46 3.52 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.344 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.61 -10.09 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -118.44 -52.14 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -156.45 162.15 28.09 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 0.0 110.805 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 134.2 27.35 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.46 ' HG2' ' CZ ' ' A' ' 37' ' ' ARG . 53.9 Cg_endo -69.71 114.09 3.58 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.5 mp -74.57 -30.46 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.136 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.443 ' CE2' ' OG ' ' A' ' 63' ' ' SER . 14.8 m-85 -130.99 94.95 3.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.46 ' CZ ' ' HG2' ' A' ' 34' ' ' PRO . 20.4 mmt180 -53.89 160.24 1.49 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -62.73 151.99 36.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.58 -18.02 7.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.405 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -71.43 132.37 44.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.871 0.367 . . . . 0.0 110.903 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 25.6 ttmt -85.41 135.73 33.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.3 mt -128.14 148.41 50.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.873 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -98.62 130.51 45.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.878 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 18' ' ' ASP . 57.6 t -68.58 114.17 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.125 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -90.4 -53.46 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.147 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 t -146.45 154.15 41.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.847 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -120.04 119.07 32.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -127.62 98.9 5.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.15 -130.43 50.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.65 9.0 63.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.531 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -137.07 140.39 41.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 110.926 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.48 ' CZ2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.77 164.64 26.78 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.918 179.995 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.562 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 16.1 tttp -104.09 147.03 27.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.904 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.6 159.77 42.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.131 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.3 tt -126.39 141.71 45.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 20.1 p -78.25 129.87 35.58 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.7 mt -80.51 9.26 6.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.966 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -99.24 -49.4 4.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.812 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.2 p -112.77 -39.69 4.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.097 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.74 27.52 5.7 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.437 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -83.08 128.07 34.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.761 0.315 . . . . 0.0 110.862 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.478 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 8.1 mt-10 -102.02 117.27 34.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.443 ' OG ' ' CE2' ' A' ' 36' ' ' PHE . 1.8 p -147.58 169.27 19.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.562 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 24.8 m-85 -110.08 118.98 37.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -125.69 150.01 67.07 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.654 0.74 . . . . 0.0 111.081 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.565 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.77 134.03 26.97 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.308 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.99 -31.13 5.51 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.482 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.7 tp -64.84 -32.74 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.806 0.336 . . . . 0.0 111.113 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 11.6 m -80.35 2.85 23.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.457 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 33.4 m -140.52 170.63 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.35 125.99 32.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.075 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 -65.74 108.19 2.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.1 t -81.3 145.18 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.119 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 38.4 t -149.82 164.22 35.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 149.9 -174.67 29.3 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.486 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 2.29 3.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.734 2.289 . . . . 0.0 112.337 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.0 t -40.18 154.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.847 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 88.9 p -149.26 133.26 17.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.86 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.512 -179.91 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.8 m -102.3 117.46 34.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.9 m -126.8 160.02 32.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.3 -159.6 14.57 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.533 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.7 m -118.01 137.77 52.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.896 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.3 m -71.78 164.6 25.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.845 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.88 146.31 18.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.489 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 178.3 4.74 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.65 2.233 . . . . 0.0 112.331 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.7 mt -39.74 153.41 0.19 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.571 0.7 . . . . 0.0 110.948 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -20.36 34.8 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.667 2.245 . . . . 0.0 112.361 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -115.36 140.05 25.33 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.9 Cg_endo -69.71 1.83 4.05 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.689 2.259 . . . . 0.0 112.359 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 12' ' ' PRO . 2.4 pt-20 35.18 31.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . -154.71 -106.41 0.27 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 38.2 tp -121.15 102.93 8.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.814 0.34 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 p30 -56.55 161.36 2.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 30.5 t -91.47 163.91 14.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.438 ' OD2' ' NH2' ' A' ' 72' ' ' ARG . 0.8 OUTLIER -61.83 132.45 53.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.887 179.957 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -108.63 145.02 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.56 HD21 ' CH2' ' A' ' 52' ' ' TRP . 1.7 mt -134.49 110.56 9.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.63 127.09 31.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.103 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.7 t -61.75 101.36 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.1 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.464 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 8.6 mt -61.92 -31.01 71.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -160.21 128.17 4.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -40.12 140.82 0.54 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.844 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.615 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -158.94 149.18 15.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.687 0.756 . . . . 0.0 110.914 -179.848 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.569 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.3 Cg_endo -69.8 -174.52 9.7 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.34 -0.064 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -73.22 154.09 90.37 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 1.63 4.29 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.655 2.236 . . . . 0.0 112.369 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -105.86 -14.69 15.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.81 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -113.05 -51.96 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 m -158.34 162.26 27.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 133.99 26.88 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.699 2.266 . . . . 0.0 112.339 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 124.08 10.72 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.75 2.3 . . . . 0.0 112.307 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.1 mp -86.84 -25.28 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.146 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.529 ' CG ' HD21 ' A' ' 42' ' ' LEU . 10.3 m-85 -130.97 93.92 3.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -56.29 150.16 15.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 39.9 ttp85 -50.76 147.56 4.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.05 -17.84 8.87 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -68.04 138.37 55.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.926 0.394 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.5 ttmp? -89.94 143.12 27.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.529 HD21 ' CG ' ' A' ' 36' ' ' PHE . 1.7 mt -139.41 142.4 37.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.951 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.3 ttt180 -95.45 132.03 40.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.864 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.47 HG21 ' CD1' ' A' ' 20' ' ' LEU . 95.8 t -68.0 112.63 3.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.096 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.459 HD13 ' CG2' ' A' ' 55' ' ' ILE . 1.1 mp -91.39 -53.28 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 m -137.66 143.07 41.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.09 115.01 28.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.865 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -126.68 85.97 2.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.893 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.1 -125.36 38.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.81 -19.07 73.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.49 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.579 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 24.3 m95 -113.39 131.87 55.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.56 ' CH2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -131.94 164.35 26.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.918 179.962 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.558 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.0 tttp -99.95 144.16 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.894 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.0 160.33 44.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.07 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CG2' HD13 ' A' ' 45' ' ' ILE . 20.4 tt -130.55 139.66 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.078 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.1 m -72.37 129.41 38.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.857 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.0 mt -79.15 5.66 11.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.1 t -106.03 -51.08 3.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.7 p -99.31 -44.24 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.185 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 100.95 26.76 7.75 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.518 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 64.5 mtt180 -86.19 128.19 34.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.448 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 12.9 mt-10 -98.21 117.45 32.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.1 t -147.34 169.38 19.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 9.2 m-85 -112.63 114.79 27.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.405 ' H ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.53 150.76 58.6 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 111.138 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.579 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.81 135.99 31.75 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.637 2.225 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.9 -36.86 20.9 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.539 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.464 HG22 ' N ' ' A' ' 69' ' ' CYS . 8.3 tt -59.96 -26.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.808 0.337 . . . . 0.0 111.071 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . 0.464 ' N ' HG22 ' A' ' 68' ' ' ILE . 1.7 m -82.56 -7.6 59.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.8 m -131.22 164.45 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.149 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.464 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -125.93 133.31 51.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.092 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.438 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.2 tpt180 -61.0 97.72 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 3.8 t -74.83 140.34 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.144 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.8 t -121.78 51.74 1.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.852 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 176.23 165.78 32.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.526 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 179.88 3.4 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.67 2.246 . . . . 0.0 112.322 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -70.16 89.25 0.63 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 7.7 m -81.67 -54.44 5.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.897 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.478 179.973 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.486 -0.245 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 93.4 p -124.97 83.44 2.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.808 0.337 . . . . 0.0 110.865 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.2 p -170.84 120.86 0.55 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.58 -61.87 0.63 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.465 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.2 t -130.05 40.87 3.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.863 0.364 . . . . 0.0 110.867 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 7' ' ' GLY . 45.1 m -71.43 107.77 4.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.853 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 6' ' ' SER . . . 34.43 69.49 0.19 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.513 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 171.35 14.65 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.681 2.254 . . . . 0.0 112.311 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.428 HD13 ' N ' ' A' ' 11' ' ' ASN . 4.5 pp -96.88 152.56 38.48 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 0.0 110.945 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -43.51 2.64 Favored 'Trans proline' 0 C--N 1.34 0.127 0 C-N-CA 122.677 2.252 . . . . 0.0 112.329 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.428 ' N ' HD13 ' A' ' 9' ' ' LEU . 2.5 m-80 -46.96 159.51 0.38 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 0.0 110.907 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 0.01 6.28 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.682 2.255 . . . . 0.0 112.308 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -65.15 111.18 2.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.925 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.32 85.74 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.473 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.5 mt -94.68 118.7 32.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.802 0.334 . . . . 0.0 110.882 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -58.98 144.16 45.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 39.1 t -113.57 155.21 25.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.802 -179.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.432 ' CB ' HG22 ' A' ' 44' ' ' VAL . 28.1 m-20 -68.03 137.37 55.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.86 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -107.24 150.04 27.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 7.3 mt -132.56 121.31 23.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -92.09 119.54 31.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.063 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.462 ' CG2' HD13 ' A' ' 42' ' ' LEU . 96.2 t -59.11 96.67 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.16 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.493 ' CD1' ' O ' ' A' ' 68' ' ' ILE . 7.7 mt -54.95 -35.32 64.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.929 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 t -157.46 128.65 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.841 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.69 137.98 1.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.881 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.609 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -155.18 148.55 18.48 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.685 0.755 . . . . 0.0 110.918 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.548 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.4 Cg_endo -69.71 -173.98 9.0 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.379 -0.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 6.1 m -74.67 155.51 87.15 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.689 0.757 . . . . 0.0 110.843 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 3.44 2.79 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.658 2.238 . . . . 0.0 112.379 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -107.77 -18.22 13.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -109.18 -47.92 7.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.0 OUTLIER -164.1 163.58 15.25 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.644 0.735 . . . . 0.0 110.864 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 132.24 22.87 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.675 2.25 . . . . 0.0 112.309 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 118.24 5.57 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.649 2.233 . . . . 0.0 112.306 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.31 -28.42 13.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.091 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.507 ' CG ' HD23 ' A' ' 42' ' ' LEU . 16.8 m-85 -127.3 98.42 5.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.65 160.38 4.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.854 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -62.22 144.61 55.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.23 -11.43 23.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.461 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -71.25 130.56 41.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.869 0.366 . . . . 0.0 110.896 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -81.46 137.02 35.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.507 HD23 ' CG ' ' A' ' 36' ' ' PHE . 4.4 mt -133.16 139.78 47.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttt180 -90.19 130.66 36.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.831 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.432 HG22 ' CB ' ' A' ' 18' ' ' ASP . 57.3 t -66.89 110.66 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.481 ' CG2' ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -80.19 -54.97 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.124 179.896 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 70.9 m -157.32 147.46 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -98.58 115.47 28.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 35.5 mt-10 -113.99 85.78 2.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.72 -122.99 30.58 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -77.77 -22.58 69.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.473 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 10.1 m95 -113.92 150.51 33.62 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.754 0.312 . . . . 0.0 110.915 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.428 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -136.08 164.2 28.57 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.949 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.53 ' HE2' ' CE2' ' A' ' 64' ' ' TYR . 4.7 ttmm -103.22 150.83 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.937 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -158.91 143.77 15.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.072 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.2 tt -108.1 144.62 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.1 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 p -83.68 130.27 34.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.0 mt -77.21 7.94 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.3 t -95.18 -51.96 4.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.843 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.8 p -111.29 -43.16 3.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.144 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.69 26.45 5.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -86.27 127.72 34.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.763 0.316 . . . . 0.0 110.857 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -99.15 118.11 35.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 9.0 t -147.11 167.75 23.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.53 ' CE2' ' HE2' ' A' ' 53' ' ' LYS . 4.3 m-85 -105.96 129.42 54.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.942 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.478 HD11 ' N ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -135.16 150.97 74.3 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.594 0.711 . . . . 0.0 111.125 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.563 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.9 Cg_endo -69.74 133.21 25.06 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.732 2.288 . . . . 0.0 112.332 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.59 -30.02 8.17 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.465 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.493 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 13.5 tt -65.5 -30.12 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.834 0.349 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . 0.433 ' N ' HG21 ' A' ' 68' ' ' ILE . 4.8 m -80.36 -5.72 56.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.461 ' N ' HD12 ' A' ' 23' ' ' LEU . 34.9 m -135.03 171.35 17.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.465 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -134.64 132.43 38.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.076 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -69.3 106.79 3.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.857 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.6 t -74.15 143.54 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 m -99.4 41.69 1.14 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.42 -161.3 52.51 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 105.78 1.54 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.681 2.254 . . . . 0.0 112.365 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 58.0 m -89.97 79.73 6.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.9 t -108.4 41.51 1.55 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.883 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 81.7 p -89.9 140.79 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.831 0.348 . . . . 0.0 110.872 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 t 45.53 42.17 7.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 88.11 -156.09 26.96 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -101.97 -60.14 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.0 p -120.86 167.92 12.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.829 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.74 163.11 14.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.443 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 147.11 62.31 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.683 2.255 . . . . 0.0 112.365 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.401 ' H ' ' CD2' ' A' ' 9' ' ' LEU . 3.4 mm? -44.08 148.25 0.83 Allowed Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.601 0.715 . . . . 0.0 110.888 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 79.96 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.295 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -113.69 142.84 28.36 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.603 0.716 . . . . 0.0 110.88 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -1.39 8.38 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.693 2.262 . . . . 0.0 112.372 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.1 111.8 1.04 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.41 -50.4 3.28 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 72.0 mt -92.98 138.6 31.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.823 0.344 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -91.93 144.63 25.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.817 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 30.7 t -123.11 160.85 25.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.874 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.432 ' CB ' HG22 ' A' ' 44' ' ' VAL . 60.7 m-20 -99.22 119.34 37.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.858 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -101.62 143.68 31.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.921 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.558 HD22 ' CH2' ' A' ' 52' ' ' TRP . 11.0 mt -130.45 108.76 10.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.06 122.92 28.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.063 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 57.3 t -58.86 103.62 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.12 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.47 HD21 ' CB ' ' A' ' 71' ' ' ALA . 11.5 mt -67.17 -33.42 75.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 25' ' ' ASP . 27.6 t -153.64 121.85 6.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.834 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -37.03 149.38 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.875 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.646 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -169.82 150.52 3.85 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.685 0.755 . . . . 0.0 110.922 -179.85 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.576 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.3 10.69 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.304 -0.059 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 48.0 m -74.74 155.06 87.22 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.662 0.744 . . . . 0.0 110.855 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 3.42 2.76 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.716 2.277 . . . . 0.0 112.359 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -105.27 -22.33 13.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.843 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.7 mt -105.77 -48.59 8.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.7 OUTLIER -164.11 164.67 14.14 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.682 0.753 . . . . 0.0 110.836 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 135.62 30.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.642 2.228 . . . . 0.0 112.35 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 125.24 11.88 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.298 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 3.6 mp -86.6 -26.4 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.524 ' CG ' HD23 ' A' ' 42' ' ' LEU . 10.5 m-85 -131.9 100.58 5.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -63.28 155.25 29.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.814 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -55.21 150.35 11.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.807 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.3 -10.36 16.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -72.4 151.52 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.868 0.366 . . . . 0.0 110.906 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.2 tttt -102.26 138.76 38.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.928 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.524 HD23 ' CG ' ' A' ' 36' ' ' PHE . 5.6 mt -135.12 152.52 51.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.927 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.4 ttt180 -105.1 129.65 53.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.87 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.432 HG22 ' CB ' ' A' ' 18' ' ' ASP . 99.1 t -65.19 111.82 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.406 HD11 ' CG2' ' A' ' 55' ' ' ILE . 1.0 OUTLIER -93.19 -52.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.161 179.882 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.8 m -141.15 150.96 43.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -118.43 109.82 16.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.875 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -116.31 86.0 2.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.75 -123.27 32.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.64 -23.51 69.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.48 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.572 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.3 m95 -109.91 141.93 41.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.558 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.15 164.27 28.05 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.563 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.2 tttp -100.75 141.51 33.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.905 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.46 159.75 44.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.455 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -131.81 130.82 61.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 t -67.82 130.88 44.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.69 9.4 5.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.946 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 15.1 t -105.55 -48.01 3.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.2 p -104.41 -35.79 7.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.45 27.84 18.87 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.496 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.418 ' C ' HG13 ' A' ' 55' ' ' ILE . 44.0 mtt85 -89.25 124.98 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.797 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.475 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 5.0 mt-10 -94.31 117.33 29.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.943 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.2 t -147.6 169.63 19.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.824 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 28.3 m-85 -110.96 118.13 35.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.55 HG22 ' CD1' ' A' ' 26' ' ' TYR . 0.2 OUTLIER -126.19 152.54 73.66 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.593 0.711 . . . . 0.0 111.146 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.572 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.77 137.66 35.97 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.679 2.252 . . . . 0.0 112.351 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.81 -33.23 6.39 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.5 tp -64.88 -31.11 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 111.162 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.1 t -72.87 -12.77 61.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 20' ' ' LEU . 18.4 m -131.04 170.21 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.47 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -133.48 136.45 45.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -67.94 108.37 3.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 12.2 t -87.52 142.69 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.141 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.9 m -75.59 -48.66 21.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.81 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 175.51 164.72 30.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.491 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.86 90.27 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.653 2.235 . . . . 0.0 112.309 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 24.8 p -107.28 40.83 1.6 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 59.8 p -45.0 120.67 2.46 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.911 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.475 -179.967 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 N-CA-C 112.528 -0.229 . . . . 0.0 112.528 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 t -46.29 171.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.36 . . . . 0.0 110.853 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.6 t -78.35 90.53 4.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.87 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -106.77 -121.44 4.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.4 m -115.36 45.74 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.862 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.8 t -77.76 -43.91 29.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -72.78 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.518 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 173.01 11.68 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.701 2.267 . . . . 0.0 112.302 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.419 ' CD2' ' H ' ' A' ' 9' ' ' LEU . 3.5 mm? -43.41 143.96 1.36 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.581 0.705 . . . . 0.0 110.902 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.9 Cg_endo -69.8 -16.7 37.53 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.697 2.265 . . . . 0.0 112.319 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' PRO . 7.7 m-20 -34.52 150.67 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.655 0.741 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.6 Cg_endo -69.79 0.63 5.39 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.686 2.257 . . . . 0.0 112.348 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.447 ' C ' ' O ' ' A' ' 12' ' ' PRO . 9.0 pt-20 -34.98 94.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.872 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . -136.61 45.47 1.08 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.462 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 64.0 mt -93.67 141.67 28.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.35 . . . . 0.0 110.896 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -71.97 134.94 46.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.856 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 23.1 t -101.48 164.82 11.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.46 ' CB ' HG22 ' A' ' 44' ' ' VAL . 73.3 m-20 -78.14 127.66 32.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.883 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -111.77 152.63 27.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.506 HD12 ' CE2' ' A' ' 52' ' ' TRP . 7.7 mt -137.43 116.03 12.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.57 127.52 33.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.469 ' CG2' HD13 ' A' ' 42' ' ' LEU . 84.4 t -66.85 97.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.454 HD21 ' CB ' ' A' ' 71' ' ' ALA . 9.4 mt -57.19 -35.93 70.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.5 t -156.38 128.2 7.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.898 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -39.1 149.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.639 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -170.61 150.05 3.14 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.729 0.776 . . . . 0.0 110.911 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.553 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.7 -174.7 9.79 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.717 -1.785 . . . . 0.0 112.355 -0.098 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.6 m -80.35 158.46 71.65 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.874 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 3.52 2.75 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.649 2.232 . . . . 0.0 112.321 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -103.89 -13.22 16.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.3 mt -119.95 -49.34 3.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.101 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -162.83 163.46 17.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.717 0.77 . . . . 0.0 110.843 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 133.56 25.8 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.676 2.251 . . . . 0.0 112.353 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 114.74 3.81 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.313 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.8 mp -73.45 -30.52 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.57 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.3 m-85 -130.66 110.83 11.67 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.92 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -69.56 165.79 20.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.443 ' CG ' ' O ' ' A' ' 23' ' ' LEU . 2.4 tmt_? -67.22 141.14 57.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.46 11.52 81.85 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.486 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.4 ' OE1' ' O ' ' A' ' 41' ' ' LYS . 0.4 OUTLIER -100.35 138.22 37.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.976 0.417 . . . . 0.0 110.843 -179.857 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.4 ' O ' ' OE1' ' A' ' 40' ' ' GLU . 30.2 ttmt -85.54 140.63 30.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.469 HD13 ' CG2' ' A' ' 22' ' ' VAL . 10.1 mt -134.2 149.69 51.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 29.7 ttt180 -103.89 129.15 51.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.46 HG22 ' CB ' ' A' ' 18' ' ' ASP . 45.8 t -67.97 114.82 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.095 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -88.8 -52.58 10.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.9 t -157.53 128.32 6.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -89.15 125.95 35.26 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -125.06 85.96 2.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.898 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.68 -128.08 37.49 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.8 -24.99 75.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 13.2 m95 -112.69 146.55 38.51 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.786 0.327 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.506 ' CE2' HD12 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.98 164.84 26.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.992 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.575 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.0 tttp -103.37 145.15 30.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.45 163.72 38.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.458 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 21.0 tt -131.19 135.21 60.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.57 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 37.4 p -76.23 129.09 36.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.8 mt -77.59 9.28 3.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.1 m -95.92 -49.74 5.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 12.2 p -114.75 -28.92 6.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.143 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.11 26.48 18.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.508 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 23.7 mtt85 -83.12 128.08 34.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.756 0.312 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.458 ' HG3' ' CD1' ' A' ' 55' ' ' ILE . 10.1 mt-10 -97.66 117.26 31.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.4 t -147.55 170.11 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.575 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 10.6 m-85 -110.78 123.62 50.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.467 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -130.2 150.64 76.66 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.669 0.747 . . . . 0.0 111.134 179.909 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.574 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.9 Cg_endo -69.73 130.67 19.78 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.675 2.25 . . . . 0.0 112.374 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.13 -36.21 7.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 6.3 tt -58.9 -33.55 50.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 111.111 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' GLY . 25.5 m -125.13 174.04 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.454 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -134.21 132.15 39.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.115 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.452 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.1 tpp85 -62.77 105.66 0.69 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.83 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.0 t -78.79 144.4 11.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.6 m -90.56 -51.91 5.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.34 -157.79 15.74 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.527 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 -34.24 14.85 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.698 2.266 . . . . 0.0 112.308 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.7 t -105.47 133.05 50.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 88.9 p -47.59 -49.71 26.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.843 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.517 -179.96 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.367 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.0 m -162.23 116.39 1.83 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.3 t -139.16 123.26 17.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.868 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.71 105.22 3.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.484 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.5 m -117.86 -56.67 2.17 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.902 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.8 t -172.85 174.62 3.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.36 145.15 4.35 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.5 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 164.16 35.64 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.721 2.28 . . . . 0.0 112.328 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.444 HD12 ' N ' ' A' ' 11' ' ' ASN . 4.4 pp -67.69 152.34 96.38 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.595 0.712 . . . . 0.0 110.909 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 -45.41 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.683 2.256 . . . . 0.0 112.363 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.444 ' N ' HD12 ' A' ' 9' ' ' LEU . 12.3 p-10 -166.45 143.78 4.28 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.577 0.703 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -1.59 8.72 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.691 2.261 . . . . 0.0 112.394 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 59.14 42.89 18.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.66 -48.73 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.523 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 30.7 mt -94.38 124.38 38.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 110.93 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -67.48 170.18 7.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.1 t -110.41 165.03 12.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.839 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.499 ' O ' ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -95.46 131.12 41.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.829 179.947 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.78 150.68 22.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.525 HD21 ' CZ2' ' A' ' 52' ' ' TRP . 10.0 mt -132.91 111.03 10.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.926 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.46 126.33 31.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.2 96.25 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.165 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 7.9 mt -59.13 -28.84 66.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.916 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.7 t -161.27 125.67 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.838 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -38.79 143.48 0.15 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.859 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -160.28 150.32 14.81 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.67 0.747 . . . . 0.0 110.917 -179.811 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.566 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.77 171.49 53.48 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.684 -1.798 . . . . 0.0 112.381 -0.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.17 148.38 11.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.634 0.731 . . . . 0.0 110.852 -179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 5.28 1.76 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.7 2.267 . . . . 0.0 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -109.01 -21.75 12.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -101.65 -53.43 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.097 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.51 164.28 21.03 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.669 0.747 . . . . 0.0 110.832 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 132.16 22.84 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.27 . . . . 0.0 112.364 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 124.42 11.06 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.666 2.244 . . . . 0.0 112.366 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mp -89.25 -25.31 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.165 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.565 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.6 m-85 -127.47 89.65 2.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.885 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 20.3 mmm-85 -51.01 160.11 0.52 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.449 ' CZ ' ' O ' ' A' ' 23' ' ' LEU . 11.1 ttt85 -61.58 147.22 46.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.97 -13.3 14.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -69.7 136.5 51.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.895 0.379 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -86.63 139.06 31.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.869 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.505 HD23 ' CG ' ' A' ' 36' ' ' PHE . 8.1 mt -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.7 ttt-85 -87.53 132.94 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' A' ' 18' ' ' ASP . 58.2 t -71.22 108.2 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -78.56 -50.15 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.177 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -158.71 157.43 31.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -109.1 118.85 37.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.877 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.8 mm-40 -120.44 85.92 2.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.47 -126.02 38.71 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.1 -25.0 74.63 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.554 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.4 m0 -111.69 153.53 26.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.765 0.317 . . . . 0.0 110.923 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.525 ' CZ2' HD21 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.04 164.13 28.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.561 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.8 tttm -98.94 143.07 29.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.895 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.94 164.08 39.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.416 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 19.3 tt -132.02 146.15 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.115 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.565 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 82.0 p -86.21 126.44 34.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.6 mt -76.09 5.92 6.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.6 t -90.6 -49.84 6.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.6 p -116.28 -34.7 4.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.14 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 102.46 23.89 8.65 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.457 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.9 mtt180 -82.08 124.51 29.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.846 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.418 ' HB3' ' NZ ' ' A' ' 53' ' ' LYS . 8.1 mt-10 -98.87 118.55 35.88 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.5 t -147.23 169.97 18.25 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.1 m-85 -105.05 119.79 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.437 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.42 147.52 60.51 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.663 0.744 . . . . 0.0 111.09 179.904 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.554 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.78 133.77 26.34 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.694 2.262 . . . . 0.0 112.345 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.33 -30.88 6.13 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.503 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.8 tp -64.68 -32.69 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 9.4 m -80.01 6.94 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.416 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 36.0 m -147.56 169.81 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.459 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -134.2 136.08 43.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.136 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.437 ' NH1' ' OD2' ' A' ' 18' ' ' ASP . 2.9 tpp85 -68.13 112.44 5.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.407 HG13 ' N ' ' A' ' 74' ' ' SER . 15.2 t -80.52 144.06 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.407 ' N ' HG13 ' A' ' 73' ' ' VAL . 20.0 m -110.36 105.49 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.829 -179.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 44.83 -157.91 0.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.493 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 89.2 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.704 2.269 . . . . 0.0 112.327 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 93.0 p -109.28 86.42 2.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 48.7 p -79.78 168.92 18.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.829 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 179.98 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.8 m -72.73 -60.53 2.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.827 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m 64.65 42.9 4.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 139.4 119.42 1.67 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.499 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.2 t -100.95 143.94 30.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.9 0.381 . . . . 0.0 110.848 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t -157.27 156.43 32.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.25 -164.14 13.05 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.483 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 148.98 66.22 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.692 2.261 . . . . 0.0 112.396 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.1 mt -104.51 156.3 36.08 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.627 0.727 . . . . 0.0 110.901 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.5 Cg_endo -69.77 2.48 3.5 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.68 2.253 . . . . 0.0 112.328 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PRO . 31.3 m120 -34.34 143.29 0.21 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.641 0.734 . . . . 0.0 110.886 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.487 ' O ' ' N ' ' A' ' 14' ' ' GLY . 54.1 Cg_endo -69.73 -0.36 6.78 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.68 2.253 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -39.05 93.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.875 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 153.75 -83.34 0.16 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.504 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 56.9 mt -117.72 121.43 40.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 110.897 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -75.75 157.39 33.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 13.4 t -101.52 162.04 13.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.869 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.434 ' CB ' HG22 ' A' ' 44' ' ' VAL . 2.6 m-20 -74.93 128.99 36.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.879 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -105.29 148.95 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 2.4 mt -135.87 109.53 8.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.08 126.15 30.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.466 HG23 ' CD1' ' A' ' 42' ' ' LEU . 84.0 t -60.8 101.6 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.432 HD23 ' CB ' ' A' ' 71' ' ' ALA . 16.2 mt -62.13 -30.84 71.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.3 t -158.4 127.54 5.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -40.72 145.52 0.19 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.837 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.581 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.9 148.43 6.43 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.636 0.732 . . . . 0.0 110.959 -179.849 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.558 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.81 -174.12 9.26 Favored 'Cis proline' 0 C--O 1.231 0.154 0 C-N-CA 122.708 -1.788 . . . . 0.0 112.331 -0.036 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.5 m -77.06 155.83 82.38 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.651 0.739 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 2.78 3.23 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.676 2.251 . . . . 0.0 112.346 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -106.71 -14.04 15.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.02 -48.66 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -163.58 163.04 16.74 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.675 0.75 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 133.03 24.56 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.719 2.28 . . . . 0.0 112.316 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 119.7 6.6 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.6 mp -81.02 -22.81 10.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.51 ' CG ' HD23 ' A' ' 42' ' ' LEU . 13.6 m-85 -134.66 99.77 4.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.881 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -58.65 163.9 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.442 ' HD3' ' N ' ' A' ' 39' ' ' GLY . 3.8 tmt_? -65.69 142.44 58.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.826 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.442 ' N ' ' HD3' ' A' ' 38' ' ' ARG . . . 77.96 6.81 87.5 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -86.36 144.0 27.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.464 ' CG ' HD13 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -87.29 141.1 28.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 36' ' ' PHE . 4.8 mt -140.0 145.1 37.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -103.78 128.48 51.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.434 HG22 ' CB ' ' A' ' 18' ' ' ASP . 59.5 t -65.87 108.53 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.147 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.422 ' CG2' ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -79.87 -50.51 17.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.125 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.4 t -163.14 135.83 5.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -89.45 129.3 35.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -130.05 86.2 2.38 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 65.29 -131.46 35.58 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.509 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.42 -20.36 78.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.467 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.57 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -116.89 152.12 35.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.741 0.305 . . . . 0.0 110.923 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.18 164.23 28.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.56 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 19.3 tttp -102.17 142.53 33.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.953 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.54 156.14 36.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.135 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.404 HG13 ' C ' ' A' ' 61' ' ' ARG . 19.6 tt -124.08 137.17 57.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.1 t -68.04 128.16 35.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.865 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.464 HD13 ' CG ' ' A' ' 41' ' ' LYS . 6.4 mt -78.32 8.39 5.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.6 t -111.65 -45.98 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.862 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.416 ' HG1' ' N ' ' A' ' 60' ' ' GLY . 51.4 p -102.14 -36.14 8.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.135 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.416 ' N ' ' HG1' ' A' ' 59' ' ' THR . . . 86.58 33.13 13.93 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.469 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.404 ' C ' HG13 ' A' ' 55' ' ' ILE . 42.7 mtt180 -96.8 125.96 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.761 0.315 . . . . 0.0 110.89 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -90.66 117.43 29.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.6 t -147.66 169.99 18.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.812 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.56 ' CE1' ' HG3' ' A' ' 53' ' ' LYS . 18.9 m-85 -112.75 117.37 32.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.889 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -126.78 151.12 73.1 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.629 0.728 . . . . 0.0 111.123 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.57 ' HD3' ' CH2' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.83 135.76 31.09 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.661 2.241 . . . . 0.0 112.331 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.17 -30.95 8.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 69' ' ' CYS . 6.7 tp -65.55 -30.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.831 0.348 . . . . 0.0 111.162 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . 0.463 ' N ' HG22 ' A' ' 68' ' ' ILE . 4.4 m -79.78 -0.19 33.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.99 163.11 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.432 ' CB ' HD23 ' A' ' 23' ' ' LEU . . . -128.2 137.48 52.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.063 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.33 112.19 2.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.851 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.4 t -90.62 148.91 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.139 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.8 m -78.32 -55.62 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 140.94 -158.69 26.36 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.447 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -34.76 14.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.661 2.241 . . . . 0.0 112.405 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.8 t -138.36 169.06 18.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.872 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 30.6 t -124.32 112.35 16.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.865 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.46 179.985 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 91.2 p -68.27 -34.88 77.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.883 0.373 . . . . 0.0 110.877 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.2 t 58.76 46.27 14.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.58 112.87 0.55 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.492 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.0 p -150.03 163.71 37.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.891 0.377 . . . . 0.0 110.814 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 t -56.6 121.96 10.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.37 77.58 0.11 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 150.89 68.53 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.403 ' N ' HD22 ' A' ' 9' ' ' LEU . 1.9 mm? -47.25 157.66 0.51 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.613 0.721 . . . . 0.0 110.905 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.9 Cg_endo -69.74 2.06 3.86 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.355 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' PRO . 29.0 m-20 -34.46 143.96 0.2 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.605 0.717 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.466 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.6 Cg_endo -69.76 2.53 3.45 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.701 2.267 . . . . 0.0 112.359 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -47.06 91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 176.92 -97.12 0.11 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.485 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 43.4 tp -121.16 122.98 41.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.787 0.327 . . . . 0.0 110.934 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -59.55 149.5 29.81 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.881 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.1 t -113.91 169.63 8.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.437 ' CB ' HG22 ' A' ' 44' ' ' VAL . 3.9 m-20 -71.45 136.89 47.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.916 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -109.89 150.8 27.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.556 HD23 ' CZ2' ' A' ' 52' ' ' TRP . 5.3 mt -129.64 114.47 16.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.22 116.73 23.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 95.2 t -54.92 103.65 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.114 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.467 HD13 ' N ' ' A' ' 70' ' ' VAL . 8.6 mt -66.53 -31.0 71.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 25' ' ' ASP . 30.6 t -160.33 118.79 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.859 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 24' ' ' SER . 10.4 p-10 -34.28 140.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.644 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.14 149.81 18.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.69 0.757 . . . . 0.0 110.923 -179.801 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.56 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.85 179.54 22.2 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.319 -0.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 p -72.46 157.2 89.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.05 2.41 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.677 2.252 . . . . 0.0 112.316 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -101.28 -13.18 18.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.839 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 4.8 mt -120.53 -60.6 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -147.96 163.07 28.82 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.651 0.738 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 137.36 35.06 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.681 2.254 . . . . 0.0 112.323 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 118.96 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.424 HG22 ' CD ' ' A' ' 61' ' ' ARG . 2.4 mp -80.86 -26.19 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.525 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 13.6 m-85 -131.32 93.55 3.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -54.8 161.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.8 ttm180 -62.06 147.79 46.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.96 -5.85 57.45 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -79.85 134.42 36.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.924 0.392 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -84.33 138.06 33.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.522 HD21 ' CG ' ' A' ' 36' ' ' PHE . 9.0 mt -130.56 141.32 50.46 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.3 ttp180 -93.18 126.73 38.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.437 HG22 ' CB ' ' A' ' 18' ' ' ASP . 96.1 t -66.05 112.16 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -88.27 -53.3 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.15 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -144.45 145.31 31.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.838 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -108.68 118.41 36.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -129.4 86.44 2.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.881 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.26 -123.78 33.99 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.05 -19.03 65.93 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 25.3 m95 -113.42 131.56 55.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.752 0.311 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.556 ' CZ2' HD23 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.44 164.36 26.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.956 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.572 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 8.3 tttp -100.2 142.27 31.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -150.78 157.83 43.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.112 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 19.0 tt -121.78 145.26 28.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.525 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 6.1 p -86.75 126.0 34.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 8.0 mt -75.14 5.75 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 t -92.01 -48.83 6.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.9 p -118.11 -28.69 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.85 25.92 13.94 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.48 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.424 ' CD ' HG22 ' A' ' 35' ' ' ILE . 76.6 mtt180 -80.86 132.29 35.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.306 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.439 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 4.9 mt-10 -103.29 117.38 34.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.866 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.0 t -147.67 170.18 18.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.572 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 38.5 m-85 -110.55 120.8 43.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.909 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.405 ' N ' ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.13 149.69 70.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.56 0.695 . . . . 0.0 111.174 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.574 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.72 134.58 28.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.67 2.247 . . . . 0.0 112.382 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.81 -30.33 8.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 69' ' ' CYS . 6.5 tp -65.36 -30.1 49.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.802 0.334 . . . . 0.0 111.152 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . 0.444 ' N ' HG22 ' A' ' 68' ' ' ILE . 16.6 m -84.19 8.23 16.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.467 ' N ' HD13 ' A' ' 23' ' ' LEU . 22.9 m -148.95 168.9 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.461 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -131.62 131.98 43.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -68.92 112.18 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.885 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t -86.67 144.21 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.164 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -118.47 42.42 2.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.852 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.83 160.42 11.59 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.501 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -174.93 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.685 2.257 . . . . 0.0 112.31 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 35.0 t -85.87 -57.55 3.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.0 m -86.77 140.57 29.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.501 -179.992 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.8 t -163.14 121.54 2.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.908 0.385 . . . . 0.0 110.881 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 98.5 p -117.71 151.03 38.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.892 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.98 112.07 0.27 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.3 m -84.16 -52.84 5.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 110.838 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 97.8 p -116.59 43.44 2.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.861 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.49 125.0 0.59 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.542 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 146.9 61.66 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.663 2.242 . . . . 0.0 112.35 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.3 mt -144.23 151.41 51.59 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.631 0.729 . . . . 0.0 110.912 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 79.7 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.662 2.241 . . . . 0.0 112.352 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -143.82 156.16 59.22 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.644 0.735 . . . . 0.0 110.86 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 1.15 4.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.693 2.262 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.98 95.14 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.868 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.91 -61.11 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 33.9 mt -91.99 145.63 24.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.821 0.343 . . . . 0.0 110.905 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.63 171.01 7.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.414 ' HB3' ' CG ' ' A' ' 43' ' ' ARG . 23.5 t -118.64 166.24 12.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.847 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -83.07 148.41 27.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -109.11 144.87 36.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.493 HD22 ' CH2' ' A' ' 52' ' ' TRP . 4.2 mt -131.05 112.07 12.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.61 126.38 30.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.144 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.424 ' CG2' HD13 ' A' ' 42' ' ' LEU . 95.4 t -66.52 102.44 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.461 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 4.7 mt -61.84 -32.16 72.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.906 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.3 t -156.23 125.24 6.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.846 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -41.47 148.09 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.57 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -167.37 148.42 5.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.778 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.563 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.76 -174.36 9.47 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.323 -0.081 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.9 m -81.59 158.57 68.34 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.69 0.757 . . . . 0.0 110.85 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 3.17 2.95 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.668 2.245 . . . . 0.0 112.324 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -107.16 -6.15 17.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.39 -43.17 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.151 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.2 m -170.92 163.32 5.43 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.653 0.74 . . . . 0.0 110.842 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 131.62 21.66 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.387 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.18 3.61 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.378 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.7 mp -72.56 -29.21 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.489 ' CD1' ' OG ' ' A' ' 56' ' ' SER . 10.1 m-85 -127.75 104.64 7.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.88 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.451 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.9 OUTLIER -65.59 159.65 24.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.859 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 25.6 ttp180 -62.49 141.39 58.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.25 7.69 88.3 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -91.92 139.75 30.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -88.54 137.2 32.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.933 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.424 HD13 ' CG2' ' A' ' 22' ' ' VAL . 4.9 mt -134.65 149.71 50.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.414 ' CG ' ' HB3' ' A' ' 17' ' ' SER . 17.7 ttp180 -100.62 131.66 46.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.479 HG22 ' CD1' ' A' ' 20' ' ' LEU . 45.7 t -71.41 116.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -89.58 -49.41 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -152.3 149.36 28.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -108.52 119.27 39.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.842 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -122.93 85.84 2.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.67 -122.14 28.08 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.509 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.76 -24.99 61.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.0 m95 -111.6 141.67 44.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.79 0.329 . . . . 0.0 110.942 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.493 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.35 164.71 25.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.893 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.56 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 19.0 tttt -99.73 146.61 26.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.56 167.07 31.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 18.7 tt -138.49 146.8 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.155 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.489 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 5.7 m -81.18 132.66 35.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.3 mt -80.08 9.43 5.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.939 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 m -113.17 -51.12 2.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 77.8 p -97.49 -33.95 11.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.31 27.79 35.38 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 54.2 mtt-85 -90.05 122.87 33.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.804 0.335 . . . . 0.0 110.882 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -92.54 118.53 31.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.3 m -147.11 165.78 28.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.56 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 27.9 m-85 -108.73 120.2 41.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.914 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.467 ' N ' HD12 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.36 151.81 75.34 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.636 0.731 . . . . 0.0 111.149 179.909 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.563 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.69 130.14 18.91 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.37 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.45 -31.69 6.96 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.503 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 11.7 tt -63.0 -31.92 54.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.838 0.352 . . . . 0.0 111.125 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.7 m -77.08 -15.51 59.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 25.2 m -121.3 167.77 14.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.108 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.461 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -131.15 131.64 44.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.448 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 7.1 tpp85 -63.14 106.14 0.81 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 74' ' ' SER . 44.1 t -76.68 148.62 6.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.155 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.403 ' C ' ' O ' ' A' ' 73' ' ' VAL . 7.8 m -37.61 149.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.855 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -99.94 163.51 19.38 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.437 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 91.75 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.688 2.259 . . . . 0.0 112.363 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 78.9 p -128.04 108.75 10.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.84 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 58.6 p -45.98 151.44 0.47 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.988 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.0 m -148.21 168.74 21.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.866 0.365 . . . . 0.0 110.861 -179.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 85.3 p -122.38 118.85 29.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.821 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.94 130.8 0.34 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.475 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 m -103.05 43.29 1.09 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.868 0.366 . . . . 0.0 110.882 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 99.9 p -102.33 134.25 45.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.95 -94.97 0.13 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.481 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 140.58 43.3 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.386 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.9 mt -124.46 144.14 45.17 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.585 0.707 . . . . 0.0 110.924 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -46.11 1.34 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.727 2.284 . . . . 0.0 112.323 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -107.18 161.25 23.59 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.624 0.726 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.668 2.245 . . . . 0.0 112.342 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -55.0 96.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 141.02 -82.33 0.24 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -69.18 138.38 54.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.811 0.339 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -75.78 162.06 28.5 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.3 t -127.99 149.86 50.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.839 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.461 ' CB ' HG21 ' A' ' 44' ' ' VAL . 70.4 m-20 -84.6 119.57 25.36 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.898 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 m-85 -105.21 148.11 27.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.416 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . 6.7 mt -130.21 107.89 9.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.37 123.42 26.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 58.5 t -60.09 97.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.13 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.471 ' CD1' ' O ' ' A' ' 70' ' ' VAL . 11.2 mt -61.02 -33.9 73.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -162.25 130.1 3.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.913 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 p30 -41.15 146.73 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.634 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.85 149.67 7.1 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.633 0.73 . . . . 0.0 110.929 -179.841 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.553 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.8 Cg_endo -69.76 -177.42 14.5 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.314 -0.031 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 1.2 t -69.55 153.92 95.29 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.722 0.773 . . . . 0.0 110.86 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 4.0 2.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.685 2.256 . . . . 0.0 112.325 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -107.87 -24.34 11.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.869 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.2 mt -101.59 -54.78 6.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.129 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -153.95 164.34 20.99 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.91 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 128.28 15.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 121.0 7.71 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.727 2.285 . . . . 0.0 112.355 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.0 mp -80.24 -28.08 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.521 ' CG ' HD22 ' A' ' 42' ' ' LEU . 12.6 m-85 -131.14 110.51 11.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.4 ' O ' ' C ' ' A' ' 38' ' ' ARG . 10.0 mmm180 -78.11 138.11 38.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.414 ' NH1' ' HB3' ' A' ' 38' ' ' ARG . 15.3 ttp-105 -37.51 144.99 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.21 -8.66 79.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.498 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -88.14 146.4 25.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.885 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.6 ttmp? -99.33 147.7 24.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.869 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.521 HD22 ' CG ' ' A' ' 36' ' ' PHE . 5.6 mt -137.2 153.92 50.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -108.38 127.92 54.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.461 HG21 ' CB ' ' A' ' 18' ' ' ASP . 61.6 t -61.99 109.61 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -86.1 -55.05 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.5 t -152.07 125.65 8.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -88.05 126.17 34.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -129.97 85.86 2.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.72 -127.48 36.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.513 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.53 -22.69 74.9 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' TRP . . . . . 0.582 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 19.6 m95 -113.76 137.1 52.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.789 0.328 . . . . 0.0 110.923 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.401 ' CZ2' ' HA2' ' A' ' 67' ' ' GLY . 0.1 OUTLIER -129.05 164.64 22.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.566 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 11.5 tttp -100.9 142.94 31.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.68 159.67 43.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.117 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.41 ' CD1' ' HG3' ' A' ' 62' ' ' GLU . 18.6 tt -131.83 138.84 51.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.138 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.1 t -74.39 126.52 30.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.1 mt -77.28 8.57 3.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.7 t -107.34 -44.8 4.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.4 p -104.7 -41.22 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.188 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.9 32.68 7.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.41 ' C ' HG13 ' A' ' 55' ' ' ILE . 45.8 mtt180 -97.6 122.71 41.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.811 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.41 ' HG3' ' CD1' ' A' ' 55' ' ' ILE . 8.5 mt-10 -91.15 116.99 29.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.6 t -147.96 165.99 29.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 15.0 m-85 -105.6 128.99 53.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.479 HD11 ' N ' ' A' ' 65' ' ' ILE . 0.3 OUTLIER -138.57 151.13 68.32 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.656 0.741 . . . . 0.0 111.12 179.9 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.582 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 53.8 Cg_endo -69.7 133.7 26.31 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.65 2.233 . . . . 0.0 112.35 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.401 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -31.57 6.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.459 HG23 ' N ' ' A' ' 69' ' ' CYS . 6.1 tp -64.63 -32.03 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.821 0.343 . . . . 0.0 111.142 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' CYS . . . . . 0.459 ' N ' HG23 ' A' ' 68' ' ' ILE . 1.8 m -75.28 -12.68 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.888 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.471 ' O ' ' CD1' ' A' ' 23' ' ' LEU . 13.3 m -127.29 169.86 18.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.467 ' HB3' ' CD2' ' A' ' 23' ' ' LEU . . . -129.96 132.54 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.115 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -69.53 105.13 2.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.0 t -81.15 145.83 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.151 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 36.1 t 49.94 43.12 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.82 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -117.48 170.53 13.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.457 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -10.86 29.6 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.343 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 44.0 p -91.57 144.66 25.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.5 m 59.67 25.78 14.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.906 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.9 m-20 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.839 0.352 . . . . 0.0 110.89 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -105.06 148.25 26.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.639 HD11 HG22 ' A' ' 44' ' ' VAL . 4.8 mt -129.93 114.2 15.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -83.11 126.26 32.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.118 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 36' ' ' PHE . 93.1 t -62.33 104.3 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.095 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.971 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.8 mt -66.44 -33.48 75.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.889 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.426 ' O ' ' C ' ' A' ' 25' ' ' ASP . 28.8 t -156.17 120.43 4.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 24' ' ' SER . 4.3 p-10 -35.97 140.07 0.13 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.572 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.1 OUTLIER -156.75 147.65 16.45 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 0.0 110.899 -179.866 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.564 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -173.57 8.6 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.351 -0.062 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 m -75.8 156.21 84.69 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.727 0.775 . . . . 0.0 110.841 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 3.33 2.82 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.691 2.261 . . . . 0.0 112.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -106.92 -16.55 14.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -112.2 -46.53 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.164 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -165.75 163.0 12.87 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.685 0.755 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 133.33 25.23 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.365 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 120.37 7.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 0.0 112.333 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.731 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.3 mp -79.15 -25.87 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.11 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.648 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.5 m-85 -131.22 93.83 3.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.95 155.27 8.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 55.7 ttp85 -54.82 148.11 13.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -16.28 11.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.483 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -68.98 138.35 54.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.918 0.39 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -92.74 137.65 32.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mt -131.16 147.6 52.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.921 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.528 ' O ' HD12 ' A' ' 45' ' ' ILE . 28.2 ttt180 -99.41 132.11 44.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 18' ' ' ASP . 90.9 t -68.04 110.28 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.149 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.666 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -87.47 -52.38 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.117 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 m -143.59 146.91 33.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -111.27 116.7 31.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.852 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 6.6 mm-40 -125.66 85.94 2.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.76 -122.52 30.29 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 -22.52 63.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.519 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 26.3 m95 -110.84 137.33 48.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.305 . . . . 0.0 110.899 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.409 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.27 164.37 27.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.875 -179.994 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.666 ' HD3' HG21 ' A' ' 45' ' ' ILE . 38.5 tttt -100.09 140.9 33.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.82 160.01 43.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.74 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.5 tt -131.45 141.54 45.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.4 t -76.48 130.45 37.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.85 6.58 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.2 t -109.7 -44.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 53.2 p -103.53 -34.68 8.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.156 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.95 32.46 23.66 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.519 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.436 ' C ' HG13 ' A' ' 55' ' ' ILE . 28.1 mtt180 -95.83 125.26 40.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.777 0.322 . . . . 0.0 110.88 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.74 ' HG3' HD12 ' A' ' 55' ' ' ILE . 7.1 mt-10 -91.51 118.13 30.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 36' ' ' PHE . 4.2 m -147.01 168.81 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.824 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 31.6 m-85 -113.28 120.33 40.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.963 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.825 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -130.43 151.27 78.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.632 0.73 . . . . 0.0 111.124 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.6 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 132.23 22.87 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.699 2.266 . . . . 0.0 112.306 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -45.17 -33.97 4.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.494 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.6 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -61.37 -34.75 62.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.351 . . . . 0.0 111.111 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.15 -13.86 61.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.406 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.9 m -124.93 171.78 13.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.161 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.971 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.73 132.5 43.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.093 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 3.2 tpp85 -65.87 102.82 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.937 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.554 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.8 m-20 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -106.32 146.82 29.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.882 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.881 HD11 HG22 ' A' ' 44' ' ' VAL . 7.4 mt -131.91 108.96 9.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.01 128.64 33.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 ' O ' ' A' ' 36' ' ' PHE . 74.1 t -65.25 100.05 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.104 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.028 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.6 mt -61.48 -26.69 68.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -166.64 132.47 2.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.93 142.43 0.91 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 150.46 12.93 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.643 0.735 . . . . 0.0 110.911 -179.807 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.8 175.08 38.12 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.652 -1.812 . . . . 0.0 112.342 -0.07 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.4 p -68.5 156.31 90.85 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.679 0.752 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 5.24 1.75 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.88 -6.42 18.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.896 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.56 -53.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.03 163.93 23.4 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.683 0.754 . . . . 0.0 110.849 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 134.53 28.19 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.692 2.262 . . . . 0.0 112.354 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.14 11.81 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.72 2.28 . . . . 0.0 112.368 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.606 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -87.66 -23.66 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.479 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.7 m-85 -134.74 101.37 4.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.8 mmt85 -60.95 158.98 12.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.465 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.6 tmm_? -56.87 144.34 33.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.858 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.443 ' N ' ' HD2' ' A' ' 38' ' ' ARG . . . 83.69 -16.07 33.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -68.78 138.68 55.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.936 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.62 142.05 27.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 56' ' ' SER . 3.0 mt -138.71 135.16 34.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.934 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.533 ' O ' HD12 ' A' ' 45' ' ' ILE . 50.4 ttt180 -87.3 133.54 33.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.881 HG22 HD11 ' A' ' 20' ' ' LEU . 89.6 t -68.39 113.58 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.125 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -91.28 -50.41 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.155 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.1 p -143.8 150.36 38.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.9 p-10 -114.3 115.66 27.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.92 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.0 mt-10 -122.17 85.84 2.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.935 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.45 -119.62 18.23 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.506 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.48 -24.12 61.42 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.51 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 18.3 m95 -110.81 140.31 45.36 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.781 0.325 . . . . 0.0 110.945 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.18 164.32 27.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.911 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.526 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 33.4 tttt -98.26 145.62 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.674 HD12 ' HG3' ' A' ' 62' ' ' GLU . 16.1 tt -127.68 144.95 35.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.53 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.9 t -78.13 129.16 34.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.844 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.28 8.95 6.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.8 m -114.75 -44.22 3.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.9 p -101.26 -41.82 6.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.114 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.32 25.87 17.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.483 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 40.1 mtt180 -92.27 125.93 37.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.674 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.75 117.92 30.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 17.7 m -146.87 169.35 19.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 19.8 m-85 -112.06 118.83 36.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.778 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.43 151.25 69.78 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.148 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.656 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.6 Cg_endo -69.74 133.11 24.81 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.697 2.265 . . . . 0.0 112.331 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.9 -31.26 5.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.466 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.656 HG22 ' HB2' ' A' ' 66' ' ' PRO . 9.1 tt -64.27 -32.59 58.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.776 0.322 . . . . 0.0 111.097 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.3 m -75.58 -13.05 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.688 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.6 m -126.97 175.23 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.028 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -141.84 139.83 32.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.119 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -67.9 110.45 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.129 179.934 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.7 m-20 . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.845 0.355 . . . . 0.0 110.918 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -105.11 149.88 25.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.839 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.656 HD11 HG22 ' A' ' 44' ' ' VAL . 14.5 mt -132.71 115.13 14.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.48 120.47 26.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.643 HG11 ' O ' ' A' ' 36' ' ' PHE . 87.7 t -55.68 106.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.1 mt -66.79 -34.01 76.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.917 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.9 t -157.2 128.13 6.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.852 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.97 134.05 2.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.643 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.87 149.74 22.76 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 110.942 -179.811 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.48 11.0 Favored 'Cis proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.304 -0.045 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.1 m -73.61 155.65 89.11 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.671 0.748 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 2.92 3.09 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.699 2.266 . . . . 0.0 112.359 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -106.82 -16.61 14.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -111.81 -46.94 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.172 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.11 162.01 14.34 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.622 0.725 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 135.94 31.59 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.637 2.224 . . . . 0.0 112.348 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 124.87 11.48 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.684 2.256 . . . . 0.0 112.338 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.597 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -87.52 -25.08 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.149 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.643 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.1 m-85 -131.65 89.77 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -50.49 156.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.872 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -58.43 150.97 21.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.62 -6.4 17.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.455 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -76.09 135.41 39.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 35.0 tttt -86.12 137.78 32.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.516 HD23 ' HA ' ' A' ' 56' ' ' SER . 9.7 mt -132.98 154.51 50.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.468 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.9 ttp180 -105.06 131.42 52.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 18' ' ' ASP . 89.9 t -70.88 112.73 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.625 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.88 -51.66 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.8 t -151.83 159.36 43.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.828 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -116.33 111.71 20.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.3 mt-10 -110.53 86.41 2.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.98 -122.68 31.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.23 -21.62 78.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.496 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.8 m95 -114.97 151.87 33.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.432 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.09 164.52 27.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.941 -179.985 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.625 ' HD3' HG21 ' A' ' 45' ' ' ILE . 25.8 tttt -100.85 143.88 30.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.81 160.95 42.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.822 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -129.88 146.76 33.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.516 ' HA ' HD23 ' A' ' 42' ' ' LEU . 87.6 p -81.37 128.52 33.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.871 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.4 mt -77.49 8.66 4.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.5 m -99.9 -52.69 3.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.816 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.4 p -107.37 -45.4 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.193 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.573 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 107.92 29.43 4.35 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.9 mtt180 -86.95 123.99 32.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.746 0.308 . . . . 0.0 110.864 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.822 ' HG3' HD12 ' A' ' 55' ' ' ILE . 6.2 mt-10 -93.97 117.86 30.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -147.19 165.63 29.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.873 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.45 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 17.0 m-85 -107.27 123.93 49.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.935 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.821 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.36 151.25 77.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.671 0.748 . . . . 0.0 111.144 179.905 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.568 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.75 132.56 23.61 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.646 2.231 . . . . 0.0 112.382 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.66 -31.33 7.22 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.462 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.461 ' O ' HD12 ' A' ' 23' ' ' LEU . 8.0 tt -63.92 -31.91 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 111.108 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' CYS . . . . . 0.401 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.2 m -76.6 -11.12 59.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.563 ' O ' HD11 ' A' ' 23' ' ' LEU . 31.0 m -127.84 169.72 18.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.906 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -127.85 129.08 46.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -64.8 108.8 1.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.9 t . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.181 179.942 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.2 m-20 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.865 0.364 . . . . 0.0 110.861 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -108.46 153.7 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.851 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.918 HD11 HG22 ' A' ' 44' ' ' VAL . 3.6 mt -140.03 114.55 9.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.9 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.65 128.93 34.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.493 ' CG2' HD11 ' A' ' 42' ' ' LEU . 92.4 t -65.1 109.44 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.072 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.914 HD21 ' HB2' ' A' ' 71' ' ' ALA . 6.5 mt -68.8 -31.93 71.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.932 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.436 ' O ' ' C ' ' A' ' 25' ' ' ASP . 24.6 t -160.76 125.98 3.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.7 OUTLIER -35.37 148.34 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.846 179.953 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.59 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -166.04 148.89 6.49 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.64 0.733 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.8 -174.27 9.41 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.347 0.025 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -71.17 153.63 94.27 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 0.0 110.876 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 3.04 3.02 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.678 2.252 . . . . 0.0 112.338 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -106.0 -23.13 12.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.5 -57.15 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.128 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 m -150.8 162.93 25.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.679 0.752 . . . . 0.0 110.851 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 132.89 24.17 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.339 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 122.59 9.26 Favored 'Trans proline' 0 N--CA 1.465 -0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.347 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.678 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -87.17 -26.11 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.431 ' HB3' HG21 ' A' ' 22' ' ' VAL . 6.0 m-85 -128.87 99.22 5.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 28.6 mmm-85 -63.44 157.75 22.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 ttm180 -56.81 143.82 35.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.03 9.42 86.96 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -93.15 136.0 33.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.401 ' O ' HD23 ' A' ' 42' ' ' LEU . 22.1 ttmt -87.99 139.6 30.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.493 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.1 mt -136.94 146.86 45.93 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.552 ' O ' HD12 ' A' ' 45' ' ' ILE . 15.1 ttm180 -100.5 125.34 46.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.927 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.918 HG22 HD11 ' A' ' 20' ' ' LEU . 43.6 t -63.44 111.03 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.552 HD12 ' O ' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -85.12 -47.74 16.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -149.09 157.89 43.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -117.21 113.15 21.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.2 mt-10 -115.22 86.25 2.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 57.68 -118.4 12.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.43 -23.0 61.41 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.508 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.9 m95 -112.28 135.72 52.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.76 0.314 . . . . 0.0 110.896 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.507 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -124.75 164.76 19.26 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.932 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.552 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 14.5 tttp -102.61 147.77 26.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.74 163.81 39.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.104 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.737 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.5 tt -131.47 151.33 35.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.156 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.407 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 49.1 m -83.18 127.77 33.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.3 mt -78.43 9.38 3.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 m -116.8 -43.88 2.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 68.6 p -101.4 -42.74 6.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.02 25.79 16.19 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 50.8 mtt-85 -89.86 124.49 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.779 0.323 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.737 ' HG3' HD12 ' A' ' 55' ' ' ILE . 9.6 mt-10 -93.92 117.38 30.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.1 t -147.76 166.28 27.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.832 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.552 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 12.9 m-85 -108.79 122.74 47.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.738 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -129.8 151.12 77.62 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.65 0.738 . . . . 0.0 111.157 179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.706 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.79 134.8 28.78 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.325 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.75 -30.58 9.03 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.469 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.2 tp -65.39 -30.46 50.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.7 m -78.6 -6.87 56.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.838 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.443 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.5 m -133.02 167.57 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.914 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.94 134.67 48.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.6 tpt85 -64.98 112.36 3.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 -179.986 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.853 ' O ' HG23 ' A' ' 44' ' ' VAL . 13.2 m-20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.89 0.376 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -103.14 152.66 21.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.853 HD11 HG22 ' A' ' 44' ' ' VAL . 0.9 OUTLIER -137.51 112.89 9.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.923 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 125.52 30.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.075 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.634 HG11 ' O ' ' A' ' 36' ' ' PHE . 46.9 t -61.63 99.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.143 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.886 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -57.33 -33.69 67.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.894 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.2 t -157.95 133.17 8.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.36 135.29 3.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.65 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -153.39 150.18 23.01 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.665 0.745 . . . . 0.0 110.929 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.76 -175.09 10.34 Favored 'Cis proline' 0 C--O 1.231 0.156 0 C-N-CA 122.723 -1.782 . . . . 0.0 112.33 -0.004 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 31.2 m -75.24 155.64 86.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.729 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 1.14 4.69 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.682 2.255 . . . . 0.0 112.394 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.16 -5.38 18.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.863 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.72 -47.03 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.1 161.63 14.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.638 0.732 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 134.28 27.62 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.367 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 125.29 12.01 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.67 2.247 . . . . 0.0 112.357 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.651 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -87.19 -25.22 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.114 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.634 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.89 96.94 3.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.81 162.95 1.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.868 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -59.88 149.66 30.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.08 -9.76 17.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.99 137.09 48.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.878 0.371 . . . . 0.0 110.891 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 1.2 ttmp? -90.89 138.94 31.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.7 mt -137.99 142.63 40.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.941 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 45' ' ' ILE . 27.6 ttt-85 -94.97 131.66 40.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.853 HG22 HD11 ' A' ' 20' ' ' LEU . 69.0 t -68.01 109.84 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.149 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.648 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -83.65 -46.26 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.94 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 68.8 m -156.27 152.75 28.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -110.91 117.09 32.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.885 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -120.43 86.09 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.7 -122.99 30.63 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.01 -23.37 66.53 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.511 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.6 m95 -112.42 146.72 37.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.747 0.308 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.42 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.55 164.45 27.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.921 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.648 ' HD3' HG21 ' A' ' 45' ' ' ILE . 34.7 tttt -100.37 143.39 30.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.27 163.26 39.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.078 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.57 HG22 HD11 ' A' ' 45' ' ' ILE . 12.0 tt -133.9 136.89 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.116 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.432 ' HA ' HD23 ' A' ' 42' ' ' LEU . 2.6 t -70.87 129.09 38.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.69 8.64 5.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.946 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.7 m -112.6 -44.91 3.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.811 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 70.6 p -103.24 -33.65 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.79 29.44 32.04 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.48 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -92.24 123.94 35.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.793 0.33 . . . . 0.0 110.903 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.425 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.6 mt-10 -90.88 117.63 29.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.869 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.6 m -147.26 167.41 24.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.832 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.459 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.6 m-85 -110.5 115.72 30.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.811 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.49 151.4 63.15 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.641 0.734 . . . . 0.0 111.173 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.4 Cg_endo -69.77 134.41 27.9 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.686 2.257 . . . . 0.0 112.351 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.431 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -50.36 -28.85 15.27 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.513 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 18.2 tt -66.0 -28.0 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.8 0.334 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 6.4 m -85.1 1.13 49.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 35.9 m -136.37 157.99 37.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.886 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -120.45 130.83 54.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.053 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -64.89 107.63 1.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.958 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.79 ' O ' HG23 ' A' ' 44' ' ' VAL . 5.8 m-20 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.858 0.361 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -104.72 152.73 22.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.843 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.701 HD11 HG22 ' A' ' 44' ' ' VAL . 3.8 mt -134.62 108.71 8.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.5 125.47 29.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.6 t -63.9 103.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.8 mt -62.54 -33.28 74.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.421 ' O ' ' C ' ' A' ' 25' ' ' ASP . 35.3 t -158.34 123.24 4.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.873 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.3 OUTLIER -36.36 144.55 0.05 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.841 179.993 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.601 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 148.9 11.6 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.743 . . . . 0.0 110.939 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.56 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.75 178.69 24.56 Favored 'Cis proline' 0 N--CA 1.465 -0.147 0 C-N-CA 122.713 -1.786 . . . . 0.0 112.358 -0.044 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -66.36 153.33 92.93 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.724 0.773 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.86 3.16 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.663 2.242 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -104.48 -23.99 13.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.847 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.23 -54.51 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.167 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.53 164.18 21.76 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.684 0.754 . . . . 0.0 110.888 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 131.54 21.48 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.72 3.79 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.664 2.242 . . . . 0.0 112.324 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.728 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -75.65 -27.56 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.531 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 8.2 m-85 -129.5 102.3 6.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -62.65 162.77 10.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.926 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.5 ttt180 -62.15 146.95 49.12 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.5 -9.75 26.81 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.498 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -73.06 131.62 42.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.916 0.389 . . . . 0.0 110.854 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.441 ' HB3' HD12 ' A' ' 57' ' ' LEU . 25.3 ttmt -81.52 136.48 35.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.892 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.619 HD23 ' HA ' ' A' ' 56' ' ' SER . 13.7 mt -129.36 139.67 51.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.584 HH12 HG21 ' A' ' 55' ' ' ILE . 7.9 ttp-105 -90.38 129.8 36.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.79 HG23 ' O ' ' A' ' 18' ' ' ASP . 99.3 t -69.46 111.77 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.153 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.64 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.6 -52.89 10.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 t -152.88 159.82 43.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -115.96 112.27 21.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -110.61 85.9 2.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.33 -122.16 29.17 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.14 -23.62 75.55 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -113.67 152.66 30.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.763 0.315 . . . . 0.0 110.978 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.463 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.11 164.29 28.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.64 ' HD3' HG21 ' A' ' 45' ' ' ILE . 14.8 tttt -101.28 139.55 36.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.88 168.7 20.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.8 tt -135.75 140.35 44.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.163 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.619 ' HA ' HD23 ' A' ' 42' ' ' LEU . 96.3 p -79.42 128.27 33.14 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.441 HD12 ' HB3' ' A' ' 41' ' ' LYS . 7.9 mt -78.7 9.49 4.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.888 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.0 t -104.15 -45.34 4.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.918 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.7 p -110.69 -34.83 6.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 91.95 24.11 25.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -87.94 128.25 35.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.799 0.333 . . . . 0.0 110.866 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 55' ' ' ILE . 15.5 mt-10 -95.55 117.79 31.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 44.7 t -147.11 159.48 43.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.882 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -98.2 129.9 44.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.826 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -138.16 151.45 69.78 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.552 0.691 . . . . 0.0 111.182 179.884 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.713 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.71 132.02 22.54 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.703 2.269 . . . . 0.0 112.329 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.401 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -48.45 -29.77 7.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.505 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.713 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.3 tt -64.94 -30.87 51.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 111.118 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.4 m -77.68 -11.52 59.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.401 HG22 ' HA2' ' A' ' 67' ' ' GLY . 19.2 m -126.71 165.58 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.089 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.837 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -124.21 130.22 52.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 tpt180 -67.12 99.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 179.945 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.869 ' O ' HG23 ' A' ' 44' ' ' VAL . 41.5 m-20 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.794 0.33 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -102.97 151.2 22.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.777 HD11 HG22 ' A' ' 44' ' ' VAL . 4.7 mt -135.54 109.18 7.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.69 131.32 35.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.056 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 36' ' ' PHE . 63.7 t -65.81 109.11 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.159 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.068 HD21 ' HB2' ' A' ' 71' ' ' ALA . 5.0 mt -74.52 -29.63 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 25' ' ' ASP . 29.2 t -157.02 115.52 3.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -34.99 139.96 0.08 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.588 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -156.65 148.59 17.38 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.687 0.756 . . . . 0.0 110.924 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.74 -174.67 9.79 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 -1.801 . . . . 0.0 112.358 -0.074 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.477 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 4.0 m -77.0 158.8 79.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.696 0.76 . . . . 0.0 110.857 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 5.15 1.79 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 29.4 p-10 -104.26 -27.93 11.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.405 HG13 ' OD1' ' A' ' 30' ' ' ASP . 7.3 mt -101.95 -53.45 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -159.47 163.82 22.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 137.71 35.97 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 124.82 11.48 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.713 2.276 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.593 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -86.89 -20.85 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.635 ' O ' HG11 ' A' ' 22' ' ' VAL . 19.5 m-85 -134.47 87.17 2.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.887 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.77 156.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.435 ' HG3' ' C ' ' A' ' 23' ' ' LEU . 2.6 ttm105 -60.68 144.03 52.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.65 -9.41 62.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.471 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -76.95 136.15 38.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 110.911 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.408 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 49.8 tttt -84.26 137.55 33.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.453 HD11 ' CG2' ' A' ' 22' ' ' VAL . 9.9 mt -131.64 150.0 52.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.556 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.1 ttp180 -105.09 128.85 53.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 18' ' ' ASP . 91.5 t -64.35 110.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.646 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -87.79 -51.73 12.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.4 p -146.9 135.51 22.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -100.06 115.82 30.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.0 mm-40 -127.3 86.89 2.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.95 -123.41 32.6 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.49 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.39 63.06 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.595 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 32.1 m95 -113.98 123.26 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.735 0.302 . . . . 0.0 110.88 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.486 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -123.2 164.29 18.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.924 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.646 ' HD3' HG21 ' A' ' 45' ' ' ILE . 10.9 tttp -98.5 144.7 27.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.884 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.95 152.66 31.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.107 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.582 HG22 HD11 ' A' ' 45' ' ' ILE . 12.6 tt -126.23 131.84 71.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.443 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.3 t -68.77 128.82 38.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 4.5 mt -79.22 9.37 4.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.0 t -109.26 -45.53 3.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.841 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.5 p -102.02 -39.73 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.14 32.15 9.16 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.428 ' C ' HG13 ' A' ' 55' ' ' ILE . 36.7 mtt180 -98.19 127.0 43.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.826 0.346 . . . . 0.0 110.867 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.573 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.19 117.24 29.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.861 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.2 m -147.89 168.31 22.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 30.0 m-85 -109.66 135.64 50.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.411 HG22 ' CE1' ' A' ' 26' ' ' TYR . 0.2 OUTLIER -144.36 151.37 50.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.59 0.71 . . . . 0.0 111.165 179.86 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.696 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.72 133.81 26.55 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -48.56 -30.21 8.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.696 HG22 ' HB2' ' A' ' 66' ' ' PRO . 4.6 tp -65.54 -30.45 50.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.816 0.341 . . . . 0.0 111.164 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' CYS . . . . . 0.4 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 2.9 m -78.5 -3.84 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.604 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.2 m -136.59 169.8 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.068 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.98 139.25 45.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.2 tpp85 -68.62 112.03 5.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.876 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.8 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.105 -179.994 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.895 ' O ' HG23 ' A' ' 44' ' ' VAL . 10.9 m-20 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.867 0.365 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.44 152.13 21.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.713 HD11 HG22 ' A' ' 44' ' ' VAL . 3.7 mt -134.78 112.3 10.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.913 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.24 119.96 24.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.055 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.536 HG21 ' HB3' ' A' ' 36' ' ' PHE . 98.4 t -57.27 99.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.015 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.4 mt -59.34 -23.44 62.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 47.2 t -169.76 133.67 1.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.835 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.28 146.54 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.868 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.651 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -164.75 149.95 8.5 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.702 0.763 . . . . 0.0 110.913 -179.826 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.537 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.75 -174.69 9.83 Favored 'Cis proline' 0 C--N 1.342 0.201 0 C-N-CA 122.711 -1.787 . . . . 0.0 112.377 -0.049 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.463 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 44.2 m -72.29 154.58 91.99 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.641 0.734 . . . . 0.0 110.878 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 3.52 2.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.679 2.253 . . . . 0.0 112.357 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.463 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 23.6 p-10 -109.39 -17.03 13.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -109.44 -46.43 6.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -164.77 163.17 14.44 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.672 0.749 . . . . 0.0 110.821 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 131.67 21.66 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 124.74 11.37 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.377 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.6 mp -89.22 -24.38 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.155 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.536 ' HB3' HG21 ' A' ' 22' ' ' VAL . 14.4 m-85 -130.98 103.02 6.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -64.22 160.34 18.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.6 ttp85 -58.37 149.4 24.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.928 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.75 -9.71 22.04 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -71.13 154.12 41.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.902 0.382 . . . . 0.0 110.904 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 7.9 tttp -107.16 140.24 40.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.914 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.3 mt -136.85 135.26 37.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.594 ' O ' HD12 ' A' ' 45' ' ' ILE . 19.2 ttt-85 -86.48 131.02 34.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 18' ' ' ASP . 60.5 t -66.99 108.8 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.737 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -87.74 -52.36 11.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -143.82 155.03 43.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -119.49 113.05 20.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -117.31 86.39 2.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.4 -123.6 33.87 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.39 -21.07 78.22 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.486 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.564 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -113.26 144.74 42.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.724 0.297 . . . . 0.0 110.941 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.401 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.83 164.46 27.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.92 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HD3' HG21 ' A' ' 45' ' ' ILE . 28.9 tttt -101.04 141.04 34.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.906 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.17 162.57 39.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.737 HG22 HD11 ' A' ' 45' ' ' ILE . 16.4 tt -134.67 134.55 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -69.8 128.28 35.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.843 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.484 HD21 ' HB2' ' A' ' 43' ' ' ARG . 2.0 mt -78.78 2.68 19.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.89 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.3 m -99.41 -47.81 5.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.3 p -105.33 -37.35 6.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.142 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.85 29.34 9.94 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.485 ' HD2' HG23 ' A' ' 35' ' ' ILE . 33.7 mtt180 -90.04 127.8 36.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.873 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.665 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.7 mt-10 -97.86 118.0 33.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.1 t -147.02 167.38 24.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 14.8 m-85 -110.07 114.33 27.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.795 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.91 151.18 60.64 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.63 0.729 . . . . 0.0 111.164 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.78 133.88 26.59 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.673 2.249 . . . . 0.0 112.341 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -47.44 -30.26 5.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 5.4 tp -65.09 -32.47 58.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.801 0.334 . . . . 0.0 111.116 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 8.0 m -78.91 -4.82 51.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.513 ' O ' HD11 ' A' ' 23' ' ' LEU . 32.4 m -132.56 166.08 30.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.015 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -130.53 129.45 42.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.069 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.95 107.6 1.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.859 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.099 179.987 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.578 ' O ' HG23 ' A' ' 44' ' ' VAL . 85.7 m-20 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.827 0.346 . . . . 0.0 110.883 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -111.17 150.15 29.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.663 HD11 HG22 ' A' ' 44' ' ' VAL . 9.3 mt -133.38 114.08 13.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.42 127.12 32.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.08 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.695 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.8 t -65.04 98.6 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.149 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.962 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -59.71 -31.49 69.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.931 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.7 t -161.3 127.95 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.77 138.98 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.647 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.72 150.12 17.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.695 0.76 . . . . 0.0 110.936 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -175.28 10.64 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.695 -1.794 . . . . 0.0 112.337 -0.048 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 3.1 m -76.28 158.29 81.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -102.07 -22.39 14.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 mt -109.25 -54.99 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -155.3 163.44 24.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.615 0.721 . . . . 0.0 110.888 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 137.81 36.43 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 119.04 6.05 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.679 2.252 . . . . 0.0 112.371 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -83.06 -25.71 8.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.128 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.695 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.3 m-85 -131.4 96.24 3.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.0 mmm-85 -56.41 158.38 4.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 52.1 ttt-85 -61.08 144.5 53.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.62 -14.46 35.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -72.75 136.54 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.5 ttmt -87.02 137.84 32.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.593 HD23 ' HA ' ' A' ' 56' ' ' SER . 10.4 mt -132.17 140.6 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.919 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.428 ' O ' HD12 ' A' ' 45' ' ' ILE . 42.8 ttt180 -91.12 134.49 34.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.663 HG22 HD11 ' A' ' 20' ' ' LEU . 97.6 t -71.43 112.11 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.635 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -86.05 -46.32 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -155.56 147.75 23.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.46 116.07 31.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.902 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -122.35 85.91 2.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.12 -120.7 23.89 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.33 -23.08 59.4 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.438 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 21.9 m95 -111.68 137.9 48.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.79 0.329 . . . . 0.0 110.88 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.516 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.3 164.83 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.635 ' HD3' HG21 ' A' ' 45' ' ' ILE . 9.4 tttp -101.49 141.95 33.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.911 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.13 168.34 22.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.816 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.3 tt -138.39 142.45 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.593 ' HA ' HD23 ' A' ' 42' ' ' LEU . 50.5 p -76.82 133.49 39.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.6 mt -82.96 8.86 11.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.2 t -104.78 -42.77 5.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -113.56 -44.57 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.103 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.529 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 103.35 27.88 6.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.473 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -84.19 122.04 28.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 110.853 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.816 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -92.09 117.48 29.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.0 t -147.44 169.61 19.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.905 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.57 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 7.1 m-85 -112.1 118.09 34.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.83 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.5 151.26 69.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.656 0.741 . . . . 0.0 111.153 179.866 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.631 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.0 Cg_endo -69.79 132.67 23.75 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.704 2.27 . . . . 0.0 112.312 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.45 -33.5 5.99 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.631 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.8 tt -61.81 -33.39 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.359 . . . . 0.0 111.177 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.1 -15.92 61.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.569 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.7 m -125.47 175.86 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.962 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -136.72 134.5 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -66.32 102.44 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 179.964 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.713 ' O ' HG23 ' A' ' 44' ' ' VAL . 14.1 m-20 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.799 0.333 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -108.79 154.42 22.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.94 HD11 HG22 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -139.98 111.68 7.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.881 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.12 122.81 28.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.092 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 36' ' ' PHE . 92.2 t -55.33 104.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.022 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -65.74 -33.81 76.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.7 t -155.35 128.95 8.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -39.43 146.55 0.09 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.605 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.77 148.82 6.73 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.659 0.742 . . . . 0.0 110.944 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.83 -174.27 9.44 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 -1.796 . . . . 0.0 112.295 0.023 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.9 m -70.57 153.77 94.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.656 0.741 . . . . 0.0 110.873 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 1.21 4.59 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.676 2.251 . . . . 0.0 112.37 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -106.26 -18.37 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -107.29 -54.03 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.16 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.4 m -155.71 162.63 26.97 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 134.37 27.82 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.327 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 120.87 7.59 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.724 2.282 . . . . 0.0 112.314 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.666 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.9 mp -85.6 -30.45 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.117 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.62 ' O ' HG11 ' A' ' 22' ' ' VAL . 11.8 m-85 -124.0 90.82 3.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -51.07 161.16 0.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.896 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 16.2 ttt-85 -66.17 144.15 56.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.35 -9.89 65.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.403 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -83.09 132.64 35.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 110.906 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.544 ' CD ' HG21 ' A' ' 73' ' ' VAL . 19.5 ttpt -88.99 143.74 26.65 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.467 HD11 ' CG2' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -135.0 141.25 46.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.89 179.94 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.414 ' HB2' HD21 ' A' ' 57' ' ' LEU . 35.8 ttt180 -85.64 127.57 34.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.94 HG22 HD11 ' A' ' 20' ' ' LEU . 84.5 t -64.46 111.37 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.71 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -78.62 -54.7 11.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.094 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.1 t -155.58 150.85 26.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.846 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -102.26 121.99 43.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.923 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 44.5 mm-40 -126.5 86.15 2.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.907 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.44 -121.5 24.24 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -85.08 -18.57 60.75 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.529 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.578 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.5 m95 -115.71 140.09 49.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.71 0.291 . . . . 0.0 110.937 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.404 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.79 164.44 26.82 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.878 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.71 ' HD2' HG21 ' A' ' 45' ' ' ILE . 3.7 ttmt -101.58 151.56 21.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -159.11 150.1 19.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.492 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.4 tt -116.34 144.34 24.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.13 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.434 ' HA ' HD23 ' A' ' 42' ' ' LEU . 6.7 m -73.59 130.6 40.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.414 HD21 ' HB2' ' A' ' 43' ' ' ARG . 7.5 mt -78.21 9.71 3.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 t -116.92 -52.79 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.828 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.2 p -95.9 -34.56 11.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.474 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.85 31.57 17.55 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.496 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.0 mtt180 -91.37 122.1 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.3 mt-10 -91.9 117.76 30.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.43 ' HB3' ' CE2' ' A' ' 36' ' ' PHE . 18.4 t -147.32 169.51 19.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HE3' ' A' ' 53' ' ' LYS . 4.2 m-85 -110.26 122.34 47.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.877 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.21 151.47 78.42 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.597 0.713 . . . . 0.0 111.113 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.637 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.3 Cg_endo -69.8 131.87 22.08 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.7 2.267 . . . . 0.0 112.279 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.442 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -46.78 -30.57 4.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.476 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.637 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -64.72 -33.33 62.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 0.0 111.11 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 7.4 m -78.05 -7.58 57.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.442 HG22 ' HA2' ' A' ' 67' ' ' GLY . 33.8 m -128.69 164.98 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.022 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.44 134.88 46.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.7 tpp180 -61.41 110.14 1.36 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.831 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.544 HG21 ' CD ' ' A' ' 41' ' ' LYS . 2.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.174 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.5 m-20 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.811 0.338 . . . . 0.0 110.866 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -112.14 150.68 30.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.721 HD11 HG22 ' A' ' 44' ' ' VAL . 7.2 mt -134.83 110.66 9.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.912 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.39 122.06 27.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 36' ' ' PHE . 76.6 t -58.53 100.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.141 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.945 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.8 mt -59.94 -36.14 76.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.936 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.6 t -155.97 127.08 7.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.874 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.21 135.09 1.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.645 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.08 149.6 23.73 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.716 0.77 . . . . 0.0 110.887 -179.807 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.547 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.82 -178.67 17.33 Favored 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.371 -0.023 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 59.6 m -68.36 153.44 95.6 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.652 0.739 . . . . 0.0 110.861 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 2.46 3.52 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.344 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.61 -10.09 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -118.44 -52.14 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -156.45 162.15 28.09 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 0.0 110.805 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 134.2 27.35 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.49 ' HG2' ' CZ ' ' A' ' 37' ' ' ARG . 53.9 Cg_endo -69.71 114.09 3.58 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.744 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.5 mp -74.57 -30.46 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.136 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.601 ' O ' HG11 ' A' ' 22' ' ' VAL . 14.8 m-85 -130.99 94.95 3.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.49 ' CZ ' ' HG2' ' A' ' 34' ' ' PRO . 20.4 mmt180 -53.89 160.24 1.49 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -62.73 151.99 36.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.58 -18.02 7.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.405 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -71.43 132.37 44.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.871 0.367 . . . . 0.0 110.903 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 25.6 ttmt -85.41 135.73 33.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.471 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.3 mt -128.14 148.41 50.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.501 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.4 ttt180 -98.62 130.51 45.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.878 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.721 HG22 HD11 ' A' ' 20' ' ' LEU . 57.6 t -68.58 114.17 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.125 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.501 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -90.4 -53.46 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.147 179.941 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 t -146.45 154.15 41.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.847 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -120.04 119.07 32.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -127.62 98.9 5.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.15 -130.43 50.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.65 9.0 63.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.531 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.555 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -137.07 140.39 41.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 110.926 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.415 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -133.77 164.64 26.78 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.918 179.995 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 16.1 tttp -104.09 147.03 27.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.904 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.6 159.77 42.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.131 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.686 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -126.39 141.71 45.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 20.1 p -78.25 129.87 35.58 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.7 mt -80.51 9.26 6.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.966 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -99.24 -49.4 4.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.812 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.2 p -112.77 -39.69 4.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.097 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.74 27.52 5.7 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.437 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -83.08 128.07 34.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.761 0.315 . . . . 0.0 110.862 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.686 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -102.02 117.27 34.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.8 p -147.58 169.27 19.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 24.8 m-85 -110.08 118.98 37.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.855 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.69 150.01 67.07 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.654 0.74 . . . . 0.0 111.081 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.671 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.0 Cg_endo -69.77 134.03 26.97 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.308 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.99 -31.13 5.51 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.482 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.671 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -64.84 -32.74 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.806 0.336 . . . . 0.0 111.113 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 11.6 m -80.35 2.85 23.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.618 ' O ' HD11 ' A' ' 23' ' ' LEU . 33.4 m -140.52 170.63 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.945 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -132.35 125.99 32.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 -65.74 108.19 2.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.119 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.461 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.825 0.345 . . . . 0.0 110.887 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -108.63 145.02 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.886 HD11 HG22 ' A' ' 44' ' ' VAL . 1.7 mt -134.49 110.56 9.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.421 ' HB2' ' CG2' ' A' ' 73' ' ' VAL . . . -79.63 127.09 31.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.103 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.566 HG11 ' O ' ' A' ' 36' ' ' PHE . 88.7 t -61.75 101.36 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.1 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.954 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -61.92 -31.01 71.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -160.21 128.17 4.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -40.12 140.82 0.54 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.844 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.615 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -158.94 149.18 15.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.687 0.756 . . . . 0.0 110.914 -179.848 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.545 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.3 Cg_endo -69.8 -174.52 9.7 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.34 -0.064 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -73.22 154.09 90.37 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 1.63 4.29 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.655 2.236 . . . . 0.0 112.369 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -105.86 -14.69 15.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.81 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -113.05 -51.96 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 m -158.34 162.26 27.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 133.99 26.88 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.699 2.266 . . . . 0.0 112.339 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 124.08 10.72 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.75 2.3 . . . . 0.0 112.307 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.654 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -86.84 -25.28 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.146 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.566 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.3 m-85 -130.97 93.92 3.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -56.29 150.16 15.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.409 ' HA ' HG12 ' A' ' 22' ' ' VAL . 39.9 ttp85 -50.76 147.56 4.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.05 -17.84 8.87 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -68.04 138.37 55.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.926 0.394 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.572 ' O ' HD23 ' A' ' 42' ' ' LEU . 2.5 ttmp? -89.94 143.12 27.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.572 HD23 ' O ' ' A' ' 41' ' ' LYS . 1.7 mt -139.41 142.4 37.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.951 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.561 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttt180 -95.45 132.03 40.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.864 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.886 HG22 HD11 ' A' ' 20' ' ' LEU . 95.8 t -68.0 112.63 3.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.096 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.725 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -91.39 -53.28 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 m -137.66 143.07 41.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.09 115.01 28.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.865 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -126.68 85.97 2.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.893 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.1 -125.36 38.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.81 -19.07 73.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.49 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 24.3 m95 -113.39 131.87 55.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -131.94 164.35 26.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.918 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.0 tttp -99.95 144.16 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.894 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.0 160.33 44.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.07 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.748 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.4 tt -130.55 139.66 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.078 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.1 m -72.37 129.41 38.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.857 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.0 mt -79.15 5.66 11.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.1 t -106.03 -51.08 3.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.7 p -99.31 -44.24 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.185 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.402 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 100.95 26.76 7.75 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.518 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 64.5 mtt180 -86.19 128.19 34.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.748 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.9 mt-10 -98.21 117.45 32.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.1 t -147.34 169.38 19.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.546 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 9.2 m-85 -112.63 114.79 27.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.87 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.53 150.76 58.6 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 111.138 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.597 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.81 135.99 31.75 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.637 2.225 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.9 -36.86 20.9 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.539 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.597 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -59.96 -26.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.808 0.337 . . . . 0.0 111.071 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.7 m -82.56 -7.6 59.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.8 m -131.22 164.45 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.149 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.954 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -125.93 133.31 51.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.092 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.438 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.2 tpt180 -61.0 97.72 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.421 ' CG2' ' HB2' ' A' ' 21' ' ' ALA . 3.8 t . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.144 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.698 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.1 m-20 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.839 0.352 . . . . 0.0 110.86 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -107.24 150.04 27.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.686 HD11 HG22 ' A' ' 44' ' ' VAL . 7.3 mt -132.56 121.31 23.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -92.09 119.54 31.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.063 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.585 ' CG2' HD11 ' A' ' 42' ' ' LEU . 96.2 t -59.11 96.67 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.16 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.957 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.7 mt -54.95 -35.32 64.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.929 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 t -157.46 128.65 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.841 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.69 137.98 1.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.881 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.609 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -155.18 148.55 18.48 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.685 0.755 . . . . 0.0 110.918 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.559 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.4 Cg_endo -69.71 -173.98 9.0 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.379 -0.107 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 6.1 m -74.67 155.51 87.15 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.689 0.757 . . . . 0.0 110.843 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 3.44 2.79 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.658 2.238 . . . . 0.0 112.379 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -107.77 -18.22 13.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -109.18 -47.92 7.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.0 OUTLIER -164.1 163.58 15.25 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.644 0.735 . . . . 0.0 110.864 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 132.24 22.87 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.675 2.25 . . . . 0.0 112.309 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 118.24 5.57 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.649 2.233 . . . . 0.0 112.306 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.709 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.2 mp -79.31 -28.42 13.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.091 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 22' ' ' VAL . 16.8 m-85 -127.3 98.42 5.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.65 160.38 4.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.854 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -62.22 144.61 55.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.23 -11.43 23.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.461 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -71.25 130.56 41.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.869 0.366 . . . . 0.0 110.896 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -81.46 137.02 35.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.585 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.4 mt -133.16 139.78 47.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttt180 -90.19 130.66 36.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.831 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 18' ' ' ASP . 57.3 t -66.89 110.66 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -80.19 -54.97 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.124 179.896 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 70.9 m -157.32 147.46 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -98.58 115.47 28.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 35.5 mt-10 -113.99 85.78 2.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.72 -122.99 30.58 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -77.77 -22.58 69.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.473 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 10.1 m95 -113.92 150.51 33.62 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.754 0.312 . . . . 0.0 110.915 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.428 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -136.08 164.2 28.57 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.949 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD2' HG21 ' A' ' 45' ' ' ILE . 4.7 ttmm -103.22 150.83 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.937 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.426 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -158.91 143.77 15.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.072 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.2 tt -108.1 144.62 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.1 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 p -83.68 130.27 34.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.0 mt -77.21 7.94 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.3 t -95.18 -51.96 4.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.843 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.8 p -111.29 -43.16 3.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.144 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.608 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 108.69 26.45 5.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -86.27 127.72 34.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.763 0.316 . . . . 0.0 110.857 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.708 ' HG3' HD12 ' A' ' 55' ' ' ILE . 13.0 mt-10 -99.15 118.11 35.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 9.0 t -147.11 167.75 23.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.527 ' CE2' ' HE2' ' A' ' 53' ' ' LYS . 4.3 m-85 -105.96 129.42 54.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.942 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.682 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -135.16 150.97 74.3 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.594 0.711 . . . . 0.0 111.125 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.672 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.74 133.21 25.06 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.732 2.288 . . . . 0.0 112.332 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.59 -30.02 8.17 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.465 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.672 HG22 ' HB2' ' A' ' 66' ' ' PRO . 13.5 tt -65.5 -30.12 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.834 0.349 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.8 m -80.36 -5.72 56.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.523 ' O ' HD11 ' A' ' 23' ' ' LEU . 34.9 m -135.03 171.35 17.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.957 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.64 132.43 38.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.076 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -69.3 106.79 3.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.857 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.6 t . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 44' ' ' VAL . 60.7 m-20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.823 0.344 . . . . 0.0 110.858 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -101.62 143.68 31.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.921 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.932 HD11 HG22 ' A' ' 44' ' ' VAL . 11.0 mt -130.45 108.76 10.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.06 122.92 28.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.063 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.51 HG11 ' O ' ' A' ' 36' ' ' PHE . 57.3 t -58.86 103.62 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.819 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.5 mt -67.17 -33.42 75.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 25' ' ' ASP . 27.6 t -153.64 121.85 6.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.834 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -37.03 149.38 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.875 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.799 ' CE1' HG22 ' A' ' 65' ' ' ILE . 0.0 OUTLIER -169.82 150.52 3.85 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.685 0.755 . . . . 0.0 110.922 -179.85 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.3 10.69 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.304 -0.059 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 48.0 m -74.74 155.06 87.22 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.662 0.744 . . . . 0.0 110.855 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 3.42 2.76 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.716 2.277 . . . . 0.0 112.359 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -105.27 -22.33 13.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.843 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.7 mt -105.77 -48.59 8.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.7 OUTLIER -164.11 164.67 14.14 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.682 0.753 . . . . 0.0 110.836 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 135.62 30.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.642 2.228 . . . . 0.0 112.35 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 125.24 11.88 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.298 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.6 mp -86.6 -26.4 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.51 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.5 m-85 -131.9 100.58 5.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -63.28 155.25 29.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.814 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -55.21 150.35 11.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.807 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.3 -10.36 16.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -72.4 151.52 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.868 0.366 . . . . 0.0 110.906 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.417 ' O ' HD23 ' A' ' 42' ' ' LEU . 58.2 tttt -102.26 138.76 38.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.928 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.541 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -135.12 152.52 51.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.927 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.63 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.4 ttt180 -105.1 129.65 53.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.87 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.932 HG22 HD11 ' A' ' 20' ' ' LEU . 99.1 t -65.19 111.82 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.669 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -93.19 -52.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.161 179.882 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.8 m -141.15 150.96 43.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -118.43 109.82 16.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.875 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -116.31 86.0 2.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.75 -123.27 32.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.64 -23.51 69.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.48 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.3 m95 -109.91 141.93 41.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.41 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.15 164.27 28.05 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.2 tttp -100.75 141.51 33.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.905 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.46 159.75 44.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.821 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -131.81 130.82 61.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.541 ' HA ' HD23 ' A' ' 42' ' ' LEU . 4.8 t -67.82 130.88 44.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.69 9.4 5.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.946 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 15.1 t -105.55 -48.01 3.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.2 p -104.41 -35.79 7.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.495 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 90.45 27.84 18.87 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.496 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.424 ' C ' HG13 ' A' ' 55' ' ' ILE . 44.0 mtt85 -89.25 124.98 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.797 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.821 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.0 mt-10 -94.31 117.33 29.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.943 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.2 t -147.6 169.63 19.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.824 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 28.3 m-85 -110.96 118.13 35.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.899 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.19 152.54 73.66 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.593 0.711 . . . . 0.0 111.146 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 137.66 35.97 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.679 2.252 . . . . 0.0 112.351 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.81 -33.23 6.39 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 3.5 tp -64.88 -31.11 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 111.162 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.1 t -72.87 -12.77 61.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.489 ' CG2' ' HB3' ' A' ' 20' ' ' LEU . 18.4 m -131.04 170.21 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.819 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.48 136.45 45.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -67.94 108.37 3.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.141 179.961 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . 73.3 m-20 . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.829 0.347 . . . . 0.0 110.883 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -111.77 152.63 27.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 44' ' ' VAL . 7.7 mt -137.43 116.03 12.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.57 127.52 33.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.677 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.4 t -66.85 97.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.101 HD21 ' HB2' ' A' ' 71' ' ' ALA . 9.4 mt -57.19 -35.93 70.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.5 t -156.38 128.2 7.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.898 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -39.1 149.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.639 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -170.61 150.05 3.14 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.729 0.776 . . . . 0.0 110.911 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.7 -174.7 9.79 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.717 -1.785 . . . . 0.0 112.355 -0.098 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.6 m -80.35 158.46 71.65 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.874 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 3.52 2.75 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.649 2.232 . . . . 0.0 112.321 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -103.89 -13.22 16.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.3 mt -119.95 -49.34 3.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.101 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -162.83 163.46 17.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.717 0.77 . . . . 0.0 110.843 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 133.56 25.8 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.676 2.251 . . . . 0.0 112.353 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 114.74 3.81 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.313 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.732 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -73.45 -30.52 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.3 m-85 -130.66 110.83 11.67 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.92 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -69.56 165.79 20.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.443 ' CG ' ' O ' ' A' ' 23' ' ' LEU . 2.4 tmt_? -67.22 141.14 57.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.46 11.52 81.85 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.486 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.4 ' OE1' ' O ' ' A' ' 41' ' ' LYS . 0.4 OUTLIER -100.35 138.22 37.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.976 0.417 . . . . 0.0 110.843 -179.857 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.4 ' O ' ' OE1' ' A' ' 40' ' ' GLU . 30.2 ttmt -85.54 140.63 30.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.677 HD11 ' CG2' ' A' ' 22' ' ' VAL . 10.1 mt -134.2 149.69 51.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.458 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.7 ttt180 -103.89 129.15 51.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 18' ' ' ASP . 45.8 t -67.97 114.82 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.095 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.493 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -88.8 -52.58 10.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.096 179.928 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.9 t -157.53 128.32 6.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -89.15 125.95 35.26 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -125.06 85.96 2.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.898 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.68 -128.08 37.49 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.8 -24.99 75.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 13.2 m95 -112.69 146.55 38.51 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.786 0.327 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.477 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.98 164.84 26.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.992 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.561 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.0 tttp -103.37 145.15 30.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.45 163.72 38.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.878 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.0 tt -131.19 135.21 60.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.567 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 37.4 p -76.23 129.09 36.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.8 mt -77.59 9.28 3.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.1 m -95.92 -49.74 5.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 12.2 p -114.75 -28.92 6.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.143 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 92.11 26.48 18.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.508 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 23.7 mtt85 -83.12 128.08 34.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.756 0.312 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.878 ' HG3' HD12 ' A' ' 55' ' ' ILE . 10.1 mt-10 -97.66 117.26 31.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.4 t -147.55 170.11 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 10.6 m-85 -110.78 123.62 50.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.901 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -130.2 150.64 76.66 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.669 0.747 . . . . 0.0 111.134 179.909 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.603 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.73 130.67 19.78 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.675 2.25 . . . . 0.0 112.374 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.13 -36.21 7.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.603 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.3 tt -58.9 -33.55 50.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.498 HG12 ' HA ' ' A' ' 22' ' ' VAL . 25.5 m -125.13 174.04 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.101 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.21 132.15 39.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.115 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.472 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.1 tpp85 -62.77 105.66 0.69 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.83 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.0 t . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.138 179.96 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.906 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.873 0.368 . . . . 0.0 110.829 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.78 150.68 22.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.696 HD11 HG22 ' A' ' 44' ' ' VAL . 10.0 mt -132.91 111.03 10.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.926 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.46 126.33 31.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 36' ' ' PHE . 89.4 t -63.2 96.25 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.165 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -59.13 -28.84 66.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.916 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.7 t -161.27 125.67 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.838 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -38.79 143.48 0.15 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.859 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -160.28 150.32 14.81 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.67 0.747 . . . . 0.0 110.917 -179.811 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.77 171.49 53.48 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.684 -1.798 . . . . 0.0 112.381 -0.05 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.407 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -52.17 148.38 11.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.634 0.731 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 53.8 Cg_endo -69.77 5.28 1.76 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.7 2.267 . . . . 0.0 112.346 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -109.01 -21.75 12.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -101.65 -53.43 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.097 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.51 164.28 21.03 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.669 0.747 . . . . 0.0 110.832 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 132.16 22.84 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.27 . . . . 0.0 112.364 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 124.42 11.06 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.666 2.244 . . . . 0.0 112.366 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.587 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -89.25 -25.31 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.165 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.669 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.6 m-85 -127.47 89.65 2.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.885 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 20.3 mmm-85 -51.01 160.11 0.52 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.449 ' CZ ' ' O ' ' A' ' 23' ' ' LEU . 11.1 ttt85 -61.58 147.22 46.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.97 -13.3 14.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -69.7 136.5 51.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.895 0.379 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -86.63 139.06 31.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.869 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.612 HD23 ' HA ' ' A' ' 56' ' ' SER . 8.1 mt -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.7 ttt-85 -87.53 132.94 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 18' ' ' ASP . 58.2 t -71.22 108.2 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.525 HD12 ' HA ' ' A' ' 54' ' ' ALA . 1.1 mp -78.56 -50.15 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.177 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -158.71 157.43 31.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -109.1 118.85 37.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.877 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.8 mm-40 -120.44 85.92 2.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.47 -126.02 38.71 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.1 -25.0 74.63 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.556 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.4 m0 -111.69 153.53 26.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.765 0.317 . . . . 0.0 110.923 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.421 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.04 164.13 28.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.8 tttm -98.94 143.07 29.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.895 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.525 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -153.94 164.08 39.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.716 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.3 tt -132.02 146.15 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.115 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.612 ' HA ' HD23 ' A' ' 42' ' ' LEU . 82.0 p -86.21 126.44 34.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.6 mt -76.09 5.92 6.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.6 t -90.6 -49.84 6.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.6 p -116.28 -34.7 4.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.14 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 102.46 23.89 8.65 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.457 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.9 mtt180 -82.08 124.51 29.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.846 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.716 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -98.87 118.55 35.88 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.5 t -147.23 169.97 18.25 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.1 m-85 -105.05 119.79 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.889 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.42 147.52 60.51 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.663 0.744 . . . . 0.0 111.09 179.904 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.556 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.78 133.77 26.34 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.694 2.262 . . . . 0.0 112.345 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -30.88 6.13 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.503 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.548 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.8 tp -64.68 -32.69 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 9.4 m -80.01 6.94 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.462 ' O ' HD11 ' A' ' 23' ' ' LEU . 36.0 m -147.56 169.81 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.2 136.08 43.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.136 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.9 tpp85 -68.13 112.44 5.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.951 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.743 ' O ' HG23 ' A' ' 44' ' ' VAL . 2.6 m-20 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.861 0.363 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -105.29 148.95 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.85 HD11 HG22 ' A' ' 44' ' ' VAL . 2.4 mt -135.87 109.53 8.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.08 126.15 30.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.742 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.0 t -60.8 101.6 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.901 HD21 ' HB2' ' A' ' 71' ' ' ALA . 16.2 mt -62.13 -30.84 71.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.3 t -158.4 127.54 5.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -40.72 145.52 0.19 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.837 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.581 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.9 148.43 6.43 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.636 0.732 . . . . 0.0 110.959 -179.849 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.81 -174.12 9.26 Favored 'Cis proline' 0 C--O 1.231 0.154 0 C-N-CA 122.708 -1.788 . . . . 0.0 112.331 -0.036 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.5 m -77.06 155.83 82.38 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.651 0.739 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 2.78 3.23 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.676 2.251 . . . . 0.0 112.346 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -106.71 -14.04 15.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.02 -48.66 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -163.58 163.04 16.74 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.675 0.75 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 133.03 24.56 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.719 2.28 . . . . 0.0 112.316 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 119.7 6.6 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.7 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -81.02 -22.81 10.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.528 ' HB3' HG21 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.66 99.77 4.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.881 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -58.65 163.9 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.437 ' HD3' ' N ' ' A' ' 39' ' ' GLY . 3.8 tmt_? -65.69 142.44 58.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.826 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.437 ' N ' ' HD3' ' A' ' 38' ' ' ARG . . . 77.96 6.81 87.5 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -86.36 144.0 27.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.66 ' HB3' HD12 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -87.29 141.1 28.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.742 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.8 mt -140.0 145.1 37.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.481 ' O ' HD12 ' A' ' 45' ' ' ILE . 16.5 ttm180 -103.78 128.48 51.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.85 HG22 HD11 ' A' ' 20' ' ' LEU . 59.5 t -65.87 108.53 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.147 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -79.87 -50.51 17.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.125 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.4 t -163.14 135.83 5.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -89.45 129.3 35.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -130.05 86.2 2.38 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 65.29 -131.46 35.58 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.509 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.42 -20.36 78.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.467 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -116.89 152.12 35.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.741 0.305 . . . . 0.0 110.923 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.18 164.23 28.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD3' HG21 ' A' ' 45' ' ' ILE . 19.3 tttp -102.17 142.53 33.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.953 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.54 156.14 36.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.135 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.585 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -124.08 137.17 57.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.729 ' HA ' HD23 ' A' ' 42' ' ' LEU . 5.1 t -68.04 128.16 35.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.865 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.66 HD12 ' HB3' ' A' ' 41' ' ' LYS . 6.4 mt -78.32 8.39 5.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.6 t -111.65 -45.98 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.862 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 51.4 p -102.14 -36.14 8.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.463 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.58 33.13 13.93 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.469 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.414 ' HD3' HG23 ' A' ' 35' ' ' ILE . 42.7 mtt180 -96.8 125.96 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.761 0.315 . . . . 0.0 110.89 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -90.66 117.43 29.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.6 t -147.66 169.99 18.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.812 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.551 ' CE1' ' HG3' ' A' ' 53' ' ' LYS . 18.9 m-85 -112.75 117.37 32.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.889 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.829 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.78 151.12 73.1 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.629 0.728 . . . . 0.0 111.123 179.932 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.677 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.83 135.76 31.09 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.661 2.241 . . . . 0.0 112.331 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.17 -30.95 8.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.7 tp -65.55 -30.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.831 0.348 . . . . 0.0 111.162 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.4 m -79.78 -0.19 33.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.99 163.11 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.901 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.2 137.48 52.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.063 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.33 112.19 2.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.851 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.48 HG21 ' HE2' ' A' ' 41' ' ' LYS . 15.4 t . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.139 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . 3.9 m-20 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.805 0.336 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -109.89 150.8 27.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.602 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 5.3 mt -129.64 114.47 16.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.22 116.73 23.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.567 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.2 t -54.92 103.65 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.114 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.045 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -66.53 -31.0 71.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 25' ' ' ASP . 30.6 t -160.33 118.79 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.859 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 24' ' ' SER . 10.4 p-10 -34.28 140.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.644 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.14 149.81 18.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.69 0.757 . . . . 0.0 110.923 -179.801 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.85 179.54 22.2 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.319 -0.008 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 p -72.46 157.2 89.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.05 2.41 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.677 2.252 . . . . 0.0 112.316 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -101.28 -13.18 18.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.839 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 4.8 mt -120.53 -60.6 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -147.96 163.07 28.82 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.651 0.738 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 137.36 35.06 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.681 2.254 . . . . 0.0 112.323 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 118.96 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.705 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -80.86 -26.19 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.567 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -131.32 93.55 3.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -54.8 161.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.411 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.8 ttm180 -62.06 147.79 46.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.96 -5.85 57.45 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -79.85 134.42 36.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.924 0.392 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -84.33 138.06 33.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.427 HD21 ' HB3' ' A' ' 36' ' ' PHE . 9.0 mt -130.56 141.32 50.46 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.54 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttp180 -93.18 126.73 38.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 18' ' ' ASP . 96.1 t -66.05 112.16 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.54 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -88.27 -53.3 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.15 179.913 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -144.45 145.31 31.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.838 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -108.68 118.41 36.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -129.4 86.44 2.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.881 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.26 -123.78 33.99 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.05 -19.03 65.93 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 25.3 m95 -113.42 131.56 55.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.752 0.311 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.602 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.44 164.36 26.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.956 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 8.3 tttp -100.2 142.27 31.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -150.78 157.83 43.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.112 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.431 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.0 tt -121.78 145.26 28.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.519 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 6.1 p -86.75 126.0 34.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 8.0 mt -75.14 5.75 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 t -92.01 -48.83 6.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.9 p -118.11 -28.69 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.85 25.92 13.94 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.48 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.404 ' CD ' HG23 ' A' ' 35' ' ' ILE . 76.6 mtt180 -80.86 132.29 35.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.306 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.438 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 4.9 mt-10 -103.29 117.38 34.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.866 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.0 t -147.67 170.18 18.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 38.5 m-85 -110.55 120.8 43.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.909 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.835 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.13 149.69 70.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.56 0.695 . . . . 0.0 111.174 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.72 134.58 28.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.67 2.247 . . . . 0.0 112.382 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.81 -30.33 8.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.5 tp -65.36 -30.1 49.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.802 0.334 . . . . 0.0 111.152 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 16.6 m -84.19 8.23 16.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.553 ' O ' HD11 ' A' ' 23' ' ' LEU . 22.9 m -148.95 168.9 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.045 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.62 131.98 43.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -68.92 112.18 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.885 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.164 179.956 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.7 t0 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.896 0.379 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -109.11 144.87 36.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.92 HD11 HG22 ' A' ' 44' ' ' VAL . 4.2 mt -131.05 112.07 12.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.61 126.38 30.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.144 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.565 ' CG2' HD11 ' A' ' 42' ' ' LEU . 95.4 t -66.52 102.44 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.058 HD21 ' HB2' ' A' ' 71' ' ' ALA . 4.7 mt -61.84 -32.16 72.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.906 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.3 t -156.23 125.24 6.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.846 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -41.47 148.09 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.57 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -167.37 148.42 5.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.778 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.76 -174.36 9.47 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.323 -0.081 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.9 m -81.59 158.57 68.34 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.69 0.757 . . . . 0.0 110.85 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 3.17 2.95 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.668 2.245 . . . . 0.0 112.324 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -107.16 -6.15 17.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.39 -43.17 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.151 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.2 m -170.92 163.32 5.43 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.653 0.74 . . . . 0.0 110.842 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 131.62 21.66 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.387 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.18 3.61 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.378 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.779 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.7 mp -72.56 -29.21 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.502 ' HB3' HG21 ' A' ' 22' ' ' VAL . 10.1 m-85 -127.75 104.64 7.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.88 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.9 OUTLIER -65.59 159.65 24.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.859 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 25.6 ttp180 -62.49 141.39 58.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.25 7.69 88.3 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -91.92 139.75 30.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -88.54 137.2 32.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.933 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.9 mt -134.65 149.71 50.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.427 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.7 ttp180 -100.62 131.66 46.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.92 HG22 HD11 ' A' ' 20' ' ' LEU . 45.7 t -71.41 116.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.614 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -89.58 -49.41 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -152.3 149.36 28.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -108.52 119.27 39.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.842 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -122.93 85.84 2.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.67 -122.14 28.08 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.509 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.76 -24.99 61.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.0 m95 -111.6 141.67 44.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.79 0.329 . . . . 0.0 110.942 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.558 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.35 164.71 25.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.893 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.545 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 19.0 tttt -99.73 146.61 26.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.56 167.07 31.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.644 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.7 tt -138.49 146.8 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.155 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.489 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 5.7 m -81.18 132.66 35.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.3 mt -80.08 9.43 5.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.939 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 m -113.17 -51.12 2.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 77.8 p -97.49 -33.95 11.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.31 27.79 35.38 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 54.2 mtt-85 -90.05 122.87 33.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.804 0.335 . . . . 0.0 110.882 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.644 ' HG3' HD12 ' A' ' 55' ' ' ILE . 11.4 mt-10 -92.54 118.53 31.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.3 m -147.11 165.78 28.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.545 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 27.9 m-85 -108.73 120.2 41.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.914 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.798 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.36 151.81 75.34 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.636 0.731 . . . . 0.0 111.149 179.909 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.69 130.14 18.91 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.37 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.45 -31.69 6.96 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.503 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.675 HG22 ' HB2' ' A' ' 66' ' ' PRO . 11.7 tt -63.0 -31.92 54.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.838 0.352 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' CYS . . . . . 0.402 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.7 m -77.08 -15.51 59.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.412 ' O ' HD11 ' A' ' 23' ' ' LEU . 25.2 m -121.3 167.77 14.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.108 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.058 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.15 131.64 44.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.466 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 7.1 tpp85 -63.14 106.14 0.81 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.155 179.99 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.533 ' O ' HG23 ' A' ' 44' ' ' VAL . 70.4 m-20 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.807 0.337 . . . . 0.0 110.898 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 m-85 -105.21 148.11 27.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.74 HD11 HG22 ' A' ' 44' ' ' VAL . 6.7 mt -130.21 107.89 9.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.37 123.42 26.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 40' ' ' GLU . 58.5 t -60.09 97.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.05 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.2 mt -61.02 -33.9 73.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -162.25 130.1 3.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.913 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 p30 -41.15 146.73 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.634 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.85 149.67 7.1 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.633 0.73 . . . . 0.0 110.929 -179.841 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.8 Cg_endo -69.76 -177.42 14.5 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.314 -0.031 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 1.2 t -69.55 153.92 95.29 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.722 0.773 . . . . 0.0 110.86 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 4.0 2.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.685 2.256 . . . . 0.0 112.325 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -107.87 -24.34 11.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.869 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.2 mt -101.59 -54.78 6.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.129 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -153.95 164.34 20.99 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.91 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 128.28 15.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 121.0 7.71 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.727 2.285 . . . . 0.0 112.355 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.742 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -80.24 -28.08 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.143 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.464 ' HB3' HG21 ' A' ' 22' ' ' VAL . 12.6 m-85 -131.14 110.51 11.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.4 ' O ' ' C ' ' A' ' 38' ' ' ARG . 10.0 mmm180 -78.11 138.11 38.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.447 ' HA ' HG12 ' A' ' 22' ' ' VAL . 15.3 ttp-105 -37.51 144.99 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.21 -8.66 79.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.498 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.541 ' O ' HG23 ' A' ' 22' ' ' VAL . 7.3 mt-10 -88.14 146.4 25.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.885 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' HD23 ' A' ' 42' ' ' LEU . 3.6 ttmp? -99.33 147.7 24.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.869 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.533 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -137.2 153.92 50.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.577 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.5 ttm180 -108.38 127.92 54.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.74 HG22 HD11 ' A' ' 20' ' ' LEU . 61.6 t -61.99 109.61 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.595 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -86.1 -55.05 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.897 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 45' ' ' ILE . 43.5 t -152.07 125.65 8.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -88.05 126.17 34.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -129.97 85.86 2.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.72 -127.48 36.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.513 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.53 -22.69 74.9 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' TRP . . . . . 0.585 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 19.6 m95 -113.76 137.1 52.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.789 0.328 . . . . 0.0 110.923 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.419 ' CZ2' ' HA2' ' A' ' 67' ' ' GLY . 0.1 OUTLIER -129.05 164.64 22.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.595 ' HD3' HG21 ' A' ' 45' ' ' ILE . 11.5 tttp -100.9 142.94 31.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.68 159.67 43.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.117 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.808 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.6 tt -131.83 138.84 51.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.138 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.533 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.1 t -74.39 126.52 30.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.897 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.1 mt -77.28 8.57 3.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.7 t -107.34 -44.8 4.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.4 p -104.7 -41.22 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.188 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.9 32.68 7.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.416 ' C ' HG13 ' A' ' 55' ' ' ILE . 45.8 mtt180 -97.6 122.71 41.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.811 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.808 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.5 mt-10 -91.15 116.99 29.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.6 t -147.96 165.99 29.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.559 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 15.0 m-85 -105.6 128.99 53.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.486 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.3 OUTLIER -138.57 151.13 68.32 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.656 0.741 . . . . 0.0 111.12 179.9 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.702 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.7 133.7 26.31 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.65 2.233 . . . . 0.0 112.35 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -31.57 6.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.1 tp -64.63 -32.03 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.821 0.343 . . . . 0.0 111.142 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -75.28 -12.68 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.888 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.611 ' O ' HD11 ' A' ' 23' ' ' LEU . 13.3 m -127.29 169.86 18.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.05 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -129.96 132.54 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.115 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.651 ' NH1' HG21 ' A' ' 44' ' ' VAL . 1.7 tpt180 -69.53 105.13 2.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.0 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.151 179.972 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 59.0 p -45.33 129.4 8.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.864 0.364 . . . . 0.0 110.85 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.9 t -85.28 -60.34 2.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.869 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.48 -167.94 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.6 t -148.47 152.64 37.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.906 0.384 . . . . 0.0 110.829 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 52.2 p -90.54 117.04 28.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.868 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.37 -157.52 13.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 157.63 59.85 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.688 2.259 . . . . 0.0 112.393 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 mt -74.27 148.39 86.17 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -42.16 3.63 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.661 2.241 . . . . 0.0 112.351 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -38.31 144.84 0.36 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.665 0.745 . . . . 0.0 110.904 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.43 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.7 Cg_endo -69.78 -7.63 21.56 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.674 2.249 . . . . 0.0 112.315 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 12' ' ' PRO . 0.5 OUTLIER 35.48 41.28 0.09 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.874 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.94 -49.31 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.481 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.2 mp -105.95 116.53 32.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.826 0.346 . . . . 0.0 110.899 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.07 143.97 47.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.4 t -94.68 161.35 14.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.84 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.9 m-20 -77.99 126.9 31.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.89 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -105.06 148.25 26.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.639 HD11 HG22 ' A' ' 44' ' ' VAL . 4.8 mt -129.93 114.2 15.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -83.11 126.26 32.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.118 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 36' ' ' PHE . 93.1 t -62.33 104.3 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.095 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.971 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.8 mt -66.44 -33.48 75.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.889 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.426 ' O ' ' C ' ' A' ' 25' ' ' ASP . 28.8 t -156.17 120.43 4.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 24' ' ' SER . 4.3 p-10 -35.97 140.07 0.13 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.572 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.1 OUTLIER -156.75 147.65 16.45 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 0.0 110.899 -179.866 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.564 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -173.57 8.6 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.351 -0.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 m -75.8 156.21 84.69 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.727 0.775 . . . . 0.0 110.841 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 3.33 2.82 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.691 2.261 . . . . 0.0 112.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -106.92 -16.55 14.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -112.2 -46.53 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.164 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -165.75 163.0 12.87 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.685 0.755 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 133.33 25.23 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.365 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 120.37 7.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 0.0 112.333 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.731 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.3 mp -79.15 -25.87 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.11 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.648 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.5 m-85 -131.22 93.83 3.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.95 155.27 8.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 55.7 ttp85 -54.82 148.11 13.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -16.28 11.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.483 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -68.98 138.35 54.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.918 0.39 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -92.74 137.65 32.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mt -131.16 147.6 52.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.921 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.528 ' O ' HD12 ' A' ' 45' ' ' ILE . 28.2 ttt180 -99.41 132.11 44.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 18' ' ' ASP . 90.9 t -68.04 110.28 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.149 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.666 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -87.47 -52.38 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.117 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 m -143.59 146.91 33.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -111.27 116.7 31.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.852 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 6.6 mm-40 -125.66 85.94 2.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.76 -122.52 30.29 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 -22.52 63.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.519 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 26.3 m95 -110.84 137.33 48.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.305 . . . . 0.0 110.899 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.409 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.27 164.37 27.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.875 -179.994 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.666 ' HD3' HG21 ' A' ' 45' ' ' ILE . 38.5 tttt -100.09 140.9 33.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.82 160.01 43.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.74 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.5 tt -131.45 141.54 45.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.4 t -76.48 130.45 37.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.85 6.58 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.2 t -109.7 -44.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 53.2 p -103.53 -34.68 8.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.156 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.95 32.46 23.66 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.519 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.436 ' C ' HG13 ' A' ' 55' ' ' ILE . 28.1 mtt180 -95.83 125.26 40.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.777 0.322 . . . . 0.0 110.88 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.74 ' HG3' HD12 ' A' ' 55' ' ' ILE . 7.1 mt-10 -91.51 118.13 30.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 36' ' ' PHE . 4.2 m -147.01 168.81 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.824 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 31.6 m-85 -113.28 120.33 40.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.963 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.825 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -130.43 151.27 78.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.632 0.73 . . . . 0.0 111.124 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.6 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 132.23 22.87 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.699 2.266 . . . . 0.0 112.306 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -45.17 -33.97 4.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.494 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.6 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -61.37 -34.75 62.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.351 . . . . 0.0 111.111 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.15 -13.86 61.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.406 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.9 m -124.93 171.78 13.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.161 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.971 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.73 132.5 43.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.093 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 3.2 tpp85 -65.87 102.82 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.6 t -73.19 145.27 11.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.7 m -105.44 -49.99 3.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.871 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 176.14 168.93 37.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.498 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 -175.66 1.21 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.713 2.275 . . . . 0.0 112.382 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 79.9 p -129.09 -46.7 1.23 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.7 t -95.13 114.05 25.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.92 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.4 p -108.14 134.95 50.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.887 0.375 . . . . 0.0 110.84 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.5 t -123.06 83.75 2.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.79 97.34 0.31 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.487 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 34.4 t -125.52 155.66 40.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.837 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.9 m -77.19 -51.72 10.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.94 143.54 3.73 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -176.65 1.54 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.235 . . . . 0.0 112.385 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.0 mt -67.41 154.08 93.66 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.941 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -35.43 12.54 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 p-10 -175.02 148.42 1.11 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.617 0.722 . . . . 0.0 110.864 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -2.94 11.04 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.318 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.43 38.57 22.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.43 -40.44 6.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.5 mp -118.41 151.34 37.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -87.56 171.0 10.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.7 t -108.24 155.4 20.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.554 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.8 m-20 -100.95 127.51 47.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.865 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -106.32 146.82 29.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.882 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.881 HD11 HG22 ' A' ' 44' ' ' VAL . 7.4 mt -131.91 108.96 9.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.01 128.64 33.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 ' O ' ' A' ' 36' ' ' PHE . 74.1 t -65.25 100.05 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.104 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.028 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.6 mt -61.48 -26.69 68.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -166.64 132.47 2.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.93 142.43 0.91 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 150.46 12.93 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.643 0.735 . . . . 0.0 110.911 -179.807 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.8 175.08 38.12 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.652 -1.812 . . . . 0.0 112.342 -0.07 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.4 p -68.5 156.31 90.85 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.679 0.752 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 5.24 1.75 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.88 -6.42 18.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.896 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.56 -53.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.03 163.93 23.4 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.683 0.754 . . . . 0.0 110.849 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 134.53 28.19 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.692 2.262 . . . . 0.0 112.354 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.14 11.81 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.72 2.28 . . . . 0.0 112.368 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.606 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -87.66 -23.66 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.479 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.7 m-85 -134.74 101.37 4.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.8 mmt85 -60.95 158.98 12.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.465 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.6 tmm_? -56.87 144.34 33.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.858 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.443 ' N ' ' HD2' ' A' ' 38' ' ' ARG . . . 83.69 -16.07 33.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -68.78 138.68 55.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.936 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.62 142.05 27.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 56' ' ' SER . 3.0 mt -138.71 135.16 34.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.934 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.533 ' O ' HD12 ' A' ' 45' ' ' ILE . 50.4 ttt180 -87.3 133.54 33.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.881 HG22 HD11 ' A' ' 20' ' ' LEU . 89.6 t -68.39 113.58 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.125 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -91.28 -50.41 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.155 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.1 p -143.8 150.36 38.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.9 p-10 -114.3 115.66 27.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.92 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.0 mt-10 -122.17 85.84 2.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.935 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.45 -119.62 18.23 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.506 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.48 -24.12 61.42 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.51 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 18.3 m95 -110.81 140.31 45.36 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.781 0.325 . . . . 0.0 110.945 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.18 164.32 27.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.911 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.526 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 33.4 tttt -98.26 145.62 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.674 HD12 ' HG3' ' A' ' 62' ' ' GLU . 16.1 tt -127.68 144.95 35.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.53 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.9 t -78.13 129.16 34.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.844 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.28 8.95 6.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.8 m -114.75 -44.22 3.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.9 p -101.26 -41.82 6.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.114 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.32 25.87 17.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.483 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 40.1 mtt180 -92.27 125.93 37.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.674 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.75 117.92 30.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 17.7 m -146.87 169.35 19.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 19.8 m-85 -112.06 118.83 36.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.778 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.43 151.25 69.78 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.148 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.656 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.6 Cg_endo -69.74 133.11 24.81 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.697 2.265 . . . . 0.0 112.331 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.9 -31.26 5.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.466 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.656 HG22 ' HB2' ' A' ' 66' ' ' PRO . 9.1 tt -64.27 -32.59 58.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.776 0.322 . . . . 0.0 111.097 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.3 m -75.58 -13.05 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.688 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.6 m -126.97 175.23 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.028 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -141.84 139.83 32.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.119 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -67.9 110.45 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 23.7 t -81.88 144.37 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.129 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.4 t -166.32 142.91 4.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.87 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 149.04 -158.74 27.77 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 77' ' ' SER . 53.8 Cg_endo -69.76 2.78 3.22 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 76' ' ' PRO . 10.2 p -34.9 134.88 0.21 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 54.8 m -92.74 171.12 9.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.832 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.475 179.996 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 m -117.25 128.87 55.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.858 0.361 . . . . 0.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.1 p -153.68 147.01 24.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.813 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 61.78 152.72 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.0 t -83.58 157.94 22.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.832 0.349 . . . . 0.0 110.891 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.7 p -152.64 122.29 6.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.816 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.46 137.18 3.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.523 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -174.51 0.92 Allowed 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.687 2.258 . . . . 0.0 112.366 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.497 ' CD2' ' HD2' ' A' ' 10' ' ' PRO . 13.5 mt -90.64 157.67 43.76 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.617 0.722 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.497 ' HD2' ' CD2' ' A' ' 9' ' ' LEU . 53.4 Cg_endo -69.77 1.95 3.98 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.672 2.248 . . . . 0.0 112.316 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.447 ' C ' ' O ' ' A' ' 10' ' ' PRO . 7.5 t-20 -34.64 135.56 0.39 Allowed Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.695 0.76 . . . . 0.0 110.84 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 1.67 4.28 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.662 2.242 . . . . 0.0 112.313 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -47.14 101.63 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.14 -47.77 0.58 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.532 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.1 mt -87.16 113.83 23.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 110.934 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -87.06 157.12 19.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.4 t -117.85 152.8 34.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.7 m-20 -66.65 135.32 53.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -105.11 149.88 25.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.839 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.656 HD11 HG22 ' A' ' 44' ' ' VAL . 14.5 mt -132.71 115.13 14.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.48 120.47 26.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.643 HG11 ' O ' ' A' ' 36' ' ' PHE . 87.7 t -55.68 106.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.1 mt -66.79 -34.01 76.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.917 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.9 t -157.2 128.13 6.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.852 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.97 134.05 2.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.643 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.87 149.74 22.76 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 110.942 -179.811 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.48 11.0 Favored 'Cis proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.304 -0.045 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.1 m -73.61 155.65 89.11 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.671 0.748 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 2.92 3.09 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.699 2.266 . . . . 0.0 112.359 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -106.82 -16.61 14.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -111.81 -46.94 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.172 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.11 162.01 14.34 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.622 0.725 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 135.94 31.59 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.637 2.224 . . . . 0.0 112.348 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 124.87 11.48 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.684 2.256 . . . . 0.0 112.338 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.597 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -87.52 -25.08 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.149 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.643 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.1 m-85 -131.65 89.77 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -50.49 156.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.872 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -58.43 150.97 21.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.62 -6.4 17.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.455 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -76.09 135.41 39.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 35.0 tttt -86.12 137.78 32.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.516 HD23 ' HA ' ' A' ' 56' ' ' SER . 9.7 mt -132.98 154.51 50.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.468 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.9 ttp180 -105.06 131.42 52.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 18' ' ' ASP . 89.9 t -70.88 112.73 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.625 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.88 -51.66 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.8 t -151.83 159.36 43.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.828 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -116.33 111.71 20.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.3 mt-10 -110.53 86.41 2.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.98 -122.68 31.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.23 -21.62 78.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.496 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.8 m95 -114.97 151.87 33.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.432 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.09 164.52 27.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.941 -179.985 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.625 ' HD3' HG21 ' A' ' 45' ' ' ILE . 25.8 tttt -100.85 143.88 30.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.81 160.95 42.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.822 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -129.88 146.76 33.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.516 ' HA ' HD23 ' A' ' 42' ' ' LEU . 87.6 p -81.37 128.52 33.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.871 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.4 mt -77.49 8.66 4.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.5 m -99.9 -52.69 3.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.816 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.4 p -107.37 -45.4 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.193 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.573 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 107.92 29.43 4.35 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.9 mtt180 -86.95 123.99 32.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.746 0.308 . . . . 0.0 110.864 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.822 ' HG3' HD12 ' A' ' 55' ' ' ILE . 6.2 mt-10 -93.97 117.86 30.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -147.19 165.63 29.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.873 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.45 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 17.0 m-85 -107.27 123.93 49.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.935 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.821 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.36 151.25 77.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.671 0.748 . . . . 0.0 111.144 179.905 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.568 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.75 132.56 23.61 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.646 2.231 . . . . 0.0 112.382 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.66 -31.33 7.22 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.462 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.461 ' O ' HD12 ' A' ' 23' ' ' LEU . 8.0 tt -63.92 -31.91 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 111.108 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' CYS . . . . . 0.401 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.2 m -76.6 -11.12 59.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.563 ' O ' HD11 ' A' ' 23' ' ' LEU . 31.0 m -127.84 169.72 18.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.906 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -127.85 129.08 46.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -64.8 108.8 1.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.455 HG12 ' N ' ' A' ' 74' ' ' SER . 7.9 t -91.23 160.27 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.181 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.455 ' N ' HG12 ' A' ' 73' ' ' VAL . 50.7 m -140.55 154.65 46.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.86 162.73 45.11 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.513 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 1.27 4.6 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.697 2.265 . . . . 0.0 112.315 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 78' ' ' SER . 86.1 p -49.31 -50.87 37.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.882 -179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.41 ' C ' ' O ' ' A' ' 77' ' ' SER . 27.8 p -37.06 124.91 0.93 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.871 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.962 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.489 -0.245 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 97.2 p 38.36 41.86 0.47 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.947 0.403 . . . . 0.0 110.897 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 t -98.27 154.95 17.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.869 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -98.87 -93.38 2.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.3 p 40.56 44.72 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.361 . . . . 0.0 110.81 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.3 p -37.79 -38.91 0.32 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.836 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 149.02 179.28 24.78 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.493 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 163.24 38.97 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.701 2.267 . . . . 0.0 112.351 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 68.5 mt -129.75 150.73 76.63 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.55 0.691 . . . . 0.0 110.926 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.29 23.23 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -118.53 134.74 23.46 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.615 0.722 . . . . 0.0 110.893 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -4.77 14.72 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.729 2.286 . . . . 0.0 112.31 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -87.96 49.35 1.79 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -85.51 -80.09 1.14 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.497 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.1 mp -79.78 102.96 9.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.793 0.33 . . . . 0.0 110.931 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -90.58 -179.22 5.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.406 ' HB3' ' CZ ' ' A' ' 19' ' ' PHE . 9.7 t -129.23 151.97 49.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.2 m-20 -87.39 115.36 24.75 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.861 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.406 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.2 m-85 -108.46 153.7 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.851 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.918 HD11 HG22 ' A' ' 44' ' ' VAL . 3.6 mt -140.03 114.55 9.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.9 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.65 128.93 34.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.493 ' CG2' HD11 ' A' ' 42' ' ' LEU . 92.4 t -65.1 109.44 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.072 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.914 HD21 ' HB2' ' A' ' 71' ' ' ALA . 6.5 mt -68.8 -31.93 71.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.932 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.436 ' O ' ' C ' ' A' ' 25' ' ' ASP . 24.6 t -160.76 125.98 3.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.7 OUTLIER -35.37 148.34 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.846 179.953 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.59 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -166.04 148.89 6.49 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.64 0.733 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.8 -174.27 9.41 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.347 0.025 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -71.17 153.63 94.27 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 0.0 110.876 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 3.04 3.02 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.678 2.252 . . . . 0.0 112.338 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -106.0 -23.13 12.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.5 -57.15 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.128 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 m -150.8 162.93 25.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.679 0.752 . . . . 0.0 110.851 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 132.89 24.17 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.339 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 122.59 9.26 Favored 'Trans proline' 0 N--CA 1.465 -0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.347 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.678 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -87.17 -26.11 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.431 ' HB3' HG21 ' A' ' 22' ' ' VAL . 6.0 m-85 -128.87 99.22 5.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 28.6 mmm-85 -63.44 157.75 22.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 ttm180 -56.81 143.82 35.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.03 9.42 86.96 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -93.15 136.0 33.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.401 ' O ' HD23 ' A' ' 42' ' ' LEU . 22.1 ttmt -87.99 139.6 30.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.493 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.1 mt -136.94 146.86 45.93 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.552 ' O ' HD12 ' A' ' 45' ' ' ILE . 15.1 ttm180 -100.5 125.34 46.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.927 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.918 HG22 HD11 ' A' ' 20' ' ' LEU . 43.6 t -63.44 111.03 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.552 HD12 ' O ' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -85.12 -47.74 16.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -149.09 157.89 43.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -117.21 113.15 21.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.2 mt-10 -115.22 86.25 2.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 57.68 -118.4 12.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.43 -23.0 61.41 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.508 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.9 m95 -112.28 135.72 52.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.76 0.314 . . . . 0.0 110.896 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.507 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -124.75 164.76 19.26 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.932 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.552 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 14.5 tttp -102.61 147.77 26.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.74 163.81 39.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.104 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.737 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.5 tt -131.47 151.33 35.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.156 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.407 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 49.1 m -83.18 127.77 33.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.3 mt -78.43 9.38 3.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 m -116.8 -43.88 2.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 68.6 p -101.4 -42.74 6.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.02 25.79 16.19 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 50.8 mtt-85 -89.86 124.49 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.779 0.323 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.737 ' HG3' HD12 ' A' ' 55' ' ' ILE . 9.6 mt-10 -93.92 117.38 30.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.1 t -147.76 166.28 27.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.832 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.552 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 12.9 m-85 -108.79 122.74 47.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.738 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -129.8 151.12 77.62 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.65 0.738 . . . . 0.0 111.157 179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.706 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.79 134.8 28.78 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.325 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.75 -30.58 9.03 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.469 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.2 tp -65.39 -30.46 50.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.7 m -78.6 -6.87 56.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.838 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.443 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.5 m -133.02 167.57 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.914 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.94 134.67 48.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.6 tpt85 -64.98 112.36 3.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 19.1 t -87.2 144.49 9.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.0 t -143.62 118.58 10.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.18 160.73 32.28 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -40.87 4.82 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.658 2.239 . . . . 0.0 112.316 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 80.8 p -57.76 -45.19 86.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 67.0 m -120.55 120.22 35.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.853 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.451 179.981 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 t 67.29 42.09 2.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.934 0.397 . . . . 0.0 110.916 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 t -64.02 100.34 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.855 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -43.81 125.72 5.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.7 m -79.1 91.21 4.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.824 0.345 . . . . 0.0 110.864 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 71.0 m -132.49 127.82 36.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.842 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.82 173.37 14.06 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.522 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 140.78 43.66 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.715 2.276 . . . . 0.0 112.314 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.0 mt -62.78 144.33 96.56 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 80.02 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.672 2.248 . . . . 0.0 112.33 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -49.07 109.99 1.38 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.634 0.73 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -5.38 16.08 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.36 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -85.25 33.84 0.56 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.63 -82.92 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.455 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 44.0 mt -101.2 121.96 42.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.767 0.317 . . . . 0.0 110.945 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.47 175.76 5.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 t -118.04 149.72 40.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.853 ' O ' HG23 ' A' ' 44' ' ' VAL . 13.2 m-20 -93.23 117.02 29.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -103.14 152.66 21.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.853 HD11 HG22 ' A' ' 44' ' ' VAL . 0.9 OUTLIER -137.51 112.89 9.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.923 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 125.52 30.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.075 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.634 HG11 ' O ' ' A' ' 36' ' ' PHE . 46.9 t -61.63 99.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.143 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.886 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -57.33 -33.69 67.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.894 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.2 t -157.95 133.17 8.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.36 135.29 3.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.65 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -153.39 150.18 23.01 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.665 0.745 . . . . 0.0 110.929 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.76 -175.09 10.34 Favored 'Cis proline' 0 C--O 1.231 0.156 0 C-N-CA 122.723 -1.782 . . . . 0.0 112.33 -0.004 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 31.2 m -75.24 155.64 86.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.729 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 1.14 4.69 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.682 2.255 . . . . 0.0 112.394 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.16 -5.38 18.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.863 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.72 -47.03 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.1 161.63 14.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.638 0.732 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 134.28 27.62 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.367 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 125.29 12.01 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.67 2.247 . . . . 0.0 112.357 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.651 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -87.19 -25.22 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.114 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.634 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.89 96.94 3.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.81 162.95 1.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.868 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -59.88 149.66 30.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.08 -9.76 17.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.99 137.09 48.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.878 0.371 . . . . 0.0 110.891 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 1.2 ttmp? -90.89 138.94 31.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.7 mt -137.99 142.63 40.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.941 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 45' ' ' ILE . 27.6 ttt-85 -94.97 131.66 40.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.853 HG22 HD11 ' A' ' 20' ' ' LEU . 69.0 t -68.01 109.84 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.149 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.648 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -83.65 -46.26 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.94 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 68.8 m -156.27 152.75 28.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -110.91 117.09 32.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.885 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -120.43 86.09 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.7 -122.99 30.63 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.01 -23.37 66.53 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.511 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.6 m95 -112.42 146.72 37.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.747 0.308 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.42 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.55 164.45 27.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.921 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.648 ' HD3' HG21 ' A' ' 45' ' ' ILE . 34.7 tttt -100.37 143.39 30.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.27 163.26 39.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.078 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.57 HG22 HD11 ' A' ' 45' ' ' ILE . 12.0 tt -133.9 136.89 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.116 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.432 ' HA ' HD23 ' A' ' 42' ' ' LEU . 2.6 t -70.87 129.09 38.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.69 8.64 5.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.946 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.7 m -112.6 -44.91 3.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.811 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 70.6 p -103.24 -33.65 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.79 29.44 32.04 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.48 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -92.24 123.94 35.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.793 0.33 . . . . 0.0 110.903 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.425 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.6 mt-10 -90.88 117.63 29.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.869 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.6 m -147.26 167.41 24.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.832 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.459 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.6 m-85 -110.5 115.72 30.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.811 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.49 151.4 63.15 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.641 0.734 . . . . 0.0 111.173 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.4 Cg_endo -69.77 134.41 27.9 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.686 2.257 . . . . 0.0 112.351 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.431 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -50.36 -28.85 15.27 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.513 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 18.2 tt -66.0 -28.0 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.8 0.334 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 6.4 m -85.1 1.13 49.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 35.9 m -136.37 157.99 37.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.886 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -120.45 130.83 54.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.053 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -64.89 107.63 1.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.08 144.09 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 44.1 t -114.96 107.19 15.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.21 179.09 41.4 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -40.11 5.67 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.708 2.272 . . . . 0.0 112.304 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 73.8 m 42.51 43.04 3.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.6 p -115.24 130.33 56.88 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.838 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.0 t -98.56 140.0 33.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.887 0.375 . . . . 0.0 110.848 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.2 p -126.89 151.29 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.7 168.57 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.529 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.1 p -163.41 124.67 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.352 . . . . 0.0 110.883 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.7 t 68.3 49.15 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.847 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.72 143.12 15.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 155.16 66.78 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.65 2.233 . . . . 0.0 112.356 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.7 mt -132.07 153.93 81.51 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 110.872 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.453 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.8 Cg_endo -69.8 3.0 3.05 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.66 2.24 . . . . 0.0 112.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 10' ' ' PRO . 8.5 m-20 -33.32 143.21 0.18 Allowed Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.601 0.715 . . . . 0.0 110.938 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.497 ' O ' ' N ' ' A' ' 14' ' ' GLY . 54.0 Cg_endo -69.67 2.5 3.42 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.704 2.269 . . . . 0.0 112.337 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 -50.65 87.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 123.29 -49.9 0.87 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.524 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 68.1 mt -114.27 130.52 56.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.864 0.364 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.02 136.8 33.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.869 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.3 t -96.58 155.06 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.79 ' O ' HG23 ' A' ' 44' ' ' VAL . 5.8 m-20 -69.17 132.68 46.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -104.72 152.73 22.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.843 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.701 HD11 HG22 ' A' ' 44' ' ' VAL . 3.8 mt -134.62 108.71 8.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.5 125.47 29.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.6 t -63.9 103.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.8 mt -62.54 -33.28 74.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.421 ' O ' ' C ' ' A' ' 25' ' ' ASP . 35.3 t -158.34 123.24 4.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.873 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.3 OUTLIER -36.36 144.55 0.05 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.841 179.993 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.601 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 148.9 11.6 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.743 . . . . 0.0 110.939 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.56 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.75 178.69 24.56 Favored 'Cis proline' 0 N--CA 1.465 -0.147 0 C-N-CA 122.713 -1.786 . . . . 0.0 112.358 -0.044 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -66.36 153.33 92.93 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.724 0.773 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.86 3.16 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.663 2.242 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -104.48 -23.99 13.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.847 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.23 -54.51 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.167 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.53 164.18 21.76 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.684 0.754 . . . . 0.0 110.888 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 131.54 21.48 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.72 3.79 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.664 2.242 . . . . 0.0 112.324 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.728 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -75.65 -27.56 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.531 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 8.2 m-85 -129.5 102.3 6.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -62.65 162.77 10.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.926 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.5 ttt180 -62.15 146.95 49.12 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.5 -9.75 26.81 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.498 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -73.06 131.62 42.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.916 0.389 . . . . 0.0 110.854 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.441 ' HB3' HD12 ' A' ' 57' ' ' LEU . 25.3 ttmt -81.52 136.48 35.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.892 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.619 HD23 ' HA ' ' A' ' 56' ' ' SER . 13.7 mt -129.36 139.67 51.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.584 HH12 HG21 ' A' ' 55' ' ' ILE . 7.9 ttp-105 -90.38 129.8 36.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.79 HG23 ' O ' ' A' ' 18' ' ' ASP . 99.3 t -69.46 111.77 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.153 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.64 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.6 -52.89 10.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 t -152.88 159.82 43.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -115.96 112.27 21.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -110.61 85.9 2.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.33 -122.16 29.17 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.14 -23.62 75.55 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -113.67 152.66 30.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.763 0.315 . . . . 0.0 110.978 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.463 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.11 164.29 28.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.64 ' HD3' HG21 ' A' ' 45' ' ' ILE . 14.8 tttt -101.28 139.55 36.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.88 168.7 20.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.8 tt -135.75 140.35 44.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.163 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.619 ' HA ' HD23 ' A' ' 42' ' ' LEU . 96.3 p -79.42 128.27 33.14 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.441 HD12 ' HB3' ' A' ' 41' ' ' LYS . 7.9 mt -78.7 9.49 4.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.888 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.0 t -104.15 -45.34 4.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.918 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.7 p -110.69 -34.83 6.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 91.95 24.11 25.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -87.94 128.25 35.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.799 0.333 . . . . 0.0 110.866 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 55' ' ' ILE . 15.5 mt-10 -95.55 117.79 31.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 44.7 t -147.11 159.48 43.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.882 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -98.2 129.9 44.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.826 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -138.16 151.45 69.78 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.552 0.691 . . . . 0.0 111.182 179.884 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.713 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.71 132.02 22.54 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.703 2.269 . . . . 0.0 112.329 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.401 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -48.45 -29.77 7.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.505 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.713 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.3 tt -64.94 -30.87 51.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 111.118 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.4 m -77.68 -11.52 59.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.401 HG22 ' HA2' ' A' ' 67' ' ' GLY . 19.2 m -126.71 165.58 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.089 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.837 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -124.21 130.22 52.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 tpt180 -67.12 99.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.4 t -75.51 154.12 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -118.37 49.94 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 42.74 -156.47 0.11 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.16 2.22 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.665 2.244 . . . . 0.0 112.326 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 50.7 m -55.25 -56.61 17.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 3.3 t -133.56 162.52 31.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.831 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.8 m -88.36 -47.46 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.864 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -64.35 -47.38 79.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.881 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.98 -133.79 11.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.2 m -101.65 102.86 13.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.912 0.387 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -169.39 167.41 10.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.896 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.49 159.87 17.55 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.496 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 179.08 3.98 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.701 2.267 . . . . 0.0 112.339 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 11.0 mt -127.41 144.01 49.33 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.535 0.684 . . . . 0.0 110.958 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 80.1 0.88 Allowed 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.74 2.293 . . . . 0.0 112.356 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -74.65 143.99 79.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.653 0.74 . . . . 0.0 110.86 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 0.24 5.97 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.672 2.248 . . . . 0.0 112.34 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -61.94 108.75 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -101.13 -50.44 1.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.482 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 12.9 mt -120.41 155.67 32.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.779 0.324 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -53.48 157.27 2.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.892 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.7 t -83.03 158.62 22.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.869 ' O ' HG23 ' A' ' 44' ' ' VAL . 41.5 m-20 -60.7 130.54 47.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -102.97 151.2 22.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.777 HD11 HG22 ' A' ' 44' ' ' VAL . 4.7 mt -135.54 109.18 7.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.69 131.32 35.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.056 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 36' ' ' PHE . 63.7 t -65.81 109.11 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.159 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.068 HD21 ' HB2' ' A' ' 71' ' ' ALA . 5.0 mt -74.52 -29.63 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 25' ' ' ASP . 29.2 t -157.02 115.52 3.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -34.99 139.96 0.08 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.588 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -156.65 148.59 17.38 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.687 0.756 . . . . 0.0 110.924 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.74 -174.67 9.79 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 -1.801 . . . . 0.0 112.358 -0.074 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.477 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 4.0 m -77.0 158.8 79.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.696 0.76 . . . . 0.0 110.857 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 5.15 1.79 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 29.4 p-10 -104.26 -27.93 11.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.405 HG13 ' OD1' ' A' ' 30' ' ' ASP . 7.3 mt -101.95 -53.45 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -159.47 163.82 22.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 137.71 35.97 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 124.82 11.48 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.713 2.276 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.593 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -86.89 -20.85 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.635 ' O ' HG11 ' A' ' 22' ' ' VAL . 19.5 m-85 -134.47 87.17 2.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.887 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.77 156.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.435 ' HG3' ' C ' ' A' ' 23' ' ' LEU . 2.6 ttm105 -60.68 144.03 52.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.65 -9.41 62.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.471 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -76.95 136.15 38.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 110.911 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 49.8 tttt -84.26 137.55 33.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.453 HD11 ' CG2' ' A' ' 22' ' ' VAL . 9.9 mt -131.64 150.0 52.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.556 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.1 ttp180 -105.09 128.85 53.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 18' ' ' ASP . 91.5 t -64.35 110.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.646 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -87.79 -51.73 12.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.4 p -146.9 135.51 22.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -100.06 115.82 30.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.0 mm-40 -127.3 86.89 2.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.95 -123.41 32.6 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.49 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.39 63.06 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.595 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 32.1 m95 -113.98 123.26 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.735 0.302 . . . . 0.0 110.88 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.486 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -123.2 164.29 18.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.924 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.646 ' HD3' HG21 ' A' ' 45' ' ' ILE . 10.9 tttp -98.5 144.7 27.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.884 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.95 152.66 31.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.107 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.582 HG22 HD11 ' A' ' 45' ' ' ILE . 12.6 tt -126.23 131.84 71.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.443 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.3 t -68.77 128.82 38.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 4.5 mt -79.22 9.37 4.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.0 t -109.26 -45.53 3.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.841 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.5 p -102.02 -39.73 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.14 32.15 9.16 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.428 ' C ' HG13 ' A' ' 55' ' ' ILE . 36.7 mtt180 -98.19 127.0 43.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.826 0.346 . . . . 0.0 110.867 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.573 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.19 117.24 29.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.861 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.2 m -147.89 168.31 22.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 30.0 m-85 -109.66 135.64 50.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.411 HG22 ' CE1' ' A' ' 26' ' ' TYR . 0.2 OUTLIER -144.36 151.37 50.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.59 0.71 . . . . 0.0 111.165 179.86 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.696 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.72 133.81 26.55 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -48.56 -30.21 8.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.696 HG22 ' HB2' ' A' ' 66' ' ' PRO . 4.6 tp -65.54 -30.45 50.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.816 0.341 . . . . 0.0 111.164 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' CYS . . . . . 0.4 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 2.9 m -78.5 -3.84 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.604 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.2 m -136.59 169.8 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.068 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.98 139.25 45.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.2 tpp85 -68.62 112.03 5.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.876 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.8 t -83.18 143.92 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.105 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 15.1 t -69.8 -44.85 69.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.854 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.54 -158.11 22.64 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.527 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 154.15 68.06 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.718 2.279 . . . . 0.0 112.375 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 11.0 t -125.94 -55.66 1.48 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.893 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 16.1 t -91.96 86.75 5.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.81 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.461 -179.999 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.2 t -133.26 116.83 16.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 t -155.09 150.99 27.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.859 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.55 164.69 11.62 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m -66.97 114.16 5.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.858 0.361 . . . . 0.0 110.848 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.1 p -91.11 172.63 8.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.74 144.88 1.38 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.448 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 143.84 51.87 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.662 2.241 . . . . 0.0 112.315 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.9 mt -48.73 143.04 8.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.593 0.711 . . . . 0.0 110.94 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -10.9 29.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.656 2.238 . . . . 0.0 112.359 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -97.64 114.61 65.17 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -8.91 24.8 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.262 . . . . 0.0 112.323 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.0 mm-40 -79.24 87.6 4.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.867 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.48 -91.84 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.451 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 20.1 mt -79.47 113.18 17.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.87 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -64.35 -179.47 0.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.881 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 43.1 t -122.0 163.28 19.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.85 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.895 ' O ' HG23 ' A' ' 44' ' ' VAL . 10.9 m-20 -57.03 130.6 46.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.44 152.13 21.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.713 HD11 HG22 ' A' ' 44' ' ' VAL . 3.7 mt -134.78 112.3 10.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.913 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.24 119.96 24.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.055 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.536 HG21 ' HB3' ' A' ' 36' ' ' PHE . 98.4 t -57.27 99.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.015 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.4 mt -59.34 -23.44 62.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 47.2 t -169.76 133.67 1.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.835 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.28 146.54 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.868 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.651 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -164.75 149.95 8.5 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.702 0.763 . . . . 0.0 110.913 -179.826 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.537 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.75 -174.69 9.83 Favored 'Cis proline' 0 C--N 1.342 0.201 0 C-N-CA 122.711 -1.787 . . . . 0.0 112.377 -0.049 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.463 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 44.2 m -72.29 154.58 91.99 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.641 0.734 . . . . 0.0 110.878 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 3.52 2.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.679 2.253 . . . . 0.0 112.357 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.463 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 23.6 p-10 -109.39 -17.03 13.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -109.44 -46.43 6.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -164.77 163.17 14.44 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.672 0.749 . . . . 0.0 110.821 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 131.67 21.66 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 124.74 11.37 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.377 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.6 mp -89.22 -24.38 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.155 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.536 ' HB3' HG21 ' A' ' 22' ' ' VAL . 14.4 m-85 -130.98 103.02 6.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -64.22 160.34 18.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.6 ttp85 -58.37 149.4 24.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.928 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.75 -9.71 22.04 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -71.13 154.12 41.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.902 0.382 . . . . 0.0 110.904 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 7.9 tttp -107.16 140.24 40.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.914 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.3 mt -136.85 135.26 37.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.594 ' O ' HD12 ' A' ' 45' ' ' ILE . 19.2 ttt-85 -86.48 131.02 34.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 18' ' ' ASP . 60.5 t -66.99 108.8 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.737 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -87.74 -52.36 11.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -143.82 155.03 43.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -119.49 113.05 20.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -117.31 86.39 2.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.4 -123.6 33.87 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.39 -21.07 78.22 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.486 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.564 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -113.26 144.74 42.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.724 0.297 . . . . 0.0 110.941 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.401 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.83 164.46 27.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.92 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HD3' HG21 ' A' ' 45' ' ' ILE . 28.9 tttt -101.04 141.04 34.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.906 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.17 162.57 39.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.737 HG22 HD11 ' A' ' 45' ' ' ILE . 16.4 tt -134.67 134.55 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -69.8 128.28 35.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.843 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.484 HD21 ' HB2' ' A' ' 43' ' ' ARG . 2.0 mt -78.78 2.68 19.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.89 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.3 m -99.41 -47.81 5.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.3 p -105.33 -37.35 6.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.142 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.85 29.34 9.94 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.485 ' HD2' HG23 ' A' ' 35' ' ' ILE . 33.7 mtt180 -90.04 127.8 36.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.873 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.665 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.7 mt-10 -97.86 118.0 33.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.1 t -147.02 167.38 24.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 14.8 m-85 -110.07 114.33 27.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.795 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.91 151.18 60.64 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.63 0.729 . . . . 0.0 111.164 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.78 133.88 26.59 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.673 2.249 . . . . 0.0 112.341 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -47.44 -30.26 5.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 5.4 tp -65.09 -32.47 58.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.801 0.334 . . . . 0.0 111.116 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 8.0 m -78.91 -4.82 51.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.513 ' O ' HD11 ' A' ' 23' ' ' LEU . 32.4 m -132.56 166.08 30.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.015 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -130.53 129.45 42.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.069 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.95 107.6 1.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.859 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.435 ' O ' ' C ' ' A' ' 74' ' ' SER . 4.0 t -72.38 142.21 15.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.099 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 73' ' ' VAL . 48.4 p -35.06 137.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.87 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -179.66 -177.95 48.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.428 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 124.58 11.26 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.368 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 17.7 t -72.0 -45.24 61.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.864 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 47.1 t -56.61 136.9 54.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 -179.99 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.504 -0.239 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.1 t -124.05 -45.31 2.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.7 p -52.58 135.5 34.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.859 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -168.08 -46.4 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.481 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.6 t -73.86 126.26 30.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.941 0.4 . . . . 0.0 110.839 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 m -107.23 105.87 16.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.862 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 138.5 -120.26 1.93 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.495 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 -174.93 1.01 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.714 2.276 . . . . 0.0 112.304 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 63.7 mt -86.44 155.6 56.83 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.64 0.733 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 2.39 3.62 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.659 2.239 . . . . 0.0 112.343 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -85.8 136.98 36.07 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.663 0.744 . . . . 0.0 110.868 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.8 Cg_endo -69.8 2.88 3.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.643 2.229 . . . . 0.0 112.361 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.436 ' C ' ' O ' ' A' ' 12' ' ' PRO . 8.0 tt0 -34.57 116.45 0.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.869 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -144.28 69.1 0.41 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 22.7 mt -107.17 130.92 54.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.783 0.325 . . . . 0.0 110.927 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.9 147.81 25.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -107.2 167.5 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.833 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.578 ' O ' HG23 ' A' ' 44' ' ' VAL . 85.7 m-20 -84.54 130.84 34.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.883 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -111.17 150.15 29.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.663 HD11 HG22 ' A' ' 44' ' ' VAL . 9.3 mt -133.38 114.08 13.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.42 127.12 32.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.08 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.695 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.8 t -65.04 98.6 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.149 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.962 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -59.71 -31.49 69.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.931 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.7 t -161.3 127.95 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.77 138.98 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.647 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.72 150.12 17.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.695 0.76 . . . . 0.0 110.936 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -175.28 10.64 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.695 -1.794 . . . . 0.0 112.337 -0.048 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 3.1 m -76.28 158.29 81.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -102.07 -22.39 14.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 mt -109.25 -54.99 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -155.3 163.44 24.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.615 0.721 . . . . 0.0 110.888 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 137.81 36.43 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 119.04 6.05 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.679 2.252 . . . . 0.0 112.371 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -83.06 -25.71 8.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.128 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.695 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.3 m-85 -131.4 96.24 3.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.0 mmm-85 -56.41 158.38 4.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 52.1 ttt-85 -61.08 144.5 53.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.62 -14.46 35.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -72.75 136.54 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.5 ttmt -87.02 137.84 32.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.593 HD23 ' HA ' ' A' ' 56' ' ' SER . 10.4 mt -132.17 140.6 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.919 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.428 ' O ' HD12 ' A' ' 45' ' ' ILE . 42.8 ttt180 -91.12 134.49 34.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.663 HG22 HD11 ' A' ' 20' ' ' LEU . 97.6 t -71.43 112.11 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.635 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -86.05 -46.32 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -155.56 147.75 23.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.46 116.07 31.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.902 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -122.35 85.91 2.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.12 -120.7 23.89 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.33 -23.08 59.4 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.438 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 21.9 m95 -111.68 137.9 48.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.79 0.329 . . . . 0.0 110.88 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.516 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.3 164.83 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.635 ' HD3' HG21 ' A' ' 45' ' ' ILE . 9.4 tttp -101.49 141.95 33.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.911 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.13 168.34 22.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.816 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.3 tt -138.39 142.45 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.593 ' HA ' HD23 ' A' ' 42' ' ' LEU . 50.5 p -76.82 133.49 39.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.6 mt -82.96 8.86 11.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.2 t -104.78 -42.77 5.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -113.56 -44.57 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.103 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.529 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 103.35 27.88 6.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.473 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -84.19 122.04 28.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 110.853 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.816 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -92.09 117.48 29.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.0 t -147.44 169.61 19.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.905 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.57 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 7.1 m-85 -112.1 118.09 34.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.83 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.5 151.26 69.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.656 0.741 . . . . 0.0 111.153 179.866 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.631 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.0 Cg_endo -69.79 132.67 23.75 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.704 2.27 . . . . 0.0 112.312 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.45 -33.5 5.99 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.631 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.8 tt -61.81 -33.39 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.359 . . . . 0.0 111.177 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.1 -15.92 61.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.569 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.7 m -125.47 175.86 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.962 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -136.72 134.5 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -66.32 102.44 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.4 t -73.94 144.45 12.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.6 t 62.38 49.15 4.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.847 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.37 175.33 25.72 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 77' ' ' SER . 53.9 Cg_endo -69.77 0.91 4.96 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.654 2.236 . . . . 0.0 112.331 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 76' ' ' PRO . 38.0 m -35.04 132.71 0.34 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.853 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.1 t -75.45 162.32 28.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.859 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.5 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -82.99 156.56 23.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.909 0.385 . . . . 0.0 110.867 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 t -171.79 112.89 0.33 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.1 147.39 0.15 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.467 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.1 m -93.76 93.94 8.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.878 0.371 . . . . 0.0 110.845 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 t -113.05 33.59 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.904 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -56.65 -158.2 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.489 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -168.23 0.26 Allowed 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.711 2.274 . . . . 0.0 112.324 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.839 ' O ' HD12 ' A' ' 9' ' ' LEU . 2.6 pp -111.82 152.21 44.02 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.623 0.725 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.444 ' O ' ' C ' ' A' ' 11' ' ' ASN . 54.0 Cg_endo -69.8 -45.77 1.45 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 2.258 . . . . 0.0 112.317 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.444 ' C ' ' O ' ' A' ' 10' ' ' PRO . 1.9 m120 -34.61 150.19 0.08 OUTLIER Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.573 0.701 . . . . 0.0 110.929 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 1.63 4.24 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -100.23 73.69 1.71 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.893 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.27 99.52 0.18 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.435 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.1 mp -104.6 147.88 27.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.866 0.365 . . . . 0.0 110.884 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -68.14 168.09 12.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.908 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.4 t -129.86 153.06 48.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.836 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.713 ' O ' HG23 ' A' ' 44' ' ' VAL . 14.1 m-20 -72.44 127.98 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.881 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -108.79 154.42 22.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.94 HD11 HG22 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -139.98 111.68 7.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.881 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.12 122.81 28.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.092 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 36' ' ' PHE . 92.2 t -55.33 104.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.022 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -65.74 -33.81 76.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.7 t -155.35 128.95 8.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -39.43 146.55 0.09 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.605 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.77 148.82 6.73 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.659 0.742 . . . . 0.0 110.944 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.83 -174.27 9.44 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 -1.796 . . . . 0.0 112.295 0.023 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.9 m -70.57 153.77 94.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.656 0.741 . . . . 0.0 110.873 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 1.21 4.59 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.676 2.251 . . . . 0.0 112.37 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -106.26 -18.37 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -107.29 -54.03 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.16 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.4 m -155.71 162.63 26.97 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 134.37 27.82 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.327 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 120.87 7.59 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.724 2.282 . . . . 0.0 112.314 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.666 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.9 mp -85.6 -30.45 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.117 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.62 ' O ' HG11 ' A' ' 22' ' ' VAL . 11.8 m-85 -124.0 90.82 3.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -51.07 161.16 0.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.896 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 16.2 ttt-85 -66.17 144.15 56.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.35 -9.89 65.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.403 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -83.09 132.64 35.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 110.906 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.544 ' CD ' HG21 ' A' ' 73' ' ' VAL . 19.5 ttpt -88.99 143.74 26.65 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.467 HD11 ' CG2' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -135.0 141.25 46.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.89 179.94 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.414 ' HB2' HD21 ' A' ' 57' ' ' LEU . 35.8 ttt180 -85.64 127.57 34.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.94 HG22 HD11 ' A' ' 20' ' ' LEU . 84.5 t -64.46 111.37 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.71 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -78.62 -54.7 11.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.094 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.1 t -155.58 150.85 26.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.846 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -102.26 121.99 43.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.923 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 44.5 mm-40 -126.5 86.15 2.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.907 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.44 -121.5 24.24 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -85.08 -18.57 60.75 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.529 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.578 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.5 m95 -115.71 140.09 49.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.71 0.291 . . . . 0.0 110.937 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.404 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.79 164.44 26.82 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.878 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.71 ' HD2' HG21 ' A' ' 45' ' ' ILE . 3.7 ttmt -101.58 151.56 21.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -159.11 150.1 19.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.492 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.4 tt -116.34 144.34 24.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.13 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.434 ' HA ' HD23 ' A' ' 42' ' ' LEU . 6.7 m -73.59 130.6 40.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.414 HD21 ' HB2' ' A' ' 43' ' ' ARG . 7.5 mt -78.21 9.71 3.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 t -116.92 -52.79 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.828 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.2 p -95.9 -34.56 11.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.474 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.85 31.57 17.55 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.496 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.0 mtt180 -91.37 122.1 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.3 mt-10 -91.9 117.76 30.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.43 ' HB3' ' CE2' ' A' ' 36' ' ' PHE . 18.4 t -147.32 169.51 19.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HE3' ' A' ' 53' ' ' LYS . 4.2 m-85 -110.26 122.34 47.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.877 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.21 151.47 78.42 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.597 0.713 . . . . 0.0 111.113 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.637 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.3 Cg_endo -69.8 131.87 22.08 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.7 2.267 . . . . 0.0 112.279 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.442 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -46.78 -30.57 4.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.476 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.637 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -64.72 -33.33 62.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 0.0 111.11 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 7.4 m -78.05 -7.58 57.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.442 HG22 ' HA2' ' A' ' 67' ' ' GLY . 33.8 m -128.69 164.98 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.022 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.44 134.88 46.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.7 tpp180 -61.41 110.14 1.36 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.831 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.544 HG21 ' CD ' ' A' ' 41' ' ' LYS . 2.9 t -70.94 139.6 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.174 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 m -107.77 79.4 1.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 55.71 161.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.496 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 168.23 22.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.698 2.266 . . . . 0.0 112.324 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.4 t -78.68 136.05 37.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.847 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 34.3 t -51.11 106.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.814 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.252 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.441 -179.987 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.0 m -99.1 149.42 23.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.881 0.372 . . . . 0.0 110.859 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.6 t -123.93 -53.47 1.75 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.843 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.39 -42.65 14.22 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 48.8 m -57.71 152.88 14.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.917 0.389 . . . . 0.0 110.853 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.3 t -166.82 154.32 9.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 -179.808 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.05 -75.49 0.19 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 143.17 49.64 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.658 2.239 . . . . 0.0 112.325 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 30.8 mt -85.78 156.12 58.5 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.628 0.728 . . . . 0.0 110.922 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 11' ' ' ASN . 54.1 Cg_endo -69.79 2.98 3.06 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.277 . . . . 0.0 112.322 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PRO . 14.1 m120 -34.61 144.02 0.2 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.4 Cg_endo -69.82 1.72 4.22 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.677 2.252 . . . . 0.0 112.332 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.449 ' C ' ' O ' ' A' ' 12' ' ' PRO . 17.7 mm-40 32.62 48.69 0.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -101.37 -38.64 3.22 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.499 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 mp -71.88 101.5 2.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -63.17 138.0 58.41 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.827 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.4 t -87.41 161.6 17.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.5 m-20 -94.01 136.46 34.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -112.14 150.68 30.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.721 HD11 HG22 ' A' ' 44' ' ' VAL . 7.2 mt -134.83 110.66 9.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.912 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.39 122.06 27.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 36' ' ' PHE . 76.6 t -58.53 100.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.141 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.945 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.8 mt -59.94 -36.14 76.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.936 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.6 t -155.97 127.08 7.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.874 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.21 135.09 1.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.645 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.08 149.6 23.73 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.716 0.77 . . . . 0.0 110.887 -179.807 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.547 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.82 -178.67 17.33 Favored 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.371 -0.023 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 59.6 m -68.36 153.44 95.6 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.652 0.739 . . . . 0.0 110.861 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 2.46 3.52 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.344 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.61 -10.09 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -118.44 -52.14 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -156.45 162.15 28.09 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 0.0 110.805 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 134.2 27.35 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.49 ' HG2' ' CZ ' ' A' ' 37' ' ' ARG . 53.9 Cg_endo -69.71 114.09 3.58 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.744 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.5 mp -74.57 -30.46 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.136 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.601 ' O ' HG11 ' A' ' 22' ' ' VAL . 14.8 m-85 -130.99 94.95 3.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.49 ' CZ ' ' HG2' ' A' ' 34' ' ' PRO . 20.4 mmt180 -53.89 160.24 1.49 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -62.73 151.99 36.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.58 -18.02 7.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.405 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -71.43 132.37 44.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.871 0.367 . . . . 0.0 110.903 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 25.6 ttmt -85.41 135.73 33.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.471 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.3 mt -128.14 148.41 50.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.501 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.4 ttt180 -98.62 130.51 45.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.878 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.721 HG22 HD11 ' A' ' 20' ' ' LEU . 57.6 t -68.58 114.17 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.125 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.501 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -90.4 -53.46 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.147 179.941 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 t -146.45 154.15 41.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.847 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -120.04 119.07 32.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -127.62 98.9 5.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.15 -130.43 50.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.65 9.0 63.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.531 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.555 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -137.07 140.39 41.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 110.926 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.415 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -133.77 164.64 26.78 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.918 179.995 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 16.1 tttp -104.09 147.03 27.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.904 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.6 159.77 42.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.131 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.686 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -126.39 141.71 45.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 20.1 p -78.25 129.87 35.58 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.7 mt -80.51 9.26 6.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.966 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -99.24 -49.4 4.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.812 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.2 p -112.77 -39.69 4.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.097 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.74 27.52 5.7 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.437 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -83.08 128.07 34.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.761 0.315 . . . . 0.0 110.862 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.686 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -102.02 117.27 34.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.8 p -147.58 169.27 19.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 24.8 m-85 -110.08 118.98 37.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.855 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.69 150.01 67.07 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.654 0.74 . . . . 0.0 111.081 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.671 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.0 Cg_endo -69.77 134.03 26.97 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.308 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.99 -31.13 5.51 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.482 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.671 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -64.84 -32.74 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.806 0.336 . . . . 0.0 111.113 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 11.6 m -80.35 2.85 23.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.618 ' O ' HD11 ' A' ' 23' ' ' LEU . 33.4 m -140.52 170.63 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.945 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -132.35 125.99 32.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 -65.74 108.19 2.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.1 t -81.3 145.18 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.119 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 38.4 t -149.82 164.22 35.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 149.9 -174.67 29.3 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.486 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 2.29 3.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.734 2.289 . . . . 0.0 112.337 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.0 t -40.18 154.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.847 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 88.9 p -149.26 133.26 17.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.86 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.512 -179.91 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.8 m -102.3 117.46 34.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.9 m -126.8 160.02 32.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.3 -159.6 14.57 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.533 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.7 m -118.01 137.77 52.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.896 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.3 m -71.78 164.6 25.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.845 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.88 146.31 18.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.489 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 178.3 4.74 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.65 2.233 . . . . 0.0 112.331 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.7 mt -39.74 153.41 0.19 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.571 0.7 . . . . 0.0 110.948 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -20.36 34.8 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.667 2.245 . . . . 0.0 112.361 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -115.36 140.05 25.33 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.9 Cg_endo -69.71 1.83 4.05 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.689 2.259 . . . . 0.0 112.359 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 12' ' ' PRO . 2.4 pt-20 35.18 31.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . -154.71 -106.41 0.27 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 38.2 tp -121.15 102.93 8.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.814 0.34 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 p30 -56.55 161.36 2.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 30.5 t -91.47 163.91 14.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.461 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -61.83 132.45 53.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.887 179.957 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -108.63 145.02 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.886 HD11 HG22 ' A' ' 44' ' ' VAL . 1.7 mt -134.49 110.56 9.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.421 ' HB2' ' CG2' ' A' ' 73' ' ' VAL . . . -79.63 127.09 31.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.103 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.566 HG11 ' O ' ' A' ' 36' ' ' PHE . 88.7 t -61.75 101.36 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.1 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.954 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -61.92 -31.01 71.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -160.21 128.17 4.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -40.12 140.82 0.54 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.844 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.615 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -158.94 149.18 15.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.687 0.756 . . . . 0.0 110.914 -179.848 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.545 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.3 Cg_endo -69.8 -174.52 9.7 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.34 -0.064 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -73.22 154.09 90.37 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 1.63 4.29 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.655 2.236 . . . . 0.0 112.369 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -105.86 -14.69 15.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.81 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -113.05 -51.96 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 m -158.34 162.26 27.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 133.99 26.88 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.699 2.266 . . . . 0.0 112.339 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 124.08 10.72 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.75 2.3 . . . . 0.0 112.307 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.654 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -86.84 -25.28 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.146 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.566 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.3 m-85 -130.97 93.92 3.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -56.29 150.16 15.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.409 ' HA ' HG12 ' A' ' 22' ' ' VAL . 39.9 ttp85 -50.76 147.56 4.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.05 -17.84 8.87 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -68.04 138.37 55.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.926 0.394 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.572 ' O ' HD23 ' A' ' 42' ' ' LEU . 2.5 ttmp? -89.94 143.12 27.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.572 HD23 ' O ' ' A' ' 41' ' ' LYS . 1.7 mt -139.41 142.4 37.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.951 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.561 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttt180 -95.45 132.03 40.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.864 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.886 HG22 HD11 ' A' ' 20' ' ' LEU . 95.8 t -68.0 112.63 3.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.096 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.725 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -91.39 -53.28 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 m -137.66 143.07 41.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.09 115.01 28.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.865 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -126.68 85.97 2.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.893 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.1 -125.36 38.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.81 -19.07 73.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.49 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 24.3 m95 -113.39 131.87 55.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -131.94 164.35 26.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.918 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.0 tttp -99.95 144.16 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.894 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.0 160.33 44.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.07 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.748 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.4 tt -130.55 139.66 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.078 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.1 m -72.37 129.41 38.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.857 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.0 mt -79.15 5.66 11.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.1 t -106.03 -51.08 3.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.7 p -99.31 -44.24 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.185 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.402 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 100.95 26.76 7.75 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.518 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 64.5 mtt180 -86.19 128.19 34.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.748 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.9 mt-10 -98.21 117.45 32.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.1 t -147.34 169.38 19.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.546 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 9.2 m-85 -112.63 114.79 27.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.87 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.53 150.76 58.6 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 111.138 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.597 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.81 135.99 31.75 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.637 2.225 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.9 -36.86 20.9 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.539 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.597 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -59.96 -26.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.808 0.337 . . . . 0.0 111.071 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.7 m -82.56 -7.6 59.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.8 m -131.22 164.45 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.149 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.954 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -125.93 133.31 51.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.092 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.438 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.2 tpt180 -61.0 97.72 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.421 ' CG2' ' HB2' ' A' ' 21' ' ' ALA . 3.8 t -74.83 140.34 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.144 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.8 t -121.78 51.74 1.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.852 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 176.23 165.78 32.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.526 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 179.88 3.4 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.67 2.246 . . . . 0.0 112.322 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -70.16 89.25 0.63 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 7.7 m -81.67 -54.44 5.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.897 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.478 179.973 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.486 -0.245 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 93.4 p -124.97 83.44 2.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.808 0.337 . . . . 0.0 110.865 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.2 p -170.84 120.86 0.55 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.58 -61.87 0.63 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.465 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.2 t -130.05 40.87 3.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.863 0.364 . . . . 0.0 110.867 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 7' ' ' GLY . 45.1 m -71.43 107.77 4.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.853 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 6' ' ' SER . . . 34.43 69.49 0.19 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.513 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 171.35 14.65 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.681 2.254 . . . . 0.0 112.311 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.734 HD13 ' HB2' ' A' ' 11' ' ' ASN . 4.5 pp -96.88 152.56 38.48 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 0.0 110.945 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -43.51 2.64 Favored 'Trans proline' 0 C--N 1.34 0.127 0 C-N-CA 122.677 2.252 . . . . 0.0 112.329 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.734 ' HB2' HD13 ' A' ' 9' ' ' LEU . 4.3 m120 -46.96 159.51 0.38 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 0.0 110.907 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.549 ' HA ' HD21 ' A' ' 15' ' ' LEU . 53.2 Cg_endo -69.78 0.01 6.28 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.682 2.255 . . . . 0.0 112.308 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -65.15 111.18 2.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.925 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.32 85.74 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.473 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.549 HD21 ' HA ' ' A' ' 12' ' ' PRO . 84.5 mt -94.68 118.7 32.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.802 0.334 . . . . 0.0 110.882 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -58.98 144.16 45.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 39.1 t -113.57 155.21 25.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.802 -179.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.698 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.1 m-20 -68.03 137.37 55.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.86 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -107.24 150.04 27.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.686 HD11 HG22 ' A' ' 44' ' ' VAL . 7.3 mt -132.56 121.31 23.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -92.09 119.54 31.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.063 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.585 ' CG2' HD11 ' A' ' 42' ' ' LEU . 96.2 t -59.11 96.67 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.16 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.957 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.7 mt -54.95 -35.32 64.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.929 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 t -157.46 128.65 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.841 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.69 137.98 1.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.881 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.609 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -155.18 148.55 18.48 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.685 0.755 . . . . 0.0 110.918 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.559 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.4 Cg_endo -69.71 -173.98 9.0 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.379 -0.107 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 6.1 m -74.67 155.51 87.15 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.689 0.757 . . . . 0.0 110.843 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 3.44 2.79 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.658 2.238 . . . . 0.0 112.379 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -107.77 -18.22 13.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -109.18 -47.92 7.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.0 OUTLIER -164.1 163.58 15.25 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.644 0.735 . . . . 0.0 110.864 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 132.24 22.87 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.675 2.25 . . . . 0.0 112.309 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 118.24 5.57 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.649 2.233 . . . . 0.0 112.306 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.709 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.2 mp -79.31 -28.42 13.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.091 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 22' ' ' VAL . 16.8 m-85 -127.3 98.42 5.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.65 160.38 4.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.854 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -62.22 144.61 55.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.23 -11.43 23.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.461 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -71.25 130.56 41.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.869 0.366 . . . . 0.0 110.896 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -81.46 137.02 35.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.585 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.4 mt -133.16 139.78 47.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttt180 -90.19 130.66 36.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.831 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 18' ' ' ASP . 57.3 t -66.89 110.66 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -80.19 -54.97 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.124 179.896 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 70.9 m -157.32 147.46 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -98.58 115.47 28.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 35.5 mt-10 -113.99 85.78 2.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.72 -122.99 30.58 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -77.77 -22.58 69.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.473 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 10.1 m95 -113.92 150.51 33.62 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.754 0.312 . . . . 0.0 110.915 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.428 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -136.08 164.2 28.57 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.949 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD2' HG21 ' A' ' 45' ' ' ILE . 4.7 ttmm -103.22 150.83 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.937 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.426 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -158.91 143.77 15.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.072 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.2 tt -108.1 144.62 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.1 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 p -83.68 130.27 34.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.0 mt -77.21 7.94 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.3 t -95.18 -51.96 4.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.843 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.8 p -111.29 -43.16 3.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.144 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.608 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 108.69 26.45 5.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -86.27 127.72 34.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.763 0.316 . . . . 0.0 110.857 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.708 ' HG3' HD12 ' A' ' 55' ' ' ILE . 13.0 mt-10 -99.15 118.11 35.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 9.0 t -147.11 167.75 23.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.527 ' CE2' ' HE2' ' A' ' 53' ' ' LYS . 4.3 m-85 -105.96 129.42 54.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.942 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.682 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -135.16 150.97 74.3 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.594 0.711 . . . . 0.0 111.125 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.672 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.74 133.21 25.06 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.732 2.288 . . . . 0.0 112.332 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.59 -30.02 8.17 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.465 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.672 HG22 ' HB2' ' A' ' 66' ' ' PRO . 13.5 tt -65.5 -30.12 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.834 0.349 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.8 m -80.36 -5.72 56.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.523 ' O ' HD11 ' A' ' 23' ' ' LEU . 34.9 m -135.03 171.35 17.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.957 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.64 132.43 38.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.076 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -69.3 106.79 3.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.857 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.6 t -74.15 143.54 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 m -99.4 41.69 1.14 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.42 -161.3 52.51 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 105.78 1.54 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.681 2.254 . . . . 0.0 112.365 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 58.0 m -89.97 79.73 6.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.9 t -108.4 41.51 1.55 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.883 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 81.7 p -89.9 140.79 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.831 0.348 . . . . 0.0 110.872 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 t 45.53 42.17 7.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 88.11 -156.09 26.96 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -101.97 -60.14 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.0 p -120.86 167.92 12.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.829 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.74 163.11 14.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.443 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 147.11 62.31 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.683 2.255 . . . . 0.0 112.365 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.473 ' H ' ' CD2' ' A' ' 9' ' ' LEU . 3.4 mm? -44.08 148.25 0.83 Allowed Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.601 0.715 . . . . 0.0 110.888 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 79.96 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.295 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -113.69 142.84 28.36 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.603 0.716 . . . . 0.0 110.88 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -1.39 8.38 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.693 2.262 . . . . 0.0 112.372 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.1 111.8 1.04 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.41 -50.4 3.28 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 72.0 mt -92.98 138.6 31.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.823 0.344 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -91.93 144.63 25.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.817 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 30.7 t -123.11 160.85 25.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.874 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 44' ' ' VAL . 60.7 m-20 -99.22 119.34 37.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.858 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -101.62 143.68 31.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.921 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.932 HD11 HG22 ' A' ' 44' ' ' VAL . 11.0 mt -130.45 108.76 10.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.06 122.92 28.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.063 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.51 HG11 ' O ' ' A' ' 36' ' ' PHE . 57.3 t -58.86 103.62 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.819 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.5 mt -67.17 -33.42 75.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 25' ' ' ASP . 27.6 t -153.64 121.85 6.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.834 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -37.03 149.38 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.875 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.799 ' CE1' HG22 ' A' ' 65' ' ' ILE . 0.0 OUTLIER -169.82 150.52 3.85 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.685 0.755 . . . . 0.0 110.922 -179.85 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.3 10.69 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.304 -0.059 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 48.0 m -74.74 155.06 87.22 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.662 0.744 . . . . 0.0 110.855 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 3.42 2.76 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.716 2.277 . . . . 0.0 112.359 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -105.27 -22.33 13.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.843 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.7 mt -105.77 -48.59 8.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.7 OUTLIER -164.11 164.67 14.14 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.682 0.753 . . . . 0.0 110.836 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 135.62 30.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.642 2.228 . . . . 0.0 112.35 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 125.24 11.88 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.298 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.6 mp -86.6 -26.4 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.51 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.5 m-85 -131.9 100.58 5.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -63.28 155.25 29.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.814 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -55.21 150.35 11.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.807 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.3 -10.36 16.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -72.4 151.52 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.868 0.366 . . . . 0.0 110.906 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.417 ' O ' HD23 ' A' ' 42' ' ' LEU . 58.2 tttt -102.26 138.76 38.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.928 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.541 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -135.12 152.52 51.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.927 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.63 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.4 ttt180 -105.1 129.65 53.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.87 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.932 HG22 HD11 ' A' ' 20' ' ' LEU . 99.1 t -65.19 111.82 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.669 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -93.19 -52.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.161 179.882 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.8 m -141.15 150.96 43.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -118.43 109.82 16.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.875 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -116.31 86.0 2.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.75 -123.27 32.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.64 -23.51 69.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.48 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.3 m95 -109.91 141.93 41.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.41 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.15 164.27 28.05 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.2 tttp -100.75 141.51 33.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.905 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.46 159.75 44.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.821 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -131.81 130.82 61.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.541 ' HA ' HD23 ' A' ' 42' ' ' LEU . 4.8 t -67.82 130.88 44.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.69 9.4 5.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.946 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 15.1 t -105.55 -48.01 3.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.2 p -104.41 -35.79 7.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.495 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 90.45 27.84 18.87 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.496 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.424 ' C ' HG13 ' A' ' 55' ' ' ILE . 44.0 mtt85 -89.25 124.98 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.797 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.821 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.0 mt-10 -94.31 117.33 29.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.943 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.2 t -147.6 169.63 19.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.824 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 28.3 m-85 -110.96 118.13 35.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.899 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.19 152.54 73.66 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.593 0.711 . . . . 0.0 111.146 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 137.66 35.97 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.679 2.252 . . . . 0.0 112.351 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.81 -33.23 6.39 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 3.5 tp -64.88 -31.11 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 111.162 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.1 t -72.87 -12.77 61.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.489 ' CG2' ' HB3' ' A' ' 20' ' ' LEU . 18.4 m -131.04 170.21 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.819 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.48 136.45 45.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -67.94 108.37 3.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 12.2 t -87.52 142.69 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.141 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.9 m -75.59 -48.66 21.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.81 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 175.51 164.72 30.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.491 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.86 90.27 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.653 2.235 . . . . 0.0 112.309 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 24.8 p -107.28 40.83 1.6 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 59.8 p -45.0 120.67 2.46 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.911 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.475 -179.967 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 N-CA-C 112.528 -0.229 . . . . 0.0 112.528 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 t -46.29 171.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.36 . . . . 0.0 110.853 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.6 t -78.35 90.53 4.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.87 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -106.77 -121.44 4.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.4 m -115.36 45.74 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.862 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.8 t -77.76 -43.91 29.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -72.78 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.518 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 173.01 11.68 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.701 2.267 . . . . 0.0 112.302 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.492 ' H ' ' CD2' ' A' ' 9' ' ' LEU . 3.5 mm? -43.41 143.96 1.36 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.581 0.705 . . . . 0.0 110.902 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.9 Cg_endo -69.8 -16.7 37.53 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.697 2.265 . . . . 0.0 112.319 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' PRO . 7.7 m-20 -34.52 150.67 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.655 0.741 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.6 Cg_endo -69.79 0.63 5.39 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.686 2.257 . . . . 0.0 112.348 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.447 ' C ' ' O ' ' A' ' 12' ' ' PRO . 9.0 pt-20 -34.98 94.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.872 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . -136.61 45.47 1.08 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.462 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 64.0 mt -93.67 141.67 28.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.35 . . . . 0.0 110.896 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -71.97 134.94 46.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.856 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 23.1 t -101.48 164.82 11.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . 73.3 m-20 -78.14 127.66 32.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.883 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -111.77 152.63 27.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 44' ' ' VAL . 7.7 mt -137.43 116.03 12.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.57 127.52 33.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.677 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.4 t -66.85 97.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.101 HD21 ' HB2' ' A' ' 71' ' ' ALA . 9.4 mt -57.19 -35.93 70.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.5 t -156.38 128.2 7.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.898 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -39.1 149.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.639 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -170.61 150.05 3.14 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.729 0.776 . . . . 0.0 110.911 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.7 -174.7 9.79 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.717 -1.785 . . . . 0.0 112.355 -0.098 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.6 m -80.35 158.46 71.65 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.874 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 3.52 2.75 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.649 2.232 . . . . 0.0 112.321 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -103.89 -13.22 16.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.3 mt -119.95 -49.34 3.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.101 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -162.83 163.46 17.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.717 0.77 . . . . 0.0 110.843 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 133.56 25.8 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.676 2.251 . . . . 0.0 112.353 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 114.74 3.81 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.313 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.732 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -73.45 -30.52 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.3 m-85 -130.66 110.83 11.67 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.92 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -69.56 165.79 20.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.443 ' CG ' ' O ' ' A' ' 23' ' ' LEU . 2.4 tmt_? -67.22 141.14 57.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.46 11.52 81.85 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.486 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.4 ' OE1' ' O ' ' A' ' 41' ' ' LYS . 0.4 OUTLIER -100.35 138.22 37.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.976 0.417 . . . . 0.0 110.843 -179.857 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.4 ' O ' ' OE1' ' A' ' 40' ' ' GLU . 30.2 ttmt -85.54 140.63 30.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.677 HD11 ' CG2' ' A' ' 22' ' ' VAL . 10.1 mt -134.2 149.69 51.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.458 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.7 ttt180 -103.89 129.15 51.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 18' ' ' ASP . 45.8 t -67.97 114.82 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.095 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.493 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -88.8 -52.58 10.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.096 179.928 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.9 t -157.53 128.32 6.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -89.15 125.95 35.26 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -125.06 85.96 2.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.898 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.68 -128.08 37.49 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.8 -24.99 75.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 13.2 m95 -112.69 146.55 38.51 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.786 0.327 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.477 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.98 164.84 26.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.992 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.561 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.0 tttp -103.37 145.15 30.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.45 163.72 38.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.878 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.0 tt -131.19 135.21 60.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.567 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 37.4 p -76.23 129.09 36.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.8 mt -77.59 9.28 3.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.1 m -95.92 -49.74 5.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 12.2 p -114.75 -28.92 6.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.143 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 92.11 26.48 18.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.508 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 23.7 mtt85 -83.12 128.08 34.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.756 0.312 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.878 ' HG3' HD12 ' A' ' 55' ' ' ILE . 10.1 mt-10 -97.66 117.26 31.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.4 t -147.55 170.11 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 10.6 m-85 -110.78 123.62 50.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.901 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -130.2 150.64 76.66 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.669 0.747 . . . . 0.0 111.134 179.909 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.603 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.73 130.67 19.78 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.675 2.25 . . . . 0.0 112.374 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.13 -36.21 7.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.603 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.3 tt -58.9 -33.55 50.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.498 HG12 ' HA ' ' A' ' 22' ' ' VAL . 25.5 m -125.13 174.04 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.101 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.21 132.15 39.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.115 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.472 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.1 tpp85 -62.77 105.66 0.69 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.83 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.0 t -78.79 144.4 11.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.6 m -90.56 -51.91 5.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.34 -157.79 15.74 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.527 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 -34.24 14.85 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.698 2.266 . . . . 0.0 112.308 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.7 t -105.47 133.05 50.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 88.9 p -47.59 -49.71 26.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.843 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.517 -179.96 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.367 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.0 m -162.23 116.39 1.83 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.3 t -139.16 123.26 17.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.868 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.71 105.22 3.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.484 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.5 m -117.86 -56.67 2.17 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.902 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.8 t -172.85 174.62 3.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.36 145.15 4.35 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.5 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 164.16 35.64 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.721 2.28 . . . . 0.0 112.328 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.554 ' C ' HD12 ' A' ' 9' ' ' LEU . 4.4 pp -67.69 152.34 96.38 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.595 0.712 . . . . 0.0 110.909 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 -45.41 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.683 2.256 . . . . 0.0 112.363 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -166.45 143.78 4.28 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.577 0.703 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -1.59 8.72 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.691 2.261 . . . . 0.0 112.394 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 59.14 42.89 18.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.66 -48.73 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.523 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 30.7 mt -94.38 124.38 38.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 110.93 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -67.48 170.18 7.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.1 t -110.41 165.03 12.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.839 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.906 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.9 OUTLIER -95.46 131.12 41.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.829 179.947 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.78 150.68 22.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.696 HD11 HG22 ' A' ' 44' ' ' VAL . 10.0 mt -132.91 111.03 10.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.926 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.46 126.33 31.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 36' ' ' PHE . 89.4 t -63.2 96.25 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.165 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -59.13 -28.84 66.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.916 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.7 t -161.27 125.67 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.838 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -38.79 143.48 0.15 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.859 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -160.28 150.32 14.81 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.67 0.747 . . . . 0.0 110.917 -179.811 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.77 171.49 53.48 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.684 -1.798 . . . . 0.0 112.381 -0.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.407 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -52.17 148.38 11.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.634 0.731 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 53.8 Cg_endo -69.77 5.28 1.76 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.7 2.267 . . . . 0.0 112.346 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -109.01 -21.75 12.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -101.65 -53.43 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.097 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.51 164.28 21.03 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.669 0.747 . . . . 0.0 110.832 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 132.16 22.84 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.27 . . . . 0.0 112.364 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 124.42 11.06 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.666 2.244 . . . . 0.0 112.366 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.587 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -89.25 -25.31 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.165 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.669 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.6 m-85 -127.47 89.65 2.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.885 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 20.3 mmm-85 -51.01 160.11 0.52 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.449 ' CZ ' ' O ' ' A' ' 23' ' ' LEU . 11.1 ttt85 -61.58 147.22 46.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.97 -13.3 14.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -69.7 136.5 51.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.895 0.379 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -86.63 139.06 31.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.869 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.612 HD23 ' HA ' ' A' ' 56' ' ' SER . 8.1 mt -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.7 ttt-85 -87.53 132.94 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 18' ' ' ASP . 58.2 t -71.22 108.2 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.525 HD12 ' HA ' ' A' ' 54' ' ' ALA . 1.1 mp -78.56 -50.15 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.177 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -158.71 157.43 31.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -109.1 118.85 37.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.877 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.8 mm-40 -120.44 85.92 2.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.47 -126.02 38.71 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.1 -25.0 74.63 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.556 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.4 m0 -111.69 153.53 26.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.765 0.317 . . . . 0.0 110.923 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.421 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.04 164.13 28.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.8 tttm -98.94 143.07 29.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.895 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.525 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -153.94 164.08 39.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.716 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.3 tt -132.02 146.15 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.115 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.612 ' HA ' HD23 ' A' ' 42' ' ' LEU . 82.0 p -86.21 126.44 34.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.6 mt -76.09 5.92 6.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.6 t -90.6 -49.84 6.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.6 p -116.28 -34.7 4.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.14 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 102.46 23.89 8.65 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.457 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.9 mtt180 -82.08 124.51 29.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.846 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.716 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -98.87 118.55 35.88 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.5 t -147.23 169.97 18.25 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.1 m-85 -105.05 119.79 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.889 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.42 147.52 60.51 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.663 0.744 . . . . 0.0 111.09 179.904 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.556 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.78 133.77 26.34 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.694 2.262 . . . . 0.0 112.345 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -30.88 6.13 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.503 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.548 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.8 tp -64.68 -32.69 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 9.4 m -80.01 6.94 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.462 ' O ' HD11 ' A' ' 23' ' ' LEU . 36.0 m -147.56 169.81 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.2 136.08 43.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.136 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.9 tpp85 -68.13 112.44 5.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.2 t -80.52 144.06 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 20.0 m -110.36 105.49 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.829 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 44.83 -157.91 0.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.493 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 89.2 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.704 2.269 . . . . 0.0 112.327 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 93.0 p -109.28 86.42 2.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 48.7 p -79.78 168.92 18.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.829 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 179.98 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.8 m -72.73 -60.53 2.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.827 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m 64.65 42.9 4.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 139.4 119.42 1.67 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.499 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.2 t -100.95 143.94 30.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.9 0.381 . . . . 0.0 110.848 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t -157.27 156.43 32.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.25 -164.14 13.05 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.483 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 148.98 66.22 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.692 2.261 . . . . 0.0 112.396 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.1 mt -104.51 156.3 36.08 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.627 0.727 . . . . 0.0 110.901 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.5 Cg_endo -69.77 2.48 3.5 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.68 2.253 . . . . 0.0 112.328 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PRO . 31.3 m120 -34.34 143.29 0.21 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.641 0.734 . . . . 0.0 110.886 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.487 ' O ' ' N ' ' A' ' 14' ' ' GLY . 54.1 Cg_endo -69.73 -0.36 6.78 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.68 2.253 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -39.05 93.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.875 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 153.75 -83.34 0.16 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.504 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 56.9 mt -117.72 121.43 40.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 110.897 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -75.75 157.39 33.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 13.4 t -101.52 162.04 13.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.869 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.743 ' O ' HG23 ' A' ' 44' ' ' VAL . 2.6 m-20 -74.93 128.99 36.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.879 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -105.29 148.95 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.85 HD11 HG22 ' A' ' 44' ' ' VAL . 2.4 mt -135.87 109.53 8.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.08 126.15 30.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.742 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.0 t -60.8 101.6 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.901 HD21 ' HB2' ' A' ' 71' ' ' ALA . 16.2 mt -62.13 -30.84 71.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.3 t -158.4 127.54 5.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -40.72 145.52 0.19 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.837 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.581 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.9 148.43 6.43 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.636 0.732 . . . . 0.0 110.959 -179.849 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.81 -174.12 9.26 Favored 'Cis proline' 0 C--O 1.231 0.154 0 C-N-CA 122.708 -1.788 . . . . 0.0 112.331 -0.036 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.5 m -77.06 155.83 82.38 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.651 0.739 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 2.78 3.23 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.676 2.251 . . . . 0.0 112.346 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -106.71 -14.04 15.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.02 -48.66 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -163.58 163.04 16.74 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.675 0.75 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 133.03 24.56 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.719 2.28 . . . . 0.0 112.316 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 119.7 6.6 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.7 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -81.02 -22.81 10.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.528 ' HB3' HG21 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.66 99.77 4.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.881 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -58.65 163.9 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.437 ' HD3' ' N ' ' A' ' 39' ' ' GLY . 3.8 tmt_? -65.69 142.44 58.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.826 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.437 ' N ' ' HD3' ' A' ' 38' ' ' ARG . . . 77.96 6.81 87.5 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -86.36 144.0 27.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.66 ' HB3' HD12 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -87.29 141.1 28.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.742 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.8 mt -140.0 145.1 37.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.481 ' O ' HD12 ' A' ' 45' ' ' ILE . 16.5 ttm180 -103.78 128.48 51.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.85 HG22 HD11 ' A' ' 20' ' ' LEU . 59.5 t -65.87 108.53 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.147 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -79.87 -50.51 17.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.125 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.4 t -163.14 135.83 5.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -89.45 129.3 35.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -130.05 86.2 2.38 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 65.29 -131.46 35.58 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.509 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.42 -20.36 78.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.467 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -116.89 152.12 35.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.741 0.305 . . . . 0.0 110.923 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.18 164.23 28.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD3' HG21 ' A' ' 45' ' ' ILE . 19.3 tttp -102.17 142.53 33.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.953 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.54 156.14 36.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.135 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.585 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -124.08 137.17 57.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.729 ' HA ' HD23 ' A' ' 42' ' ' LEU . 5.1 t -68.04 128.16 35.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.865 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.66 HD12 ' HB3' ' A' ' 41' ' ' LYS . 6.4 mt -78.32 8.39 5.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.6 t -111.65 -45.98 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.862 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 51.4 p -102.14 -36.14 8.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.463 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.58 33.13 13.93 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.469 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.414 ' HD3' HG23 ' A' ' 35' ' ' ILE . 42.7 mtt180 -96.8 125.96 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.761 0.315 . . . . 0.0 110.89 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -90.66 117.43 29.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.6 t -147.66 169.99 18.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.812 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.551 ' CE1' ' HG3' ' A' ' 53' ' ' LYS . 18.9 m-85 -112.75 117.37 32.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.889 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.829 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.78 151.12 73.1 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.629 0.728 . . . . 0.0 111.123 179.932 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.677 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.83 135.76 31.09 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.661 2.241 . . . . 0.0 112.331 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.17 -30.95 8.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.7 tp -65.55 -30.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.831 0.348 . . . . 0.0 111.162 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.4 m -79.78 -0.19 33.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.99 163.11 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.901 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.2 137.48 52.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.063 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.33 112.19 2.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.851 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.48 HG21 ' HE2' ' A' ' 41' ' ' LYS . 15.4 t -90.62 148.91 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.139 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.8 m -78.32 -55.62 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 140.94 -158.69 26.36 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.447 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -34.76 14.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.661 2.241 . . . . 0.0 112.405 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.8 t -138.36 169.06 18.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.872 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 30.6 t -124.32 112.35 16.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.865 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.46 179.985 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 91.2 p -68.27 -34.88 77.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.883 0.373 . . . . 0.0 110.877 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.2 t 58.76 46.27 14.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.58 112.87 0.55 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.492 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.0 p -150.03 163.71 37.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.891 0.377 . . . . 0.0 110.814 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 t -56.6 121.96 10.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.37 77.58 0.11 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 150.89 68.53 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -47.25 157.66 0.51 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.613 0.721 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.9 Cg_endo -69.74 2.06 3.86 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.355 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' PRO . 29.0 m-20 -34.46 143.96 0.2 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.605 0.717 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.466 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.6 Cg_endo -69.76 2.53 3.45 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.701 2.267 . . . . 0.0 112.359 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -47.06 91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 176.92 -97.12 0.11 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.485 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 43.4 tp -121.16 122.98 41.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.787 0.327 . . . . 0.0 110.934 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -59.55 149.5 29.81 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.881 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.1 t -113.91 169.63 8.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . 3.9 m-20 -71.45 136.89 47.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.916 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -109.89 150.8 27.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.602 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 5.3 mt -129.64 114.47 16.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.22 116.73 23.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.567 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.2 t -54.92 103.65 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.114 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.045 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -66.53 -31.0 71.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 25' ' ' ASP . 30.6 t -160.33 118.79 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.859 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 24' ' ' SER . 10.4 p-10 -34.28 140.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.644 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.14 149.81 18.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.69 0.757 . . . . 0.0 110.923 -179.801 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.85 179.54 22.2 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.319 -0.008 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 p -72.46 157.2 89.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.05 2.41 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.677 2.252 . . . . 0.0 112.316 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -101.28 -13.18 18.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.839 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 4.8 mt -120.53 -60.6 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -147.96 163.07 28.82 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.651 0.738 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 137.36 35.06 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.681 2.254 . . . . 0.0 112.323 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 118.96 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.705 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -80.86 -26.19 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.567 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -131.32 93.55 3.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -54.8 161.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.411 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.8 ttm180 -62.06 147.79 46.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.96 -5.85 57.45 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -79.85 134.42 36.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.924 0.392 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -84.33 138.06 33.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.427 HD21 ' HB3' ' A' ' 36' ' ' PHE . 9.0 mt -130.56 141.32 50.46 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.54 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttp180 -93.18 126.73 38.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 18' ' ' ASP . 96.1 t -66.05 112.16 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.54 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -88.27 -53.3 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.15 179.913 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -144.45 145.31 31.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.838 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -108.68 118.41 36.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -129.4 86.44 2.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.881 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.26 -123.78 33.99 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.05 -19.03 65.93 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 25.3 m95 -113.42 131.56 55.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.752 0.311 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.602 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.44 164.36 26.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.956 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 8.3 tttp -100.2 142.27 31.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -150.78 157.83 43.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.112 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.431 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.0 tt -121.78 145.26 28.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.519 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 6.1 p -86.75 126.0 34.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 8.0 mt -75.14 5.75 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 t -92.01 -48.83 6.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.9 p -118.11 -28.69 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.85 25.92 13.94 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.48 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.404 ' CD ' HG23 ' A' ' 35' ' ' ILE . 76.6 mtt180 -80.86 132.29 35.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.306 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.438 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 4.9 mt-10 -103.29 117.38 34.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.866 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.0 t -147.67 170.18 18.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 38.5 m-85 -110.55 120.8 43.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.909 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.835 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.13 149.69 70.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.56 0.695 . . . . 0.0 111.174 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.72 134.58 28.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.67 2.247 . . . . 0.0 112.382 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.81 -30.33 8.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.5 tp -65.36 -30.1 49.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.802 0.334 . . . . 0.0 111.152 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 16.6 m -84.19 8.23 16.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.553 ' O ' HD11 ' A' ' 23' ' ' LEU . 22.9 m -148.95 168.9 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.045 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.62 131.98 43.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -68.92 112.18 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.885 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t -86.67 144.21 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.164 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -118.47 42.42 2.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.852 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.83 160.42 11.59 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.501 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -174.93 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.685 2.257 . . . . 0.0 112.31 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 35.0 t -85.87 -57.55 3.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.0 m -86.77 140.57 29.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.501 -179.992 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.8 t -163.14 121.54 2.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.908 0.385 . . . . 0.0 110.881 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 98.5 p -117.71 151.03 38.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.892 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.98 112.07 0.27 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.3 m -84.16 -52.84 5.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 110.838 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 97.8 p -116.59 43.44 2.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.861 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.49 125.0 0.59 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.542 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 146.9 61.66 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.663 2.242 . . . . 0.0 112.35 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.3 mt -144.23 151.41 51.59 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.631 0.729 . . . . 0.0 110.912 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 79.7 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.662 2.241 . . . . 0.0 112.352 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -143.82 156.16 59.22 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.644 0.735 . . . . 0.0 110.86 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 1.15 4.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.693 2.262 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.98 95.14 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.868 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.91 -61.11 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 33.9 mt -91.99 145.63 24.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.821 0.343 . . . . 0.0 110.905 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.63 171.01 7.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.417 ' HB3' ' CG ' ' A' ' 43' ' ' ARG . 23.5 t -118.64 166.24 12.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.847 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -83.07 148.41 27.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -109.11 144.87 36.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.92 HD11 HG22 ' A' ' 44' ' ' VAL . 4.2 mt -131.05 112.07 12.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.61 126.38 30.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.144 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.565 ' CG2' HD11 ' A' ' 42' ' ' LEU . 95.4 t -66.52 102.44 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.058 HD21 ' HB2' ' A' ' 71' ' ' ALA . 4.7 mt -61.84 -32.16 72.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.906 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.3 t -156.23 125.24 6.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.846 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -41.47 148.09 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.57 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -167.37 148.42 5.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.778 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.76 -174.36 9.47 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.323 -0.081 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.9 m -81.59 158.57 68.34 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.69 0.757 . . . . 0.0 110.85 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 3.17 2.95 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.668 2.245 . . . . 0.0 112.324 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -107.16 -6.15 17.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.39 -43.17 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.151 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.2 m -170.92 163.32 5.43 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.653 0.74 . . . . 0.0 110.842 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 131.62 21.66 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.387 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.18 3.61 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.378 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.779 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.7 mp -72.56 -29.21 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.502 ' HB3' HG21 ' A' ' 22' ' ' VAL . 10.1 m-85 -127.75 104.64 7.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.88 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.9 OUTLIER -65.59 159.65 24.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.859 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 25.6 ttp180 -62.49 141.39 58.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.25 7.69 88.3 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -91.92 139.75 30.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -88.54 137.2 32.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.933 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.9 mt -134.65 149.71 50.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.427 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.7 ttp180 -100.62 131.66 46.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.92 HG22 HD11 ' A' ' 20' ' ' LEU . 45.7 t -71.41 116.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.614 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -89.58 -49.41 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -152.3 149.36 28.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -108.52 119.27 39.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.842 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -122.93 85.84 2.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.67 -122.14 28.08 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.509 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.76 -24.99 61.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.0 m95 -111.6 141.67 44.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.79 0.329 . . . . 0.0 110.942 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.558 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.35 164.71 25.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.893 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.545 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 19.0 tttt -99.73 146.61 26.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.56 167.07 31.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.644 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.7 tt -138.49 146.8 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.155 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.489 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 5.7 m -81.18 132.66 35.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.3 mt -80.08 9.43 5.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.939 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 m -113.17 -51.12 2.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 77.8 p -97.49 -33.95 11.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.31 27.79 35.38 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 54.2 mtt-85 -90.05 122.87 33.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.804 0.335 . . . . 0.0 110.882 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.644 ' HG3' HD12 ' A' ' 55' ' ' ILE . 11.4 mt-10 -92.54 118.53 31.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.3 m -147.11 165.78 28.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.545 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 27.9 m-85 -108.73 120.2 41.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.914 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.798 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.36 151.81 75.34 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.636 0.731 . . . . 0.0 111.149 179.909 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.69 130.14 18.91 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.37 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.45 -31.69 6.96 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.503 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.675 HG22 ' HB2' ' A' ' 66' ' ' PRO . 11.7 tt -63.0 -31.92 54.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.838 0.352 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' CYS . . . . . 0.402 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.7 m -77.08 -15.51 59.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.412 ' O ' HD11 ' A' ' 23' ' ' LEU . 25.2 m -121.3 167.77 14.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.108 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.058 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.15 131.64 44.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.466 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 7.1 tpp85 -63.14 106.14 0.81 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 74' ' ' SER . 44.1 t -76.68 148.62 6.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.155 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.403 ' C ' ' O ' ' A' ' 73' ' ' VAL . 7.8 m -37.61 149.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.855 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -99.94 163.51 19.38 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.437 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 91.75 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.688 2.259 . . . . 0.0 112.363 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 78.9 p -128.04 108.75 10.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.84 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 58.6 p -45.98 151.44 0.47 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.988 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.0 m -148.21 168.74 21.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.866 0.365 . . . . 0.0 110.861 -179.74 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 85.3 p -122.38 118.85 29.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.821 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.94 130.8 0.34 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.475 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 m -103.05 43.29 1.09 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.868 0.366 . . . . 0.0 110.882 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 99.9 p -102.33 134.25 45.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.95 -94.97 0.13 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.481 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 140.58 43.3 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.386 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.9 mt -124.46 144.14 45.17 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.585 0.707 . . . . 0.0 110.924 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -46.11 1.34 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.727 2.284 . . . . 0.0 112.323 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -107.18 161.25 23.59 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.624 0.726 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.668 2.245 . . . . 0.0 112.342 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -55.0 96.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 141.02 -82.33 0.24 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -69.18 138.38 54.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.811 0.339 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -75.78 162.06 28.5 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.3 t -127.99 149.86 50.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.839 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.533 ' O ' HG23 ' A' ' 44' ' ' VAL . 70.4 m-20 -84.6 119.57 25.36 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.898 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 m-85 -105.21 148.11 27.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.74 HD11 HG22 ' A' ' 44' ' ' VAL . 6.7 mt -130.21 107.89 9.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.37 123.42 26.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 40' ' ' GLU . 58.5 t -60.09 97.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.05 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.2 mt -61.02 -33.9 73.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -162.25 130.1 3.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.913 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 p30 -41.15 146.73 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.634 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.85 149.67 7.1 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.633 0.73 . . . . 0.0 110.929 -179.841 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.8 Cg_endo -69.76 -177.42 14.5 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.314 -0.031 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 1.2 t -69.55 153.92 95.29 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.722 0.773 . . . . 0.0 110.86 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 4.0 2.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.685 2.256 . . . . 0.0 112.325 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -107.87 -24.34 11.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.869 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.2 mt -101.59 -54.78 6.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.129 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -153.95 164.34 20.99 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.91 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 128.28 15.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 121.0 7.71 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.727 2.285 . . . . 0.0 112.355 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.742 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -80.24 -28.08 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.143 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.464 ' HB3' HG21 ' A' ' 22' ' ' VAL . 12.6 m-85 -131.14 110.51 11.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.4 ' O ' ' C ' ' A' ' 38' ' ' ARG . 10.0 mmm180 -78.11 138.11 38.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.447 ' HA ' HG12 ' A' ' 22' ' ' VAL . 15.3 ttp-105 -37.51 144.99 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.21 -8.66 79.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.498 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.541 ' O ' HG23 ' A' ' 22' ' ' VAL . 7.3 mt-10 -88.14 146.4 25.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.885 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' HD23 ' A' ' 42' ' ' LEU . 3.6 ttmp? -99.33 147.7 24.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.869 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.533 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -137.2 153.92 50.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.577 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.5 ttm180 -108.38 127.92 54.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.74 HG22 HD11 ' A' ' 20' ' ' LEU . 61.6 t -61.99 109.61 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.595 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -86.1 -55.05 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.897 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 45' ' ' ILE . 43.5 t -152.07 125.65 8.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -88.05 126.17 34.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -129.97 85.86 2.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.72 -127.48 36.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.513 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.53 -22.69 74.9 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' TRP . . . . . 0.585 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 19.6 m95 -113.76 137.1 52.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.789 0.328 . . . . 0.0 110.923 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.419 ' CZ2' ' HA2' ' A' ' 67' ' ' GLY . 0.1 OUTLIER -129.05 164.64 22.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.595 ' HD3' HG21 ' A' ' 45' ' ' ILE . 11.5 tttp -100.9 142.94 31.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.68 159.67 43.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.117 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.808 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.6 tt -131.83 138.84 51.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.138 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.533 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.1 t -74.39 126.52 30.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.897 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.1 mt -77.28 8.57 3.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.7 t -107.34 -44.8 4.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.4 p -104.7 -41.22 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.188 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.9 32.68 7.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.416 ' C ' HG13 ' A' ' 55' ' ' ILE . 45.8 mtt180 -97.6 122.71 41.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.811 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.808 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.5 mt-10 -91.15 116.99 29.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.6 t -147.96 165.99 29.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.559 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 15.0 m-85 -105.6 128.99 53.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.486 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.3 OUTLIER -138.57 151.13 68.32 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.656 0.741 . . . . 0.0 111.12 179.9 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.702 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.7 133.7 26.31 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.65 2.233 . . . . 0.0 112.35 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -31.57 6.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.1 tp -64.63 -32.03 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.821 0.343 . . . . 0.0 111.142 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -75.28 -12.68 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.888 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.611 ' O ' HD11 ' A' ' 23' ' ' LEU . 13.3 m -127.29 169.86 18.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.05 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -129.96 132.54 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.115 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.651 ' NH1' HG21 ' A' ' 44' ' ' VAL . 1.7 tpt180 -69.53 105.13 2.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.0 t -81.15 145.83 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.151 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 36.1 t 49.94 43.12 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.82 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -117.48 170.53 13.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.457 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -10.86 29.6 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.343 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 44.0 p -91.57 144.66 25.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.5 m 59.67 25.78 14.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.906 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 -179.958 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.9 m-20 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.839 0.352 . . . . 0.0 110.89 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -105.06 148.25 26.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.639 HD11 HG22 ' A' ' 44' ' ' VAL . 4.8 mt -129.93 114.2 15.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -83.11 126.26 32.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.118 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 36' ' ' PHE . 93.1 t -62.33 104.3 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.095 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.971 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.8 mt -66.44 -33.48 75.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.889 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.426 ' O ' ' C ' ' A' ' 25' ' ' ASP . 28.8 t -156.17 120.43 4.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 24' ' ' SER . 4.3 p-10 -35.97 140.07 0.13 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.572 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.1 OUTLIER -156.75 147.65 16.45 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 0.0 110.899 -179.866 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.564 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -173.57 8.6 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.351 -0.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 m -75.8 156.21 84.69 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.727 0.775 . . . . 0.0 110.841 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 3.33 2.82 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.691 2.261 . . . . 0.0 112.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -106.92 -16.55 14.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -112.2 -46.53 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.164 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -165.75 163.0 12.87 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.685 0.755 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 133.33 25.23 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.365 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 120.37 7.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 0.0 112.333 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.731 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.3 mp -79.15 -25.87 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.11 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.648 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.5 m-85 -131.22 93.83 3.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.95 155.27 8.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 55.7 ttp85 -54.82 148.11 13.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -16.28 11.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.483 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -68.98 138.35 54.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.918 0.39 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -92.74 137.65 32.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mt -131.16 147.6 52.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.921 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.528 ' O ' HD12 ' A' ' 45' ' ' ILE . 28.2 ttt180 -99.41 132.11 44.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 18' ' ' ASP . 90.9 t -68.04 110.28 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.149 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.666 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -87.47 -52.38 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.117 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 m -143.59 146.91 33.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -111.27 116.7 31.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.852 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 6.6 mm-40 -125.66 85.94 2.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.76 -122.52 30.29 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 -22.52 63.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.519 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 26.3 m95 -110.84 137.33 48.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.305 . . . . 0.0 110.899 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.409 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.27 164.37 27.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.875 -179.994 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.666 ' HD3' HG21 ' A' ' 45' ' ' ILE . 38.5 tttt -100.09 140.9 33.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.82 160.01 43.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.74 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.5 tt -131.45 141.54 45.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.4 t -76.48 130.45 37.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.85 6.58 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.2 t -109.7 -44.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 53.2 p -103.53 -34.68 8.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.156 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.95 32.46 23.66 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.519 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.436 ' C ' HG13 ' A' ' 55' ' ' ILE . 28.1 mtt180 -95.83 125.26 40.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.777 0.322 . . . . 0.0 110.88 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.74 ' HG3' HD12 ' A' ' 55' ' ' ILE . 7.1 mt-10 -91.51 118.13 30.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 36' ' ' PHE . 4.2 m -147.01 168.81 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.824 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 31.6 m-85 -113.28 120.33 40.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.963 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.825 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -130.43 151.27 78.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.632 0.73 . . . . 0.0 111.124 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.6 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 132.23 22.87 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.699 2.266 . . . . 0.0 112.306 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -45.17 -33.97 4.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.494 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.6 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -61.37 -34.75 62.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.351 . . . . 0.0 111.111 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.15 -13.86 61.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.406 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.9 m -124.93 171.78 13.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.161 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.971 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.73 132.5 43.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.093 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 3.2 tpp85 -65.87 102.82 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.937 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.554 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.8 m-20 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -106.32 146.82 29.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.882 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.881 HD11 HG22 ' A' ' 44' ' ' VAL . 7.4 mt -131.91 108.96 9.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.01 128.64 33.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 ' O ' ' A' ' 36' ' ' PHE . 74.1 t -65.25 100.05 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.104 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.028 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.6 mt -61.48 -26.69 68.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -166.64 132.47 2.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.93 142.43 0.91 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 150.46 12.93 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.643 0.735 . . . . 0.0 110.911 -179.807 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.8 175.08 38.12 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.652 -1.812 . . . . 0.0 112.342 -0.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.4 p -68.5 156.31 90.85 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.679 0.752 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 5.24 1.75 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.88 -6.42 18.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.896 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.56 -53.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.03 163.93 23.4 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.683 0.754 . . . . 0.0 110.849 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 134.53 28.19 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.692 2.262 . . . . 0.0 112.354 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.14 11.81 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.72 2.28 . . . . 0.0 112.368 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.606 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -87.66 -23.66 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.479 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.7 m-85 -134.74 101.37 4.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.8 mmt85 -60.95 158.98 12.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.465 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.6 tmm_? -56.87 144.34 33.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.858 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.443 ' N ' ' HD2' ' A' ' 38' ' ' ARG . . . 83.69 -16.07 33.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -68.78 138.68 55.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.936 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.62 142.05 27.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 56' ' ' SER . 3.0 mt -138.71 135.16 34.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.934 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.533 ' O ' HD12 ' A' ' 45' ' ' ILE . 50.4 ttt180 -87.3 133.54 33.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.881 HG22 HD11 ' A' ' 20' ' ' LEU . 89.6 t -68.39 113.58 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.125 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -91.28 -50.41 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.155 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.1 p -143.8 150.36 38.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.9 p-10 -114.3 115.66 27.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.92 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.0 mt-10 -122.17 85.84 2.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.935 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.45 -119.62 18.23 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.506 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.48 -24.12 61.42 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.51 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 18.3 m95 -110.81 140.31 45.36 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.781 0.325 . . . . 0.0 110.945 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.18 164.32 27.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.911 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.526 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 33.4 tttt -98.26 145.62 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.674 HD12 ' HG3' ' A' ' 62' ' ' GLU . 16.1 tt -127.68 144.95 35.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.53 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.9 t -78.13 129.16 34.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.844 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.28 8.95 6.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.8 m -114.75 -44.22 3.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.9 p -101.26 -41.82 6.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.114 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.32 25.87 17.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.483 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 40.1 mtt180 -92.27 125.93 37.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.674 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.75 117.92 30.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 17.7 m -146.87 169.35 19.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 19.8 m-85 -112.06 118.83 36.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.778 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.43 151.25 69.78 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.148 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.656 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.6 Cg_endo -69.74 133.11 24.81 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.697 2.265 . . . . 0.0 112.331 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.9 -31.26 5.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.466 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.656 HG22 ' HB2' ' A' ' 66' ' ' PRO . 9.1 tt -64.27 -32.59 58.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.776 0.322 . . . . 0.0 111.097 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.3 m -75.58 -13.05 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.688 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.6 m -126.97 175.23 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.028 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -141.84 139.83 32.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.119 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -67.9 110.45 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.129 179.934 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.7 m-20 . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.845 0.355 . . . . 0.0 110.918 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -105.11 149.88 25.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.839 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.656 HD11 HG22 ' A' ' 44' ' ' VAL . 14.5 mt -132.71 115.13 14.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.48 120.47 26.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.643 HG11 ' O ' ' A' ' 36' ' ' PHE . 87.7 t -55.68 106.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.1 mt -66.79 -34.01 76.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.917 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.9 t -157.2 128.13 6.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.852 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.97 134.05 2.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.643 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.87 149.74 22.76 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 110.942 -179.811 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.48 11.0 Favored 'Cis proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.304 -0.045 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.1 m -73.61 155.65 89.11 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.671 0.748 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 2.92 3.09 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.699 2.266 . . . . 0.0 112.359 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -106.82 -16.61 14.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -111.81 -46.94 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.172 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.11 162.01 14.34 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.622 0.725 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 135.94 31.59 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.637 2.224 . . . . 0.0 112.348 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 124.87 11.48 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.684 2.256 . . . . 0.0 112.338 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.597 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -87.52 -25.08 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.149 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.643 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.1 m-85 -131.65 89.77 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -50.49 156.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.872 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -58.43 150.97 21.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.62 -6.4 17.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.455 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -76.09 135.41 39.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 35.0 tttt -86.12 137.78 32.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.516 HD23 ' HA ' ' A' ' 56' ' ' SER . 9.7 mt -132.98 154.51 50.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.468 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.9 ttp180 -105.06 131.42 52.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 18' ' ' ASP . 89.9 t -70.88 112.73 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.625 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.88 -51.66 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.8 t -151.83 159.36 43.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.828 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -116.33 111.71 20.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.3 mt-10 -110.53 86.41 2.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.98 -122.68 31.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.23 -21.62 78.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.496 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.8 m95 -114.97 151.87 33.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.432 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.09 164.52 27.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.941 -179.985 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.625 ' HD3' HG21 ' A' ' 45' ' ' ILE . 25.8 tttt -100.85 143.88 30.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.81 160.95 42.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.822 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -129.88 146.76 33.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.516 ' HA ' HD23 ' A' ' 42' ' ' LEU . 87.6 p -81.37 128.52 33.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.871 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.4 mt -77.49 8.66 4.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.5 m -99.9 -52.69 3.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.816 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.4 p -107.37 -45.4 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.193 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.573 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 107.92 29.43 4.35 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.9 mtt180 -86.95 123.99 32.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.746 0.308 . . . . 0.0 110.864 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.822 ' HG3' HD12 ' A' ' 55' ' ' ILE . 6.2 mt-10 -93.97 117.86 30.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -147.19 165.63 29.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.873 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.45 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 17.0 m-85 -107.27 123.93 49.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.935 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.821 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.36 151.25 77.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.671 0.748 . . . . 0.0 111.144 179.905 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.568 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.75 132.56 23.61 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.646 2.231 . . . . 0.0 112.382 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.66 -31.33 7.22 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.462 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.461 ' O ' HD12 ' A' ' 23' ' ' LEU . 8.0 tt -63.92 -31.91 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 111.108 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . 0.401 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.2 m -76.6 -11.12 59.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.563 ' O ' HD11 ' A' ' 23' ' ' LEU . 31.0 m -127.84 169.72 18.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.906 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -127.85 129.08 46.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -64.8 108.8 1.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.9 t . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.181 179.942 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.2 m-20 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.865 0.364 . . . . 0.0 110.861 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -108.46 153.7 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.851 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.918 HD11 HG22 ' A' ' 44' ' ' VAL . 3.6 mt -140.03 114.55 9.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.9 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.65 128.93 34.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.493 ' CG2' HD11 ' A' ' 42' ' ' LEU . 92.4 t -65.1 109.44 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.072 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.914 HD21 ' HB2' ' A' ' 71' ' ' ALA . 6.5 mt -68.8 -31.93 71.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.932 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.436 ' O ' ' C ' ' A' ' 25' ' ' ASP . 24.6 t -160.76 125.98 3.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.7 OUTLIER -35.37 148.34 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.846 179.953 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.59 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -166.04 148.89 6.49 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.64 0.733 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.8 -174.27 9.41 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.347 0.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -71.17 153.63 94.27 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 0.0 110.876 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 3.04 3.02 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.678 2.252 . . . . 0.0 112.338 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -106.0 -23.13 12.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.5 -57.15 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.128 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 m -150.8 162.93 25.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.679 0.752 . . . . 0.0 110.851 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 132.89 24.17 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.339 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 122.59 9.26 Favored 'Trans proline' 0 N--CA 1.465 -0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.347 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.678 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -87.17 -26.11 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.431 ' HB3' HG21 ' A' ' 22' ' ' VAL . 6.0 m-85 -128.87 99.22 5.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 28.6 mmm-85 -63.44 157.75 22.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 ttm180 -56.81 143.82 35.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.03 9.42 86.96 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -93.15 136.0 33.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.401 ' O ' HD23 ' A' ' 42' ' ' LEU . 22.1 ttmt -87.99 139.6 30.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.493 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.1 mt -136.94 146.86 45.93 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.552 ' O ' HD12 ' A' ' 45' ' ' ILE . 15.1 ttm180 -100.5 125.34 46.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.927 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.918 HG22 HD11 ' A' ' 20' ' ' LEU . 43.6 t -63.44 111.03 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.552 HD12 ' O ' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -85.12 -47.74 16.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -149.09 157.89 43.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -117.21 113.15 21.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.2 mt-10 -115.22 86.25 2.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 57.68 -118.4 12.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.43 -23.0 61.41 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.508 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.9 m95 -112.28 135.72 52.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.76 0.314 . . . . 0.0 110.896 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.507 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -124.75 164.76 19.26 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.932 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.552 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 14.5 tttp -102.61 147.77 26.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.74 163.81 39.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.104 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.737 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.5 tt -131.47 151.33 35.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.156 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.407 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 49.1 m -83.18 127.77 33.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.3 mt -78.43 9.38 3.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 m -116.8 -43.88 2.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 68.6 p -101.4 -42.74 6.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.02 25.79 16.19 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 50.8 mtt-85 -89.86 124.49 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.779 0.323 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.737 ' HG3' HD12 ' A' ' 55' ' ' ILE . 9.6 mt-10 -93.92 117.38 30.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.1 t -147.76 166.28 27.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.832 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.552 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 12.9 m-85 -108.79 122.74 47.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.738 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -129.8 151.12 77.62 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.65 0.738 . . . . 0.0 111.157 179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.706 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.79 134.8 28.78 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.325 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.75 -30.58 9.03 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.469 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.2 tp -65.39 -30.46 50.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.7 m -78.6 -6.87 56.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.838 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.443 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.5 m -133.02 167.57 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.914 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.94 134.67 48.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.6 tpt85 -64.98 112.36 3.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 -179.986 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.853 ' O ' HG23 ' A' ' 44' ' ' VAL . 13.2 m-20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.89 0.376 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -103.14 152.66 21.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.853 HD11 HG22 ' A' ' 44' ' ' VAL . 0.9 OUTLIER -137.51 112.89 9.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.923 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 125.52 30.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.075 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.634 HG11 ' O ' ' A' ' 36' ' ' PHE . 46.9 t -61.63 99.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.143 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.886 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -57.33 -33.69 67.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.894 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.2 t -157.95 133.17 8.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.36 135.29 3.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.65 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -153.39 150.18 23.01 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.665 0.745 . . . . 0.0 110.929 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.76 -175.09 10.34 Favored 'Cis proline' 0 C--O 1.231 0.156 0 C-N-CA 122.723 -1.782 . . . . 0.0 112.33 -0.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 31.2 m -75.24 155.64 86.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.729 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 1.14 4.69 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.682 2.255 . . . . 0.0 112.394 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.16 -5.38 18.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.863 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.72 -47.03 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.1 161.63 14.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.638 0.732 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 134.28 27.62 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.367 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 125.29 12.01 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.67 2.247 . . . . 0.0 112.357 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.651 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -87.19 -25.22 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.114 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.634 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.89 96.94 3.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.81 162.95 1.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.868 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -59.88 149.66 30.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.08 -9.76 17.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.99 137.09 48.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.878 0.371 . . . . 0.0 110.891 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 1.2 ttmp? -90.89 138.94 31.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.7 mt -137.99 142.63 40.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.941 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 45' ' ' ILE . 27.6 ttt-85 -94.97 131.66 40.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.853 HG22 HD11 ' A' ' 20' ' ' LEU . 69.0 t -68.01 109.84 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.149 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.648 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -83.65 -46.26 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.94 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 68.8 m -156.27 152.75 28.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -110.91 117.09 32.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.885 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -120.43 86.09 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.7 -122.99 30.63 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.01 -23.37 66.53 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.511 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.6 m95 -112.42 146.72 37.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.747 0.308 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.42 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.55 164.45 27.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.921 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.648 ' HD3' HG21 ' A' ' 45' ' ' ILE . 34.7 tttt -100.37 143.39 30.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.27 163.26 39.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.078 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.57 HG22 HD11 ' A' ' 45' ' ' ILE . 12.0 tt -133.9 136.89 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.116 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.432 ' HA ' HD23 ' A' ' 42' ' ' LEU . 2.6 t -70.87 129.09 38.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.69 8.64 5.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.946 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.7 m -112.6 -44.91 3.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.811 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 70.6 p -103.24 -33.65 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.79 29.44 32.04 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.48 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -92.24 123.94 35.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.793 0.33 . . . . 0.0 110.903 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.425 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.6 mt-10 -90.88 117.63 29.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.869 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.6 m -147.26 167.41 24.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.832 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.459 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.6 m-85 -110.5 115.72 30.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.811 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.49 151.4 63.15 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.641 0.734 . . . . 0.0 111.173 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.4 Cg_endo -69.77 134.41 27.9 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.686 2.257 . . . . 0.0 112.351 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.431 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -50.36 -28.85 15.27 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.513 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 18.2 tt -66.0 -28.0 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.8 0.334 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 6.4 m -85.1 1.13 49.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 35.9 m -136.37 157.99 37.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.886 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -120.45 130.83 54.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.053 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -64.89 107.63 1.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.958 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.79 ' O ' HG23 ' A' ' 44' ' ' VAL . 5.8 m-20 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.858 0.361 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -104.72 152.73 22.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.843 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.701 HD11 HG22 ' A' ' 44' ' ' VAL . 3.8 mt -134.62 108.71 8.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.5 125.47 29.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.6 t -63.9 103.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.8 mt -62.54 -33.28 74.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.421 ' O ' ' C ' ' A' ' 25' ' ' ASP . 35.3 t -158.34 123.24 4.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.873 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.3 OUTLIER -36.36 144.55 0.05 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.841 179.993 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.601 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 148.9 11.6 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.743 . . . . 0.0 110.939 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.56 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.75 178.69 24.56 Favored 'Cis proline' 0 N--CA 1.465 -0.147 0 C-N-CA 122.713 -1.786 . . . . 0.0 112.358 -0.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -66.36 153.33 92.93 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.724 0.773 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.86 3.16 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.663 2.242 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -104.48 -23.99 13.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.847 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.23 -54.51 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.167 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.53 164.18 21.76 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.684 0.754 . . . . 0.0 110.888 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 131.54 21.48 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.72 3.79 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.664 2.242 . . . . 0.0 112.324 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.728 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -75.65 -27.56 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.531 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 8.2 m-85 -129.5 102.3 6.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -62.65 162.77 10.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.926 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.5 ttt180 -62.15 146.95 49.12 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.5 -9.75 26.81 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.498 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -73.06 131.62 42.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.916 0.389 . . . . 0.0 110.854 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.441 ' HB3' HD12 ' A' ' 57' ' ' LEU . 25.3 ttmt -81.52 136.48 35.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.892 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.619 HD23 ' HA ' ' A' ' 56' ' ' SER . 13.7 mt -129.36 139.67 51.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.584 HH12 HG21 ' A' ' 55' ' ' ILE . 7.9 ttp-105 -90.38 129.8 36.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.79 HG23 ' O ' ' A' ' 18' ' ' ASP . 99.3 t -69.46 111.77 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.153 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.64 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.6 -52.89 10.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 t -152.88 159.82 43.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -115.96 112.27 21.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -110.61 85.9 2.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.33 -122.16 29.17 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.14 -23.62 75.55 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -113.67 152.66 30.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.763 0.315 . . . . 0.0 110.978 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.463 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.11 164.29 28.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.64 ' HD3' HG21 ' A' ' 45' ' ' ILE . 14.8 tttt -101.28 139.55 36.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.88 168.7 20.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.8 tt -135.75 140.35 44.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.163 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.619 ' HA ' HD23 ' A' ' 42' ' ' LEU . 96.3 p -79.42 128.27 33.14 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.441 HD12 ' HB3' ' A' ' 41' ' ' LYS . 7.9 mt -78.7 9.49 4.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.888 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.0 t -104.15 -45.34 4.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.918 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.7 p -110.69 -34.83 6.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 91.95 24.11 25.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -87.94 128.25 35.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.799 0.333 . . . . 0.0 110.866 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 55' ' ' ILE . 15.5 mt-10 -95.55 117.79 31.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 44.7 t -147.11 159.48 43.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.882 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -98.2 129.9 44.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.826 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -138.16 151.45 69.78 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.552 0.691 . . . . 0.0 111.182 179.884 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.713 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.71 132.02 22.54 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.703 2.269 . . . . 0.0 112.329 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.401 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -48.45 -29.77 7.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.505 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.713 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.3 tt -64.94 -30.87 51.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 111.118 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.4 m -77.68 -11.52 59.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.401 HG22 ' HA2' ' A' ' 67' ' ' GLY . 19.2 m -126.71 165.58 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.089 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.837 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -124.21 130.22 52.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 tpt180 -67.12 99.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 179.945 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.869 ' O ' HG23 ' A' ' 44' ' ' VAL . 41.5 m-20 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.794 0.33 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -102.97 151.2 22.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.777 HD11 HG22 ' A' ' 44' ' ' VAL . 4.7 mt -135.54 109.18 7.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.69 131.32 35.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.056 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 36' ' ' PHE . 63.7 t -65.81 109.11 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.159 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.068 HD21 ' HB2' ' A' ' 71' ' ' ALA . 5.0 mt -74.52 -29.63 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 25' ' ' ASP . 29.2 t -157.02 115.52 3.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -34.99 139.96 0.08 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.588 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -156.65 148.59 17.38 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.687 0.756 . . . . 0.0 110.924 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.74 -174.67 9.79 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 -1.801 . . . . 0.0 112.358 -0.074 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.477 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 4.0 m -77.0 158.8 79.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.696 0.76 . . . . 0.0 110.857 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 5.15 1.79 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 29.4 p-10 -104.26 -27.93 11.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.405 HG13 ' OD1' ' A' ' 30' ' ' ASP . 7.3 mt -101.95 -53.45 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -159.47 163.82 22.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 137.71 35.97 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 124.82 11.48 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.713 2.276 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.593 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -86.89 -20.85 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.635 ' O ' HG11 ' A' ' 22' ' ' VAL . 19.5 m-85 -134.47 87.17 2.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.887 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.77 156.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.435 ' HG3' ' C ' ' A' ' 23' ' ' LEU . 2.6 ttm105 -60.68 144.03 52.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.65 -9.41 62.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.471 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -76.95 136.15 38.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 110.911 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.408 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 49.8 tttt -84.26 137.55 33.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.453 HD11 ' CG2' ' A' ' 22' ' ' VAL . 9.9 mt -131.64 150.0 52.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.556 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.1 ttp180 -105.09 128.85 53.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 18' ' ' ASP . 91.5 t -64.35 110.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.646 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -87.79 -51.73 12.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.4 p -146.9 135.51 22.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -100.06 115.82 30.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.0 mm-40 -127.3 86.89 2.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.95 -123.41 32.6 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.49 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.39 63.06 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.595 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 32.1 m95 -113.98 123.26 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.735 0.302 . . . . 0.0 110.88 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.486 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -123.2 164.29 18.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.924 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.646 ' HD3' HG21 ' A' ' 45' ' ' ILE . 10.9 tttp -98.5 144.7 27.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.884 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.95 152.66 31.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.107 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.582 HG22 HD11 ' A' ' 45' ' ' ILE . 12.6 tt -126.23 131.84 71.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.443 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.3 t -68.77 128.82 38.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 4.5 mt -79.22 9.37 4.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.0 t -109.26 -45.53 3.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.841 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.5 p -102.02 -39.73 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.14 32.15 9.16 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.428 ' C ' HG13 ' A' ' 55' ' ' ILE . 36.7 mtt180 -98.19 127.0 43.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.826 0.346 . . . . 0.0 110.867 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.573 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.19 117.24 29.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.861 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.2 m -147.89 168.31 22.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 30.0 m-85 -109.66 135.64 50.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.411 HG22 ' CE1' ' A' ' 26' ' ' TYR . 0.2 OUTLIER -144.36 151.37 50.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.59 0.71 . . . . 0.0 111.165 179.86 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.696 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.72 133.81 26.55 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -48.56 -30.21 8.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.696 HG22 ' HB2' ' A' ' 66' ' ' PRO . 4.6 tp -65.54 -30.45 50.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.816 0.341 . . . . 0.0 111.164 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . 0.4 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 2.9 m -78.5 -3.84 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.604 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.2 m -136.59 169.8 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.068 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.98 139.25 45.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.2 tpp85 -68.62 112.03 5.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.876 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.8 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.105 -179.994 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.895 ' O ' HG23 ' A' ' 44' ' ' VAL . 10.9 m-20 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.867 0.365 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.44 152.13 21.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.713 HD11 HG22 ' A' ' 44' ' ' VAL . 3.7 mt -134.78 112.3 10.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.913 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.24 119.96 24.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.055 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.536 HG21 ' HB3' ' A' ' 36' ' ' PHE . 98.4 t -57.27 99.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.015 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.4 mt -59.34 -23.44 62.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 47.2 t -169.76 133.67 1.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.835 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.28 146.54 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.868 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.651 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -164.75 149.95 8.5 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.702 0.763 . . . . 0.0 110.913 -179.826 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.537 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.75 -174.69 9.83 Favored 'Cis proline' 0 C--N 1.342 0.201 0 C-N-CA 122.711 -1.787 . . . . 0.0 112.377 -0.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.463 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 44.2 m -72.29 154.58 91.99 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.641 0.734 . . . . 0.0 110.878 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 3.52 2.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.679 2.253 . . . . 0.0 112.357 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.463 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 23.6 p-10 -109.39 -17.03 13.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -109.44 -46.43 6.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -164.77 163.17 14.44 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.672 0.749 . . . . 0.0 110.821 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 131.67 21.66 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 124.74 11.37 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.377 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.6 mp -89.22 -24.38 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.155 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.536 ' HB3' HG21 ' A' ' 22' ' ' VAL . 14.4 m-85 -130.98 103.02 6.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -64.22 160.34 18.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.6 ttp85 -58.37 149.4 24.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.928 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.75 -9.71 22.04 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -71.13 154.12 41.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.902 0.382 . . . . 0.0 110.904 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 7.9 tttp -107.16 140.24 40.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.914 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.3 mt -136.85 135.26 37.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.594 ' O ' HD12 ' A' ' 45' ' ' ILE . 19.2 ttt-85 -86.48 131.02 34.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 18' ' ' ASP . 60.5 t -66.99 108.8 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.737 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -87.74 -52.36 11.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -143.82 155.03 43.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -119.49 113.05 20.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -117.31 86.39 2.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.4 -123.6 33.87 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.39 -21.07 78.22 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.486 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.564 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -113.26 144.74 42.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.724 0.297 . . . . 0.0 110.941 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.401 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.83 164.46 27.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.92 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HD3' HG21 ' A' ' 45' ' ' ILE . 28.9 tttt -101.04 141.04 34.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.906 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.17 162.57 39.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.737 HG22 HD11 ' A' ' 45' ' ' ILE . 16.4 tt -134.67 134.55 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -69.8 128.28 35.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.843 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.484 HD21 ' HB2' ' A' ' 43' ' ' ARG . 2.0 mt -78.78 2.68 19.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.89 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.3 m -99.41 -47.81 5.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.3 p -105.33 -37.35 6.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.142 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.85 29.34 9.94 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.485 ' HD2' HG23 ' A' ' 35' ' ' ILE . 33.7 mtt180 -90.04 127.8 36.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.873 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.665 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.7 mt-10 -97.86 118.0 33.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.1 t -147.02 167.38 24.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 14.8 m-85 -110.07 114.33 27.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.795 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.91 151.18 60.64 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.63 0.729 . . . . 0.0 111.164 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.78 133.88 26.59 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.673 2.249 . . . . 0.0 112.341 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -47.44 -30.26 5.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 5.4 tp -65.09 -32.47 58.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.801 0.334 . . . . 0.0 111.116 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 8.0 m -78.91 -4.82 51.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.513 ' O ' HD11 ' A' ' 23' ' ' LEU . 32.4 m -132.56 166.08 30.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.015 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -130.53 129.45 42.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.069 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.95 107.6 1.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.859 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.099 179.987 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.578 ' O ' HG23 ' A' ' 44' ' ' VAL . 85.7 m-20 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.827 0.346 . . . . 0.0 110.883 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -111.17 150.15 29.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.663 HD11 HG22 ' A' ' 44' ' ' VAL . 9.3 mt -133.38 114.08 13.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.42 127.12 32.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.08 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.695 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.8 t -65.04 98.6 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.149 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.962 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -59.71 -31.49 69.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.931 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.7 t -161.3 127.95 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.77 138.98 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.647 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.72 150.12 17.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.695 0.76 . . . . 0.0 110.936 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -175.28 10.64 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.695 -1.794 . . . . 0.0 112.337 -0.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 3.1 m -76.28 158.29 81.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -102.07 -22.39 14.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 mt -109.25 -54.99 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -155.3 163.44 24.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.615 0.721 . . . . 0.0 110.888 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 137.81 36.43 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 119.04 6.05 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.679 2.252 . . . . 0.0 112.371 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -83.06 -25.71 8.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.128 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.695 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.3 m-85 -131.4 96.24 3.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.0 mmm-85 -56.41 158.38 4.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 52.1 ttt-85 -61.08 144.5 53.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.62 -14.46 35.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -72.75 136.54 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.5 ttmt -87.02 137.84 32.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.593 HD23 ' HA ' ' A' ' 56' ' ' SER . 10.4 mt -132.17 140.6 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.919 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.428 ' O ' HD12 ' A' ' 45' ' ' ILE . 42.8 ttt180 -91.12 134.49 34.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.663 HG22 HD11 ' A' ' 20' ' ' LEU . 97.6 t -71.43 112.11 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.635 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -86.05 -46.32 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -155.56 147.75 23.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.46 116.07 31.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.902 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -122.35 85.91 2.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.12 -120.7 23.89 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.33 -23.08 59.4 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.438 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 21.9 m95 -111.68 137.9 48.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.79 0.329 . . . . 0.0 110.88 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.516 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.3 164.83 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.635 ' HD3' HG21 ' A' ' 45' ' ' ILE . 9.4 tttp -101.49 141.95 33.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.911 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.13 168.34 22.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.816 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.3 tt -138.39 142.45 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.593 ' HA ' HD23 ' A' ' 42' ' ' LEU . 50.5 p -76.82 133.49 39.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.6 mt -82.96 8.86 11.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.2 t -104.78 -42.77 5.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -113.56 -44.57 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.103 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.529 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 103.35 27.88 6.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.473 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -84.19 122.04 28.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 110.853 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.816 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -92.09 117.48 29.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.0 t -147.44 169.61 19.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.905 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.57 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 7.1 m-85 -112.1 118.09 34.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.83 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.5 151.26 69.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.656 0.741 . . . . 0.0 111.153 179.866 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.631 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.0 Cg_endo -69.79 132.67 23.75 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.704 2.27 . . . . 0.0 112.312 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.45 -33.5 5.99 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.631 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.8 tt -61.81 -33.39 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.359 . . . . 0.0 111.177 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.1 -15.92 61.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.569 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.7 m -125.47 175.86 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.962 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -136.72 134.5 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -66.32 102.44 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 179.964 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.713 ' O ' HG23 ' A' ' 44' ' ' VAL . 14.1 m-20 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.799 0.333 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -108.79 154.42 22.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.94 HD11 HG22 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -139.98 111.68 7.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.881 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.12 122.81 28.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.092 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 36' ' ' PHE . 92.2 t -55.33 104.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.022 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -65.74 -33.81 76.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.7 t -155.35 128.95 8.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -39.43 146.55 0.09 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.605 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.77 148.82 6.73 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.659 0.742 . . . . 0.0 110.944 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.83 -174.27 9.44 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 -1.796 . . . . 0.0 112.295 0.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.9 m -70.57 153.77 94.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.656 0.741 . . . . 0.0 110.873 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 1.21 4.59 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.676 2.251 . . . . 0.0 112.37 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -106.26 -18.37 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -107.29 -54.03 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.16 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.4 m -155.71 162.63 26.97 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 134.37 27.82 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.327 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 120.87 7.59 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.724 2.282 . . . . 0.0 112.314 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.666 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.9 mp -85.6 -30.45 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.117 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.62 ' O ' HG11 ' A' ' 22' ' ' VAL . 11.8 m-85 -124.0 90.82 3.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -51.07 161.16 0.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.896 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 16.2 ttt-85 -66.17 144.15 56.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.35 -9.89 65.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.403 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -83.09 132.64 35.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 110.906 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.544 ' CD ' HG21 ' A' ' 73' ' ' VAL . 19.5 ttpt -88.99 143.74 26.65 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.467 HD11 ' CG2' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -135.0 141.25 46.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.89 179.94 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.414 ' HB2' HD21 ' A' ' 57' ' ' LEU . 35.8 ttt180 -85.64 127.57 34.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.94 HG22 HD11 ' A' ' 20' ' ' LEU . 84.5 t -64.46 111.37 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.71 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -78.62 -54.7 11.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.094 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.1 t -155.58 150.85 26.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.846 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -102.26 121.99 43.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.923 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 44.5 mm-40 -126.5 86.15 2.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.907 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.44 -121.5 24.24 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -85.08 -18.57 60.75 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.529 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.578 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.5 m95 -115.71 140.09 49.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.71 0.291 . . . . 0.0 110.937 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.404 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.79 164.44 26.82 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.878 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.71 ' HD2' HG21 ' A' ' 45' ' ' ILE . 3.7 ttmt -101.58 151.56 21.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -159.11 150.1 19.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.492 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.4 tt -116.34 144.34 24.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.13 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.434 ' HA ' HD23 ' A' ' 42' ' ' LEU . 6.7 m -73.59 130.6 40.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.414 HD21 ' HB2' ' A' ' 43' ' ' ARG . 7.5 mt -78.21 9.71 3.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 t -116.92 -52.79 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.828 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.2 p -95.9 -34.56 11.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.474 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.85 31.57 17.55 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.496 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.0 mtt180 -91.37 122.1 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.3 mt-10 -91.9 117.76 30.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.43 ' HB3' ' CE2' ' A' ' 36' ' ' PHE . 18.4 t -147.32 169.51 19.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HE3' ' A' ' 53' ' ' LYS . 4.2 m-85 -110.26 122.34 47.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.877 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.21 151.47 78.42 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.597 0.713 . . . . 0.0 111.113 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.637 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.3 Cg_endo -69.8 131.87 22.08 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.7 2.267 . . . . 0.0 112.279 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.442 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -46.78 -30.57 4.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.476 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.637 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -64.72 -33.33 62.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 0.0 111.11 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 7.4 m -78.05 -7.58 57.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.442 HG22 ' HA2' ' A' ' 67' ' ' GLY . 33.8 m -128.69 164.98 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.022 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.44 134.88 46.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.7 tpp180 -61.41 110.14 1.36 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.831 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.544 HG21 ' CD ' ' A' ' 41' ' ' LYS . 2.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.174 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.5 m-20 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.811 0.338 . . . . 0.0 110.866 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -112.14 150.68 30.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.721 HD11 HG22 ' A' ' 44' ' ' VAL . 7.2 mt -134.83 110.66 9.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.912 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.39 122.06 27.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 36' ' ' PHE . 76.6 t -58.53 100.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.141 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.945 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.8 mt -59.94 -36.14 76.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.936 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.6 t -155.97 127.08 7.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.874 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.21 135.09 1.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.645 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.08 149.6 23.73 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.716 0.77 . . . . 0.0 110.887 -179.807 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.547 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.82 -178.67 17.33 Favored 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.371 -0.023 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 59.6 m -68.36 153.44 95.6 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.652 0.739 . . . . 0.0 110.861 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 2.46 3.52 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.344 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.61 -10.09 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -118.44 -52.14 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -156.45 162.15 28.09 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 0.0 110.805 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 134.2 27.35 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.49 ' HG2' ' CZ ' ' A' ' 37' ' ' ARG . 53.9 Cg_endo -69.71 114.09 3.58 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.744 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.5 mp -74.57 -30.46 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.136 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.601 ' O ' HG11 ' A' ' 22' ' ' VAL . 14.8 m-85 -130.99 94.95 3.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.49 ' CZ ' ' HG2' ' A' ' 34' ' ' PRO . 20.4 mmt180 -53.89 160.24 1.49 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -62.73 151.99 36.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.58 -18.02 7.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.405 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -71.43 132.37 44.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.871 0.367 . . . . 0.0 110.903 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 25.6 ttmt -85.41 135.73 33.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.471 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.3 mt -128.14 148.41 50.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.501 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.4 ttt180 -98.62 130.51 45.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.878 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.721 HG22 HD11 ' A' ' 20' ' ' LEU . 57.6 t -68.58 114.17 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.125 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.501 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -90.4 -53.46 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.147 179.941 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 t -146.45 154.15 41.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.847 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -120.04 119.07 32.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -127.62 98.9 5.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.15 -130.43 50.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.65 9.0 63.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.531 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.555 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -137.07 140.39 41.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 110.926 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.415 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -133.77 164.64 26.78 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.918 179.995 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 16.1 tttp -104.09 147.03 27.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.904 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.6 159.77 42.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.131 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.686 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -126.39 141.71 45.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 20.1 p -78.25 129.87 35.58 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.7 mt -80.51 9.26 6.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.966 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -99.24 -49.4 4.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.812 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.2 p -112.77 -39.69 4.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.097 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.74 27.52 5.7 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.437 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -83.08 128.07 34.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.761 0.315 . . . . 0.0 110.862 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.686 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -102.02 117.27 34.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.8 p -147.58 169.27 19.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 24.8 m-85 -110.08 118.98 37.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.855 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.69 150.01 67.07 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.654 0.74 . . . . 0.0 111.081 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.671 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.0 Cg_endo -69.77 134.03 26.97 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.308 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.99 -31.13 5.51 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.482 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.671 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -64.84 -32.74 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.806 0.336 . . . . 0.0 111.113 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 11.6 m -80.35 2.85 23.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.618 ' O ' HD11 ' A' ' 23' ' ' LEU . 33.4 m -140.52 170.63 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.945 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -132.35 125.99 32.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 -65.74 108.19 2.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.119 179.968 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.461 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.825 0.345 . . . . 0.0 110.887 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -108.63 145.02 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.886 HD11 HG22 ' A' ' 44' ' ' VAL . 1.7 mt -134.49 110.56 9.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.421 ' HB2' ' CG2' ' A' ' 73' ' ' VAL . . . -79.63 127.09 31.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.103 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.566 HG11 ' O ' ' A' ' 36' ' ' PHE . 88.7 t -61.75 101.36 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.1 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.954 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -61.92 -31.01 71.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -160.21 128.17 4.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -40.12 140.82 0.54 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.844 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.615 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -158.94 149.18 15.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.687 0.756 . . . . 0.0 110.914 -179.848 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.545 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.3 Cg_endo -69.8 -174.52 9.7 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.34 -0.064 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -73.22 154.09 90.37 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 1.63 4.29 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.655 2.236 . . . . 0.0 112.369 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -105.86 -14.69 15.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.81 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -113.05 -51.96 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 m -158.34 162.26 27.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 133.99 26.88 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.699 2.266 . . . . 0.0 112.339 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 124.08 10.72 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.75 2.3 . . . . 0.0 112.307 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.654 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -86.84 -25.28 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.146 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.566 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.3 m-85 -130.97 93.92 3.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -56.29 150.16 15.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.409 ' HA ' HG12 ' A' ' 22' ' ' VAL . 39.9 ttp85 -50.76 147.56 4.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.05 -17.84 8.87 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -68.04 138.37 55.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.926 0.394 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.572 ' O ' HD23 ' A' ' 42' ' ' LEU . 2.5 ttmp? -89.94 143.12 27.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.572 HD23 ' O ' ' A' ' 41' ' ' LYS . 1.7 mt -139.41 142.4 37.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.951 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.561 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttt180 -95.45 132.03 40.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.864 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.886 HG22 HD11 ' A' ' 20' ' ' LEU . 95.8 t -68.0 112.63 3.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.096 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.725 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -91.39 -53.28 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 m -137.66 143.07 41.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.09 115.01 28.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.865 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -126.68 85.97 2.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.893 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.1 -125.36 38.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.81 -19.07 73.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.49 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 24.3 m95 -113.39 131.87 55.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -131.94 164.35 26.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.918 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.0 tttp -99.95 144.16 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.894 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.0 160.33 44.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.07 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.748 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.4 tt -130.55 139.66 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.078 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.1 m -72.37 129.41 38.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.857 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.0 mt -79.15 5.66 11.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.1 t -106.03 -51.08 3.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.7 p -99.31 -44.24 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.185 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.402 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 100.95 26.76 7.75 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.518 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 64.5 mtt180 -86.19 128.19 34.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.748 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.9 mt-10 -98.21 117.45 32.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.1 t -147.34 169.38 19.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.546 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 9.2 m-85 -112.63 114.79 27.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.87 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.53 150.76 58.6 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 111.138 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.597 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.81 135.99 31.75 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.637 2.225 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.9 -36.86 20.9 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.539 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.597 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -59.96 -26.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.808 0.337 . . . . 0.0 111.071 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.7 m -82.56 -7.6 59.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.8 m -131.22 164.45 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.149 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.954 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -125.93 133.31 51.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.092 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.438 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.2 tpt180 -61.0 97.72 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.421 ' CG2' ' HB2' ' A' ' 21' ' ' ALA . 3.8 t . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.144 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.698 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.1 m-20 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.839 0.352 . . . . 0.0 110.86 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -107.24 150.04 27.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.686 HD11 HG22 ' A' ' 44' ' ' VAL . 7.3 mt -132.56 121.31 23.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -92.09 119.54 31.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.063 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.585 ' CG2' HD11 ' A' ' 42' ' ' LEU . 96.2 t -59.11 96.67 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.16 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.957 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.7 mt -54.95 -35.32 64.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.929 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 t -157.46 128.65 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.841 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.69 137.98 1.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.881 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.609 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -155.18 148.55 18.48 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.685 0.755 . . . . 0.0 110.918 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.559 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.4 Cg_endo -69.71 -173.98 9.0 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.379 -0.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 6.1 m -74.67 155.51 87.15 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.689 0.757 . . . . 0.0 110.843 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 3.44 2.79 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.658 2.238 . . . . 0.0 112.379 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -107.77 -18.22 13.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -109.18 -47.92 7.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.0 OUTLIER -164.1 163.58 15.25 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.644 0.735 . . . . 0.0 110.864 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 132.24 22.87 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.675 2.25 . . . . 0.0 112.309 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 118.24 5.57 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.649 2.233 . . . . 0.0 112.306 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.709 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.2 mp -79.31 -28.42 13.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.091 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 22' ' ' VAL . 16.8 m-85 -127.3 98.42 5.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.65 160.38 4.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.854 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -62.22 144.61 55.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.23 -11.43 23.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.461 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -71.25 130.56 41.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.869 0.366 . . . . 0.0 110.896 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -81.46 137.02 35.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.585 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.4 mt -133.16 139.78 47.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttt180 -90.19 130.66 36.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.831 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 18' ' ' ASP . 57.3 t -66.89 110.66 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -80.19 -54.97 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.124 179.896 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 70.9 m -157.32 147.46 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -98.58 115.47 28.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 35.5 mt-10 -113.99 85.78 2.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.72 -122.99 30.58 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -77.77 -22.58 69.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.473 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 10.1 m95 -113.92 150.51 33.62 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.754 0.312 . . . . 0.0 110.915 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.428 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -136.08 164.2 28.57 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.949 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD2' HG21 ' A' ' 45' ' ' ILE . 4.7 ttmm -103.22 150.83 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.937 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.426 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -158.91 143.77 15.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.072 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.2 tt -108.1 144.62 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.1 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 p -83.68 130.27 34.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.0 mt -77.21 7.94 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.3 t -95.18 -51.96 4.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.843 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.8 p -111.29 -43.16 3.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.144 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.608 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 108.69 26.45 5.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -86.27 127.72 34.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.763 0.316 . . . . 0.0 110.857 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.708 ' HG3' HD12 ' A' ' 55' ' ' ILE . 13.0 mt-10 -99.15 118.11 35.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 9.0 t -147.11 167.75 23.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.527 ' CE2' ' HE2' ' A' ' 53' ' ' LYS . 4.3 m-85 -105.96 129.42 54.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.942 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.682 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -135.16 150.97 74.3 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.594 0.711 . . . . 0.0 111.125 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.672 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.74 133.21 25.06 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.732 2.288 . . . . 0.0 112.332 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.59 -30.02 8.17 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.465 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.672 HG22 ' HB2' ' A' ' 66' ' ' PRO . 13.5 tt -65.5 -30.12 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.834 0.349 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.8 m -80.36 -5.72 56.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.523 ' O ' HD11 ' A' ' 23' ' ' LEU . 34.9 m -135.03 171.35 17.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.957 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.64 132.43 38.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.076 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -69.3 106.79 3.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.857 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.6 t . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 44' ' ' VAL . 60.7 m-20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.823 0.344 . . . . 0.0 110.858 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -101.62 143.68 31.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.921 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.932 HD11 HG22 ' A' ' 44' ' ' VAL . 11.0 mt -130.45 108.76 10.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.06 122.92 28.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.063 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.51 HG11 ' O ' ' A' ' 36' ' ' PHE . 57.3 t -58.86 103.62 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.819 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.5 mt -67.17 -33.42 75.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 25' ' ' ASP . 27.6 t -153.64 121.85 6.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.834 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -37.03 149.38 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.875 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.799 ' CE1' HG22 ' A' ' 65' ' ' ILE . 0.0 OUTLIER -169.82 150.52 3.85 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.685 0.755 . . . . 0.0 110.922 -179.85 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.3 10.69 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.304 -0.059 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 48.0 m -74.74 155.06 87.22 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.662 0.744 . . . . 0.0 110.855 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 3.42 2.76 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.716 2.277 . . . . 0.0 112.359 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -105.27 -22.33 13.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.843 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.7 mt -105.77 -48.59 8.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.7 OUTLIER -164.11 164.67 14.14 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.682 0.753 . . . . 0.0 110.836 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 135.62 30.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.642 2.228 . . . . 0.0 112.35 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 125.24 11.88 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.298 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.6 mp -86.6 -26.4 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.51 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.5 m-85 -131.9 100.58 5.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -63.28 155.25 29.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.814 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -55.21 150.35 11.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.807 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.3 -10.36 16.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -72.4 151.52 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.868 0.366 . . . . 0.0 110.906 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.417 ' O ' HD23 ' A' ' 42' ' ' LEU . 58.2 tttt -102.26 138.76 38.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.928 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.541 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -135.12 152.52 51.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.927 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.63 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.4 ttt180 -105.1 129.65 53.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.87 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.932 HG22 HD11 ' A' ' 20' ' ' LEU . 99.1 t -65.19 111.82 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.669 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -93.19 -52.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.161 179.882 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.8 m -141.15 150.96 43.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -118.43 109.82 16.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.875 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -116.31 86.0 2.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.75 -123.27 32.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.64 -23.51 69.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.48 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.3 m95 -109.91 141.93 41.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.41 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.15 164.27 28.05 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.2 tttp -100.75 141.51 33.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.905 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.46 159.75 44.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.821 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -131.81 130.82 61.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.541 ' HA ' HD23 ' A' ' 42' ' ' LEU . 4.8 t -67.82 130.88 44.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.69 9.4 5.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.946 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 15.1 t -105.55 -48.01 3.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.2 p -104.41 -35.79 7.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.495 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 90.45 27.84 18.87 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.496 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.424 ' C ' HG13 ' A' ' 55' ' ' ILE . 44.0 mtt85 -89.25 124.98 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.797 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.821 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.0 mt-10 -94.31 117.33 29.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.943 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.2 t -147.6 169.63 19.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.824 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 28.3 m-85 -110.96 118.13 35.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.899 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.19 152.54 73.66 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.593 0.711 . . . . 0.0 111.146 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 137.66 35.97 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.679 2.252 . . . . 0.0 112.351 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.81 -33.23 6.39 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 3.5 tp -64.88 -31.11 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 111.162 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.1 t -72.87 -12.77 61.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.489 ' CG2' ' HB3' ' A' ' 20' ' ' LEU . 18.4 m -131.04 170.21 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.819 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.48 136.45 45.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -67.94 108.37 3.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 12.2 t . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.141 179.961 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . 73.3 m-20 . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.829 0.347 . . . . 0.0 110.883 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -111.77 152.63 27.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 44' ' ' VAL . 7.7 mt -137.43 116.03 12.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.57 127.52 33.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.677 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.4 t -66.85 97.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.101 HD21 ' HB2' ' A' ' 71' ' ' ALA . 9.4 mt -57.19 -35.93 70.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.5 t -156.38 128.2 7.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.898 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -39.1 149.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.639 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -170.61 150.05 3.14 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.729 0.776 . . . . 0.0 110.911 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.7 -174.7 9.79 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.717 -1.785 . . . . 0.0 112.355 -0.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.6 m -80.35 158.46 71.65 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.874 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 3.52 2.75 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.649 2.232 . . . . 0.0 112.321 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -103.89 -13.22 16.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.3 mt -119.95 -49.34 3.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.101 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -162.83 163.46 17.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.717 0.77 . . . . 0.0 110.843 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 133.56 25.8 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.676 2.251 . . . . 0.0 112.353 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 114.74 3.81 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.313 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.732 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -73.45 -30.52 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.3 m-85 -130.66 110.83 11.67 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.92 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -69.56 165.79 20.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.443 ' CG ' ' O ' ' A' ' 23' ' ' LEU . 2.4 tmt_? -67.22 141.14 57.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.46 11.52 81.85 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.486 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.4 ' OE1' ' O ' ' A' ' 41' ' ' LYS . 0.4 OUTLIER -100.35 138.22 37.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.976 0.417 . . . . 0.0 110.843 -179.857 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.4 ' O ' ' OE1' ' A' ' 40' ' ' GLU . 30.2 ttmt -85.54 140.63 30.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.677 HD11 ' CG2' ' A' ' 22' ' ' VAL . 10.1 mt -134.2 149.69 51.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.458 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.7 ttt180 -103.89 129.15 51.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 18' ' ' ASP . 45.8 t -67.97 114.82 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.095 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.493 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -88.8 -52.58 10.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.096 179.928 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.9 t -157.53 128.32 6.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -89.15 125.95 35.26 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -125.06 85.96 2.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.898 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.68 -128.08 37.49 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.8 -24.99 75.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 13.2 m95 -112.69 146.55 38.51 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.786 0.327 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.477 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.98 164.84 26.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.992 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.561 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.0 tttp -103.37 145.15 30.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.45 163.72 38.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.878 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.0 tt -131.19 135.21 60.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.567 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 37.4 p -76.23 129.09 36.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.8 mt -77.59 9.28 3.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.1 m -95.92 -49.74 5.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 12.2 p -114.75 -28.92 6.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.143 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 92.11 26.48 18.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.508 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 23.7 mtt85 -83.12 128.08 34.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.756 0.312 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.878 ' HG3' HD12 ' A' ' 55' ' ' ILE . 10.1 mt-10 -97.66 117.26 31.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.4 t -147.55 170.11 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 10.6 m-85 -110.78 123.62 50.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.901 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -130.2 150.64 76.66 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.669 0.747 . . . . 0.0 111.134 179.909 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.603 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.73 130.67 19.78 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.675 2.25 . . . . 0.0 112.374 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.13 -36.21 7.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.603 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.3 tt -58.9 -33.55 50.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.498 HG12 ' HA ' ' A' ' 22' ' ' VAL . 25.5 m -125.13 174.04 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.101 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.21 132.15 39.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.115 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.472 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.1 tpp85 -62.77 105.66 0.69 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.83 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.0 t . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.138 179.96 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.906 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.873 0.368 . . . . 0.0 110.829 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.78 150.68 22.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.696 HD11 HG22 ' A' ' 44' ' ' VAL . 10.0 mt -132.91 111.03 10.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.926 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.46 126.33 31.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 36' ' ' PHE . 89.4 t -63.2 96.25 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.165 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -59.13 -28.84 66.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.916 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.7 t -161.27 125.67 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.838 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -38.79 143.48 0.15 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.859 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -160.28 150.32 14.81 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.67 0.747 . . . . 0.0 110.917 -179.811 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.77 171.49 53.48 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.684 -1.798 . . . . 0.0 112.381 -0.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.407 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -52.17 148.38 11.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.634 0.731 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 53.8 Cg_endo -69.77 5.28 1.76 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.7 2.267 . . . . 0.0 112.346 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -109.01 -21.75 12.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -101.65 -53.43 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.097 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.51 164.28 21.03 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.669 0.747 . . . . 0.0 110.832 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 132.16 22.84 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.27 . . . . 0.0 112.364 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 124.42 11.06 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.666 2.244 . . . . 0.0 112.366 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.587 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -89.25 -25.31 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.165 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.669 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.6 m-85 -127.47 89.65 2.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.885 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 20.3 mmm-85 -51.01 160.11 0.52 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.449 ' CZ ' ' O ' ' A' ' 23' ' ' LEU . 11.1 ttt85 -61.58 147.22 46.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.97 -13.3 14.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -69.7 136.5 51.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.895 0.379 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -86.63 139.06 31.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.869 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.612 HD23 ' HA ' ' A' ' 56' ' ' SER . 8.1 mt -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.7 ttt-85 -87.53 132.94 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 18' ' ' ASP . 58.2 t -71.22 108.2 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.525 HD12 ' HA ' ' A' ' 54' ' ' ALA . 1.1 mp -78.56 -50.15 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.177 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -158.71 157.43 31.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -109.1 118.85 37.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.877 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.8 mm-40 -120.44 85.92 2.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.47 -126.02 38.71 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.1 -25.0 74.63 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.556 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.4 m0 -111.69 153.53 26.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.765 0.317 . . . . 0.0 110.923 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.421 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.04 164.13 28.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.8 tttm -98.94 143.07 29.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.895 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.525 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -153.94 164.08 39.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.716 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.3 tt -132.02 146.15 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.115 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.612 ' HA ' HD23 ' A' ' 42' ' ' LEU . 82.0 p -86.21 126.44 34.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.6 mt -76.09 5.92 6.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.6 t -90.6 -49.84 6.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.6 p -116.28 -34.7 4.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.14 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 102.46 23.89 8.65 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.457 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.9 mtt180 -82.08 124.51 29.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.846 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.716 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -98.87 118.55 35.88 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.5 t -147.23 169.97 18.25 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.1 m-85 -105.05 119.79 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.889 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.42 147.52 60.51 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.663 0.744 . . . . 0.0 111.09 179.904 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.556 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.78 133.77 26.34 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.694 2.262 . . . . 0.0 112.345 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -30.88 6.13 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.503 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.548 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.8 tp -64.68 -32.69 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 9.4 m -80.01 6.94 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.462 ' O ' HD11 ' A' ' 23' ' ' LEU . 36.0 m -147.56 169.81 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.2 136.08 43.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.136 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.9 tpp85 -68.13 112.44 5.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.951 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.743 ' O ' HG23 ' A' ' 44' ' ' VAL . 2.6 m-20 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.861 0.363 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -105.29 148.95 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.85 HD11 HG22 ' A' ' 44' ' ' VAL . 2.4 mt -135.87 109.53 8.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.08 126.15 30.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.742 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.0 t -60.8 101.6 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.901 HD21 ' HB2' ' A' ' 71' ' ' ALA . 16.2 mt -62.13 -30.84 71.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.3 t -158.4 127.54 5.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -40.72 145.52 0.19 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.837 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.581 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.9 148.43 6.43 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.636 0.732 . . . . 0.0 110.959 -179.849 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.81 -174.12 9.26 Favored 'Cis proline' 0 C--O 1.231 0.154 0 C-N-CA 122.708 -1.788 . . . . 0.0 112.331 -0.036 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.5 m -77.06 155.83 82.38 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.651 0.739 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 2.78 3.23 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.676 2.251 . . . . 0.0 112.346 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -106.71 -14.04 15.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.02 -48.66 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -163.58 163.04 16.74 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.675 0.75 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 133.03 24.56 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.719 2.28 . . . . 0.0 112.316 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 119.7 6.6 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.7 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -81.02 -22.81 10.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.528 ' HB3' HG21 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.66 99.77 4.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.881 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -58.65 163.9 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.437 ' HD3' ' N ' ' A' ' 39' ' ' GLY . 3.8 tmt_? -65.69 142.44 58.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.826 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.437 ' N ' ' HD3' ' A' ' 38' ' ' ARG . . . 77.96 6.81 87.5 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -86.36 144.0 27.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.66 ' HB3' HD12 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -87.29 141.1 28.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.742 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.8 mt -140.0 145.1 37.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.481 ' O ' HD12 ' A' ' 45' ' ' ILE . 16.5 ttm180 -103.78 128.48 51.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.85 HG22 HD11 ' A' ' 20' ' ' LEU . 59.5 t -65.87 108.53 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.147 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -79.87 -50.51 17.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.125 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.4 t -163.14 135.83 5.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -89.45 129.3 35.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -130.05 86.2 2.38 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 65.29 -131.46 35.58 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.509 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.42 -20.36 78.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.467 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -116.89 152.12 35.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.741 0.305 . . . . 0.0 110.923 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.18 164.23 28.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD3' HG21 ' A' ' 45' ' ' ILE . 19.3 tttp -102.17 142.53 33.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.953 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.54 156.14 36.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.135 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.585 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -124.08 137.17 57.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.729 ' HA ' HD23 ' A' ' 42' ' ' LEU . 5.1 t -68.04 128.16 35.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.865 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.66 HD12 ' HB3' ' A' ' 41' ' ' LYS . 6.4 mt -78.32 8.39 5.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.6 t -111.65 -45.98 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.862 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 51.4 p -102.14 -36.14 8.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.463 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.58 33.13 13.93 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.469 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.414 ' HD3' HG23 ' A' ' 35' ' ' ILE . 42.7 mtt180 -96.8 125.96 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.761 0.315 . . . . 0.0 110.89 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -90.66 117.43 29.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.6 t -147.66 169.99 18.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.812 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.551 ' CE1' ' HG3' ' A' ' 53' ' ' LYS . 18.9 m-85 -112.75 117.37 32.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.889 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.829 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.78 151.12 73.1 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.629 0.728 . . . . 0.0 111.123 179.932 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.677 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.83 135.76 31.09 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.661 2.241 . . . . 0.0 112.331 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.17 -30.95 8.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.7 tp -65.55 -30.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.831 0.348 . . . . 0.0 111.162 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.4 m -79.78 -0.19 33.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.99 163.11 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.901 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.2 137.48 52.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.063 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.33 112.19 2.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.851 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.48 HG21 ' HE2' ' A' ' 41' ' ' LYS . 15.4 t . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.139 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . 3.9 m-20 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.805 0.336 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -109.89 150.8 27.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.602 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 5.3 mt -129.64 114.47 16.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.22 116.73 23.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.567 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.2 t -54.92 103.65 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.114 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.045 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -66.53 -31.0 71.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 25' ' ' ASP . 30.6 t -160.33 118.79 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.859 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 24' ' ' SER . 10.4 p-10 -34.28 140.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.644 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.14 149.81 18.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.69 0.757 . . . . 0.0 110.923 -179.801 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.85 179.54 22.2 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.319 -0.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 p -72.46 157.2 89.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.05 2.41 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.677 2.252 . . . . 0.0 112.316 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -101.28 -13.18 18.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.839 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 4.8 mt -120.53 -60.6 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -147.96 163.07 28.82 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.651 0.738 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 137.36 35.06 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.681 2.254 . . . . 0.0 112.323 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 118.96 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.705 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -80.86 -26.19 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.567 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -131.32 93.55 3.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -54.8 161.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.411 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.8 ttm180 -62.06 147.79 46.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.96 -5.85 57.45 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -79.85 134.42 36.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.924 0.392 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -84.33 138.06 33.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.427 HD21 ' HB3' ' A' ' 36' ' ' PHE . 9.0 mt -130.56 141.32 50.46 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.54 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttp180 -93.18 126.73 38.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 18' ' ' ASP . 96.1 t -66.05 112.16 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.54 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -88.27 -53.3 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.15 179.913 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -144.45 145.31 31.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.838 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -108.68 118.41 36.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -129.4 86.44 2.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.881 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.26 -123.78 33.99 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.05 -19.03 65.93 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 25.3 m95 -113.42 131.56 55.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.752 0.311 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.602 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.44 164.36 26.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.956 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 8.3 tttp -100.2 142.27 31.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -150.78 157.83 43.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.112 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.431 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.0 tt -121.78 145.26 28.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.519 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 6.1 p -86.75 126.0 34.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 8.0 mt -75.14 5.75 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 t -92.01 -48.83 6.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.9 p -118.11 -28.69 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.85 25.92 13.94 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.48 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.404 ' CD ' HG23 ' A' ' 35' ' ' ILE . 76.6 mtt180 -80.86 132.29 35.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.306 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.438 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 4.9 mt-10 -103.29 117.38 34.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.866 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.0 t -147.67 170.18 18.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 38.5 m-85 -110.55 120.8 43.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.909 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.835 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.13 149.69 70.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.56 0.695 . . . . 0.0 111.174 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.72 134.58 28.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.67 2.247 . . . . 0.0 112.382 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.81 -30.33 8.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.5 tp -65.36 -30.1 49.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.802 0.334 . . . . 0.0 111.152 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 16.6 m -84.19 8.23 16.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.553 ' O ' HD11 ' A' ' 23' ' ' LEU . 22.9 m -148.95 168.9 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.045 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.62 131.98 43.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -68.92 112.18 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.885 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.164 179.956 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.7 t0 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.896 0.379 . . . . 0.0 110.858 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -109.11 144.87 36.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.92 HD11 HG22 ' A' ' 44' ' ' VAL . 4.2 mt -131.05 112.07 12.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.61 126.38 30.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.144 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.565 ' CG2' HD11 ' A' ' 42' ' ' LEU . 95.4 t -66.52 102.44 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.058 HD21 ' HB2' ' A' ' 71' ' ' ALA . 4.7 mt -61.84 -32.16 72.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.906 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.3 t -156.23 125.24 6.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.846 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -41.47 148.09 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.57 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -167.37 148.42 5.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.778 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.76 -174.36 9.47 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.323 -0.081 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.9 m -81.59 158.57 68.34 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.69 0.757 . . . . 0.0 110.85 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 3.17 2.95 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.668 2.245 . . . . 0.0 112.324 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -107.16 -6.15 17.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.39 -43.17 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.151 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.2 m -170.92 163.32 5.43 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.653 0.74 . . . . 0.0 110.842 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 131.62 21.66 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.387 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.18 3.61 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.378 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.779 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.7 mp -72.56 -29.21 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.502 ' HB3' HG21 ' A' ' 22' ' ' VAL . 10.1 m-85 -127.75 104.64 7.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.88 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.9 OUTLIER -65.59 159.65 24.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.859 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 25.6 ttp180 -62.49 141.39 58.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.25 7.69 88.3 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -91.92 139.75 30.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -88.54 137.2 32.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.933 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.9 mt -134.65 149.71 50.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.427 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.7 ttp180 -100.62 131.66 46.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.92 HG22 HD11 ' A' ' 20' ' ' LEU . 45.7 t -71.41 116.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.614 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -89.58 -49.41 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -152.3 149.36 28.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -108.52 119.27 39.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.842 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -122.93 85.84 2.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.67 -122.14 28.08 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.509 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.76 -24.99 61.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.0 m95 -111.6 141.67 44.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.79 0.329 . . . . 0.0 110.942 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.558 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.35 164.71 25.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.893 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.545 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 19.0 tttt -99.73 146.61 26.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.56 167.07 31.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.644 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.7 tt -138.49 146.8 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.155 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.489 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 5.7 m -81.18 132.66 35.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.3 mt -80.08 9.43 5.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.939 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 m -113.17 -51.12 2.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 77.8 p -97.49 -33.95 11.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.31 27.79 35.38 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 54.2 mtt-85 -90.05 122.87 33.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.804 0.335 . . . . 0.0 110.882 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.644 ' HG3' HD12 ' A' ' 55' ' ' ILE . 11.4 mt-10 -92.54 118.53 31.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.3 m -147.11 165.78 28.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.545 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 27.9 m-85 -108.73 120.2 41.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.914 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.798 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.36 151.81 75.34 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.636 0.731 . . . . 0.0 111.149 179.909 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.69 130.14 18.91 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.37 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.45 -31.69 6.96 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.503 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.675 HG22 ' HB2' ' A' ' 66' ' ' PRO . 11.7 tt -63.0 -31.92 54.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.838 0.352 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . 0.402 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.7 m -77.08 -15.51 59.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.412 ' O ' HD11 ' A' ' 23' ' ' LEU . 25.2 m -121.3 167.77 14.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.108 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.058 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.15 131.64 44.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.466 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 7.1 tpp85 -63.14 106.14 0.81 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.155 179.99 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.533 ' O ' HG23 ' A' ' 44' ' ' VAL . 70.4 m-20 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.807 0.337 . . . . 0.0 110.898 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 m-85 -105.21 148.11 27.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.74 HD11 HG22 ' A' ' 44' ' ' VAL . 6.7 mt -130.21 107.89 9.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.37 123.42 26.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 40' ' ' GLU . 58.5 t -60.09 97.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.05 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.2 mt -61.02 -33.9 73.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -162.25 130.1 3.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.913 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 p30 -41.15 146.73 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.634 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.85 149.67 7.1 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.633 0.73 . . . . 0.0 110.929 -179.841 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.8 Cg_endo -69.76 -177.42 14.5 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.314 -0.031 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 1.2 t -69.55 153.92 95.29 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.722 0.773 . . . . 0.0 110.86 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 4.0 2.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.685 2.256 . . . . 0.0 112.325 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -107.87 -24.34 11.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.869 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.2 mt -101.59 -54.78 6.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.129 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -153.95 164.34 20.99 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.91 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 128.28 15.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 121.0 7.71 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.727 2.285 . . . . 0.0 112.355 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.742 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -80.24 -28.08 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.143 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.464 ' HB3' HG21 ' A' ' 22' ' ' VAL . 12.6 m-85 -131.14 110.51 11.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.4 ' O ' ' C ' ' A' ' 38' ' ' ARG . 10.0 mmm180 -78.11 138.11 38.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.447 ' HA ' HG12 ' A' ' 22' ' ' VAL . 15.3 ttp-105 -37.51 144.99 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.21 -8.66 79.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.498 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.541 ' O ' HG23 ' A' ' 22' ' ' VAL . 7.3 mt-10 -88.14 146.4 25.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.885 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' HD23 ' A' ' 42' ' ' LEU . 3.6 ttmp? -99.33 147.7 24.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.869 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.533 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -137.2 153.92 50.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.577 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.5 ttm180 -108.38 127.92 54.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.74 HG22 HD11 ' A' ' 20' ' ' LEU . 61.6 t -61.99 109.61 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.595 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -86.1 -55.05 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.897 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 45' ' ' ILE . 43.5 t -152.07 125.65 8.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -88.05 126.17 34.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -129.97 85.86 2.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.72 -127.48 36.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.513 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.53 -22.69 74.9 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' TRP . . . . . 0.585 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 19.6 m95 -113.76 137.1 52.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.789 0.328 . . . . 0.0 110.923 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.419 ' CZ2' ' HA2' ' A' ' 67' ' ' GLY . 0.1 OUTLIER -129.05 164.64 22.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.595 ' HD3' HG21 ' A' ' 45' ' ' ILE . 11.5 tttp -100.9 142.94 31.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.68 159.67 43.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.117 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.808 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.6 tt -131.83 138.84 51.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.138 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.533 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.1 t -74.39 126.52 30.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.897 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.1 mt -77.28 8.57 3.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.7 t -107.34 -44.8 4.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.4 p -104.7 -41.22 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.188 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.9 32.68 7.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.416 ' C ' HG13 ' A' ' 55' ' ' ILE . 45.8 mtt180 -97.6 122.71 41.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.811 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.808 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.5 mt-10 -91.15 116.99 29.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.6 t -147.96 165.99 29.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.559 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 15.0 m-85 -105.6 128.99 53.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.486 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.3 OUTLIER -138.57 151.13 68.32 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.656 0.741 . . . . 0.0 111.12 179.9 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.702 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.7 133.7 26.31 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.65 2.233 . . . . 0.0 112.35 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -31.57 6.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.1 tp -64.63 -32.03 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.821 0.343 . . . . 0.0 111.142 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -75.28 -12.68 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.888 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.611 ' O ' HD11 ' A' ' 23' ' ' LEU . 13.3 m -127.29 169.86 18.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.05 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -129.96 132.54 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.115 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.651 ' NH1' HG21 ' A' ' 44' ' ' VAL . 1.7 tpt180 -69.53 105.13 2.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.0 t . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.151 179.972 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 59.0 p -45.33 129.4 8.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.864 0.364 . . . . 0.0 110.85 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.9 t -85.28 -60.34 2.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.869 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.48 -167.94 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.6 t -148.47 152.64 37.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.906 0.384 . . . . 0.0 110.829 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 52.2 p -90.54 117.04 28.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.868 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.37 -157.52 13.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 157.63 59.85 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.688 2.259 . . . . 0.0 112.393 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 mt -74.27 148.39 86.17 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -42.16 3.63 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.661 2.241 . . . . 0.0 112.351 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -38.31 144.84 0.36 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.665 0.745 . . . . 0.0 110.904 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.43 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.7 Cg_endo -69.78 -7.63 21.56 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.674 2.249 . . . . 0.0 112.315 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 12' ' ' PRO . 0.5 OUTLIER 35.48 41.28 0.09 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.874 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.94 -49.31 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.481 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.2 mp -105.95 116.53 32.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.826 0.346 . . . . 0.0 110.899 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.07 143.97 47.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.4 t -94.68 161.35 14.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.84 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.852 ' O ' HG23 ' A' ' 44' ' ' VAL . 12.9 m-20 -77.99 126.9 31.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.89 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -105.06 148.25 26.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.639 HD11 HG22 ' A' ' 44' ' ' VAL . 4.8 mt -129.93 114.2 15.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -83.11 126.26 32.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.118 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 36' ' ' PHE . 93.1 t -62.33 104.3 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.095 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.971 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.8 mt -66.44 -33.48 75.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.889 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.426 ' O ' ' C ' ' A' ' 25' ' ' ASP . 28.8 t -156.17 120.43 4.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 24' ' ' SER . 4.3 p-10 -35.97 140.07 0.13 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.572 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.1 OUTLIER -156.75 147.65 16.45 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 0.0 110.899 -179.866 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.564 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -173.57 8.6 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.351 -0.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 m -75.8 156.21 84.69 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.727 0.775 . . . . 0.0 110.841 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 3.33 2.82 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.691 2.261 . . . . 0.0 112.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -106.92 -16.55 14.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -112.2 -46.53 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.164 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -165.75 163.0 12.87 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.685 0.755 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 133.33 25.23 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.365 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 120.37 7.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 0.0 112.333 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.731 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.3 mp -79.15 -25.87 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.11 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.648 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.5 m-85 -131.22 93.83 3.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.863 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.95 155.27 8.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 55.7 ttp85 -54.82 148.11 13.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -16.28 11.65 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.483 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -68.98 138.35 54.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.918 0.39 . . . . 0.0 110.905 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -92.74 137.65 32.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.0 mt -131.16 147.6 52.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.921 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.528 ' O ' HD12 ' A' ' 45' ' ' ILE . 28.2 ttt180 -99.41 132.11 44.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 18' ' ' ASP . 90.9 t -68.04 110.28 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.149 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.666 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -87.47 -52.38 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.117 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 m -143.59 146.91 33.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -111.27 116.7 31.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.852 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 6.6 mm-40 -125.66 85.94 2.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.76 -122.52 30.29 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.501 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 -22.52 63.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.519 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 26.3 m95 -110.84 137.33 48.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.305 . . . . 0.0 110.899 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.409 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.27 164.37 27.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.875 -179.994 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.666 ' HD3' HG21 ' A' ' 45' ' ' ILE . 38.5 tttt -100.09 140.9 33.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.82 160.01 43.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.74 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.5 tt -131.45 141.54 45.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.153 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.4 t -76.48 130.45 37.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.85 6.58 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.2 t -109.7 -44.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 53.2 p -103.53 -34.68 8.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.156 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.95 32.46 23.66 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.519 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.436 ' C ' HG13 ' A' ' 55' ' ' ILE . 28.1 mtt180 -95.83 125.26 40.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.777 0.322 . . . . 0.0 110.88 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.74 ' HG3' HD12 ' A' ' 55' ' ' ILE . 7.1 mt-10 -91.51 118.13 30.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 36' ' ' PHE . 4.2 m -147.01 168.81 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.824 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 31.6 m-85 -113.28 120.33 40.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.963 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.825 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -130.43 151.27 78.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.632 0.73 . . . . 0.0 111.124 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.6 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 132.23 22.87 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.699 2.266 . . . . 0.0 112.306 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -45.17 -33.97 4.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.494 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.6 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -61.37 -34.75 62.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.836 0.351 . . . . 0.0 111.111 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.15 -13.86 61.26 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.406 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.9 m -124.93 171.78 13.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.161 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.971 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.73 132.5 43.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.093 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 3.2 tpp85 -65.87 102.82 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.6 t -73.19 145.27 11.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.7 m -105.44 -49.99 3.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.871 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 176.14 168.93 37.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.498 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 -175.66 1.21 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.713 2.275 . . . . 0.0 112.382 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 79.9 p -129.09 -46.7 1.23 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.7 t -95.13 114.05 25.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.92 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.4 p -108.14 134.95 50.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.887 0.375 . . . . 0.0 110.84 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.5 t -123.06 83.75 2.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.79 97.34 0.31 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.487 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 34.4 t -125.52 155.66 40.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.87 0.367 . . . . 0.0 110.837 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.9 m -77.19 -51.72 10.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.94 143.54 3.73 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -176.65 1.54 Allowed 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.235 . . . . 0.0 112.385 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.0 mt -67.41 154.08 93.66 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.941 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -35.43 12.54 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.656 2.237 . . . . 0.0 112.347 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.6 p-10 -175.02 148.42 1.11 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.617 0.722 . . . . 0.0 110.864 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -2.94 11.04 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.318 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.43 38.57 22.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.43 -40.44 6.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.5 mp -118.41 151.34 37.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -87.56 171.0 10.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.7 t -108.24 155.4 20.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.554 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.8 m-20 -100.95 127.51 47.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.865 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -106.32 146.82 29.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.882 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.881 HD11 HG22 ' A' ' 44' ' ' VAL . 7.4 mt -131.91 108.96 9.74 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.01 128.64 33.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 ' O ' ' A' ' 36' ' ' PHE . 74.1 t -65.25 100.05 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.104 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.028 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.6 mt -61.48 -26.69 68.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -166.64 132.47 2.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.85 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -42.93 142.43 0.91 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 150.46 12.93 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.643 0.735 . . . . 0.0 110.911 -179.807 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.8 175.08 38.12 Favored 'Cis proline' 0 C--O 1.232 0.188 0 C-N-CA 122.652 -1.812 . . . . 0.0 112.342 -0.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.4 p -68.5 156.31 90.85 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.679 0.752 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 5.24 1.75 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.688 2.259 . . . . 0.0 112.369 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.88 -6.42 18.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.896 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.56 -53.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -157.03 163.93 23.4 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.683 0.754 . . . . 0.0 110.849 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 134.53 28.19 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.692 2.262 . . . . 0.0 112.354 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.14 11.81 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.72 2.28 . . . . 0.0 112.368 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.606 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -87.66 -23.66 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.122 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.479 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.7 m-85 -134.74 101.37 4.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.8 mmt85 -60.95 158.98 12.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.465 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.6 tmm_? -56.87 144.34 33.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.858 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.443 ' N ' ' HD2' ' A' ' 38' ' ' ARG . . . 83.69 -16.07 33.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -68.78 138.68 55.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.936 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -92.62 142.05 27.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.53 HD23 ' HA ' ' A' ' 56' ' ' SER . 3.0 mt -138.71 135.16 34.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.934 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.533 ' O ' HD12 ' A' ' 45' ' ' ILE . 50.4 ttt180 -87.3 133.54 33.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.881 HG22 HD11 ' A' ' 20' ' ' LEU . 89.6 t -68.39 113.58 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.125 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -91.28 -50.41 12.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.155 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 5.1 p -143.8 150.36 38.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.9 p-10 -114.3 115.66 27.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.92 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.403 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.0 mt-10 -122.17 85.84 2.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.935 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.45 -119.62 18.23 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.506 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.48 -24.12 61.42 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.51 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 18.3 m95 -110.81 140.31 45.36 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.781 0.325 . . . . 0.0 110.945 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -134.18 164.32 27.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.911 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.526 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 33.4 tttt -98.26 145.62 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.674 HD12 ' HG3' ' A' ' 62' ' ' GLU . 16.1 tt -127.68 144.95 35.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.53 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.9 t -78.13 129.16 34.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.844 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.28 8.95 6.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.8 m -114.75 -44.22 3.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.9 p -101.26 -41.82 6.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.114 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.32 25.87 17.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.483 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 40.1 mtt180 -92.27 125.93 37.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.674 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.75 117.92 30.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 17.7 m -146.87 169.35 19.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 19.8 m-85 -112.06 118.83 36.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.871 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.778 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.43 151.25 69.78 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.148 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.656 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.6 Cg_endo -69.74 133.11 24.81 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.697 2.265 . . . . 0.0 112.331 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.9 -31.26 5.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.466 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.656 HG22 ' HB2' ' A' ' 66' ' ' PRO . 9.1 tt -64.27 -32.59 58.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.776 0.322 . . . . 0.0 111.097 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.3 m -75.58 -13.05 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.688 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.6 m -126.97 175.23 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.028 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -141.84 139.83 32.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.119 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -67.9 110.45 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.838 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 23.7 t -81.88 144.37 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.129 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.4 t -166.32 142.91 4.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.87 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 149.04 -158.74 27.77 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 77' ' ' SER . 53.8 Cg_endo -69.76 2.78 3.22 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 76' ' ' PRO . 10.2 p -34.9 134.88 0.21 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.889 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 54.8 m -92.74 171.12 9.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.832 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.475 179.996 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 m -117.25 128.87 55.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.858 0.361 . . . . 0.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.1 p -153.68 147.01 24.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.813 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 61.78 152.72 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.0 t -83.58 157.94 22.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.832 0.349 . . . . 0.0 110.891 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.7 p -152.64 122.29 6.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.816 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.46 137.18 3.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.523 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -174.51 0.92 Allowed 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.687 2.258 . . . . 0.0 112.366 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.497 ' CD2' ' HD2' ' A' ' 10' ' ' PRO . 13.5 mt -90.64 157.67 43.76 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.617 0.722 . . . . 0.0 110.896 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.497 ' HD2' ' CD2' ' A' ' 9' ' ' LEU . 53.4 Cg_endo -69.77 1.95 3.98 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.672 2.248 . . . . 0.0 112.316 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.447 ' C ' ' O ' ' A' ' 10' ' ' PRO . 7.5 t-20 -34.64 135.56 0.39 Allowed Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.695 0.76 . . . . 0.0 110.84 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.85 1.67 4.28 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.662 2.242 . . . . 0.0 112.313 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -47.14 101.63 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.14 -47.77 0.58 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.532 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.1 mt -87.16 113.83 23.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 110.934 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -87.06 157.12 19.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.889 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.4 t -117.85 152.8 34.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.7 m-20 -66.65 135.32 53.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -105.11 149.88 25.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.839 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.656 HD11 HG22 ' A' ' 44' ' ' VAL . 14.5 mt -132.71 115.13 14.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.874 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.48 120.47 26.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.643 HG11 ' O ' ' A' ' 36' ' ' PHE . 87.7 t -55.68 106.98 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' HB2' ' A' ' 71' ' ' ALA . 10.1 mt -66.79 -34.01 76.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.917 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.9 t -157.2 128.13 6.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.852 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.97 134.05 2.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.643 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.87 149.74 22.76 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 110.942 -179.811 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.48 11.0 Favored 'Cis proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 -1.791 . . . . 0.0 112.304 -0.045 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 4.1 m -73.61 155.65 89.11 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.671 0.748 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 2.92 3.09 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.699 2.266 . . . . 0.0 112.359 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -106.82 -16.61 14.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -111.81 -46.94 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.172 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.11 162.01 14.34 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.622 0.725 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 135.94 31.59 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.637 2.224 . . . . 0.0 112.348 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 124.87 11.48 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.684 2.256 . . . . 0.0 112.338 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.597 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -87.52 -25.08 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.149 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.643 ' O ' HG11 ' A' ' 22' ' ' VAL . 15.1 m-85 -131.65 89.77 2.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -50.49 156.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.872 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -58.43 150.97 21.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.62 -6.4 17.85 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.455 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -76.09 135.41 39.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.87 0.367 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 35.0 tttt -86.12 137.78 32.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.516 HD23 ' HA ' ' A' ' 56' ' ' SER . 9.7 mt -132.98 154.51 50.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.468 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.9 ttp180 -105.06 131.42 52.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 18' ' ' ASP . 89.9 t -70.88 112.73 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.625 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.88 -51.66 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.178 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.8 t -151.83 159.36 43.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.828 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -116.33 111.71 20.49 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.3 mt-10 -110.53 86.41 2.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 58.98 -122.68 31.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.23 -21.62 78.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.496 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.8 m95 -114.97 151.87 33.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.432 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.09 164.52 27.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.941 -179.985 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.625 ' HD3' HG21 ' A' ' 45' ' ' ILE . 25.8 tttt -100.85 143.88 30.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.81 160.95 42.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.822 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -129.88 146.76 33.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.516 ' HA ' HD23 ' A' ' 42' ' ' LEU . 87.6 p -81.37 128.52 33.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.871 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.4 mt -77.49 8.66 4.0 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 5.5 m -99.9 -52.69 3.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.816 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.4 p -107.37 -45.4 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.193 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.573 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 107.92 29.43 4.35 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.9 mtt180 -86.95 123.99 32.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.746 0.308 . . . . 0.0 110.864 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.822 ' HG3' HD12 ' A' ' 55' ' ' ILE . 6.2 mt-10 -93.97 117.86 30.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 23.3 t -147.19 165.63 29.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.873 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.45 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 17.0 m-85 -107.27 123.93 49.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.935 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.821 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.36 151.25 77.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.671 0.748 . . . . 0.0 111.144 179.905 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.568 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.0 Cg_endo -69.75 132.56 23.61 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.646 2.231 . . . . 0.0 112.382 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.66 -31.33 7.22 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.462 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.461 ' O ' HD12 ' A' ' 23' ' ' LEU . 8.0 tt -63.92 -31.91 55.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 111.108 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . 0.401 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.2 m -76.6 -11.12 59.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.563 ' O ' HD11 ' A' ' 23' ' ' LEU . 31.0 m -127.84 169.72 18.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.906 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -127.85 129.08 46.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 tpp180 -64.8 108.8 1.85 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.455 HG12 ' N ' ' A' ' 74' ' ' SER . 7.9 t -91.23 160.27 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.181 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.455 ' N ' HG12 ' A' ' 73' ' ' VAL . 50.7 m -140.55 154.65 46.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -80.86 162.73 45.11 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.513 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 1.27 4.6 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.697 2.265 . . . . 0.0 112.315 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 78' ' ' SER . 86.1 p -49.31 -50.87 37.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.882 -179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.41 ' C ' ' O ' ' A' ' 77' ' ' SER . 27.8 p -37.06 124.91 0.93 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.871 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.962 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.489 -0.245 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 97.2 p 38.36 41.86 0.47 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.947 0.403 . . . . 0.0 110.897 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 t -98.27 154.95 17.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.869 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -98.87 -93.38 2.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.3 p 40.56 44.72 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.361 . . . . 0.0 110.81 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.3 p -37.79 -38.91 0.32 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.836 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 149.02 179.28 24.78 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.493 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 163.24 38.97 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.701 2.267 . . . . 0.0 112.351 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 68.5 mt -129.75 150.73 76.63 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.55 0.691 . . . . 0.0 110.926 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.29 23.23 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -118.53 134.74 23.46 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.615 0.722 . . . . 0.0 110.893 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -4.77 14.72 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.729 2.286 . . . . 0.0 112.31 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -87.96 49.35 1.79 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.854 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -85.51 -80.09 1.14 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.497 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.1 mp -79.78 102.96 9.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.793 0.33 . . . . 0.0 110.931 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -90.58 -179.22 5.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.406 ' HB3' ' CZ ' ' A' ' 19' ' ' PHE . 9.7 t -129.23 151.97 49.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.2 m-20 -87.39 115.36 24.75 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.861 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.406 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.2 m-85 -108.46 153.7 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.851 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.918 HD11 HG22 ' A' ' 44' ' ' VAL . 3.6 mt -140.03 114.55 9.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.9 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.65 128.93 34.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.493 ' CG2' HD11 ' A' ' 42' ' ' LEU . 92.4 t -65.1 109.44 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.072 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.914 HD21 ' HB2' ' A' ' 71' ' ' ALA . 6.5 mt -68.8 -31.93 71.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.932 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.436 ' O ' ' C ' ' A' ' 25' ' ' ASP . 24.6 t -160.76 125.98 3.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.436 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.7 OUTLIER -35.37 148.34 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.846 179.953 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.59 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -166.04 148.89 6.49 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.64 0.733 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.8 -174.27 9.41 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.347 0.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -71.17 153.63 94.27 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 0.0 110.876 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 3.04 3.02 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.678 2.252 . . . . 0.0 112.338 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -106.0 -23.13 12.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.5 -57.15 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.128 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 m -150.8 162.93 25.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.679 0.752 . . . . 0.0 110.851 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 132.89 24.17 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.339 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 122.59 9.26 Favored 'Trans proline' 0 N--CA 1.465 -0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.347 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.678 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -87.17 -26.11 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.431 ' HB3' HG21 ' A' ' 22' ' ' VAL . 6.0 m-85 -128.87 99.22 5.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.903 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 28.6 mmm-85 -63.44 157.75 22.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 ttm180 -56.81 143.82 35.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.03 9.42 86.96 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -93.15 136.0 33.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.401 ' O ' HD23 ' A' ' 42' ' ' LEU . 22.1 ttmt -87.99 139.6 30.35 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.493 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.1 mt -136.94 146.86 45.93 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.552 ' O ' HD12 ' A' ' 45' ' ' ILE . 15.1 ttm180 -100.5 125.34 46.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.927 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.918 HG22 HD11 ' A' ' 20' ' ' LEU . 43.6 t -63.44 111.03 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.552 HD12 ' O ' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -85.12 -47.74 16.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -149.09 157.89 43.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -117.21 113.15 21.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.2 mt-10 -115.22 86.25 2.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 57.68 -118.4 12.72 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.43 -23.0 61.41 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.508 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.9 m95 -112.28 135.72 52.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.76 0.314 . . . . 0.0 110.896 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.507 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -124.75 164.76 19.26 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.932 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.552 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 14.5 tttp -102.61 147.77 26.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.864 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -155.74 163.81 39.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.104 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.737 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.5 tt -131.47 151.33 35.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.156 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.407 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 49.1 m -83.18 127.77 33.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.3 mt -78.43 9.38 3.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.0 m -116.8 -43.88 2.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.853 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 68.6 p -101.4 -42.74 6.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.137 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.02 25.79 16.19 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 50.8 mtt-85 -89.86 124.49 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.779 0.323 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.737 ' HG3' HD12 ' A' ' 55' ' ' ILE . 9.6 mt-10 -93.92 117.38 30.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.1 t -147.76 166.28 27.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.832 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.552 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 12.9 m-85 -108.79 122.74 47.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.738 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -129.8 151.12 77.62 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.65 0.738 . . . . 0.0 111.157 179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.706 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.79 134.8 28.78 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.325 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.75 -30.58 9.03 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.469 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.2 tp -65.39 -30.46 50.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.841 0.353 . . . . 0.0 111.135 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.7 m -78.6 -6.87 56.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.838 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.443 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.5 m -133.02 167.57 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.109 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.914 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.94 134.67 48.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.6 tpt85 -64.98 112.36 3.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 19.1 t -87.2 144.49 9.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.0 t -143.62 118.58 10.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -87.18 160.73 32.28 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -40.87 4.82 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.658 2.239 . . . . 0.0 112.316 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 80.8 p -57.76 -45.19 86.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 67.0 m -120.55 120.22 35.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.853 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.451 179.981 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 t 67.29 42.09 2.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.934 0.397 . . . . 0.0 110.916 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 t -64.02 100.34 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.855 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -43.81 125.72 5.52 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.7 m -79.1 91.21 4.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.824 0.345 . . . . 0.0 110.864 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 71.0 m -132.49 127.82 36.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.842 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 70.82 173.37 14.06 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.522 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 140.78 43.66 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.715 2.276 . . . . 0.0 112.314 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.0 mt -62.78 144.33 96.56 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 0.0 110.903 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 80.02 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.672 2.248 . . . . 0.0 112.33 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -49.07 109.99 1.38 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.634 0.73 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -5.38 16.08 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.36 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -85.25 33.84 0.56 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.63 -82.92 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.455 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 44.0 mt -101.2 121.96 42.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.767 0.317 . . . . 0.0 110.945 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.47 175.76 5.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.2 t -118.04 149.72 40.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.853 ' O ' HG23 ' A' ' 44' ' ' VAL . 13.2 m-20 -93.23 117.02 29.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.826 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -103.14 152.66 21.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.853 HD11 HG22 ' A' ' 44' ' ' VAL . 0.9 OUTLIER -137.51 112.89 9.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.923 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 125.52 30.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.075 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.634 HG11 ' O ' ' A' ' 36' ' ' PHE . 46.9 t -61.63 99.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.143 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.886 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -57.33 -33.69 67.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.894 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 13.2 t -157.95 133.17 8.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -43.36 135.29 3.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.65 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -153.39 150.18 23.01 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.665 0.745 . . . . 0.0 110.929 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.76 -175.09 10.34 Favored 'Cis proline' 0 C--O 1.231 0.156 0 C-N-CA 122.723 -1.782 . . . . 0.0 112.33 -0.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 31.2 m -75.24 155.64 86.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.729 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 1.14 4.69 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.682 2.255 . . . . 0.0 112.394 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.16 -5.38 18.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.863 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.72 -47.03 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -165.1 161.63 14.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.638 0.732 . . . . 0.0 110.87 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 134.28 27.62 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.367 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 125.29 12.01 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.67 2.247 . . . . 0.0 112.357 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.651 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -87.19 -25.22 6.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.114 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.634 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.89 96.94 3.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.81 162.95 1.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.868 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -59.88 149.66 30.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.08 -9.76 17.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.489 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -70.99 137.09 48.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.878 0.371 . . . . 0.0 110.891 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 1.2 ttmp? -90.89 138.94 31.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.7 mt -137.99 142.63 40.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.941 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 45' ' ' ILE . 27.6 ttt-85 -94.97 131.66 40.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.853 HG22 HD11 ' A' ' 20' ' ' LEU . 69.0 t -68.01 109.84 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.149 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.648 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -83.65 -46.26 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.94 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 68.8 m -156.27 152.75 28.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -110.91 117.09 32.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.885 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -120.43 86.09 2.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.7 -122.99 30.63 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.519 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.01 -23.37 66.53 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.511 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 13.6 m95 -112.42 146.72 37.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.747 0.308 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.42 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -135.55 164.45 27.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.921 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.648 ' HD3' HG21 ' A' ' 45' ' ' ILE . 34.7 tttt -100.37 143.39 30.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.27 163.26 39.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.078 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.57 HG22 HD11 ' A' ' 45' ' ' ILE . 12.0 tt -133.9 136.89 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.116 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.432 ' HA ' HD23 ' A' ' 42' ' ' LEU . 2.6 t -70.87 129.09 38.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.69 8.64 5.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.946 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.7 m -112.6 -44.91 3.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.811 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 70.6 p -103.24 -33.65 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.79 29.44 32.04 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.48 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -92.24 123.94 35.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.793 0.33 . . . . 0.0 110.903 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.425 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.6 mt-10 -90.88 117.63 29.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.869 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.6 m -147.26 167.41 24.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.832 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.459 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.6 m-85 -110.5 115.72 30.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.811 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.49 151.4 63.15 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.641 0.734 . . . . 0.0 111.173 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.4 Cg_endo -69.77 134.41 27.9 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.686 2.257 . . . . 0.0 112.351 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.431 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -50.36 -28.85 15.27 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.513 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 18.2 tt -66.0 -28.0 42.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.8 0.334 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 6.4 m -85.1 1.13 49.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 35.9 m -136.37 157.99 37.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.886 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -120.45 130.83 54.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.053 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.4 tpt180 -64.89 107.63 1.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.08 144.09 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.155 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 44.1 t -114.96 107.19 15.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.21 179.09 41.4 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -40.11 5.67 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.708 2.272 . . . . 0.0 112.304 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 73.8 m 42.51 43.04 3.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.862 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.6 p -115.24 130.33 56.88 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.838 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.0 t -98.56 140.0 33.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.887 0.375 . . . . 0.0 110.848 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.2 p -126.89 151.29 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.821 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.7 168.57 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.529 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.1 p -163.41 124.67 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.352 . . . . 0.0 110.883 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.7 t 68.3 49.15 0.83 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.847 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.72 143.12 15.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 155.16 66.78 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.65 2.233 . . . . 0.0 112.356 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.7 mt -132.07 153.93 81.51 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.0 110.872 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.453 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.8 Cg_endo -69.8 3.0 3.05 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.66 2.24 . . . . 0.0 112.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 10' ' ' PRO . 8.5 m-20 -33.32 143.21 0.18 Allowed Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.601 0.715 . . . . 0.0 110.938 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.497 ' O ' ' N ' ' A' ' 14' ' ' GLY . 54.0 Cg_endo -69.67 2.5 3.42 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.704 2.269 . . . . 0.0 112.337 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 -50.65 87.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 123.29 -49.9 0.87 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.524 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 68.1 mt -114.27 130.52 56.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.864 0.364 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.02 136.8 33.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.869 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.3 t -96.58 155.06 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.79 ' O ' HG23 ' A' ' 44' ' ' VAL . 5.8 m-20 -69.17 132.68 46.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -104.72 152.73 22.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.843 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.701 HD11 HG22 ' A' ' 44' ' ' VAL . 3.8 mt -134.62 108.71 8.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.5 125.47 29.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.6 t -63.9 103.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.8 mt -62.54 -33.28 74.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.421 ' O ' ' C ' ' A' ' 25' ' ' ASP . 35.3 t -158.34 123.24 4.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.873 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 24' ' ' SER . 0.3 OUTLIER -36.36 144.55 0.05 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.841 179.993 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.601 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -161.72 148.9 11.6 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.743 . . . . 0.0 110.939 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.56 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.75 178.69 24.56 Favored 'Cis proline' 0 N--CA 1.465 -0.147 0 C-N-CA 122.713 -1.786 . . . . 0.0 112.358 -0.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 t -66.36 153.33 92.93 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.724 0.773 . . . . 0.0 110.843 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 2.86 3.16 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.663 2.242 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -104.48 -23.99 13.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.847 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -103.23 -54.51 6.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.167 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.53 164.18 21.76 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.684 0.754 . . . . 0.0 110.888 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 131.54 21.48 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.72 3.79 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.664 2.242 . . . . 0.0 112.324 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.728 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -75.65 -27.56 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.531 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 8.2 m-85 -129.5 102.3 6.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -62.65 162.77 10.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.926 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.5 ttt180 -62.15 146.95 49.12 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.5 -9.75 26.81 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.498 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -73.06 131.62 42.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.916 0.389 . . . . 0.0 110.854 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.441 ' HB3' HD12 ' A' ' 57' ' ' LEU . 25.3 ttmt -81.52 136.48 35.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.892 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.619 HD23 ' HA ' ' A' ' 56' ' ' SER . 13.7 mt -129.36 139.67 51.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.902 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.584 HH12 HG21 ' A' ' 55' ' ' ILE . 7.9 ttp-105 -90.38 129.8 36.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.929 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.79 HG23 ' O ' ' A' ' 18' ' ' ASP . 99.3 t -69.46 111.77 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.153 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.64 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -87.6 -52.89 10.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.6 t -152.88 159.82 43.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.877 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -115.96 112.27 21.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -110.61 85.9 2.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.33 -122.16 29.17 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.14 -23.62 75.55 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.493 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.574 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -113.67 152.66 30.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.763 0.315 . . . . 0.0 110.978 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.463 ' CH2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.11 164.29 28.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.64 ' HD3' HG21 ' A' ' 45' ' ' ILE . 14.8 tttt -101.28 139.55 36.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.876 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.88 168.7 20.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.069 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.8 tt -135.75 140.35 44.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.163 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.619 ' HA ' HD23 ' A' ' 42' ' ' LEU . 96.3 p -79.42 128.27 33.14 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.441 HD12 ' HB3' ' A' ' 41' ' ' LYS . 7.9 mt -78.7 9.49 4.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.888 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 23.0 t -104.15 -45.34 4.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.918 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.7 p -110.69 -34.83 6.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 91.95 24.11 25.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.6 mtt85 -87.94 128.25 35.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.799 0.333 . . . . 0.0 110.866 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 55' ' ' ILE . 15.5 mt-10 -95.55 117.79 31.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 44.7 t -147.11 159.48 43.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.882 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -98.2 129.9 44.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.826 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -138.16 151.45 69.78 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.552 0.691 . . . . 0.0 111.182 179.884 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.713 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.71 132.02 22.54 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.703 2.269 . . . . 0.0 112.329 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.401 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -48.45 -29.77 7.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.505 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.713 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.3 tt -64.94 -30.87 51.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.791 0.329 . . . . 0.0 111.118 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 3.4 m -77.68 -11.52 59.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.883 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.401 HG22 ' HA2' ' A' ' 67' ' ' GLY . 19.2 m -126.71 165.58 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.089 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.837 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -124.21 130.22 52.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.0 tpt180 -67.12 99.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.863 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.4 t -75.51 154.12 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -118.37 49.94 1.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 42.74 -156.47 0.11 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.16 2.22 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.665 2.244 . . . . 0.0 112.326 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 50.7 m -55.25 -56.61 17.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 3.3 t -133.56 162.52 31.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.831 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.8 m -88.36 -47.46 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.882 0.372 . . . . 0.0 110.864 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -64.35 -47.38 79.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.881 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.98 -133.79 11.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.2 m -101.65 102.86 13.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.912 0.387 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -169.39 167.41 10.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.896 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.49 159.87 17.55 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.496 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 179.08 3.98 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.701 2.267 . . . . 0.0 112.339 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 11.0 mt -127.41 144.01 49.33 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.535 0.684 . . . . 0.0 110.958 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 80.1 0.88 Allowed 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.74 2.293 . . . . 0.0 112.356 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -74.65 143.99 79.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.653 0.74 . . . . 0.0 110.86 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 0.24 5.97 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.672 2.248 . . . . 0.0 112.34 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -61.94 108.75 1.09 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -101.13 -50.44 1.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.482 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 12.9 mt -120.41 155.67 32.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.779 0.324 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -53.48 157.27 2.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.892 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.7 t -83.03 158.62 22.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.869 ' O ' HG23 ' A' ' 44' ' ' VAL . 41.5 m-20 -60.7 130.54 47.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.874 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -102.97 151.2 22.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.868 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.777 HD11 HG22 ' A' ' 44' ' ' VAL . 4.7 mt -135.54 109.18 7.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.69 131.32 35.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.056 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 36' ' ' PHE . 63.7 t -65.81 109.11 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.159 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.068 HD21 ' HB2' ' A' ' 71' ' ' ALA . 5.0 mt -74.52 -29.63 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 25' ' ' ASP . 29.2 t -157.02 115.52 3.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.818 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -34.99 139.96 0.08 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.881 179.9 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.588 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -156.65 148.59 17.38 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.687 0.756 . . . . 0.0 110.924 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.74 -174.67 9.79 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 -1.801 . . . . 0.0 112.358 -0.074 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.477 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 4.0 m -77.0 158.8 79.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.696 0.76 . . . . 0.0 110.857 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 5.15 1.79 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 29.4 p-10 -104.26 -27.93 11.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.405 HG13 ' OD1' ' A' ' 30' ' ' ASP . 7.3 mt -101.95 -53.45 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -159.47 163.82 22.25 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.651 0.739 . . . . 0.0 110.868 -179.938 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 137.71 35.97 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 124.82 11.48 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.713 2.276 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.593 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -86.89 -20.85 7.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.635 ' O ' HG11 ' A' ' 22' ' ' VAL . 19.5 m-85 -134.47 87.17 2.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.887 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.77 156.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.435 ' HG3' ' C ' ' A' ' 23' ' ' LEU . 2.6 ttm105 -60.68 144.03 52.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.65 -9.41 62.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.471 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -76.95 136.15 38.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 110.911 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.408 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 49.8 tttt -84.26 137.55 33.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.453 HD11 ' CG2' ' A' ' 22' ' ' VAL . 9.9 mt -131.64 150.0 52.3 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.556 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.1 ttp180 -105.09 128.85 53.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 18' ' ' ASP . 91.5 t -64.35 110.6 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.646 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -87.79 -51.73 12.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.4 p -146.9 135.51 22.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -100.06 115.82 30.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.909 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 61.0 mm-40 -127.3 86.89 2.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.95 -123.41 32.6 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.49 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.39 63.06 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.595 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 32.1 m95 -113.98 123.26 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.735 0.302 . . . . 0.0 110.88 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.486 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -123.2 164.29 18.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.924 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.646 ' HD3' HG21 ' A' ' 45' ' ' ILE . 10.9 tttp -98.5 144.7 27.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.884 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.95 152.66 31.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.107 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.582 HG22 HD11 ' A' ' 45' ' ' ILE . 12.6 tt -126.23 131.84 71.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.443 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.3 t -68.77 128.82 38.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 4.5 mt -79.22 9.37 4.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.0 t -109.26 -45.53 3.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.841 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 37.5 p -102.02 -39.73 7.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.14 32.15 9.16 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.428 ' C ' HG13 ' A' ' 55' ' ' ILE . 36.7 mtt180 -98.19 127.0 43.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.826 0.346 . . . . 0.0 110.867 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.573 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.4 mt-10 -93.19 117.24 29.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.861 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.2 m -147.89 168.31 22.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.88 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 30.0 m-85 -109.66 135.64 50.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.411 HG22 ' CE1' ' A' ' 26' ' ' TYR . 0.2 OUTLIER -144.36 151.37 50.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.59 0.71 . . . . 0.0 111.165 179.86 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.696 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.72 133.81 26.55 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -48.56 -30.21 8.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.696 HG22 ' HB2' ' A' ' 66' ' ' PRO . 4.6 tp -65.54 -30.45 50.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.816 0.341 . . . . 0.0 111.164 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . 0.4 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 2.9 m -78.5 -3.84 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.604 ' O ' HD11 ' A' ' 23' ' ' LEU . 27.2 m -136.59 169.8 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.168 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.068 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.98 139.25 45.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.2 tpp85 -68.62 112.03 5.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.876 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.8 t -83.18 143.92 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.105 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 15.1 t -69.8 -44.85 69.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.854 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.54 -158.11 22.64 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.527 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 154.15 68.06 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.718 2.279 . . . . 0.0 112.375 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 11.0 t -125.94 -55.66 1.48 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.893 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 16.1 t -91.96 86.75 5.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.81 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.461 -179.999 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.2 t -133.26 116.83 16.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 t -155.09 150.99 27.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.859 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.55 164.69 11.62 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m -66.97 114.16 5.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.858 0.361 . . . . 0.0 110.848 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.1 p -91.11 172.63 8.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.74 144.88 1.38 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.448 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 143.84 51.87 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.662 2.241 . . . . 0.0 112.315 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.9 mt -48.73 143.04 8.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.593 0.711 . . . . 0.0 110.94 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -10.9 29.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.656 2.238 . . . . 0.0 112.359 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -97.64 114.61 65.17 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 110.86 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -8.91 24.8 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.262 . . . . 0.0 112.323 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 55.0 mm-40 -79.24 87.6 4.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.867 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.48 -91.84 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.451 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 20.1 mt -79.47 113.18 17.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.87 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -64.35 -179.47 0.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.881 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 43.1 t -122.0 163.28 19.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.85 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.895 ' O ' HG23 ' A' ' 44' ' ' VAL . 10.9 m-20 -57.03 130.6 46.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.892 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.44 152.13 21.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.713 HD11 HG22 ' A' ' 44' ' ' VAL . 3.7 mt -134.78 112.3 10.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.913 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.24 119.96 24.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.055 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.536 HG21 ' HB3' ' A' ' 36' ' ' PHE . 98.4 t -57.27 99.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.094 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.015 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.4 mt -59.34 -23.44 62.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 47.2 t -169.76 133.67 1.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.835 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.28 146.54 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.868 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.651 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -164.75 149.95 8.5 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.702 0.763 . . . . 0.0 110.913 -179.826 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.537 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.75 -174.69 9.83 Favored 'Cis proline' 0 C--N 1.342 0.201 0 C-N-CA 122.711 -1.787 . . . . 0.0 112.377 -0.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.463 ' CB ' ' OD1' ' A' ' 30' ' ' ASP . 44.2 m -72.29 154.58 91.99 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.641 0.734 . . . . 0.0 110.878 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 3.52 2.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.679 2.253 . . . . 0.0 112.357 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.463 ' OD1' ' CB ' ' A' ' 28' ' ' SER . 23.6 p-10 -109.39 -17.03 13.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.873 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -109.44 -46.43 6.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -164.77 163.17 14.44 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.672 0.749 . . . . 0.0 110.821 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 131.67 21.66 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 124.74 11.37 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.377 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.6 mp -89.22 -24.38 5.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.155 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.536 ' HB3' HG21 ' A' ' 22' ' ' VAL . 14.4 m-85 -130.98 103.02 6.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -64.22 160.34 18.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.6 ttp85 -58.37 149.4 24.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.928 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.75 -9.71 22.04 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -71.13 154.12 41.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.902 0.382 . . . . 0.0 110.904 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.508 ' O ' HD23 ' A' ' 42' ' ' LEU . 7.9 tttp -107.16 140.24 40.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.914 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 41' ' ' LYS . 2.3 mt -136.85 135.26 37.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.594 ' O ' HD12 ' A' ' 45' ' ' ILE . 19.2 ttt-85 -86.48 131.02 34.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 18' ' ' ASP . 60.5 t -66.99 108.8 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.737 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -87.74 -52.36 11.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 179.97 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -143.82 155.03 43.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -119.49 113.05 20.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -117.31 86.39 2.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.4 -123.6 33.87 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.39 -21.07 78.22 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.486 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.564 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -113.26 144.74 42.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.724 0.297 . . . . 0.0 110.941 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.401 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.83 164.46 27.88 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.92 179.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HD3' HG21 ' A' ' 45' ' ' ILE . 28.9 tttt -101.04 141.04 34.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.906 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.17 162.57 39.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.737 HG22 HD11 ' A' ' 45' ' ' ILE . 16.4 tt -134.67 134.55 54.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 1.3 t -69.8 128.28 35.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.843 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.484 HD21 ' HB2' ' A' ' 43' ' ' ARG . 2.0 mt -78.78 2.68 19.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.89 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 55.3 m -99.41 -47.81 5.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.3 p -105.33 -37.35 6.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.142 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.85 29.34 9.94 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.486 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.485 ' HD2' HG23 ' A' ' 35' ' ' ILE . 33.7 mtt180 -90.04 127.8 36.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.873 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.665 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.7 mt-10 -97.86 118.0 33.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.862 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.1 t -147.02 167.38 24.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.523 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 14.8 m-85 -110.07 114.33 27.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.795 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.91 151.18 60.64 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.63 0.729 . . . . 0.0 111.164 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.2 Cg_endo -69.78 133.88 26.59 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.673 2.249 . . . . 0.0 112.341 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -47.44 -30.26 5.96 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 5.4 tp -65.09 -32.47 58.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.801 0.334 . . . . 0.0 111.116 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 8.0 m -78.91 -4.82 51.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.513 ' O ' HD11 ' A' ' 23' ' ' LEU . 32.4 m -132.56 166.08 30.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.015 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -130.53 129.45 42.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.069 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.95 107.6 1.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.859 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.435 ' O ' ' C ' ' A' ' 74' ' ' SER . 4.0 t -72.38 142.21 15.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.099 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 73' ' ' VAL . 48.4 p -35.06 137.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.87 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -179.66 -177.95 48.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.428 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 124.58 11.26 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.368 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 17.7 t -72.0 -45.24 61.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.864 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 47.1 t -56.61 136.9 54.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 -179.99 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.504 -0.239 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.1 t -124.05 -45.31 2.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.7 p -52.58 135.5 34.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.859 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -168.08 -46.4 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.481 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.6 t -73.86 126.26 30.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.941 0.4 . . . . 0.0 110.839 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 m -107.23 105.87 16.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.862 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 138.5 -120.26 1.93 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.495 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 -174.93 1.01 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.714 2.276 . . . . 0.0 112.304 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 63.7 mt -86.44 155.6 56.83 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.64 0.733 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 2.39 3.62 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.659 2.239 . . . . 0.0 112.343 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -85.8 136.98 36.07 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.663 0.744 . . . . 0.0 110.868 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.8 Cg_endo -69.8 2.88 3.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.643 2.229 . . . . 0.0 112.361 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.436 ' C ' ' O ' ' A' ' 12' ' ' PRO . 8.0 tt0 -34.57 116.45 0.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.869 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -144.28 69.1 0.41 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 22.7 mt -107.17 130.92 54.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.783 0.325 . . . . 0.0 110.927 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.9 147.81 25.62 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.884 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -107.2 167.5 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.833 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.578 ' O ' HG23 ' A' ' 44' ' ' VAL . 85.7 m-20 -84.54 130.84 34.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.883 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -111.17 150.15 29.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.663 HD11 HG22 ' A' ' 44' ' ' VAL . 9.3 mt -133.38 114.08 13.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.42 127.12 32.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.08 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.695 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.8 t -65.04 98.6 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.149 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.962 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -59.71 -31.49 69.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.931 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.7 t -161.3 127.95 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.77 138.98 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.647 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.72 150.12 17.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.695 0.76 . . . . 0.0 110.936 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.75 -175.28 10.64 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.695 -1.794 . . . . 0.0 112.337 -0.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 3.1 m -76.28 158.29 81.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.65 0.738 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -102.07 -22.39 14.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.7 mt -109.25 -54.99 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -155.3 163.44 24.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.615 0.721 . . . . 0.0 110.888 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 137.81 36.43 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 119.04 6.05 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.679 2.252 . . . . 0.0 112.371 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -83.06 -25.71 8.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.128 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.695 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.3 m-85 -131.4 96.24 3.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.0 mmm-85 -56.41 158.38 4.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.902 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 52.1 ttt-85 -61.08 144.5 53.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.62 -14.46 35.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -72.75 136.54 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.853 0.359 . . . . 0.0 110.911 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.5 ttmt -87.02 137.84 32.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.593 HD23 ' HA ' ' A' ' 56' ' ' SER . 10.4 mt -132.17 140.6 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.919 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.428 ' O ' HD12 ' A' ' 45' ' ' ILE . 42.8 ttt180 -91.12 134.49 34.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.872 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.663 HG22 HD11 ' A' ' 20' ' ' LEU . 97.6 t -71.43 112.11 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.131 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.635 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.1 mp -86.05 -46.32 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -155.56 147.75 23.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.46 116.07 31.11 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.902 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -122.35 85.91 2.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.12 -120.7 23.89 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.33 -23.08 59.4 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.438 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 21.9 m95 -111.68 137.9 48.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.79 0.329 . . . . 0.0 110.88 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.516 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.3 164.83 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.927 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.635 ' HD3' HG21 ' A' ' 45' ' ' ILE . 9.4 tttp -101.49 141.95 33.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.911 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.13 168.34 22.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.816 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.3 tt -138.39 142.45 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.593 ' HA ' HD23 ' A' ' 42' ' ' LEU . 50.5 p -76.82 133.49 39.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 7.6 mt -82.96 8.86 11.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.924 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.2 t -104.78 -42.77 5.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 43.4 p -113.56 -44.57 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.103 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.529 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 103.35 27.88 6.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.473 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -84.19 122.04 28.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 110.853 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.816 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -92.09 117.48 29.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.0 t -147.44 169.61 19.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.905 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.57 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 7.1 m-85 -112.1 118.09 34.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.83 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.5 151.26 69.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.656 0.741 . . . . 0.0 111.153 179.866 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.631 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.0 Cg_endo -69.79 132.67 23.75 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.704 2.27 . . . . 0.0 112.312 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.45 -33.5 5.99 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.631 HG22 ' HB2' ' A' ' 66' ' ' PRO . 12.8 tt -61.81 -33.39 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.359 . . . . 0.0 111.177 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.1 -15.92 61.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.569 ' O ' HD11 ' A' ' 23' ' ' LEU . 35.7 m -125.47 175.86 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.962 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -136.72 134.5 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.121 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -66.32 102.44 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 20.4 t -73.94 144.45 12.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.6 t 62.38 49.15 4.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.847 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -101.37 175.33 25.72 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 77' ' ' SER . 53.9 Cg_endo -69.77 0.91 4.96 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.654 2.236 . . . . 0.0 112.331 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 76' ' ' PRO . 38.0 m -35.04 132.71 0.34 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.853 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.1 t -75.45 162.32 28.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.859 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.5 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -82.99 156.56 23.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.909 0.385 . . . . 0.0 110.867 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 t -171.79 112.89 0.33 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.899 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.1 147.39 0.15 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.467 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.1 m -93.76 93.94 8.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.878 0.371 . . . . 0.0 110.845 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 t -113.05 33.59 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.904 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -56.65 -158.2 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.489 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -168.23 0.26 Allowed 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.711 2.274 . . . . 0.0 112.324 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.839 ' O ' HD12 ' A' ' 9' ' ' LEU . 2.6 pp -111.82 152.21 44.02 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.623 0.725 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.444 ' O ' ' C ' ' A' ' 11' ' ' ASN . 54.0 Cg_endo -69.8 -45.77 1.45 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 2.258 . . . . 0.0 112.317 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.589 HD22 HD22 ' A' ' 9' ' ' LEU . 1.7 m-80 -34.61 150.19 0.08 OUTLIER Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.573 0.701 . . . . 0.0 110.929 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 1.63 4.24 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -100.23 73.69 1.71 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.893 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -160.27 99.52 0.18 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.435 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.1 mp -104.6 147.88 27.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.866 0.365 . . . . 0.0 110.884 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -68.14 168.09 12.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.908 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.4 t -129.86 153.06 48.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.836 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.713 ' O ' HG23 ' A' ' 44' ' ' VAL . 14.1 m-20 -72.44 127.98 34.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.881 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -108.79 154.42 22.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.94 HD11 HG22 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -139.98 111.68 7.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.881 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.12 122.81 28.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.092 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 36' ' ' PHE . 92.2 t -55.33 104.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.022 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -65.74 -33.81 76.73 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.7 t -155.35 128.95 8.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -39.43 146.55 0.09 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.605 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.77 148.82 6.73 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.659 0.742 . . . . 0.0 110.944 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.83 -174.27 9.44 Favored 'Cis proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 -1.796 . . . . 0.0 112.295 0.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.9 m -70.57 153.77 94.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.656 0.741 . . . . 0.0 110.873 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 1.21 4.59 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.676 2.251 . . . . 0.0 112.37 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -106.26 -18.37 14.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -107.29 -54.03 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.16 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.4 m -155.71 162.63 26.97 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 134.37 27.82 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.327 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 120.87 7.59 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.724 2.282 . . . . 0.0 112.314 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.666 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.9 mp -85.6 -30.45 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.117 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.62 ' O ' HG11 ' A' ' 22' ' ' VAL . 11.8 m-85 -124.0 90.82 3.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -51.07 161.16 0.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.896 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 16.2 ttt-85 -66.17 144.15 56.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.35 -9.89 65.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.477 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.403 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -83.09 132.64 35.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 110.906 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.544 ' CD ' HG21 ' A' ' 73' ' ' VAL . 19.5 ttpt -88.99 143.74 26.65 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.863 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.467 HD11 ' CG2' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -135.0 141.25 46.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.89 179.94 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.414 ' HB2' HD21 ' A' ' 57' ' ' LEU . 35.8 ttt180 -85.64 127.57 34.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.94 HG22 HD11 ' A' ' 20' ' ' LEU . 84.5 t -64.46 111.37 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.71 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -78.62 -54.7 11.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.094 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.1 t -155.58 150.85 26.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.846 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -102.26 121.99 43.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.923 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 44.5 mm-40 -126.5 86.15 2.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.907 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.44 -121.5 24.24 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -85.08 -18.57 60.75 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.529 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.578 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.5 m95 -115.71 140.09 49.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.71 0.291 . . . . 0.0 110.937 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.404 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.79 164.44 26.82 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.878 -179.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.71 ' HD2' HG21 ' A' ' 45' ' ' ILE . 3.7 ttmt -101.58 151.56 21.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -159.11 150.1 19.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.492 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.4 tt -116.34 144.34 24.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.13 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.434 ' HA ' HD23 ' A' ' 42' ' ' LEU . 6.7 m -73.59 130.6 40.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.414 HD21 ' HB2' ' A' ' 43' ' ' ARG . 7.5 mt -78.21 9.71 3.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 t -116.92 -52.79 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.828 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.2 p -95.9 -34.56 11.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.096 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.474 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.85 31.57 17.55 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.496 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 30.0 mtt180 -91.37 122.1 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.492 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.3 mt-10 -91.9 117.76 30.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.43 ' HB3' ' CE2' ' A' ' 36' ' ' PHE . 18.4 t -147.32 169.51 19.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HE3' ' A' ' 53' ' ' LYS . 4.2 m-85 -110.26 122.34 47.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.877 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -132.21 151.47 78.42 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.597 0.713 . . . . 0.0 111.113 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.637 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.3 Cg_endo -69.8 131.87 22.08 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.7 2.267 . . . . 0.0 112.279 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.442 ' HA2' HG22 ' A' ' 70' ' ' VAL . . . -46.78 -30.57 4.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.476 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.637 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -64.72 -33.33 62.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 0.0 111.11 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 7.4 m -78.05 -7.58 57.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.442 HG22 ' HA2' ' A' ' 67' ' ' GLY . 33.8 m -128.69 164.98 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.022 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.44 134.88 46.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 4.7 tpp180 -61.41 110.14 1.36 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.831 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.544 HG21 ' CD ' ' A' ' 41' ' ' LYS . 2.9 t -70.94 139.6 19.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.174 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 m -107.77 79.4 1.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 55.71 161.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.496 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 168.23 22.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.698 2.266 . . . . 0.0 112.324 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.4 t -78.68 136.05 37.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.847 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 34.3 t -51.11 106.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.814 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.252 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.441 -179.987 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.0 m -99.1 149.42 23.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.881 0.372 . . . . 0.0 110.859 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.6 t -123.93 -53.47 1.75 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.843 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.39 -42.65 14.22 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 48.8 m -57.71 152.88 14.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.917 0.389 . . . . 0.0 110.853 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.3 t -166.82 154.32 9.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 -179.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.05 -75.49 0.19 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.492 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 143.17 49.64 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.658 2.239 . . . . 0.0 112.325 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.424 ' HB2' ' ND2' ' A' ' 11' ' ' ASN . 30.8 mt -85.78 156.12 58.5 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.628 0.728 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 11' ' ' ASN . 54.1 Cg_endo -69.79 2.98 3.06 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.277 . . . . 0.0 112.322 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PRO . 65.4 m-20 -34.61 144.02 0.2 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 13' ' ' GLU . 53.4 Cg_endo -69.82 1.72 4.22 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.677 2.252 . . . . 0.0 112.332 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.449 ' C ' ' O ' ' A' ' 12' ' ' PRO . 17.7 mm-40 32.62 48.69 0.13 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -101.37 -38.64 3.22 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.499 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 mp -71.88 101.5 2.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -63.17 138.0 58.41 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.827 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.4 t -87.41 161.6 17.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 44' ' ' VAL . 1.5 m-20 -94.01 136.46 34.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.866 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.9 m-85 -112.14 150.68 30.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.721 HD11 HG22 ' A' ' 44' ' ' VAL . 7.2 mt -134.83 110.66 9.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.912 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.39 122.06 27.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.601 HG11 ' O ' ' A' ' 36' ' ' PHE . 76.6 t -58.53 100.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.141 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.945 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.8 mt -59.94 -36.14 76.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.936 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.6 t -155.97 127.08 7.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.874 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -40.21 135.09 1.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.645 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -152.08 149.6 23.73 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.716 0.77 . . . . 0.0 110.887 -179.807 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.547 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.82 -178.67 17.33 Favored 'Cis proline' 0 C--N 1.342 0.199 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.371 -0.023 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 59.6 m -68.36 153.44 95.6 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.652 0.739 . . . . 0.0 110.861 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 2.46 3.52 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.717 2.278 . . . . 0.0 112.344 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.61 -10.09 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -118.44 -52.14 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.6 m -156.45 162.15 28.09 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 0.0 110.805 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 134.2 27.35 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.49 ' HG2' ' CZ ' ' A' ' 37' ' ' ARG . 53.9 Cg_endo -69.71 114.09 3.58 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.744 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.5 mp -74.57 -30.46 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.136 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.601 ' O ' HG11 ' A' ' 22' ' ' VAL . 14.8 m-85 -130.99 94.95 3.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.49 ' CZ ' ' HG2' ' A' ' 34' ' ' PRO . 20.4 mmt180 -53.89 160.24 1.49 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -62.73 151.99 36.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.58 -18.02 7.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.405 ' OE2' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -71.43 132.37 44.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.871 0.367 . . . . 0.0 110.903 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OE2' ' A' ' 40' ' ' GLU . 25.6 ttmt -85.41 135.73 33.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.471 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.3 mt -128.14 148.41 50.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.501 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.4 ttt180 -98.62 130.51 45.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.878 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.721 HG22 HD11 ' A' ' 20' ' ' LEU . 57.6 t -68.58 114.17 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.125 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.501 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -90.4 -53.46 9.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.147 179.941 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 t -146.45 154.15 41.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.847 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -120.04 119.07 32.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -127.62 98.9 5.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 59.15 -130.43 50.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.65 9.0 63.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.531 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.555 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.8 m95 -137.07 140.39 41.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 110.926 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.415 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -133.77 164.64 26.78 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.918 179.995 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 16.1 tttp -104.09 147.03 27.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.904 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -153.6 159.77 42.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.131 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.686 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.3 tt -126.39 141.71 45.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 20.1 p -78.25 129.87 35.58 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.7 mt -80.51 9.26 6.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.966 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 58.5 m -99.24 -49.4 4.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.812 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 30.2 p -112.77 -39.69 4.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.097 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.74 27.52 5.7 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.437 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -83.08 128.07 34.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.761 0.315 . . . . 0.0 110.862 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.686 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -102.02 117.27 34.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 1.8 p -147.58 169.27 19.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.855 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 24.8 m-85 -110.08 118.98 37.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.855 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -125.69 150.01 67.07 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.654 0.74 . . . . 0.0 111.081 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.671 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.0 Cg_endo -69.77 134.03 26.97 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.308 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -46.99 -31.13 5.51 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.482 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.671 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.7 tp -64.84 -32.74 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.806 0.336 . . . . 0.0 111.113 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 11.6 m -80.35 2.85 23.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.618 ' O ' HD11 ' A' ' 23' ' ' LEU . 33.4 m -140.52 170.63 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.945 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -132.35 125.99 32.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.075 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.3 ttp180 -65.74 108.19 2.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.1 t -81.3 145.18 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.119 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 38.4 t -149.82 164.22 35.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 149.9 -174.67 29.3 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.486 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 2.29 3.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.734 2.289 . . . . 0.0 112.337 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.0 t -40.18 154.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.847 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 88.9 p -149.26 133.26 17.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.86 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.512 -179.91 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.8 m -102.3 117.46 34.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.885 0.374 . . . . 0.0 110.885 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.9 m -126.8 160.02 32.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.3 -159.6 14.57 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.533 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.7 m -118.01 137.77 52.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.896 -179.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.3 m -71.78 164.6 25.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.845 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.88 146.31 18.18 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.489 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 178.3 4.74 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.65 2.233 . . . . 0.0 112.331 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.7 mt -39.74 153.41 0.19 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.571 0.7 . . . . 0.0 110.948 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -20.36 34.8 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.667 2.245 . . . . 0.0 112.361 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -115.36 140.05 25.33 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.665 0.745 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.9 Cg_endo -69.71 1.83 4.05 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.689 2.259 . . . . 0.0 112.359 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 12' ' ' PRO . 2.4 pt-20 35.18 31.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . -154.71 -106.41 0.27 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 38.2 tp -121.15 102.93 8.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.814 0.34 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 p30 -56.55 161.36 2.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 30.5 t -91.47 163.91 14.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.461 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -61.83 132.45 53.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.887 179.957 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -108.63 145.02 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.886 HD11 HG22 ' A' ' 44' ' ' VAL . 1.7 mt -134.49 110.56 9.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.421 ' HB2' ' CG2' ' A' ' 73' ' ' VAL . . . -79.63 127.09 31.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.103 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.566 HG11 ' O ' ' A' ' 36' ' ' PHE . 88.7 t -61.75 101.36 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.1 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.954 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -61.92 -31.01 71.28 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -160.21 128.17 4.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -40.12 140.82 0.54 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.844 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.615 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -158.94 149.18 15.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.687 0.756 . . . . 0.0 110.914 -179.848 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.545 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.3 Cg_endo -69.8 -174.52 9.7 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.34 -0.064 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -73.22 154.09 90.37 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 1.63 4.29 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.655 2.236 . . . . 0.0 112.369 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -105.86 -14.69 15.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.81 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.8 mt -113.05 -51.96 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.154 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 m -158.34 162.26 27.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 133.99 26.88 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.699 2.266 . . . . 0.0 112.339 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 124.08 10.72 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.75 2.3 . . . . 0.0 112.307 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.654 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.1 mp -86.84 -25.28 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.146 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.566 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.3 m-85 -130.97 93.92 3.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -56.29 150.16 15.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.409 ' HA ' HG12 ' A' ' 22' ' ' VAL . 39.9 ttp85 -50.76 147.56 4.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.05 -17.84 8.87 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -68.04 138.37 55.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.926 0.394 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.572 ' O ' HD23 ' A' ' 42' ' ' LEU . 2.5 ttmp? -89.94 143.12 27.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.572 HD23 ' O ' ' A' ' 41' ' ' LYS . 1.7 mt -139.41 142.4 37.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.951 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.561 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttt180 -95.45 132.03 40.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.864 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.886 HG22 HD11 ' A' ' 20' ' ' LEU . 95.8 t -68.0 112.63 3.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.096 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.725 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -91.39 -53.28 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 m -137.66 143.07 41.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.09 115.01 28.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.865 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -126.68 85.97 2.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.893 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.1 -125.36 38.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.81 -19.07 73.9 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.49 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.573 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 24.3 m95 -113.39 131.87 55.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.775 0.321 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -131.94 164.35 26.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.918 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.0 tttp -99.95 144.16 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.894 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -151.0 160.33 44.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.07 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.748 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.4 tt -130.55 139.66 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.078 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.1 m -72.37 129.41 38.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.857 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.0 mt -79.15 5.66 11.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 35.1 t -106.03 -51.08 3.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 48.7 p -99.31 -44.24 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.185 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.402 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 100.95 26.76 7.75 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.518 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 64.5 mtt180 -86.19 128.19 34.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.748 ' HG3' HD12 ' A' ' 55' ' ' ILE . 12.9 mt-10 -98.21 117.45 32.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.1 t -147.34 169.38 19.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.897 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.546 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 9.2 m-85 -112.63 114.79 27.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.87 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -122.53 150.76 58.6 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.631 0.729 . . . . 0.0 111.138 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.597 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.81 135.99 31.75 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.637 2.225 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.9 -36.86 20.9 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.539 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.597 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.3 tt -59.96 -26.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.808 0.337 . . . . 0.0 111.071 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.7 m -82.56 -7.6 59.64 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.8 m -131.22 164.45 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.149 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.954 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -125.93 133.31 51.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.092 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.438 ' NH2' ' OD2' ' A' ' 18' ' ' ASP . 1.2 tpt180 -61.0 97.72 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.881 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.421 ' CG2' ' HB2' ' A' ' 21' ' ' ALA . 3.8 t -74.83 140.34 17.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.144 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.8 t -121.78 51.74 1.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.852 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 176.23 165.78 32.5 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.526 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 179.88 3.4 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.67 2.246 . . . . 0.0 112.322 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -70.16 89.25 0.63 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 7.7 m -81.67 -54.44 5.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.897 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.478 179.973 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.486 -0.245 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 93.4 p -124.97 83.44 2.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.808 0.337 . . . . 0.0 110.865 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.2 p -170.84 120.86 0.55 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.58 -61.87 0.63 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.465 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.2 t -130.05 40.87 3.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.863 0.364 . . . . 0.0 110.867 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 7' ' ' GLY . 45.1 m -71.43 107.77 4.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.853 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.449 ' C ' ' O ' ' A' ' 6' ' ' SER . . . 34.43 69.49 0.19 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.513 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 171.35 14.65 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.681 2.254 . . . . 0.0 112.311 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.734 HD13 ' HB2' ' A' ' 11' ' ' ASN . 4.5 pp -96.88 152.56 38.48 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 0.0 110.945 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -43.51 2.64 Favored 'Trans proline' 0 C--N 1.34 0.127 0 C-N-CA 122.677 2.252 . . . . 0.0 112.329 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.734 ' HB2' HD13 ' A' ' 9' ' ' LEU . 2.5 m-80 -46.96 159.51 0.38 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 0.0 110.907 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.549 ' HA ' HD21 ' A' ' 15' ' ' LEU . 53.2 Cg_endo -69.78 0.01 6.28 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.682 2.255 . . . . 0.0 112.308 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -65.15 111.18 2.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.925 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.32 85.74 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.473 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.549 HD21 ' HA ' ' A' ' 12' ' ' PRO . 84.5 mt -94.68 118.7 32.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.802 0.334 . . . . 0.0 110.882 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -58.98 144.16 45.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.848 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 39.1 t -113.57 155.21 25.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.802 -179.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.698 ' O ' HG23 ' A' ' 44' ' ' VAL . 28.1 m-20 -68.03 137.37 55.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.86 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -107.24 150.04 27.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.686 HD11 HG22 ' A' ' 44' ' ' VAL . 7.3 mt -132.56 121.31 23.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -92.09 119.54 31.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.063 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.585 ' CG2' HD11 ' A' ' 42' ' ' LEU . 96.2 t -59.11 96.67 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.16 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.957 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.7 mt -54.95 -35.32 64.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.929 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 t -157.46 128.65 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.841 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -40.69 137.98 1.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.881 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.609 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -155.18 148.55 18.48 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.685 0.755 . . . . 0.0 110.918 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.559 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.4 Cg_endo -69.71 -173.98 9.0 Favored 'Cis proline' 0 C--N 1.341 0.177 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.379 -0.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 6.1 m -74.67 155.51 87.15 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.689 0.757 . . . . 0.0 110.843 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 3.44 2.79 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.658 2.238 . . . . 0.0 112.379 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -107.77 -18.22 13.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mt -109.18 -47.92 7.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.0 OUTLIER -164.1 163.58 15.25 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.644 0.735 . . . . 0.0 110.864 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 132.24 22.87 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.675 2.25 . . . . 0.0 112.309 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 118.24 5.57 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.649 2.233 . . . . 0.0 112.306 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.709 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.2 mp -79.31 -28.42 13.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.091 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.576 ' O ' HG11 ' A' ' 22' ' ' VAL . 16.8 m-85 -127.3 98.42 5.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.65 160.38 4.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.854 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -62.22 144.61 55.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.23 -11.43 23.49 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.461 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -71.25 130.56 41.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.869 0.366 . . . . 0.0 110.896 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -81.46 137.02 35.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.585 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.4 mt -133.16 139.78 47.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttt180 -90.19 130.66 36.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.831 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 18' ' ' ASP . 57.3 t -66.89 110.66 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.125 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD2' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -80.19 -54.97 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.124 179.896 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 70.9 m -157.32 147.46 20.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -98.58 115.47 28.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 35.5 mt-10 -113.99 85.78 2.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.72 -122.99 30.58 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.454 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -77.77 -22.58 69.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.473 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.56 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 10.1 m95 -113.92 150.51 33.62 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.754 0.312 . . . . 0.0 110.915 -179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.428 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -136.08 164.2 28.57 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.949 -179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD2' HG21 ' A' ' 45' ' ' ILE . 4.7 ttmm -103.22 150.83 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.937 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.426 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -158.91 143.77 15.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.072 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 62' ' ' GLU . 20.2 tt -108.1 144.62 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.1 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 p -83.68 130.27 34.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.843 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.0 mt -77.21 7.94 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.3 t -95.18 -51.96 4.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.843 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.8 p -111.29 -43.16 3.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.144 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.608 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 108.69 26.45 5.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.467 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -86.27 127.72 34.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.763 0.316 . . . . 0.0 110.857 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.708 ' HG3' HD12 ' A' ' 55' ' ' ILE . 13.0 mt-10 -99.15 118.11 35.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 9.0 t -147.11 167.75 23.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.527 ' CE2' ' HE2' ' A' ' 53' ' ' LYS . 4.3 m-85 -105.96 129.42 54.1 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.942 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.682 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -135.16 150.97 74.3 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.594 0.711 . . . . 0.0 111.125 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.672 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.74 133.21 25.06 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.732 2.288 . . . . 0.0 112.332 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -48.59 -30.02 8.17 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.465 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.672 HG22 ' HB2' ' A' ' 66' ' ' PRO . 13.5 tt -65.5 -30.12 49.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.834 0.349 . . . . 0.0 111.104 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.8 m -80.36 -5.72 56.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.523 ' O ' HD11 ' A' ' 23' ' ' LEU . 34.9 m -135.03 171.35 17.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.077 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.957 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.64 132.43 38.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.076 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 -69.3 106.79 3.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.857 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.6 t -74.15 143.54 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 m -99.4 41.69 1.14 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.42 -161.3 52.51 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 105.78 1.54 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.681 2.254 . . . . 0.0 112.365 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 58.0 m -89.97 79.73 6.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.9 t -108.4 41.51 1.55 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.883 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 81.7 p -89.9 140.79 29.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.831 0.348 . . . . 0.0 110.872 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 t 45.53 42.17 7.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.883 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 88.11 -156.09 26.96 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -101.97 -60.14 1.58 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.908 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.0 p -120.86 167.92 12.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.829 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.74 163.11 14.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.443 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 147.11 62.31 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.683 2.255 . . . . 0.0 112.365 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.473 ' H ' ' CD2' ' A' ' 9' ' ' LEU . 3.4 mm? -44.08 148.25 0.83 Allowed Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.601 0.715 . . . . 0.0 110.888 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 79.96 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.72 2.28 . . . . 0.0 112.295 179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -113.69 142.84 28.36 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.603 0.716 . . . . 0.0 110.88 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -1.39 8.38 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.693 2.262 . . . . 0.0 112.372 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.1 111.8 1.04 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.41 -50.4 3.28 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 72.0 mt -92.98 138.6 31.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.823 0.344 . . . . 0.0 110.866 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -91.93 144.63 25.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.817 179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 30.7 t -123.11 160.85 25.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.874 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 44' ' ' VAL . 60.7 m-20 -99.22 119.34 37.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.858 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -101.62 143.68 31.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.921 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.932 HD11 HG22 ' A' ' 44' ' ' VAL . 11.0 mt -130.45 108.76 10.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.06 122.92 28.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.063 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.51 HG11 ' O ' ' A' ' 36' ' ' PHE . 57.3 t -58.86 103.62 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.12 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.819 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.5 mt -67.17 -33.42 75.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 25' ' ' ASP . 27.6 t -153.64 121.85 6.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.834 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -37.03 149.38 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.875 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.799 ' CE1' HG22 ' A' ' 65' ' ' ILE . 0.0 OUTLIER -169.82 150.52 3.85 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.685 0.755 . . . . 0.0 110.922 -179.85 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 53.7 Cg_endo -69.76 -175.3 10.69 Favored 'Cis proline' 0 C--N 1.341 0.162 0 C-N-CA 122.674 -1.803 . . . . 0.0 112.304 -0.059 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 48.0 m -74.74 155.06 87.22 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.662 0.744 . . . . 0.0 110.855 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 3.42 2.76 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.716 2.277 . . . . 0.0 112.359 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -105.27 -22.33 13.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.843 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.7 mt -105.77 -48.59 8.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.7 OUTLIER -164.11 164.67 14.14 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.682 0.753 . . . . 0.0 110.836 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 135.62 30.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.642 2.228 . . . . 0.0 112.35 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 125.24 11.88 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.658 2.239 . . . . 0.0 112.298 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 35' ' ' ILE . 3.6 mp -86.6 -26.4 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.51 ' O ' HG11 ' A' ' 22' ' ' VAL . 10.5 m-85 -131.9 100.58 5.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.881 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -63.28 155.25 29.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.814 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -55.21 150.35 11.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.807 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 76.3 -10.36 16.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -72.4 151.52 42.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.868 0.366 . . . . 0.0 110.906 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.417 ' O ' HD23 ' A' ' 42' ' ' LEU . 58.2 tttt -102.26 138.76 38.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.928 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.541 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -135.12 152.52 51.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.927 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.63 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.4 ttt180 -105.1 129.65 53.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.87 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.932 HG22 HD11 ' A' ' 20' ' ' LEU . 99.1 t -65.19 111.82 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.669 HD11 HG22 ' A' ' 55' ' ' ILE . 1.0 OUTLIER -93.19 -52.39 9.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.161 179.882 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.8 m -141.15 150.96 43.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -118.43 109.82 16.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.875 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -116.31 86.0 2.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.881 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.75 -123.27 32.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.64 -23.51 69.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.48 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 16.3 m95 -109.91 141.93 41.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.717 0.294 . . . . 0.0 110.945 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.41 ' CD1' ' N ' ' A' ' 52' ' ' TRP . 0.1 OUTLIER -135.15 164.27 28.05 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.925 179.978 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.55 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.2 tttp -100.75 141.51 33.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.905 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.46 159.75 44.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.821 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -131.81 130.82 61.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.541 ' HA ' HD23 ' A' ' 42' ' ' LEU . 4.8 t -67.82 130.88 44.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.69 9.4 5.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.946 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 15.1 t -105.55 -48.01 3.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.2 p -104.41 -35.79 7.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.141 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.495 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 90.45 27.84 18.87 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.496 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.424 ' C ' HG13 ' A' ' 55' ' ' ILE . 44.0 mtt85 -89.25 124.98 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.797 -179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.821 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.0 mt-10 -94.31 117.33 29.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.943 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.2 t -147.6 169.63 19.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.824 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.55 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 28.3 m-85 -110.96 118.13 35.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.899 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.19 152.54 73.66 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.593 0.711 . . . . 0.0 111.146 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.662 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.77 137.66 35.97 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.679 2.252 . . . . 0.0 112.351 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.81 -33.23 6.39 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.482 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.662 HG22 ' HB2' ' A' ' 66' ' ' PRO . 3.5 tp -64.88 -31.11 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 111.162 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 2.1 t -72.87 -12.77 61.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.489 ' CG2' ' HB3' ' A' ' 20' ' ' LEU . 18.4 m -131.04 170.21 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.819 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -133.48 136.45 45.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -67.94 108.37 3.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 12.2 t -87.52 142.69 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.141 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.9 m -75.59 -48.66 21.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.81 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 175.51 164.72 30.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.491 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.86 90.27 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.653 2.235 . . . . 0.0 112.309 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 24.8 p -107.28 40.83 1.6 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 59.8 p -45.0 120.67 2.46 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.911 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.475 -179.967 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 N-CA-C 112.528 -0.229 . . . . 0.0 112.528 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 t -46.29 171.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.36 . . . . 0.0 110.853 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.6 t -78.35 90.53 4.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.87 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -106.77 -121.44 4.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.4 m -115.36 45.74 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.862 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.8 t -77.76 -43.91 29.3 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -72.78 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.518 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 173.01 11.68 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.701 2.267 . . . . 0.0 112.302 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.492 ' H ' ' CD2' ' A' ' 9' ' ' LEU . 3.5 mm? -43.41 143.96 1.36 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.581 0.705 . . . . 0.0 110.902 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.9 Cg_endo -69.8 -16.7 37.53 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.697 2.265 . . . . 0.0 112.319 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 10' ' ' PRO . 7.7 m-20 -34.52 150.67 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.655 0.741 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.6 Cg_endo -69.79 0.63 5.39 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.686 2.257 . . . . 0.0 112.348 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.447 ' C ' ' O ' ' A' ' 12' ' ' PRO . 9.0 pt-20 -34.98 94.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.872 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . -136.61 45.47 1.08 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.462 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 64.0 mt -93.67 141.67 28.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.35 . . . . 0.0 110.896 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -71.97 134.94 46.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.856 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 23.1 t -101.48 164.82 11.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 44' ' ' VAL . 73.3 m-20 -78.14 127.66 32.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.883 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -111.77 152.63 27.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 44' ' ' VAL . 7.7 mt -137.43 116.03 12.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.935 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.57 127.52 33.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.677 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.4 t -66.85 97.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.101 HD21 ' HB2' ' A' ' 71' ' ' ALA . 9.4 mt -57.19 -35.93 70.2 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.5 t -156.38 128.2 7.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.898 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -39.1 149.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.898 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.639 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -170.61 150.05 3.14 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.729 0.776 . . . . 0.0 110.911 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.549 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.2 Cg_endo -69.7 -174.7 9.79 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.717 -1.785 . . . . 0.0 112.355 -0.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.6 m -80.35 158.46 71.65 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.874 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 3.52 2.75 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.649 2.232 . . . . 0.0 112.321 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -103.89 -13.22 16.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.3 mt -119.95 -49.34 3.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.101 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.1 m -162.83 163.46 17.58 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.717 0.77 . . . . 0.0 110.843 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 133.56 25.8 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.676 2.251 . . . . 0.0 112.353 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 114.74 3.81 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.313 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.732 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.8 mp -73.45 -30.52 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.567 ' CD1' ' HB3' ' A' ' 56' ' ' SER . 12.3 m-85 -130.66 110.83 11.67 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.92 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -69.56 165.79 20.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.443 ' CG ' ' O ' ' A' ' 23' ' ' LEU . 2.4 tmt_? -67.22 141.14 57.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.46 11.52 81.85 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.486 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.4 ' OE1' ' O ' ' A' ' 41' ' ' LYS . 0.4 OUTLIER -100.35 138.22 37.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.976 0.417 . . . . 0.0 110.843 -179.857 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.4 ' O ' ' OE1' ' A' ' 40' ' ' GLU . 30.2 ttmt -85.54 140.63 30.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.677 HD11 ' CG2' ' A' ' 22' ' ' VAL . 10.1 mt -134.2 149.69 51.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.458 ' O ' HD12 ' A' ' 45' ' ' ILE . 29.7 ttt180 -103.89 129.15 51.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.866 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 18' ' ' ASP . 45.8 t -67.97 114.82 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.095 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.493 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -88.8 -52.58 10.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.096 179.928 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.9 t -157.53 128.32 6.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -89.15 125.95 35.26 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -125.06 85.96 2.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.898 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.68 -128.08 37.49 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.8 -24.99 75.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.513 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.565 ' CH2' ' HD3' ' A' ' 66' ' ' PRO . 13.2 m95 -112.69 146.55 38.51 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.786 0.327 . . . . 0.0 110.918 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.477 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -133.98 164.84 26.41 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.992 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.561 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 10.0 tttp -103.37 145.15 30.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.45 163.72 38.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.148 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.878 HD12 ' HG3' ' A' ' 62' ' ' GLU . 21.0 tt -131.19 135.21 60.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.567 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 37.4 p -76.23 129.09 36.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.8 mt -77.59 9.28 3.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 29.1 m -95.92 -49.74 5.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 12.2 p -114.75 -28.92 6.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.143 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.55 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 92.11 26.48 18.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.508 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 23.7 mtt85 -83.12 128.08 34.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.756 0.312 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.878 ' HG3' HD12 ' A' ' 55' ' ' ILE . 10.1 mt-10 -97.66 117.26 31.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 2.4 t -147.55 170.11 18.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.561 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 10.6 m-85 -110.78 123.62 50.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.901 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -130.2 150.64 76.66 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.669 0.747 . . . . 0.0 111.134 179.909 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.603 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.9 Cg_endo -69.73 130.67 19.78 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.675 2.25 . . . . 0.0 112.374 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 70' ' ' VAL . . . -46.13 -36.21 7.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.603 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.3 tt -58.9 -33.55 50.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -73.72 -15.04 61.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.498 HG12 ' HA ' ' A' ' 22' ' ' VAL . 25.5 m -125.13 174.04 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.101 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.101 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.21 132.15 39.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.115 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.472 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.1 tpp85 -62.77 105.66 0.69 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.83 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.0 t -78.79 144.4 11.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.6 m -90.56 -51.91 5.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 106.34 -157.79 15.74 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.527 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 -34.24 14.85 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.698 2.266 . . . . 0.0 112.308 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.7 t -105.47 133.05 50.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 88.9 p -47.59 -49.71 26.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.843 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.517 -179.96 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.367 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.0 m -162.23 116.39 1.83 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.3 t -139.16 123.26 17.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.868 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.71 105.22 3.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.484 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.5 m -117.86 -56.67 2.17 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.93 0.395 . . . . 0.0 110.902 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.8 t -172.85 174.62 3.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.36 145.15 4.35 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.5 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 164.16 35.64 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.721 2.28 . . . . 0.0 112.328 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.554 ' C ' HD12 ' A' ' 9' ' ' LEU . 4.4 pp -67.69 152.34 96.38 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.595 0.712 . . . . 0.0 110.909 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 -45.41 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.683 2.256 . . . . 0.0 112.363 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -166.45 143.78 4.28 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.577 0.703 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -1.59 8.72 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.691 2.261 . . . . 0.0 112.394 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 59.14 42.89 18.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -158.66 -48.73 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.523 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 30.7 mt -94.38 124.38 38.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 110.93 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -67.48 170.18 7.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.1 t -110.41 165.03 12.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.839 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.906 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.9 OUTLIER -95.46 131.12 41.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.829 179.947 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.78 150.68 22.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.696 HD11 HG22 ' A' ' 44' ' ' VAL . 10.0 mt -132.91 111.03 10.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.926 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.46 126.33 31.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 36' ' ' PHE . 89.4 t -63.2 96.25 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.165 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 71' ' ' ALA . 7.9 mt -59.13 -28.84 66.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.916 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.7 t -161.27 125.67 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.838 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -38.79 143.48 0.15 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.859 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.657 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -160.28 150.32 14.81 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.67 0.747 . . . . 0.0 110.917 -179.811 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 54.0 Cg_endo -69.77 171.49 53.48 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.684 -1.798 . . . . 0.0 112.381 -0.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.407 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -52.17 148.38 11.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.634 0.731 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 53.8 Cg_endo -69.77 5.28 1.76 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.7 2.267 . . . . 0.0 112.346 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -109.01 -21.75 12.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 mt -101.65 -53.43 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.097 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.51 164.28 21.03 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.669 0.747 . . . . 0.0 110.832 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 132.16 22.84 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.706 2.27 . . . . 0.0 112.364 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 124.42 11.06 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.666 2.244 . . . . 0.0 112.366 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.587 ' H ' HD12 ' A' ' 35' ' ' ILE . 1.5 mp -89.25 -25.31 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.165 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.669 ' O ' HG11 ' A' ' 22' ' ' VAL . 12.6 m-85 -127.47 89.65 2.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.885 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 20.3 mmm-85 -51.01 160.11 0.52 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.888 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.449 ' CZ ' ' O ' ' A' ' 23' ' ' LEU . 11.1 ttt85 -61.58 147.22 46.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.97 -13.3 14.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -69.7 136.5 51.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.895 0.379 . . . . 0.0 110.865 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 2.6 ttmp? -86.63 139.06 31.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.869 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.612 HD23 ' HA ' ' A' ' 56' ' ' SER . 8.1 mt -134.98 135.33 41.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.7 ttt-85 -87.53 132.94 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 18' ' ' ASP . 58.2 t -71.22 108.2 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.525 HD12 ' HA ' ' A' ' 54' ' ' ALA . 1.1 mp -78.56 -50.15 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.177 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -158.71 157.43 31.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -109.1 118.85 37.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.877 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.402 ' O ' ' O ' ' A' ' 51' ' ' TRP . 12.8 mm-40 -120.44 85.92 2.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.47 -126.02 38.71 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.478 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.1 -25.0 74.63 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.556 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.4 m0 -111.69 153.53 26.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.765 0.317 . . . . 0.0 110.923 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.421 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -136.04 164.13 28.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.938 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 9.8 tttm -98.94 143.07 29.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.895 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.525 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -153.94 164.08 39.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.716 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.3 tt -132.02 146.15 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.115 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.612 ' HA ' HD23 ' A' ' 42' ' ' LEU . 82.0 p -86.21 126.44 34.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.6 mt -76.09 5.92 6.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.6 t -90.6 -49.84 6.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.6 p -116.28 -34.7 4.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.14 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.42 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 102.46 23.89 8.65 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.457 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 39.9 mtt180 -82.08 124.51 29.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.846 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.716 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.1 mt-10 -98.87 118.55 35.88 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.5 t -147.23 169.97 18.25 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 22.1 m-85 -105.05 119.79 39.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.889 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.42 147.52 60.51 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.663 0.744 . . . . 0.0 111.09 179.904 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.556 ' HD3' ' CZ3' ' A' ' 51' ' ' TRP . 54.1 Cg_endo -69.78 133.77 26.34 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.694 2.262 . . . . 0.0 112.345 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -30.88 6.13 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.503 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.548 HG22 ' HB2' ' A' ' 66' ' ' PRO . 8.8 tp -64.68 -32.69 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 9.4 m -80.01 6.94 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.462 ' O ' HD11 ' A' ' 23' ' ' LEU . 36.0 m -147.56 169.81 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -134.2 136.08 43.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.136 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 2.9 tpp85 -68.13 112.44 5.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 15.2 t -80.52 144.06 11.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 20.0 m -110.36 105.49 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.829 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 44.83 -157.91 0.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.493 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 89.2 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.704 2.269 . . . . 0.0 112.327 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 93.0 p -109.28 86.42 2.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 48.7 p -79.78 168.92 18.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.829 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 179.98 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.8 m -72.73 -60.53 2.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.827 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m 64.65 42.9 4.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 139.4 119.42 1.67 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.499 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.2 t -100.95 143.94 30.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.9 0.381 . . . . 0.0 110.848 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t -157.27 156.43 32.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 -179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.25 -164.14 13.05 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.483 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 148.98 66.22 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.692 2.261 . . . . 0.0 112.396 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.1 mt -104.51 156.3 36.08 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.627 0.727 . . . . 0.0 110.901 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.5 Cg_endo -69.77 2.48 3.5 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.68 2.253 . . . . 0.0 112.328 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.441 ' C ' ' O ' ' A' ' 10' ' ' PRO . 31.3 m120 -34.34 143.29 0.21 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.641 0.734 . . . . 0.0 110.886 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.487 ' O ' ' N ' ' A' ' 14' ' ' GLY . 54.1 Cg_endo -69.73 -0.36 6.78 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.68 2.253 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -39.05 93.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.875 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 153.75 -83.34 0.16 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.504 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 56.9 mt -117.72 121.43 40.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 110.897 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -75.75 157.39 33.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.849 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 13.4 t -101.52 162.04 13.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.869 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.743 ' O ' HG23 ' A' ' 44' ' ' VAL . 2.6 m-20 -74.93 128.99 36.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.879 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -105.29 148.95 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.85 HD11 HG22 ' A' ' 44' ' ' VAL . 2.4 mt -135.87 109.53 8.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.08 126.15 30.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.742 ' CG2' HD11 ' A' ' 42' ' ' LEU . 84.0 t -60.8 101.6 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.901 HD21 ' HB2' ' A' ' 71' ' ' ALA . 16.2 mt -62.13 -30.84 71.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.903 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.3 t -158.4 127.54 5.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -40.72 145.52 0.19 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.837 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.581 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.9 148.43 6.43 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.636 0.732 . . . . 0.0 110.959 -179.849 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.81 -174.12 9.26 Favored 'Cis proline' 0 C--O 1.231 0.154 0 C-N-CA 122.708 -1.788 . . . . 0.0 112.331 -0.036 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.5 m -77.06 155.83 82.38 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.651 0.739 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 2.78 3.23 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.676 2.251 . . . . 0.0 112.346 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -106.71 -14.04 15.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mt -115.02 -48.66 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -163.58 163.04 16.74 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.675 0.75 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 133.03 24.56 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.719 2.28 . . . . 0.0 112.316 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 119.7 6.6 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.7 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.6 mp -81.02 -22.81 10.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.528 ' HB3' HG21 ' A' ' 22' ' ' VAL . 13.6 m-85 -134.66 99.77 4.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.881 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -58.65 163.9 3.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.437 ' HD3' ' N ' ' A' ' 39' ' ' GLY . 3.8 tmt_? -65.69 142.44 58.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.826 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.437 ' N ' ' HD3' ' A' ' 38' ' ' ARG . . . 77.96 6.81 87.5 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -86.36 144.0 27.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.66 ' HB3' HD12 ' A' ' 57' ' ' LEU . 0.3 OUTLIER -87.29 141.1 28.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.742 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.8 mt -140.0 145.1 37.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.481 ' O ' HD12 ' A' ' 45' ' ' ILE . 16.5 ttm180 -103.78 128.48 51.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.85 HG22 HD11 ' A' ' 20' ' ' LEU . 59.5 t -65.87 108.53 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.147 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.674 HG21 ' HD3' ' A' ' 53' ' ' LYS . 1.0 OUTLIER -79.87 -50.51 17.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.125 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.4 t -163.14 135.83 5.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.82 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -89.45 129.3 35.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -130.05 86.2 2.38 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 65.29 -131.46 35.58 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.509 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.42 -20.36 78.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.467 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.563 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 11.5 m95 -116.89 152.12 35.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.741 0.305 . . . . 0.0 110.923 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -136.18 164.23 28.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.674 ' HD3' HG21 ' A' ' 45' ' ' ILE . 19.3 tttp -102.17 142.53 33.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.953 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.54 156.14 36.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.135 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.585 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.6 tt -124.08 137.17 57.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.729 ' HA ' HD23 ' A' ' 42' ' ' LEU . 5.1 t -68.04 128.16 35.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.865 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.66 HD12 ' HB3' ' A' ' 41' ' ' LYS . 6.4 mt -78.32 8.39 5.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.6 t -111.65 -45.98 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.862 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 51.4 p -102.14 -36.14 8.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.463 ' O ' HD11 ' A' ' 55' ' ' ILE . . . 86.58 33.13 13.93 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.469 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.414 ' HD3' HG23 ' A' ' 35' ' ' ILE . 42.7 mtt180 -96.8 125.96 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.761 0.315 . . . . 0.0 110.89 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.585 ' HG3' HD12 ' A' ' 55' ' ' ILE . 5.6 mt-10 -90.66 117.43 29.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.6 t -147.66 169.99 18.48 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.812 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.551 ' CE1' ' HG3' ' A' ' 53' ' ' LYS . 18.9 m-85 -112.75 117.37 32.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.889 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.829 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -126.78 151.12 73.1 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.629 0.728 . . . . 0.0 111.123 179.932 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.677 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.83 135.76 31.09 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.661 2.241 . . . . 0.0 112.331 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.17 -30.95 8.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.7 tp -65.55 -30.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.831 0.348 . . . . 0.0 111.162 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 4.4 m -79.78 -0.19 33.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.851 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.1 m -136.99 163.11 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.901 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -128.2 137.48 52.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.063 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.33 112.19 2.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.851 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.48 HG21 ' HE2' ' A' ' 41' ' ' LYS . 15.4 t -90.62 148.91 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.139 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.8 m -78.32 -55.62 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.867 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 140.94 -158.69 26.36 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.447 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -34.76 14.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.661 2.241 . . . . 0.0 112.405 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.8 t -138.36 169.06 18.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.872 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 30.6 t -124.32 112.35 16.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.865 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.46 179.985 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 91.2 p -68.27 -34.88 77.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.883 0.373 . . . . 0.0 110.877 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.2 t 58.76 46.27 14.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.58 112.87 0.55 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.492 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.0 p -150.03 163.71 37.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.891 0.377 . . . . 0.0 110.814 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 t -56.6 121.96 10.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.37 77.58 0.11 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 150.89 68.53 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.667 2.245 . . . . 0.0 112.333 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -47.25 157.66 0.51 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.613 0.721 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 11' ' ' ASN . 53.9 Cg_endo -69.74 2.06 3.86 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.355 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.454 ' C ' ' O ' ' A' ' 10' ' ' PRO . 29.0 m-20 -34.46 143.96 0.2 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.605 0.717 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.466 ' O ' ' N ' ' A' ' 14' ' ' GLY . 53.6 Cg_endo -69.76 2.53 3.45 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.701 2.267 . . . . 0.0 112.359 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -47.06 91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 12' ' ' PRO . . . 176.92 -97.12 0.11 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.485 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 43.4 tp -121.16 122.98 41.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.787 0.327 . . . . 0.0 110.934 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -59.55 149.5 29.81 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.881 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.1 t -113.91 169.63 8.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . 3.9 m-20 -71.45 136.89 47.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.916 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -109.89 150.8 27.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.602 HD22 ' CZ2' ' A' ' 52' ' ' TRP . 5.3 mt -129.64 114.47 16.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -85.22 116.73 23.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.145 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.567 HG11 ' O ' ' A' ' 36' ' ' PHE . 95.2 t -54.92 103.65 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.114 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.045 HD21 ' HB2' ' A' ' 71' ' ' ALA . 8.6 mt -66.53 -31.0 71.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.441 ' O ' ' C ' ' A' ' 25' ' ' ASP . 30.6 t -160.33 118.79 2.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.859 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 24' ' ' SER . 10.4 p-10 -34.28 140.19 0.07 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.644 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -157.14 149.81 18.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.69 0.757 . . . . 0.0 110.923 -179.801 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.6 Cg_endo -69.85 179.54 22.2 Favored 'Cis proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 -1.802 . . . . 0.0 112.319 -0.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 p -72.46 157.2 89.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.05 2.41 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.677 2.252 . . . . 0.0 112.316 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -101.28 -13.18 18.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.839 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 4.8 mt -120.53 -60.6 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.114 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 m -147.96 163.07 28.82 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.651 0.738 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 137.36 35.06 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.681 2.254 . . . . 0.0 112.323 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 118.96 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.705 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.4 mp -80.86 -26.19 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.567 ' O ' HG11 ' A' ' 22' ' ' VAL . 13.6 m-85 -131.32 93.55 3.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -54.8 161.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.908 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.411 ' HA ' HG12 ' A' ' 22' ' ' VAL . 6.8 ttm180 -62.06 147.79 46.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.96 -5.85 57.45 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -79.85 134.42 36.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.924 0.392 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 28.0 ttmt -84.33 138.06 33.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.427 HD21 ' HB3' ' A' ' 36' ' ' PHE . 9.0 mt -130.56 141.32 50.46 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.54 ' O ' HD12 ' A' ' 45' ' ' ILE . 25.3 ttp180 -93.18 126.73 38.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.903 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 18' ' ' ASP . 96.1 t -66.05 112.16 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.54 HD12 ' O ' ' A' ' 43' ' ' ARG . 1.0 OUTLIER -88.27 -53.3 9.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.15 179.913 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -144.45 145.31 31.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.838 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -108.68 118.41 36.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -129.4 86.44 2.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.881 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 60.26 -123.78 33.99 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.05 -19.03 65.93 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.568 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 25.3 m95 -113.42 131.56 55.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.752 0.311 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.602 ' CZ2' HD22 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.44 164.36 26.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.956 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.557 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 8.3 tttp -100.2 142.27 31.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -150.78 157.83 43.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.112 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.431 HD12 ' HG3' ' A' ' 62' ' ' GLU . 19.0 tt -121.78 145.26 28.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.519 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . 6.1 p -86.75 126.0 34.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 8.0 mt -75.14 5.75 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.894 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 t -92.01 -48.83 6.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.9 p -118.11 -28.69 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 94.85 25.92 13.94 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.48 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.404 ' CD ' HG23 ' A' ' 35' ' ' ILE . 76.6 mtt180 -80.86 132.29 35.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.744 0.306 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.438 ' HB3' ' CE ' ' A' ' 53' ' ' LYS . 4.9 mt-10 -103.29 117.38 34.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.866 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.0 t -147.67 170.18 18.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.557 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 38.5 m-85 -110.55 120.8 43.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.909 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.835 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.13 149.69 70.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.56 0.695 . . . . 0.0 111.174 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.717 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.72 134.58 28.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.67 2.247 . . . . 0.0 112.382 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -48.81 -30.33 8.91 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.717 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.5 tp -65.36 -30.1 49.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.802 0.334 . . . . 0.0 111.152 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 16.6 m -84.19 8.23 16.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.881 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.553 ' O ' HD11 ' A' ' 23' ' ' LEU . 22.9 m -148.95 168.9 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.045 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.62 131.98 43.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.095 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -68.92 112.18 5.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.885 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 4.0 t -86.67 144.21 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.164 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -118.47 42.42 2.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.852 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.83 160.42 11.59 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.501 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -174.93 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.685 2.257 . . . . 0.0 112.31 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 35.0 t -85.87 -57.55 3.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.0 m -86.77 140.57 29.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.501 -179.992 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.8 t -163.14 121.54 2.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.908 0.385 . . . . 0.0 110.881 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 98.5 p -117.71 151.03 38.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.892 -179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.98 112.07 0.27 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.3 m -84.16 -52.84 5.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.872 0.368 . . . . 0.0 110.838 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 97.8 p -116.59 43.44 2.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.861 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.49 125.0 0.59 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.542 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 146.9 61.66 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.663 2.242 . . . . 0.0 112.35 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.3 mt -144.23 151.41 51.59 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.631 0.729 . . . . 0.0 110.912 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 79.7 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.662 2.241 . . . . 0.0 112.352 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -143.82 156.16 59.22 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.644 0.735 . . . . 0.0 110.86 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 1.15 4.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.693 2.262 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.98 95.14 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.868 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.91 -61.11 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 33.9 mt -91.99 145.63 24.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.821 0.343 . . . . 0.0 110.905 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.63 171.01 7.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.417 ' HB3' ' CG ' ' A' ' 43' ' ' ARG . 23.5 t -118.64 166.24 12.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.847 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -83.07 148.41 27.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -109.11 144.87 36.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.92 HD11 HG22 ' A' ' 44' ' ' VAL . 4.2 mt -131.05 112.07 12.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.61 126.38 30.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.144 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.565 ' CG2' HD11 ' A' ' 42' ' ' LEU . 95.4 t -66.52 102.44 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.058 HD21 ' HB2' ' A' ' 71' ' ' ALA . 4.7 mt -61.84 -32.16 72.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.906 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.3 t -156.23 125.24 6.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.846 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -41.47 148.09 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.57 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -167.37 148.42 5.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.778 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.556 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.9 Cg_endo -69.76 -174.36 9.47 Favored 'Cis proline' 0 C--N 1.341 0.163 0 C-N-CA 122.67 -1.804 . . . . 0.0 112.323 -0.081 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 32' ' ' SER . 2.9 m -81.59 158.57 68.34 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.69 0.757 . . . . 0.0 110.85 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 3.17 2.95 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.668 2.245 . . . . 0.0 112.324 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -107.16 -6.15 17.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.39 -43.17 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.151 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.402 ' O ' ' O ' ' A' ' 28' ' ' SER . 1.2 m -170.92 163.32 5.43 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.653 0.74 . . . . 0.0 110.842 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 131.62 21.66 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.387 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.18 3.61 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.378 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.779 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.7 mp -72.56 -29.21 29.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.502 ' HB3' HG21 ' A' ' 22' ' ' VAL . 10.1 m-85 -127.75 104.64 7.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.88 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 37' ' ' ARG . 0.9 OUTLIER -65.59 159.65 24.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.859 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 25.6 ttp180 -62.49 141.39 58.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.25 7.69 88.3 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -91.92 139.75 30.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -88.54 137.2 32.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.933 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.565 HD11 ' CG2' ' A' ' 22' ' ' VAL . 4.9 mt -134.65 149.71 50.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.427 ' O ' HD12 ' A' ' 45' ' ' ILE . 17.7 ttp180 -100.62 131.66 46.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.92 HG22 HD11 ' A' ' 20' ' ' LEU . 45.7 t -71.41 116.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.614 HD11 HG22 ' A' ' 55' ' ' ILE . 1.1 mp -89.58 -49.41 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -152.3 149.36 28.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -108.52 119.27 39.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.842 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -122.93 85.84 2.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.914 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 61.67 -122.14 28.08 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.509 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.76 -24.99 61.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.558 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 15.0 m95 -111.6 141.67 44.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.79 0.329 . . . . 0.0 110.942 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.558 ' CE2' HD13 ' A' ' 20' ' ' LEU . 0.1 OUTLIER -132.35 164.71 25.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.893 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.545 ' HG3' ' CE2' ' A' ' 64' ' ' TYR . 19.0 tttt -99.73 146.61 26.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.56 167.07 31.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.644 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.7 tt -138.49 146.8 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.155 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.489 ' OG ' ' CD1' ' A' ' 36' ' ' PHE . 5.7 m -81.18 132.66 35.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 3.3 mt -80.08 9.43 5.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.939 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.1 m -113.17 -51.12 2.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 77.8 p -97.49 -33.95 11.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.31 27.79 35.38 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 54.2 mtt-85 -90.05 122.87 33.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.804 0.335 . . . . 0.0 110.882 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.644 ' HG3' HD12 ' A' ' 55' ' ' ILE . 11.4 mt-10 -92.54 118.53 31.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.3 m -147.11 165.78 28.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.545 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 27.9 m-85 -108.73 120.2 41.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.914 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.798 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -127.36 151.81 75.34 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.636 0.731 . . . . 0.0 111.149 179.909 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HB2' HG22 ' A' ' 68' ' ' ILE . 54.1 Cg_endo -69.69 130.14 18.91 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.37 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -47.45 -31.69 6.96 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.503 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.675 HG22 ' HB2' ' A' ' 66' ' ' PRO . 11.7 tt -63.0 -31.92 54.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.838 0.352 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . 0.402 ' SG ' ' HG2' ' A' ' 66' ' ' PRO . 3.7 m -77.08 -15.51 59.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.412 ' O ' HD11 ' A' ' 23' ' ' LEU . 25.2 m -121.3 167.77 14.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.108 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.058 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -131.15 131.64 44.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.466 ' HD3' ' CD2' ' A' ' 20' ' ' LEU . 7.1 tpp85 -63.14 106.14 0.81 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 74' ' ' SER . 44.1 t -76.68 148.62 6.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.155 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.403 ' C ' ' O ' ' A' ' 73' ' ' VAL . 7.8 m -37.61 149.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.855 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -99.94 163.51 19.38 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.437 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 91.75 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.688 2.259 . . . . 0.0 112.363 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 78.9 p -128.04 108.75 10.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.84 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 58.6 p -45.98 151.44 0.47 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.852 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.988 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.0 m -148.21 168.74 21.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.866 0.365 . . . . 0.0 110.861 -179.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 85.3 p -122.38 118.85 29.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.821 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.94 130.8 0.34 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.475 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 m -103.05 43.29 1.09 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.868 0.366 . . . . 0.0 110.882 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 99.9 p -102.33 134.25 45.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.95 -94.97 0.13 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.481 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 140.58 43.3 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.386 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.9 mt -124.46 144.14 45.17 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.585 0.707 . . . . 0.0 110.924 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -46.11 1.34 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.727 2.284 . . . . 0.0 112.323 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -107.18 161.25 23.59 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.624 0.726 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.668 2.245 . . . . 0.0 112.342 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -55.0 96.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 141.02 -82.33 0.24 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.501 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -69.18 138.38 54.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.811 0.339 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 45.9 m-20 -75.78 162.06 28.5 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.3 t -127.99 149.86 50.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.839 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.533 ' O ' HG23 ' A' ' 44' ' ' VAL . 70.4 m-20 -84.6 119.57 25.36 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.898 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 m-85 -105.21 148.11 27.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.74 HD11 HG22 ' A' ' 44' ' ' VAL . 6.7 mt -130.21 107.89 9.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.37 123.42 26.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 40' ' ' GLU . 58.5 t -60.09 97.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.05 HD21 ' HB2' ' A' ' 71' ' ' ALA . 11.2 mt -61.02 -33.9 73.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -162.25 130.1 3.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.913 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 p30 -41.15 146.73 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.634 ' C ' ' CD1' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -165.85 149.67 7.1 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.633 0.73 . . . . 0.0 110.929 -179.841 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 26' ' ' TYR . 53.8 Cg_endo -69.76 -177.42 14.5 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.687 -1.797 . . . . 0.0 112.314 -0.031 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 32' ' ' SER . 1.2 t -69.55 153.92 95.29 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.722 0.773 . . . . 0.0 110.86 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 4.0 2.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.685 2.256 . . . . 0.0 112.325 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -107.87 -24.34 11.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.869 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 2.2 mt -101.59 -54.78 6.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.129 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 28' ' ' SER . 0.9 OUTLIER -153.95 164.34 20.99 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.91 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 128.28 15.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.686 2.257 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 121.0 7.71 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.727 2.285 . . . . 0.0 112.355 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.742 ' H ' HD12 ' A' ' 35' ' ' ILE . 2.0 mp -80.24 -28.08 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.143 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.464 ' HB3' HG21 ' A' ' 22' ' ' VAL . 12.6 m-85 -131.14 110.51 11.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.4 ' O ' ' C ' ' A' ' 38' ' ' ARG . 10.0 mmm180 -78.11 138.11 38.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.447 ' HA ' HG12 ' A' ' 22' ' ' VAL . 15.3 ttp-105 -37.51 144.99 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.21 -8.66 79.34 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.498 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.541 ' O ' HG23 ' A' ' 22' ' ' VAL . 7.3 mt-10 -88.14 146.4 25.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.885 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' HD23 ' A' ' 42' ' ' LEU . 3.6 ttmp? -99.33 147.7 24.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.869 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.533 HD23 ' HA ' ' A' ' 56' ' ' SER . 5.6 mt -137.2 153.92 50.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.577 ' O ' HD12 ' A' ' 45' ' ' ILE . 39.5 ttm180 -108.38 127.92 54.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.74 HG22 HD11 ' A' ' 20' ' ' LEU . 61.6 t -61.99 109.61 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.595 HG21 ' HD3' ' A' ' 53' ' ' LYS . 0.9 OUTLIER -86.1 -55.05 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.897 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 45' ' ' ILE . 43.5 t -152.07 125.65 8.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -88.05 126.17 34.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -129.97 85.86 2.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.72 -127.48 36.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.513 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -75.53 -22.69 74.9 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' TRP . . . . . 0.585 ' CZ3' ' HD3' ' A' ' 66' ' ' PRO . 19.6 m95 -113.76 137.1 52.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.789 0.328 . . . . 0.0 110.923 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.419 ' CZ2' ' HA2' ' A' ' 67' ' ' GLY . 0.1 OUTLIER -129.05 164.64 22.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.97 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.595 ' HD3' HG21 ' A' ' 45' ' ' ILE . 11.5 tttp -100.9 142.94 31.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -152.68 159.67 43.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.117 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.808 HD12 ' HG3' ' A' ' 62' ' ' GLU . 18.6 tt -131.83 138.84 51.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.138 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.533 ' HA ' HD23 ' A' ' 42' ' ' LEU . 1.1 t -74.39 126.52 30.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.897 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . . . . . . . . . 5.1 mt -77.28 8.57 3.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 45.7 t -107.34 -44.8 4.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.4 p -104.7 -41.22 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.188 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.9 32.68 7.41 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.416 ' C ' HG13 ' A' ' 55' ' ' ILE . 45.8 mtt180 -97.6 122.71 41.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.811 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.808 ' HG3' HD12 ' A' ' 55' ' ' ILE . 8.5 mt-10 -91.15 116.99 29.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 3.6 t -147.96 165.99 29.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.559 ' CE2' ' HG3' ' A' ' 53' ' ' LYS . 15.0 m-85 -105.6 128.99 53.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.486 HD13 ' H ' ' A' ' 65' ' ' ILE . 0.3 OUTLIER -138.57 151.13 68.32 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.656 0.741 . . . . 0.0 111.12 179.9 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.702 ' HB2' HG22 ' A' ' 68' ' ' ILE . 53.8 Cg_endo -69.7 133.7 26.31 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.65 2.233 . . . . 0.0 112.35 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 52' ' ' TRP . . . -47.33 -31.57 6.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 66' ' ' PRO . 6.1 tp -64.63 -32.03 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.821 0.343 . . . . 0.0 111.142 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' CYS . . . . . . . . . . . . . 1.8 m -75.28 -12.68 60.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.888 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.611 ' O ' HD11 ' A' ' 23' ' ' LEU . 13.3 m -127.29 169.86 18.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.05 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -129.96 132.54 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.115 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.651 ' NH1' HG21 ' A' ' 44' ' ' VAL . 1.7 tpt180 -69.53 105.13 2.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.0 t -81.15 145.83 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.151 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 36.1 t 49.94 43.12 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.82 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -117.48 170.53 13.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.457 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -10.86 29.6 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.343 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 44.0 p -91.57 144.66 25.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.5 m 59.67 25.78 14.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.906 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 -179.958 . . . . . . . . 0 0 . 1 stop_ save_